PES	A1G	5.0	2015-10-15	2015-10-15	%	1.7	3.8	X 	P         
PES	A1GG	3.8	2015-10-15	2015-10-15	g/L	1.3	2.7	X 	Q         
PES	A2G	10.0	2015-10-15	2015-10-15	%	8.1	15.3	X 	P         
PES	A2GG	7.5	2015-10-15	2015-10-15	g/L	6.1	11.3	X 	Q         
LFT	ALB	40	2015-10-15	2015-10-15	g/L	38	54	B 	CP        
PES	ALBG	45.0	2015-10-15	2015-10-15	g/L	33.3	54.1	X 	Q         
PES	ALBP	60.0	2015-10-15	2015-10-15	%	51.8	67.1	X 	P         
LFT	ALP	150	2015-10-15	2015-10-15	IU/L	0	300	B 	C         
LFT	ALT	20	2015-10-15	2015-10-15	IU/L	10	35	B 	C         
PES	B1G	6.0	2015-10-15	2015-10-15	%	6.0	9.9	X 	P         
PES	B1GG	4.5	2015-10-15	2015-10-15	g/L	4.1	7.7	X 	Q         
PES	B2G	6.0	2015-10-15	2015-10-15	%			X 	P         
PES	B2GL	4.5	2015-10-15	2015-10-15	g/L	1.2	5.6	X 	Q         
B2M	B2M	2.0	2015-10-15	2015-10-15	mg/L	0	2.3	B 	AB        
LFT	BILI	10	2015-10-15	2015-10-15	umol/L	0	137	B 	CPr       
BON	CA	2.50	2015-10-15	2015-10-15	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.61	2015-10-15	2015-10-15	mmol/L	2.15	2.55	B 	C         
ELU	CREA	50	2015-10-15	2015-10-15	umol/L	28	52	B 	CPr       
ELU	GFR	Not calculated. Age less than 18yrs.	2015-10-15	2015-10-15	.			B 	          
PES	GG	15.0	2015-10-15	2015-10-15	%	8.9	20.0	X 	P         
PES	GGG	11.3	2015-10-15	2015-10-15	g/L	6.1	15.0	X 	Q         
ELU	K	4.0	2015-10-15	2015-10-15	mmol/L	3.5	5.1	B 	CP        
SFLC	KAPA	15.0	2015-10-15	2015-10-15	mg/L			B 	r         
SFLC	KLRA	0.75
Analysed at UCLH using SPAplus Freelite. Results
may differ from those using the Royal Free method.
Occasional monoclonal proteins react atypically in
the assay and give erroneous results.
Contact x72952 to discuss if discrepancy suspected	2015-10-15	2015-10-15				B 	r         
SFLC	LAMB	20.0	2015-10-15	2015-10-15	mg/L			B 	r         
LD	LDH	200	2015-10-15	2015-10-15	IU/L	240	480	B 	C         
ELU	NA	140	2015-10-15	2015-10-15	mmol/L	135	145	B 	CP        
PES	PCOM	Positive
Method changed on 24/02/14 from gel to capillary
electrophoresis. New reference ranges apply.	2015-10-15	2015-10-15				B 	A         
BON	PHOS	1.50	2015-10-15	2015-10-15	mmol/L	1.45	1.78	B 	CP        
PES	PPR	19
Method changed on 24/02/14 from gel to capillary
electrophoresis. Paraproteins average 2 g/L higher
(80% between 1 g/L lower and 5 g/L higher).
IgA PP more affected than IgG or IgM.	2015-10-15	2015-10-15	g/L	0		B 	N         
PES	PPRP	25	2015-10-15		%			X 	N         
PES	PROT	75	2015-10-15	2015-10-15	g/L	63	83	B 	CP        
ELU	UREA	4.0	2015-10-15	2015-10-15	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	6	2015-10-15		y			X 	          
MYEL	A1G	5.5	2015-10-16	2015-10-16	%	1.7	3.8	X 	P         
MYEL	A1GG	4.1	2015-10-16	2015-10-16	g/L	1.3	2.7	X 	Q         
MYEL	A2G	10.0	2015-10-16	2015-10-16	%	8.1	15.3	X 	P         
MYEL	A2GG	7.5	2015-10-16	2015-10-16	g/L	6.1	11.3	X 	Q         
LFT	ALB	45	2015-10-16	2015-10-16	g/L	38	54	B 	CP        
MYEL	ALBG	41.3	2015-10-16	2015-10-16	g/L	33.3	54.1	X 	Q         
MYEL	ALBP	55.0	2015-10-16	2015-10-16	%	51.8	67.1	X 	P         
LFT	ALP	150	2015-10-16	2015-10-16	IU/L	0	300	B 	C         
LFT	ALT	20	2015-10-16	2015-10-16	IU/L	10	35	B 	C         
MYEL	B1G	6.5	2015-10-16	2015-10-16	%	6.0	9.9	X 	P         
MYEL	B1GG	4.9	2015-10-16	2015-10-16	g/L	4.1	7.7	X 	Q         
MYEL	B2G	6.0	2015-10-16	2015-10-16	%			X 	P         
MYEL	B2GL	4.5	2015-10-16	2015-10-16	g/L	1.2	5.6	X 	Q         
MYEL	B2M	2.0	2015-10-16	2015-10-16	mg/L	0	2.3	B 	AB        
FBCZ	BA	 1.0%  0.10
Note new haematology ranges effective 05/10/15	2015-10-16	2015-10-16	x10^9/L	0.0	0.1	A 	CDSN/0    
LFT	BILI	15	2015-10-16	2015-10-16	umol/L	0	137	B 	CPr       
BON	CA	2.50	2015-10-16	2015-10-16	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.51	2015-10-16	2015-10-16	mmol/L	2.15	2.55	B 	C         
ELU	CREA	45	2015-10-16	2015-10-16	umol/L	28	52	B 	CPr       
CRP	CRP	4.0	2015-10-16	2015-10-16	mg/L	0	5.0	B 	AB        
FBCZ	EO	 4.0%  0.40	2015-10-16	2015-10-16	x10^9/L	0.0	0.8	A 	CDSN/0    
ESR	ESR	6	2015-10-16	2015-10-16	mm/hr	1	7	A 	C?/0      
ELU	GFR	Not calculated. Age less than 18yrs.	2015-10-16	2015-10-16	.			B 	          
MYEL	GG	20.0	2015-10-16	2015-10-16	%	8.9	20.0	X 	P         
MYEL	GGG	15.0	2015-10-16	2015-10-16	g/L	6.1	15.0	X 	Q         
GT	GGT	35	2015-10-16	2015-10-16	IU/L	6	42	B 	C         
GLU	GLU	5.0
Reference range applies to fasting samples only.	2015-10-16	2015-10-16	mmol/L	3.9	5.8	B 	AB        
FBCY	HBGL	120	2015-10-16	2015-10-16	g/L			A 	rCP/0     
BIC	HCO3	25	2015-10-16	2015-10-16	mmol/L	22	29	B 	CP        
FBCY	HCTU	0.400	2015-10-16	2015-10-16	L/L	0.33	0.44	A 	CPS/0     
FBCY	HGB	12.0	2015-10-16	2015-10-16	g/dl	11.0	14.0	A 	NrCP/0    
TPT	HTRT	10
Please note change in reporting units to ng/L
Old units ug/L x 1000 = new units ng/L
Effective 01/12/2014.	2015-10-16	2015-10-16	ng/L			B 	          
ELU	K	4.0	2015-10-16	2015-10-16	mmol/L	3.5	5.1	B 	CP        
MYEL	KAPA	15.0	2015-10-16	2015-10-16	mg/L			B 	r         
MYEL	KLRA	0.94
Analysed at UCLH using SPAplus Freelite. Results
may differ from those using the Royal Free method.
Occasional monoclonal proteins react atypically in
the assay and give erroneous results.
Contact x72952 to discuss if discrepancy suspected	2015-10-16	2015-10-16				B 	r         
MYEL	LAMB	16.0	2015-10-16	2015-10-16	mg/L			B 	r         
MYEL	LDH	250	2015-10-16	2015-10-16	IU/L	240	480	B 	C         
FBCZ	LY	20.0%  2.00	2015-10-16	2015-10-16	x10^9/L	1.5	7.0	A 	CDSP/0    
FBCY	MCGL	350	2015-10-16	2015-10-16	g/L			A 	CPS/0     
FBCY	MCHU	25.0	2015-10-16	2015-10-16	pg	21.0	31.0	A 	CPS/0     
FBCY	MCVU	80.0	2015-10-16	2015-10-16	fL	76	94	A 	CPS/0     
MG	MG	0.80	2015-10-16	2015-10-16	mmol/L	0.60	1.00	B 	CP        
FBCZ	MO	 5.0%  0.50	2015-10-16	2015-10-16	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	8.0	2015-10-16	2015-10-16	fL	7	13	A 	CS?/0     
ELU	NA	140	2015-10-16	2015-10-16	mmol/L	135	145	B 	CP        
FBCZ	NE	70.0%  7.00	2015-10-16	2015-10-16	x10^9/L	1.5	8.0	A 	CDS/0     
MYEL	PCOM	Positive
Method changed on 24/02/14 from gel to capillary
electrophoresis. New reference ranges apply.	2015-10-16	2015-10-16				B 	A         
BON	PHOS	1.60	2015-10-16	2015-10-16	mmol/L	1.45	1.78	B 	CP        
FBCY	PLT	250	2015-10-16	2015-10-16	x10^9/L	150	400	A 	CS/0      
MYEL	PPR	38
Method changed on 24/02/14 from gel to capillary
electrophoresis. Paraproteins average 2 g/L higher
(80% between 1 g/L lower and 5 g/L higher).
IgA PP more affected than IgG or IgM.	2015-10-16	2015-10-16	g/L	0		B 	N         
MYEL	PPRP	50	2015-10-16		%			X 	N         
MYEL	PROT	75	2015-10-16	2015-10-16	g/L	63	83	B 	CP        
FBCY	RCC	5.00	2015-10-16	2015-10-16	x10^12/L	4.1	5.4	A 	P/0       
FBCY	RDWU	12.0	2015-10-16	2015-10-16	%	11.5	15.0	A 	CS/0      
ELU	UREA	7.0	2015-10-16	2015-10-16	mmol/L	1.7	8.3	B 	CP        
FBCY	WCC	10.00	2015-10-16	2015-10-16	x10^9/L	4.5	13.5	A 	CWPS/0    
ELU	ZAGE	6	2015-10-16		y			X 	          
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-01-23	2015-01-23		133	143	B 	          
XYZA	XYZ3	5.5	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	6.0	2015-01-23	2015-01-23				B 	          
LFT	ALB	20	2015-01-23	2015-01-23	g/L	34	50	B 	CP        
LFT	ALP	150	2015-01-23	2015-01-23	IU/L	35	104	B 	C         
LFT	ALT	30	2015-01-23	2015-01-23	IU/L	10	35	B 	C         
LFT	BILI	25	2015-01-23	2015-01-23	umol/L	0	137	B 	CPr       
ESR	ESR	15	2015-01-23	2015-01-23	mm/hr	1	20	A 	C?/0      
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-01-23	2015-01-23		133	143	B 	          
XYZB	XYZ3	4	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
LFT	ALB	20	2015-01-23	2015-01-23	g/L	34	50	B 	CP        
LFT	ALP	50	2015-01-23	2015-01-23	IU/L	35	104	B 	C         
LFT	ALT	100	2015-01-23	2015-01-23	IU/L	10	35	B 	C         
LFT	BILI	15	2015-01-23	2015-01-23	umol/L	0	137	B 	CPr       
ESR	ESR	20	2015-01-23	2015-01-23	mm/hr	1	7	A 	C?/0      
MG	MG	0.80	2015-10-29	2015-10-29	mmol/L	0.60	1.00	B 	CP        
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	140	2015-01-23	2015-01-23		133	143	B 	          
XYZA	XYZ3	5.0	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
XYZB	XYZ3	12	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-01-23	2015-01-23		133	143	B 	          
XYZA	XYZ3	5	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
LFT	ALB	45	2015-01-23	2015-01-23	g/L	34	50	B 	CP        
LFT	ALP	40	2015-01-23	2015-01-23	IU/L	35	104	B 	C         
LFT	ALT	20	2015-01-23	2015-01-23	IU/L	10	35	B 	C         
LFT	BILI	15	2015-01-23	2015-01-23	umol/L	0	137	B 	CPr       
ESR	ESR	15	2015-01-23	2015-01-23	mm/hr	1	20	A 	C?/0      
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-01-23	2015-01-23		133	143	B 	          
XYZB	XYZ3	5	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-01-23	2015-01-23		133	143	B 	          
XYZA	XYZ3	5	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
LFT	ALB	30	2015-01-23	2015-01-23	g/L	38	54	B 	CP        
LFT	ALP	111	2015-01-23	2015-01-23	IU/L	0	269	B 	C         
LFT	ALT	25	2015-01-23	2015-01-23	IU/L	10	35	B 	C         
LFT	BILI	15	2015-01-23	2015-01-23	umol/L	0	137	B 	CPr       
ESR	ESR	15	2015-01-23	2015-01-23	mm/hr	1	7	A 	C?/0      
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-01-23	2015-01-23		133	143	B 	          
XYZB	XYZ3	5	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
XYZA	XYZ1	5	2015-01-23	2015-01-23		3.0	7.0	B 	          
XYZA	XYZ2	132	2015-01-23	2015-01-23		133	143	B 	          
XYZA	XYZ3	5	2015-01-23	2015-01-23		3.7	5.2	B 	          
XYZB	XYZ4	5	2015-01-23	2015-01-23				B 	          
XYZA	XYZ1	5	2016-02-11	2016-02-11		3.0	7.0	B 	          
XYZA	XYZ2	140	2016-02-11	2016-02-11		133	143	B 	          
XYZA	XYZ3	4	2016-02-11	2016-02-11		3.7	5.2	B 	          
POCH	PCCC	Please note that this test may not detect HIV
infection for up to three months after exposure.	2012-08-09	2012-08-09				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	HIV 1 + 2 antibodies NOT detected.	2012-08-09	2012-08-09				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-09	2012-08-09				H 	?r        
POCH	PCCC	Further laboratory testing recommended.
Please review ALL this patient's virology results.	2012-08-09	2012-08-09				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	Invalid	2012-08-09	2012-08-09				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-09	2012-08-09				H 	?r        
POCH	PCCC	Note that a reactive result is not diagnostic of
HIV infection without confirmatory laboratory
testing, as false positives can occur.
Please review ALL this patient's virology results.	2012-08-09	2012-08-09				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	REACTIVE	2012-08-09	2012-08-09				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-09	2012-08-09				H 	?r        
POCH	PCCC	Please note that this test may not detect HIV
infection for up to three months after exposure.	2012-08-11	2012-08-11				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	HIV 1 + 2 antibodies NOT detected.	2012-08-11	2012-08-11				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-11	2012-08-11				H 	?r        
POCH	PCCC	Please note that this test may not detect HIV
infection for up to three months after exposure.	2012-08-16	2012-08-16				H 	?r        
POCH	POCR	HIV 1 + 2 antibodies NOT detected.	2012-08-16	2012-08-16				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-16	2012-08-16				H 	?r        
POCH	PCCC	Please note that this test may not detect HIV
infection for up to three months after exposure.	2012-08-11	2012-08-11				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	HIV 1 + 2 antibodies NOT detected.	2012-08-11	2012-08-11				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-11	2012-08-11				H 	?r        
POCH	PCCC	Please note that this test may not detect HIV
infection for up to three months after exposure.	2012-08-11	2012-08-11				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	HIV 1 + 2 antibodies NOT detected.	2012-08-11	2012-08-11				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-11	2012-08-11				H 	?r        
SCRW	CMGA	.{}	2017-05-30					H 	Ir/1      
SCRX	CMGR	.{}	2017-05-30					H 	?/2       
SCRW	CMMA	.{}	2017-05-30					H 	Ir/1      
SCRX	CMMR	.{}	2017-05-30					H 	?/2m      
SCRX	EBNA	.{}	2017-05-26					H 	?/2       
SCRX	EBNL	.{}	2017-05-26					H 	Ir/2      
SCRW	HBCA	.{}	2017-05-30					H 	HIr/1     
SCRX	HBCR	.{}	2017-05-30					H 	?r/2      
SCRW	HBVA	.{}	2017-05-30					H 	HIr/1     
SCRX	HBVR	.{}	2017-05-30					H 	?r/2m     
SCRW	HCVA	.{}	2017-05-30					H 	Ir/1      
SCRX	HCVR	.{}	2017-05-30					H 	?/2m      
SCRW	HCVV	.{}	2017-05-25					H 	I/3       
SCRX	HERN	.{}	2017-05-30					H 	?rm/20    
SCRW	HIVA	.{}	2017-05-30					H 	Ir/1      
SCRX	HIVR	.{}	2017-05-30					H 	?/2       
POCH	PCCC	Note that a reactive result is not diagnostic of
HIV infection without confirmatory laboratory
testing, as false positives can occur.
Please review ALL this patient's virology results.	2012-08-11	2012-08-11				H 	?r        
PCCH	PCCH	.{}	2012-08-30					H 	I         
POCH	POCR	REACTIVE	2012-08-11	2012-08-11				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-11	2012-08-11				H 	?r        
SCRW	SAVJ	.{}	2017-05-26					H 	I?/0      
SCRX	SCR2	END OF SCR SCREEN REPORT	2017-05-26	2017-05-30				H 	NA?       
SCRX	SCRS	COMPLETE REPORT	2017-06-01	2017-06-01				H 	Hr?       
SCRW	SYPA	.{}	2017-05-30					H 	?Ir/1     
SCRX	SYPR	.{}	2017-05-30					H 	?r/2m     
SCRW	TLVA	.{}	2017-05-30					H 	Ir/1      
SCRX	TLVR	.{}	2017-05-30					H 	?/2m      
SCRX	TOXG	.{}	2017-05-30					H 	?/2       
SCRX	TOXM	.{}	2017-06-01					H 	?/2m      
SCRW	TXGA	.{}	2017-05-30					H 	Ir/1      
SCRW	TXMA	.{0.83}	2017-06-01					H 	Ir/1      
SCRW	TXMV	.{}	2017-06-01					H 	IN        
SCRX	VCAG	.{}	2017-05-26					H 	?/2       
SCRX	VCAM	.{}	2017-05-26					H 	?/2m      
SCRW	VCGL	.{}	2017-05-26					H 	Ir/2      
SCRI	VCML	.{}	2017-05-26					H 	Ir/2      
SCRI	VZG2	.{}	2017-05-26					H 	IrN       
SCRW	VZGL	.{}	2017-05-26					H 	Ir/2      
SCRX	VZGR	.{}	2017-05-26					H 	?/3r      
HCV	HCVA	0.010	2012-09-18	2012-09-18				H 	Ir/1      
HCV	HCVR	Not Detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV
infection, please contact us to discuss further
testing of this sample.	2012-09-18	2012-09-18				H 	?/2m      
HCV	HCVV	Not tested	2012-09-18	2012-09-18				H 	I/3       
HCV	HCVA	.{}	2012-09-21					H 	Ir/1      
HCV	HCVR	Not Detected	2012-09-18	2012-09-18				H 	?/2m      
HCV	HCVV	.{}	2012-09-21					H 	I/3       
XYZA	XYZ1	5	2015-04-15	2015-04-15		3.0	7.0	B 	          
XYZA	XYZ2	140.0	2015-04-15	2015-04-15		133	143	B 	          
XYZA	XYZ3	5.0	2015-04-15	2015-04-15		3.7	5.2	B 	          
XYZA	XYZ1	.	2015-05-22			3.0	7.0	B 	          
XYZA	XYZ2	.	2015-05-22			133	143	B 	          
XYZA	XYZ3	.	2015-05-22			3.7	5.2	B 	          
FLAC	FLA1	Free living amoebae NOT seen	2012-05-30	2012-05-30				P 	A?m       
FLAC	FLA2	Culture for Balamuthia mandrillaris: No Growth	2012-05-30	2012-05-30				P 	A?m       
FLAP	FLA3	Acanthamoeba spp DNA detected	2012-05-30	2012-05-30				P 	?Am       
FLAC	FLA1	Free living amoebae NOT seen	2012-05-30	2012-05-30				P 	A?m       
FLAC	FLA2	Culture for Balamuthia mandrillaris: No Growth	2012-05-30	2012-05-30				P 	A?m       
FLAP	FLA3	Balamuthia mandrillaris DNA not detected	2012-05-30	2012-05-30				P 	?Am       
FLAC	FLA4	Culture for Naegleria spp: No Growth	2012-05-30	2012-05-30				P 	A?m       
FLAC	FLA5	Culture for Acanthamoeba spp: Growth	2012-05-30	2012-05-30				P 	A?m       
FLAP	FLA6	Naegleria fowleri DNA NOT detected	2012-05-30	2012-05-30				P 	?Am       
FLAP	FLA7	Acanthamoeba spp DNA detected	2012-05-30	2012-05-30				P 	?Am       
INR	INR	4.66	2011-10-05	2011-10-06				A 	/1        
INR	PT	66.0	2011-10-05	2011-10-05	secs	10.0	12.0	A 	/1        
TT	TT	Coagulation sample too old for testing.
Please repeat.	2011-10-06	2011-10-06	secs	9	15	A 	r/1       
INR	INR	4.60	2011-10-11	2011-10-11				A 	/1        
TT	PS10	leave for sue please	2011-10-11	2011-10-11	secs			A 	N/1       
INR	PT	70.0	2011-10-11	2011-10-11	secs	10.0	12.0	A 	/1        
TT	TT	13	2011-10-11	2011-10-11	secs	9	15	A 	r/1       
ALIQ	ALIQ	12	2011-11-04					X 	          
COAG	APRA	1.7	2011-11-04	2011-11-04		2.0	3.0	A 	?/1       
COAG	APTT	55	2011-11-04	2011-11-04	secs	22	41	A 	P/1       
DRVT	DRV1	35.0	2011-11-04		secs			X 	Pr/14     
DRVT	DRV2	16.0	2011-11-04		secs			X 	NP/14     
DRVT	DRV3	1.20	2011-11-04	2011-11-04		0.90	1.20	A 	Pr/14     
DRVT	DRV4	12.0	2011-11-04		secs			X 	PN/14     
DRVT	DRV5	1.30	2011-11-04	2011-11-04		0.9	1.2	A 	NQ/14     
DRVT	DRV6	6.0	2011-11-04		secs			X 	N/14      
DRVT	DRV7	12.0	2011-11-04		secs			X 	NP/14     
DRVT	DRV8	1.30	2011-11-04	2011-11-04				A 	NP/14     
HES	HBA2	25	2011-11-04	2011-11-04	%	2.0	3.4	A 	N         
HESR	HCO1	test sample	2011-11-04	2011-11-04				A 	N?p1      
HES	HCON	.{}	2011-11-04					A 	?p1       
HES	HGBA	70.0	2011-11-04	2011-11-04	%			A 	?         
COAG	INR	1.00	2011-11-02	2011-11-02				A 	/1        
COAG	PT	15.0	2011-11-02	2011-11-02	secs	10.0	12.0	A 	/1        
COAG	TT	12	2011-11-02	2011-11-02	secs	9	15	A 	r/1       
COAG	APRA	>180.0 secs. APTT ratio > 5.7	2011-12-19	2011-12-19	n	2.0	3.0	A 	?/1       
COAG	APTM	not available	2011-12-19	2011-12-19	secs	22	41	A 	N         
HEP	APTR	>180.0 secs. APTT ratio > 5.7	2011-12-19	2011-12-19		2.0	3.0	A 	?/1       
COAG	APTT	>180 secs. APTT ratio > 5.7	2011-12-19	2011-12-19	secs	22	41	A 	P/1       
COAG	INR	1.00	2011-12-19	2011-12-19				A 	/1        
COAG	PT	12.0	2011-12-19	2011-12-19	secs	10.0	12.0	A 	/1        
COAG	TT	12	2011-12-19	2011-12-19	secs	9	15	A 	r/1       
BM	BM	bone marrow unsuitable for staining please repeat
6 slides required.	2011-10-26	2011-10-26				A 	?         
CM1 	CDS	Bone Marrow	2011-10-31	2011-10-31				A 	N?        
CM4 	CMCO	.{}	2011-10-31					A 	N?        
CM4 	CONS	.{}	2011-10-31					A 	N         
CM1 	GATE	.{}	2011-10-31					A 	N         
CM4 	SETU	.{}	2011-10-31					X 	NI        
ACLA	ACLG	5.0	2011-10-19	2011-10-19	GPLU	0	5	A 	A/10      
ACLA	ACLM	5.0	2011-10-19	2011-10-19	MPLU	0	5	A 	/10       
APCM	APCM	5.00	2011-10-19	2011-10-19		>2.0		A 	A/14      
THR1	AT3	1.00	2011-10-19	2011-10-19	IU/ml	0.80	1.30	A 	/14       
B2G	B2GG	5.0	2011-10-19	2011-10-19	GPLU	0	3.5	A 	A/14      
B2G	B2GM	5.0	2011-10-19	2011-10-19	MPLU	0	3	A 	/14       
FIB1	FIB1	4.00	2011-10-19	2011-10-19	g/L			A 	p1/14     
PC7 	FVII	0.40	2011-10-19	2011-10-19	IU/ml	0.5	1.5	A 	/14       
FVL	FVL	G/G Normal	2011-10-19	2011-10-19				A 	/21?H     
PSX 	FX	0.4	2011-10-19	2011-10-19	IU/ml			A 	/14       
THR1	PC	0.80	2011-10-19	2011-10-19	IU/ml	0.7	1.30	A 	P/14      
THR1	PC7R	2.00	2011-10-19	2011-10-19		0.76		A 	Q/14      
THR1	PSF	0.8	2011-10-19	2011-10-19	IU/ml			A 	P/14      
THR1	PSXR	2.00	2011-10-19	2011-10-19				A 	Q/14      
TVT 	TVT1	26.0	2011-10-19		secs			X 	P/14      
TVT 	TVT2	26.0	2011-10-19		secs			X 	P/14      
TVT 	TVT3	1.0	2011-10-19	2011-10-19		0.90	1.10	A 	NPQ/14    
TVT 	TVT4	26.0	2011-10-19		secs			X 	PN/14     
TVT 	TVT5	1.0	2011-10-19	2011-10-19		0.90	1.10	A 	N/14      
TVT 	TVT6	26.0	2011-10-19		secs			X 	PN/14     
TVT 	TVT7	26.0	2011-10-19		secs			X 	PN/14     
TVT 	TVT8	1.0	2011-10-19	2011-10-19				A 	N/14      
ACLA	ACLG	5.0	2011-10-26	2011-10-26	GPLU	0	5	A 	A/10      
ACLA	ACLM	5.0	2011-10-26	2011-10-26	MPLU	0	5	A 	/10       
B2G	B2GG	5.0	2011-10-26	2011-10-26	GPLU	0	3.5	A 	A/14      
B2G	B2GM	5.0	2011-10-26	2011-10-26	MPLU	0	3	A 	/14       
ACLA	ACLG	5.0	2011-10-26	2011-10-26	GPLU	0	5	A 	A/10      
ACLA	ACLM	5.0	2011-10-26	2011-10-26	MPLU	0	5	A 	/10       
B2G	B2GG	5.0	2011-10-26	2011-10-26	GPLU	0	3.5	A 	A/14      
B2G	B2GM	5.0	2011-10-26	2011-10-26	MPLU	0	3	A 	/14       
ACLA	ACLG	6.8Neg	2011-10-28	2011-10-28	GPLU	0	5	A 	A/10      
ACLA	ACLM	4.0Neg	2011-10-28	2011-10-28	MPLU	0	5	A 	/10       
B2G	B2GG	6.9	2011-11-03	2011-11-03	GPLU	0	3.5	A 	A/14      
B2G	B2GM	1.0	2011-11-03	2011-11-03	MPLU	0	3	A 	/14       
ACLA	ACLG	2.9Neg	2011-10-28	2011-10-28	GPLU	0	5	A 	A/10      
ACLA	ACLM	1.2Neg	2011-10-28	2011-10-28	MPLU	0	5	A 	/10       
B2G	B2GG	0.4	2011-11-03	2011-11-03	GPLU	0	3.5	A 	A/14      
B2G	B2GM	1.0	2011-11-03	2011-11-03	MPLU	0	3	A 	/14       
EBVS	EBN1	.{}	2011-10-21					H 	HIr/2     
EBVS	EBNA	.{}	2011-10-21					H 	?/2       
TXGV	TXGV	15.0	2011-10-21	2011-10-21				H 	IN        
TXMV	TXMV	0.30	2011-10-21	2011-10-21				H 	IN        
EBVS	VCA1	.{}	2011-10-21					H 	HIr/2     
EBVS	VCAG	.{}	2011-10-21					H 	?/2       
CMVS	CMGA	12	2011-10-21	2011-10-22				H 	Ir/1      
CMVS	CMGR	.{}	2011-10-21					H 	?/2       
CMGV	CMGV	.{}	2011-10-21					H 	Ir        
CMVS	CMMA	12.0	2011-10-21	2011-10-22				H 	Ir/1      
CMVS	CMMR	.{}	2011-10-21					H 	?/2m      
CMMV	CMMV	.{}	2011-10-21					H 	Ir        
EBVS	EBN1	0.01	2011-10-21	2011-10-22				H 	HIr/2     
EBVS	EBNA	Not Detected	2011-10-21	2011-10-22				H 	?/2       
EBVS	VCA1	10.0	2011-10-21	2011-10-22				H 	HIr/2     
EBVM	VCA2	.{}	2011-10-21					H 	HIr/2     
EBVS	VCAG	Positive	2011-10-21	2011-10-22				H 	?/2       
EBVM	VCAM	.{}	2011-10-21					H 	?/2m      
HBAG	1AG	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
CMVS	1CG	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
ACVL	1EB	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
HCV 	1HC	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
HIV 	1RV	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
HTLV	1TL	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
SYPS	1TP	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
ACVL	2AN	Cancelled - see comments	2011-10-22	2012-01-18				H 	NA?       
ACV2	ACV2	.{}	2011-10-22					H 	?r/2      
HIV 	CHIV	.{}	2011-10-22					H 	N?/2      
CMVS	CMGA	.{}	2011-10-22					H 	Ir/1      
CMVS	CMGR	.{}	2011-10-22					H 	?/2       
CMVS	CMMA	.{}	2011-10-22					H 	Ir/1      
CMVS	CMMR	.{}	2011-10-22					H 	?/2m      
HBC 	HBCA	.{}	2011-10-22					H 	HIr/1     
HBVZ	HBCC	.{}	2011-10-22					H 	Nr?/2     
HBC 	HBCO	Y	2011-10-22	2012-01-18				H 	NIr?      
HBC 	HBCR	.{}	2012-01-18					H 	?r/2      
HBAG	HBVA	.{}	2011-10-22					H 	HIr/1     
HBAG	HBVR	.{}	2012-01-18					H 	?r/2m     
HCV 	HCVA	.{}	2011-10-22					H 	Ir/1      
HCV 	HCVR	.{}	2011-10-22					H 	?/2m      
HIV 	HIVA	.{}	2011-10-22					H 	Ir/1      
HIV 	HIVR	.{}	2011-10-22					H 	?/2       
SYPS	SYPA	.{}	2011-10-22					H 	?Ir/1     
SYPS	SYPR	.{}	2011-10-22					H 	?r/2m     
HTLV	TLVA	.{}	2011-10-22					H 	Ir/1      
HTLV	TLVR	.{}	2011-10-22					H 	?/2m      
TXG 	TOXG	.{}	2011-10-22					H 	?/2       
SYPS	TPCO	Y	2011-10-22	2012-01-18				H 	IN?       
TXG 	TXGA	.{}	2011-10-22					H 	Ir/1      
ACVL	VCA1	.{}	2011-10-22					H 	HIr/2     
ACVL	VCAG	.{}	2011-10-22					H 	?/2       
VZVA	VZVA	.{}	2011-10-22					H 	HI        
VZVR	VZVR	.{}	2011-10-22					H 	?         
AHBC	AHBC	.{}	2011-10-24						
AHCV	AHCV	.{}	2011-10-24					H 	r/14      
CMGA	CMGA	.{}	2011-10-24					H 	Ir/1      
CMGR	CMGR	.{}	2011-10-24					H 	?/2       
HBCA	HBCA	.{}	2011-10-24					H 	HIr/1     
HBCR	HBCR	.{}	2011-10-24					H 	?r/2      
HBVA	HBVA	.{}	2011-10-24					H 	HIr/1     
HBVR	HBVR	.{}	2011-10-24					H 	?r/2m     
HCVA	HCVA	.{}	2011-10-24					H 	Ir/1      
HCVR	HCVR	.{}	2011-10-24					H 	?/2m      
HIVA	HIVA	.{}	2011-10-24					H 	Ir/1      
HIVR	HIVR	.{}	2011-10-24					H 	?/2       
SYPA	SYPA	.{}	2011-10-24					H 	?Ir/1     
SYPR	SYPR	.{}	2011-10-24					H 	?r/2m     
TLVA	TLVA	.{}	2011-10-24					H 	Ir/1      
TLVR	TLVR	.{}	2011-10-24					H 	?/2m      
TOXG	TOXG	.{}	2011-10-24					H 	?/2       
TXGA	TXGA	.{}	2011-10-24					H 	Ir/1      
ANDT	AND1	.{}	2011-10-24					H 	IT        
CMGA	CMGA	.{}	2011-10-24					H 	Ir/1      
CMGR	CMGR	.{}	2011-10-24					H 	?/2       
HBCA	HBCA	.{}	2011-10-24					H 	HIr/1     
HBCR	HBCR	.{}	2011-10-24					H 	?r/2      
HBVA	HBVA	.{}	2011-10-24					H 	HIr/1     
HBVR	HBVR	.{}	2011-10-24					H 	?r/2m     
HCVA	HCVA	.{}	2011-10-24					H 	Ir/1      
HCVR	HCVR	.{}	2011-10-24					H 	?/2m      
HIVA	HIVA	.{}	2011-10-24					H 	Ir/1      
HIVR	HIVR	.{}	2011-10-24					H 	?/2       
SYPA	SYPA	.{}	2011-10-24					H 	?Ir/1     
SYPR	SYPR	.{}	2011-10-24					H 	?r/2m     
TLVA	TLVA	.{}	2011-10-24					H 	Ir/1      
TLVR	TLVR	.{}	2011-10-24					H 	?/2m      
TOXG	TOXG	.{}	2011-10-24					H 	?/2       
TXGA	TXGA	.{}	2011-10-24					H 	Ir/1      
ACV1	ACV1	.{0}	2011-10-25					H 	?H/2m     
ACV2	ACV2	Not detected	2011-10-24	2011-10-25				H 	?r/2      
CMGA	CMGA	0	2011-10-24	2011-10-25				H 	Ir/1      
CMGR	CMGR	Not Detected	2011-10-24	2011-10-25				H 	?/2       
HBCA	HBCA	.{ 5.000 }	2011-10-24					H 	HIr/1     
HBCR	HBCR	Not Detected	2011-10-24	2011-10-25				H 	?r/2      
HBVA	HBVA	.{ 0.010 }	2011-10-24					H 	HIr/1     
HBVR	HBVR	Not Detected	2011-10-24	2011-10-25				H 	?r/2m     
HCVA	HCVA	0.010	2011-10-24	2011-10-25				H 	Ir/1      
HCVR	HCVR	Not Detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV
infection, please contact us to discuss further
testing of this sample.	2011-10-24	2011-10-25				H 	?/2m      
HIVA	HIVA	0.010	2011-10-24	2011-10-25				H 	Ir/1      
HIVR	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2011-10-24	2011-10-25				H 	?/2       
SYPA	SYPA	0.010	2011-10-24	2011-10-25				H 	?Ir/1     
SYPR	SYPR	Negative	2011-10-24	2011-10-25				H 	?r/2m     
TLVA	TLVA	0.010	2011-10-24	2011-10-25				H 	Ir/1      
TLVR	TLVR	Not Detected
No evidence of infection.	2011-10-24	2011-10-25				H 	?/2m      
TOXG	TOXG	Not Detected	2011-10-24	2011-10-25				H 	?/2       
TXGA	TXGA	0.01	2011-10-24	2011-10-25				H 	Ir/1      
VCA1	VCA1	0.01	2011-10-24	2011-10-25				H 	HIr/2     
VCAG	VCAG	Not Detected	2011-10-24	2011-10-25				H 	?/2       
VZVA	VZVA	5.00	2011-10-24	2011-10-25				H 	HI        
VZVR	VZVR	Positive	2011-10-24	2011-10-25				H 	?         
RHTL	18RD	.{}	2011-10-26					H 	NI        
RHTL	18SE	.{}	2011-10-26					H 	I/4       
ACVT	ACV1	.{}	2011-10-26					H 	?H/2m     
ACVT	ACV2	.{}	2011-10-26					H 	?r/2      
HBSS	BCMA	.{}	2011-10-26					H 	HIr/2     
HBSS	BCMR	.{}	2012-01-17					H 	?/2m      
HIV 	CHIV	.{}	2011-10-26					H 	N?/2      
CMGA	CMGA	.{}	2011-10-26					H 	Ir/1      
CMGR	CMGR	.{}	2011-10-26					H 	?/2       
COSC	COSC	HBVR/HCVR/HCVR/TLVR/	2011-12-07					X 	N         
COSD	COSD	Organisms sent 07/12/2011 14:17	2011-12-07					X 	N         
HCVL	CVL1	.{}	2011-10-26		IU/ml			H 	Hr?/5     
HCVL	CVL2	.{}	2011-10-26					H 	?r/5m     
HBSS	EABA	.{}	2011-10-26					H 	HIr/2     
HBSS	EABR	.{}	2012-01-17					H 	?r/2      
HBSS	EAGA	.{}	2011-10-26					H 	HIr/2     
HBSS	EAGR	.{}	2012-01-17					H 	?/2       
HBC	HBCA	.{ 0.010 }	2011-10-24					H 	HIr/1     
HBVZ	HBCC	.{}	2011-10-26					H 	Nr?/2     
HBC	HBCO	Y	2011-10-26					H 	NIr?      
HBC	HBCR	Positive	2011-10-24	2011-10-25				H 	?r/2      
HBAG	HBVA	.{ 44.000 }	2011-10-24					H 	HIr/1     
HBAG	HBVR	Positive	2011-10-24	2011-10-25				H 	?r/2m     
HBVV	HBVV	.{}	2011-10-26					H 	HI        
HCVA	HCVA	5.000	2011-10-24	2011-10-25				H 	Ir/1      
HCVR	HCVR	Positive
HCV PCR result to follow.	2011-10-24	2011-10-25				H 	?/2m      
HIV 	HIVA	55.000	2011-10-24	2011-10-25				H 	Ir/1      
HIVS	HIVI	.{}	2011-10-26					H 	IN?/2     
HIV 	HIVR	.{}	2011-10-26					H 	?/2       
HIVS	HIVV	.{}	2011-10-26					H 	Ir/2      
SSYP	RPR	.{ .{} }	2012-01-24					H 	?Hr/2m    
SYPS	SYPA	50.000	2011-10-24	2011-10-25				H 	?Ir/1     
SYPS	SYPR	Positive	2011-10-26					H 	?r/2m     
RHTL	TL1	.{}	2011-10-26					H 	r?        
RHTL	TLRA	.{}	2011-10-26					H 	A/21m     
RHTL	TLRP	.{}	2011-10-26					H 	?/21      
TLVA	TLVA	55.000	2011-10-24	2011-10-25				H 	Ir/1      
TLVR	TLVR	REACTIVE
Sent to Reference Laboratory.	2011-10-24	2011-10-25				H 	?/2m      
TOXG	TOXG	Positive	2011-10-24	2011-10-25				H 	?/2       
SYPZ	TPC	.{}	2011-10-26					H 	?/2       
SYPS	TPCO	Y	2011-10-26					H 	IN?       
SSYP	TPPA	.{ .{} }	2012-01-24					H 	?Hr/2m    
TXGA	TXGA	25	2011-10-24	2011-10-25				H 	Ir/1      
ACVT	VCA1	5.00	2011-10-24	2011-10-25				H 	HIr/2     
ACVT	VCAG	Positive	2011-10-24	2011-10-25				H 	?/2       
ACVT	VZVA	5.0	2011-10-24	2011-10-25				H 	HI        
ACVT	VZVR	Positive	2011-10-24	2011-10-25				H 	?         
RINC	9RDR	01/11/2011	2011-11-01	2011-11-02				H 	HI?       
RINC	9SER	10/10/2011	2011-11-01	2011-11-02				H 	HI/4?     
RINC	RIN1	HIV INCIDENCE TEST RESULT NOT CONSISTENT WITH
RECENTLY ACQUIRED HIV INFECTION.
These findings indicate that seroconversion
probably did not occur within the 5-6 months prior
to sample date.  However, these findings should be
interpreted with due regard to clinical and HIV
risk information.	2011-11-01	2011-11-02				H 	H?A/14    
RINC	RIN3	hpa colindale	2011-11-01	2011-11-02				H 	r?        
RINC	RINA	100	2011-11-01	2011-11-02				H 	HI        
UNC 	ADVR	.{}	2011-11-07					H 	HI/1      
HBCC	HBCC	.{}	2011-11-07					H 	Nr?/2     
HBVQ	HBQC	.{No Comment}	2011-11-07					H 	?Nr/2     
HBVQ	HBQR	100	2011-11-07	2011-11-07	IU/ml			H 	H/2       
MISM	FSDM	A sample has been received with a request form
labelled with a different patients details.
A REPEAT FORM AND SAMPLE FROM BOTH PATIENTS IS
RECOMMENDED.  The sample has not been processed
but has been saved in Virology.
The patient details on the form were:	2011-11-08	2011-11-08				H 	H?        
MISM	NFRM	.{Not Tested}	2011-11-08					H 	H?        
MISM	NSMP	.{Not Tested}	2011-11-08					H 	H?        
MISM	PATD	87654321 Thaddeus Jones	2011-11-08	2011-11-08				H 	E         
MISM	TREQ	.{Not Tested}	2011-11-08					H 	E         
ALPH	ALPH	tested	2011-11-09	2011-11-09				H 	H/21      
RCAM	CAM1	12/12/20911	2011-11-09					H 	Ir/4      
RCAM	CAM2	12/12/2019	2011-11-09					H 	I/10      
CXI	CX1G	.{}	2011-11-09					H 	?Ar/14    
CXI	CX2G	.{}	2011-11-09					H 	?r/14     
CXI	CX2M	.{}	2011-11-09					H 	?Br/14    
CXI	CXIR	Special Pathogens Reference Unit, Porton Down.	2011-11-09	2011-11-09				H 	r?        
CXI	CXIS	.{}	2011-11-09					H 	I/4       
CXI	CXIT	.{}	2011-11-09					H 	I/10      
DENG	DENG	tested	2011-11-09	2011-11-09				H 	H?/21     
FLAV	FLAV	tested	2011-11-09	2011-11-09				H 	H?A/21    
HANT	HANT	tested	2011-11-09	2011-11-09				H 	H?/21     
HEAB	HEAB	positive	2011-11-09	2011-11-09				H 	A?        
HEAB	HELB	whoever does it	2011-11-09	2011-11-09				H 	r         
HEAB	HELC	01012012	2011-11-09	2011-11-09				H 	HI        
HEAB	HELD	02012012	2011-11-09	2011-11-09				H 	HI        
PHLE	PHLE	tested	2011-11-09	2011-11-09				H 	H?/21     
RCAM	RCA1	Special Pathogens Reference Unit, Porton Down.	2011-11-09	2011-11-09				H 	r?/21     
RICK	RICO	.{}	2011-11-09					H 	?A        
RICK	RICR	Special Pathogens Reference Unit, Porton Down.	2011-11-09	2011-11-09				H 	r?        
RICK	RICS	12/12/2011	2011-11-09	2011-11-09				H 	HI/4?     
RICK	RICT	132/12/2011	2011-11-09	2011-11-09				H 	HI/10?    
RICK	RIEG	.{}	2011-11-09					H 	?/21m     
RICK	RIEM	.{}	2011-11-09					H 	?/21m     
RICK	RISG	.{}	2011-11-09					H 	?/21m     
RICK	RISM	.{}	2011-11-09					H 	?/21m     
HBCC	HBCC	If the patient was NOT previously immunised
against hepatitis B then the anti-HBs reactivity
is of doubtful significance and immunisation
may be appropriate.
~
If the patient was immunised previously, then a
vaccine booster should be considered.
See chapter 18 in the DH publication -
"Immunisation against infectious disease" 2006.	2011-11-09	2011-11-09				H 	Nr?/2     
HBS	HBCO	Y	2011-11-09	2011-11-09				H 	NIr?      
HBS	HBSA	.{ 66.00 }	2011-11-09					H 	HIr/1     
HBS	HBSI	Weak Reactive	2011-11-09	2011-11-09				H 	r?/2      
HBS	HBSR	66	2011-11-09	2011-11-09	IU/l			H 	?r/2      
RICK	RICO	.{}	2011-11-09					H 	?A        
RICK	RICR	Special Pathogens Reference Unit, Porton Down.	2011-11-09	2011-11-09				H 	r?        
RICK	RICS	.{}	2011-11-09					H 	HI/4?     
RICK	RICT	.{}	2011-11-09					H 	HI/10?    
RICK	RIEG	.{}	2011-11-09					H 	?/21m     
RICK	RIEM	.{}	2011-11-09					H 	?/21m     
RICK	RISG	.{}	2011-11-09					H 	?/21m     
RICK	RISM	.{}	2011-11-09					H 	?/21m     
ALPH	ALPH	.{}	2011-11-11					H 	H/21      
RCAM	CAM1	.{}	2011-11-09					H 	Ir/4      
RCAM	CAM2	.{}	2011-11-09					H 	I/10      
CXI	CX1G	.{}	2011-11-11					H 	?Ar/14    
CXI	CX2G	.{}	2011-11-11					H 	?r/14     
CXI	CX2M	.{}	2011-11-11					H 	?Br/14    
CXI	CXIR	.{}	2011-11-18					H 	r?        
CXI	CXIS	09/11/2011	2011-11-09	2011-11-10				H 	I/4       
CXI	CXIT	.{}	2011-11-11					H 	I/10      
DENG	DENG	.{}	2011-11-11					H 	H?/21     
FLAV	FLAV	.{}	2011-11-11					H 	H?A/21    
HANT	HANT	.{}	2011-11-11					H 	H?/21     
HBCC	HBCC	.{}	2011-11-11					H 	Nr?/2     
HBS	HBCO	Y	2011-11-09	2011-11-10				H 	NIr?      
HBS	HBSA	.{ 2.00 }	2011-11-09					H 	HIr/1     
HBS	HBSI	Not Detected	2011-11-11	2011-11-12				H 	r?/2      
HBS	HBSR	<10	2011-11-11	2011-11-12	IU/l			H 	?r/2      
PHLE	PHLE	.{}	2011-11-11					H 	H?/21     
RCAM	RCA1	.{}	2011-11-18					H 	r?/21     
RICK	RICO	.{}	2011-11-11					H 	?A        
RICK	RICR	.{}	2011-11-18					H 	r?        
RICK	RICS	.{}	2011-11-09					H 	HI/4?     
RICK	RICT	.{}	2011-11-09					H 	HI/10?    
RICK	RIEG	.{}	2011-11-11					H 	?/21m     
RICK	RIEM	.{}	2011-11-11					H 	?/21m     
RICK	RISG	.{}	2011-11-11					H 	?/21m     
RICK	RISM	.{}	2011-11-11					H 	?/21m     
ALPH	ALPH	.{}	2011-11-25					H 	H/21      
RCAM	CAM1	.{}	2011-11-25					H 	Ir/4      
RCAM	CAM2	.{}	2011-11-25					H 	I/10      
DENG	DENG	.{}	2011-11-25					H 	H?/21     
FLAV	FLAV	.{}	2011-11-25					H 	H?A/21    
HANT	HANT	.{}	2011-11-25					H 	H?/21     
HBCC	HBCC	Immune to Hepatitis B.	2011-11-09	2011-11-10				H 	Nr?/2     
HBS	HBCO	Y	2011-11-09	2011-11-10				H 	NIr?      
HBS	HBSA	.{ 200.00 }	2011-11-09					H 	HIr/1     
HBS	HBSI	Positive	2011-11-10	2011-11-10				H 	r?/2      
HBS	HBSR	>100	2011-11-10	2011-11-10	IU/l			H 	?r/2      
PHLE	PHLE	.{}	2011-11-25					H 	H?/21     
RCAM	RCA1	.{}	2011-11-25					H 	r?/21     
CXI	CX1A	NOT detected	2011-11-14	2011-11-14				H 	?r/14     
CXI	CX1G	.{}	2011-11-14					H 	?Ar/14    
CXI	CX2G	.{}	2011-11-14					H 	?r/14     
CXI	CX2M	.{}	2011-11-14					H 	?Br/14    
CXI	CXIR	.{}	2011-11-14					H 	r?        
CXI	CXIS	.{}	2011-11-14					H 	I/4       
CXI	CXIT	.{}	2011-11-14					H 	I/10      
RICK	OTSG	.{}	2011-11-14					H 	?/21m     
RICK	OTSM	.{}	2011-11-14					H 	?/21m     
RICK	RICO	.{}	2011-11-14					H 	?A        
RICK	RICR	.{}	2011-11-14					H 	r?        
RICK	RICS	.{}	2011-11-14					H 	HI/4?     
RICK	RICT	.{}	2011-11-14					H 	HI/10?    
RICK	RIEG	.{}	2011-11-14					H 	?/21m     
RICK	RIEM	.{}	2011-11-14					H 	?/21m     
RICK	RISG	.{}	2011-11-14					H 	?/21m     
RICK	RISM	.{}	2011-11-14					H 	?/21m     
MYAB	MANA	Not tested	2011-11-28	2011-11-28				I 	?         
MYAB	MJO1	1	2011-11-28	2011-11-28				I 	?         
MYAB	MMI2	Equivocal	2011-11-28	2011-11-28				I 	?         
MYAB	MSRB	Positive	2011-11-28	2011-11-28				I 	?         
MYAB	MYAC	Please discuss with laboratory	2011-11-28	2011-11-28				I 	N         
MYAB	MYAR	Royal Free Hospital	2011-11-28	2011-11-28				I 	?r        
MYAB	MYKU	Negative	2011-11-28	2011-11-28				I 	?         
RICK	OTSG	NOT Detected	2011-11-14	2011-11-14				H 	?/21m     
RICK	OTSM	NOT Detected	2011-11-14	2011-11-14				H 	?/21m     
MYAB	PL12	3	2011-11-28	2011-11-28				I 	?         
MYAB	PL7	2	2011-11-28	2011-11-28				I 	?         
MYAB	PMSC	Not tested	2011-11-28	2011-11-28				I 	?         
RICK	RICO	Results of uncertain significance.	2011-11-14	2011-11-14				H 	?A        
RICK	RICR	Mycology Reference Centre,
Leeds Teaching Hospitals NHS Trust,
LS1 3EX	2011-11-14	2011-11-14				H 	r?        
RICK	RICS	.{}	2011-11-14					H 	HI/4?     
RICK	RICT	.{}	2011-11-14					H 	HI/10?    
RICK	RIEG	NOT detected	2011-11-14	2011-11-14				H 	?/21m     
RICK	RIEM	NOT detected	2011-11-14	2011-11-14				H 	?/21m     
RICK	RISG	NOT detected	2011-11-14	2011-11-14				H 	?/21m     
RICK	RISM	NOT detected	2011-11-14	2011-11-14				H 	?/21m     
ALPH	ALCG	.{}	2011-11-17					H 	N?m       
ALPH	ALCM	.{}	2011-11-17					H 	N?m       
ALPH	ALPH	.{}	2011-11-17					H 	H/21      
ALPH	ALSV	.{}	2011-11-17					H 	N?m       
RCAM	CAM1	.{}	2011-11-17					H 	Ir/4      
RCAM	CAM2	.{}	2011-11-17					H 	I/10      
CXI	CX1A	.{}	2011-11-17					H 	?r/14     
CXI	CX1G	.{}	2011-11-17					H 	?Ar/14    
CXI	CX2G	.{}	2011-11-17					H 	?r/14     
CXI	CX2M	.{}	2011-11-17					H 	?Br/14    
CXI	CXIR	.{}	2011-11-17					H 	r?        
CXI	CXIS	.{}	2011-11-17					H 	I/4       
CXI	CXIT	.{}	2011-11-17					H 	I/10      
DENG	DENG	.{}	2011-11-17					H 	H?/21     
FLAV	DPCR	.{}	2011-11-17					H 	N?m       
FLAV	FLAV	.{}	2011-11-17					H 	H?A/21    
FLAV	FLDG	.{}	2011-11-17					H 	N?m       
FLAV	FLDM	.{}	2011-11-17					H 	N?m       
FLAV	FLJM	.{}	2011-11-17					H 	N?m       
FLAV	FLKG	.{}	2011-11-17					H 	N?m       
FLAV	FLTE	.{}	2011-11-17					H 	N?m       
FLAV	FLWG	.{}	2011-11-17					H 	N?m       
FLAV	FLWM	.{}	2011-11-17					H 	N?m       
HANT	HANT	.{}	2011-11-17					H 	H?/21     
RICK	OTSG	.{}	2011-11-17					H 	?/21m     
RICK	OTSM	.{}	2011-11-17					H 	?/21m     
PHLE	PHLE	.{}	2011-11-17					H 	H?/21     
RCAM	RCA1	.{}	2011-11-17					H 	r?/21     
RICK	RICO	.{}	2011-11-17					H 	?A        
RICK	RICR	.{}	2011-11-17					H 	r?        
RICK	RICS	.{}	2011-11-17					H 	HI/4?     
RICK	RICT	.{}	2011-11-17					H 	HI/10?    
RICK	RIEG	.{}	2011-11-17					H 	?/21m     
RICK	RIEM	.{}	2011-11-17					H 	?/21m     
RICK	RISG	.{}	2011-11-17					H 	?/21m     
RICK	RISM	.{}	2011-11-17					H 	?/21m     
ALPH	ALPH	.{}	2011-11-15					H 	H/21      
RCAM	CAM1	.{}	2011-11-15					H 	Ir/4      
RCAM	CAM2	.{}	2011-11-15					H 	I/10      
DENG	DENG	.{}	2011-11-15					H 	H?/21     
FLAV	FLAV	.{}	2011-11-15					H 	H?A/21    
HANT	HANT	.{}	2011-11-15					H 	H?/21     
PHLE	PHLE	.{}	2011-11-15					H 	H?/21     
RCAM	RCA1	.{}	2011-11-15					H 	r?/21     
ALPH	ALPH	.{}	2011-11-15					H 	H/21      
RCAM	CAM1	.{}	2011-11-15					H 	Ir/4      
RCAM	CAM2	.{}	2011-11-15					H 	I/10      
DENG	DENG	.{}	2011-11-15					H 	H?/21     
FLAV	FLAV	.{}	2011-11-15					H 	H?A/21    
HANT	HANT	.{}	2011-11-15					H 	H?/21     
PHLE	PHLE	.{}	2011-11-15					H 	H?/21     
RCAM	RCA1	.{}	2011-11-15					H 	r?/21     
ALPH	ALCG	Not Detected	2011-11-15	2011-11-15				H 	N?m       
ALPH	ALCM	Not Detected	2011-11-15	2011-11-15				H 	N?m       
ALPH	ALPH	.{}	2011-11-15					H 	H/21      
ALPH	ALSM	Evidence of previous exposure to sindbis virus	2011-11-15	2011-11-15				H 	N?        
ALPH	ALSV	Positive	2011-11-15	2011-11-15				H 	N?m       
RCAM	CAM1	12.11.2011	2011-11-15					H 	Ir/4      
RCAM	CAM2	15.11.2011	2011-11-15					H 	I/10      
DENG	DENG	.{}	2011-11-15					H 	H?/21     
FLAV	DPCR	Not Detected	2011-11-15	2011-11-15				H 	N?m       
FLAV	FLAV	.{}	2011-11-15					H 	H?A/21    
FLAV	FLDG	Not Detected	2011-11-15	2011-11-15				H 	N?m       
FLAV	FLDM	Not Detected	2011-11-15	2011-11-15				H 	N?m       
FLAV	FLJM	Not Detected	2011-11-15	2011-11-15				H 	N?m       
FLAV	FLKG	.{Not Tested}	2011-11-15					H 	N?m       
FLAV	FLTE	.{Not Tested}	2011-11-15					H 	N?m       
FLAV	FLWG	Positive	2011-11-15	2011-11-15				H 	N?m       
FLAV	FLWM	Not Detected	2011-11-15	2011-11-15				H 	N?m       
HANT	HANT	.{}	2011-11-15					H 	H?/21     
PHLE	PHLE	.{}	2011-11-15					H 	H?/21     
PHLE	PHSC	Not Tested	2011-11-15	2011-11-15				H 	N?m       
PHLE	PHSM	No evidenc of acute infection or previous exposure
to phleboviruses	2011-11-15	2011-11-15				H 	N         
PHLE	PHSN	Positive	2011-11-15	2011-11-15				H 	N?m       
PHLE	PHSS	Not Detected	2011-11-15	2011-11-15				H 	N?m       
PHLE	PHST	Not Detected	2011-11-15	2011-11-15				H 	N?m       
RCAM	RCA1	Rare & Imported Pathogens Laboratory,
Porton Down, Wilts. SP4 0JG.	2011-11-15	2011-11-15				H 	r?/21     
CXI	CX1A	Negative	2011-12-01	2011-12-01				H 	?r/14     
CXI	CX1G	Negative	2011-12-01	2011-12-01				H 	?Ar/14    
CXI	CX2G	Negative	2011-12-01	2011-12-01				H 	?r/14     
CXI	CX2M	Negative	2011-12-01	2011-12-01				H 	?Br/14    
CXI	CXCM	C burnetti PCR results are based upon a
developmental assay. Full characterisation and
validation of this assay is on-going.	2011-12-01	2011-12-01				H 	N?        
CXI	CXIR	Health Protection Agency,
61 Colindale Avenue, NW9 5HT.	2011-12-01	2011-12-01				H 	r?        
CXI	CXIS	10/11/2011	2011-12-01	2011-12-01				H 	I/4       
CXI	CXIT	01/12/2011	2011-12-01	2011-12-01				H 	I/10      
CXI	CXPC	Negative	2011-12-01	2011-12-01				H 	N/14      
FLAV	DPCR	.{}	2011-12-01					H 	N?m       
FLAV	FJMM	.{}	2011-12-01					H 	N?m       
FLAV	FLDG	.{}	2011-12-01					H 	N?m       
FLAV	FLDM	.{}	2011-12-01					H 	N?m       
FLAV	FLJG	.{}	2011-12-01					H 	N?m       
FLAV	FLJM	.{}	2011-12-01					H 	N?m       
FLAV	FLKG	.{}	2011-12-01					H 	N?m       
FLAV	FLTE	.{}	2011-12-01					H 	N?m       
FLAV	FLWG	.{}	2011-12-01					H 	N?m       
FLAV	FLWM	.{}	2011-12-01					H 	N?m       
FLAV	FLWR	.{}	2011-12-01					H 	N?m       
FLAV	FLYG	.{}	2011-12-01					H 	N?m       
AREN	ARLG	.{}	2011-12-01					H 	N?        
AREN	ARLM	.{}	2011-12-01					H 	N?        
AREN	ARLP	.{}	2011-12-01					H 	N?        
AREN	MVG	.{}	2011-12-01					H 	N?        
PHLE	PHSC	.{}	2011-12-01					H 	N?m       
PHLE	PHSN	.{}	2011-12-01					H 	N?m       
PHLE	PHSS	.{}	2011-12-01					H 	N?m       
PHLE	PHST	.{}	2011-12-01					H 	N?m       
AREN	ARLG	.{}	2011-12-01					H 	N?        
AREN	ARLM	.{}	2011-12-01					H 	N?        
AREN	ARLP	.{}	2011-12-01					H 	N?        
AREN	MVG	.{}	2011-12-01					H 	N?        
PHLE	PHSC	.{}	2011-12-01					H 	N?m       
PHLE	PHSN	.{}	2011-12-01					H 	N?m       
PHLE	PHSS	.{}	2011-12-01					H 	N?m       
PHLE	PHST	.{}	2011-12-01					H 	N?m       
PHLE	RVFG	.{}	2011-12-01					H 	N?m       
TOXO	TOXG	Not Detected	2011-12-02	2011-12-02				H 	?/2       
TOXO	TOXM	Not Detected	2011-12-02	2011-12-02				H 	?/2m      
TOXO	TXGA	0.04	2011-12-02	2011-12-02				H 	Ir/1      
TOXO	TXMA	0.04	2011-12-02	2011-12-02				H 	Ir/1      
TOXO	TXPC	No serological evidence of toxoplasma infection.
The patient is susceptible to toxoplasma.
Pregnant and immunosuppressed patients should be
advised of the appropriate precautions to avoid
infections.	2011-12-02	2011-12-02				H 	Nr?       
TOXO	TOXG	Not Detected	2011-12-02	2011-12-02				H 	?/2       
TOXO	TOXM	Not Detected	2011-12-02	2011-12-02				H 	?/2m      
TOXO	TXGA	0.2	2011-12-02	2011-12-02				H 	Ir/1      
TOXO	TXMA	0.2	2011-12-02	2011-12-02				H 	Ir/1      
TOXO	TXPC	No serological evidence of toxoplasma infection.
The patient is susceptible to toxoplasma.
Pregnant and immunosuppressed patients should be
advised of the appropriate precautions to avoid
infections.	2011-12-02	2011-12-02				H 	Nr?       
HIV	1RV	Cancelled - see comments	2011-12-20	2011-12-21				H 	NA?       
HIV	CHIV	Request entered in error	2011-12-20	2011-12-21				H 	N?/2      
HIV	HIVA	Cancelled - see comments	2011-12-21	2011-12-21				H 	Ir/1      
HIV	HIVR	Cancelled - see comments	2011-12-21	2011-12-21				H 	?/2       
RICK	OTSG	.{}	2012-01-10					H 	?/21m     
RICK	OTSM	.{}	2012-01-10					H 	?/21m     
RICK	RICO	.{}	2012-01-10					H 	?A        
RICK	RICR	.{}	2012-01-10					H 	r?        
RICK	RICS	.{}	2012-01-10					H 	HI/4?     
RICK	RICT	.{}	2012-01-10					H 	HI/10?    
RICK	RIDN	.{}	2012-01-10					H 	?/21m     
RICK	RIEG	.{}	2012-01-10					H 	?/21m     
RICK	RIEM	.{}	2012-01-10					H 	?/21m     
RICK	RISG	.{}	2012-01-10					H 	?/21m     
RICK	RISM	.{}	2012-01-10					H 	?/21m     
RPAP	13RD	.{}	2012-02-08					H 	I         
RPAP	13SE	.{}	2012-02-08					H 	I/4       
RPAP	1RPP	Cancelled - see comments	2012-02-08	2012-02-08				H 	NA?       
RPAP	RPA1	.{}	2012-02-08					H 	N         
RPAP	RPA2	.{}	2012-02-08					H 	N         
RPAP	RPA3	.{}	2012-02-08					H 	r?        
RPAP	13RD	22/02/2012	2012-02-08	2012-02-08				H 	I         
RPAP	13SE	12/02/2012	2012-02-08	2012-02-08				H 	I/4       
RPAP	ABBK	Positive	2012-02-08	2012-02-08				H 	/14       
RPAP	ABJC	Not Detected	2012-02-08	2012-02-08				H 	/14       
RPAP	PCBK	REACTIVE	2012-02-08	2012-02-08				H 	/14       
RPAP	PCJC	Not Detected	2012-02-08	2012-02-08				H 	/14       
RPAP	RPA3	Health Protection Agency,
61 Colindale Avenue, NW9 5HT.	2012-02-08	2012-02-08				H 	r?        
HAVM	2HA	Cancelled - see comments	2012-02-09	2012-02-09				H 	NA?       
COSC	COSC	HAMR/HBSR/	2012-02-13					X 	N         
COSD	COSD	Organisms sent 13/02/2012 18:16	2012-02-13					X 	N         
HAVS	HAGA	200.00	2012-02-09	2012-02-09				H 	Ir/1      
HAVS	HAGR	Positive	2012-02-09	2012-02-09				H 	?/2       
HAVM	HAMA	6.000	2012-02-09	2012-02-09				H 	Ir/1      
HAVM	HAMR	POSITIVE	2012-02-09	2012-02-09				H 	?/1m      
HAVS	HAVC	test patient	2012-02-09	2012-02-09				H 	N?        
HBC 	HBCA	.{ 0.660 }	2012-02-11					H 	HIr/1     
HBCC	HBCC	Weakly reactive anti-HBc is of doubtful clinical
significance.  Consider as susceptible to
hepatitis B and immunise if indicated.	2012-02-11	2012-02-11				H 	Nr?/2     
HBS 	HBCO	Y	2012-02-11	2012-02-11				H 	NIr?      
HBC 	HBCR	Weak Reactive	2012-02-11	2012-02-11				H 	?r/2      
HBS 	HBSA	.{ 4.00 }	2012-02-11					H 	HIr/1     
HBS 	HBSI	Not Detected	2012-02-11	2012-02-11				H 	r?/2      
HBS 	HBSR	<10	2012-02-11	2012-02-11	IU/l			H 	?r/2      
HBAG	HBVA	.{ 0.010 }	2012-02-11					H 	HIr/1     
HBAG	HBVR	Not Detected	2012-02-11	2012-02-11				H 	?r/2m     
HBAG	HBCO	Y	2012-02-11	2012-02-11				H 	NIr?      
HBAG	HBVA	.{ 0.010 }	2012-02-11					H 	HIr/1     
HBAG	HBVR	Not Detected	2012-02-11	2012-02-11				H 	?r/2m     
HBC	HBCA	.{ 0.010 }	2012-02-11					H 	HIr/1     
HBC	HBCO	Y	2012-02-11	2012-02-11				H 	NIr?      
HBC	HBCR	Positive	2012-02-11	2012-02-11				H 	?r/2      
COSC	COSC	HBSR/	2012-02-13					X 	N         
COSD	COSD	Organisms sent 13/02/2012 18:16	2012-02-13					X 	N         
HBCC	HBCC	.{No Comment}	2012-02-11					H 	Nr?/2     
HBS	HBCO	Y	2012-02-11	2012-02-11				H 	NIr?      
HBS	HBSA	.{ 3.00 }	2012-02-11					H 	HIr/1     
HBS	HBSI	Not Detected	2012-02-11	2012-02-11				H 	r?/2      
HBS	HBSR	<10	2012-02-11	2012-02-11	IU/l			H 	?r/2      
CMMA	CMMA	.{}	2012-03-13					H 	Ir/1      
NHDS	CMMR	.{}	2012-03-13					H 	?/2m      
NHDS	EBN1	.{}	2012-03-13					H 	HIr/2     
NHDS	EBNA	.{}	2012-03-13					H 	?/2       
NHDS	HAMA	.{}	2012-03-13					H 	Ir/1      
NHDS	HAMR	.{}	2012-03-13					H 	?/1m      
NBBV	HBVR	.{}	2012-03-13					H 	?r/2m     
NBBV	HBVV	.{}	2012-03-13					H 	HI        
NBBV	HCVR	.{}	2012-03-13					H 	?/2m      
NBBV	HCVV	.{}	2012-03-13					H 	I/3       
HIVC	HIVC	.{}	2012-03-13						
NBBV	HIVR	.{}	2012-03-13					H 	?/2       
NBBV	HIVV	.{}	2012-03-13					H 	Ir/2      
NEXS	NASO	.{}	2012-03-13					H 	H?        
PARG	PARG	.{}	2012-03-13		umol/L	330	126	D 	N         
NBBV	RNEQ	.{}	2012-03-13					H 	I/5       
NEXS	RUMR	.{}	2012-03-13					H 	?/2m      
NEXS	RUMV	.{}	2012-03-13					H 	HIr       
NHDS	VCA1	.{}	2012-03-13					H 	HIr/2     
NHDS	VCA2	.{}	2012-03-13					H 	HIr/2     
NHDS	VCAG	.{}	2012-03-13					H 	?/2       
NHDS	VCAM	.{}	2012-03-13					H 	?/2m      
CMMA	CMMA	.{}	2012-03-13					H 	Ir/1      
NHDS	CMMR	.{}	2012-03-13					H 	?/2m      
NHDS	EBN1	.{}	2012-03-13					H 	HIr/2     
NHDS	EBNA	.{}	2012-03-13					H 	?/2       
NHDS	HAMA	.{}	2012-03-13					H 	Ir/1      
NHDS	HAMR	.{}	2012-03-13					H 	?/1m      
NHDS	RNEQ	.{}	2012-03-13					H 	I/5       
NHDS	VCA1	.{}	2012-03-13					H 	HIr/2     
NHDS	VCA2	.{}	2012-03-13					H 	HIr/2     
NHDS	VCAG	.{}	2012-03-13					H 	?/2       
NHDS	VCAM	.{}	2012-03-13					H 	?/2m      
NEXS	NASO	.{}	2012-03-13					H 	H?        
NEXS	RNEQ	.{}	2012-03-13					H 	I/5       
NEXS	RUMR	.{}	2012-03-13					H 	?/2m      
NEXS	RUMV	.{}	2012-03-13					H 	HIr       
HIVC	HIVC	.{}	2012-03-13						
NHIV	HIVR	.{}	2012-03-13					H 	?/2       
NHIV	RNEQ	.{}	2012-03-13					H 	I/5       
NHIV	HIVI	.{}	2012-03-13					H 	IN?/2     
NHIV	HIVR	.{}	2012-03-13					H 	?/2       
NHIV	HIVV	.{}	2012-03-13					H 	Ir/2      
NHIV	RNEQ	.{}	2012-03-13					H 	I/5       
NHDS	CMMR	.{}	2012-03-13					H 	?/2m      
NHDS	CMMV	.{}	2012-03-13					H 	Ir        
NHDS	EBN1	.{}	2012-03-13					H 	HIr/2     
NHDS	EBNA	.{}	2012-03-13					H 	?/2       
NHDS	HAMA	.{}	2012-03-13					H 	Ir/1      
NHDS	HAMR	.{}	2012-03-13					H 	?/1m      
NHDS	RNEQ	.{}	2012-03-13					H 	I/5       
NHDS	VCA1	.{}	2012-03-13					H 	HIr/2     
NHDS	VCA2	.{}	2012-03-13					H 	HIr/2     
NHDS	VCAG	.{}	2012-03-13					H 	?/2       
NHDS	VCAM	.{}	2012-03-13					H 	?/2m      
NEXS	NASO	.{}	2012-03-13					H 	H?        
NEXS	PRVG	.{}	2012-03-13					H 	?r/2      
NEXS	PRVM	.{}	2012-03-13					H 	?r/2m     
NEXS	RNEQ	.{}	2012-03-13					H 	I/5       
NEXS	RUMR	.{}	2012-03-13					H 	?/2m      
NEXS	RUMV	.{}	2012-03-13					H 	HIr       
NIMS	CMGR	.{}	2012-03-13					H 	?/2       
NIMS	CMGV	.{}	2012-03-13					H 	Ir        
NIMS	HAGA	.{}	2012-03-13					H 	Ir/1      
NIMS	HAGR	.{}	2012-03-13					H 	?/2       
NIMS	RNEQ	.{}	2012-03-13					H 	I/5       
NIMS	VZGE	.{}	2012-03-13					H 	?IN/3r    
NIMS	VZGR	.{}	2012-03-13					H 	?/3r      
NIMS	VZGV	.{}	2012-03-13					H 	INr?/2    
NRUB	RNEQ	.{}	2012-03-13					H 	I/5       
NRUB	RUGR	.{}	2012-03-13					H 	?/2       
NRUB	RUGV	.{}	2012-03-13		IU/ml			H 	HIr       
NTOX	TOXG	.{}	2012-03-13					H 	?/2       
NTOX	TOXM	.{}	2012-03-13					H 	?/2m      
NTOX	TXGV	.{}	2012-03-13					H 	IN        
NTOX	TXMV	.{}	2012-03-13					H 	IN        
ACMV	CMGA	.{}	2012-03-20					H 	Ir/1      
ACMV	CMGR	.{}	2012-03-20					H 	?/2       
CMVS	CMMA	.{}	2016-08-26					H 	Ir/1      
CMVS	CMMR	.{}	2016-08-26					H 	?/2m      
CMVS	CMV 	REPORT	2016-08-26	2016-08-26				H 	NAHp1?r   
ACMV	CMGA	.{}	2012-03-20					H 	Ir/1      
ACMV	CMGR	.{}	2012-03-20					H 	?/2       
CMVS	CMMA	.{}	2016-08-26					H 	Ir/1      
CMVS	CMMR	.{}	2016-08-26					H 	?/2m      
CMVS	CMV 	REPORT	2016-08-26	2016-08-26				H 	NAHp1?r   
CMVS	CMGA	.{}	2012-03-20					H 	Ir/1      
CMVS	CMGR	.{}	2012-03-20					H 	?/2       
CMVS	CMMA	.{}	2012-03-20					H 	Ir/1      
CMVS	CMMR	.{}	2012-03-20					H 	?/2m      
ACMV	CMGA	.{}	2012-03-20					H 	Ir/1      
ACMV	CMGR	.{}	2012-03-20					H 	?/2       
CMVS	CMMA	.{}	2016-08-26					H 	Ir/1      
CMVS	CMMR	.{}	2016-08-26					H 	?/2m      
CMVS	CMV 	REPORT	2016-08-26	2016-08-26				H 	NAHp1?r   
CHIV	CHIV	.{}	2012-03-21					H 	N?/2      
CMGA	CMGA	.{}	2012-03-21					H 	Ir/1      
CMGR	CMGR	.{}	2012-03-21					H 	?/2       
HBCA	HBCA	.{}	2012-03-21					H 	HIr/1     
HBCO	HBCO	Y	2012-03-21	2012-03-21				H 	NIr?      
HBCR	HBCR	.{}	2012-03-21					H 	?r/2      
HBVA	HBVA	.{}	2012-03-21					H 	HIr/1     
HBVR	HBVR	.{}	2012-03-21					H 	?r/2m     
HCVA	HCVA	.{}	2012-03-21					H 	Ir/1      
HCVR	HCVR	.{}	2012-03-21					H 	?/2m      
HIVA	HIVA	.{}	2012-03-21					H 	Ir/1      
HIVR	HIVR	.{}	2012-03-21					H 	?/2       
SYPA	SYPA	.{}	2012-03-21					H 	?Ir/1     
SYPR	SYPR	.{}	2012-03-21					H 	?r/2m     
TLVA	TLVA	.{}	2012-03-21					H 	Ir/1      
TLVR	TLVR	.{}	2012-03-21					H 	?/2m      
TOXG	TOXG	.{}	2012-03-21					H 	?/2       
TPCO	TPCO	Y	2012-03-21	2012-03-21				H 	IN?       
TXGA	TXGA	.{}	2012-03-21					H 	Ir/1      
VCA1	VCA1	.{}	2012-03-21					H 	HIr/2     
VCAG	VCAG	.{}	2012-03-21					H 	?/2       
VZGE	VZGE	.{}	2012-03-21					H 	?IN/3r    
VZGR	VZGR	.{}	2012-03-21					H 	?/3r      
VZGV	VZGV	.{}	2012-03-21					H 	INr?/2    
CHIV	CHIV	.{}	2012-03-21					H 	N?/2      
CMGA	CMGA	.{}	2012-03-21					H 	Ir/1      
CMGR	CMGR	.{}	2012-03-21					H 	?/2       
HBCA	HBCA	.{}	2012-03-21					H 	HIr/1     
HBCO	HBCO	Y	2012-03-21	2012-03-21				H 	NIr?      
HBCR	HBCR	.{}	2012-03-21					H 	?r/2      
HBVA	HBVA	.{}	2012-03-21					H 	HIr/1     
HBVR	HBVR	.{}	2012-03-21					H 	?r/2m     
HCVA	HCVA	.{}	2012-03-21					H 	Ir/1      
HCVR	HCVR	.{}	2012-03-21					H 	?/2m      
HIVA	HIVA	.{}	2012-03-21					H 	Ir/1      
HIVR	HIVR	.{}	2012-03-21					H 	?/2       
SYPA	SYPA	.{}	2012-03-21					H 	?Ir/1     
SYPR	SYPR	.{}	2012-03-21					H 	?r/2m     
TLVA	TLVA	.{}	2012-03-21					H 	Ir/1      
TLVR	TLVR	.{}	2012-03-21					H 	?/2m      
TOXG	TOXG	.{}	2012-03-21					H 	?/2       
TPCO	TPCO	Y	2012-03-21	2012-03-21				H 	IN?       
TXGA	TXGA	.{}	2012-03-21					H 	Ir/1      
VCA1	VCA1	.{}	2012-03-21					H 	HIr/2     
VCAG	VCAG	.{}	2012-03-21					H 	?/2       
VZGE	VZGE	.{}	2012-03-21					H 	?IN/3r    
VZGR	VZGR	.{}	2012-03-21					H 	?/3r      
VZGV	VZGV	.{}	2012-03-21					H 	INr?/2    
CHIV	CHIV	.{}	2012-03-21					H 	N?/2      
CMGA	CMGA	5	2012-03-21	2012-03-21				H 	Ir/1      
CMGR	CMGR	Not Detected	2012-03-21	2012-03-21				H 	?/2       
HBCA	HBCA	.{ 0.010 }	2012-03-21					H 	HIr/1     
HBCO	HBCO	Y	2012-03-21	2012-03-21				H 	NIr?      
HBCR	HBCR	Positive	2012-03-21	2012-03-21				H 	?r/2      
HBVA	HBVA	.{ 0.010 }	2012-03-21					H 	HIr/1     
HBVR	HBVR	Not Detected	2012-03-21	2012-03-21				H 	?r/2m     
HCVA	HCVA	0.010	2012-03-21	2012-03-21				H 	Ir/1      
HCVR	HCVR	Not Detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV
infection, please contact us to discuss further
testing of this sample.	2012-03-21	2012-03-21				H 	?/2m      
HIVA	HIVA	0.010	2012-03-21	2012-03-21				H 	Ir/1      
HIVR	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2012-03-21	2012-03-21				H 	?/2       
SYPA	SYPA	0.010	2012-03-21	2012-03-21				H 	?Ir/1     
SYPR	SYPR	Negative	2012-03-21	2012-03-21				H 	?r/2m     
TLVA	TLVA	0.010	2012-03-21	2012-03-21				H 	Ir/1      
TLVR	TLVR	Not Detected
No evidence of infection.	2012-03-21	2012-03-21				H 	?/2m      
TOXG	TOXG	Not Detected	2012-03-21	2012-03-21				H 	?/2       
TPCO	TPCO	Y	2012-03-21	2012-03-21				H 	IN?       
TXGA	TXGA	0.01	2012-03-21	2012-03-21				H 	Ir/1      
VCA1	VCA1	2.0	2012-03-21	2012-03-21				H 	HIr/2     
VCAG	VCAG	Positive	2012-03-21	2012-03-21				H 	?/2       
VZGE	VZGE	Positive	2012-03-21	2012-03-21				H 	?IN/3r    
VZGR	VZGR	Positive	2012-03-21	2012-03-21				H 	?/3r      
VZGV	VZGV	Not Tested	2012-03-21	2012-03-21				H 	INr?/2    
SJCV	SJCC	The provided blood sample was tested by Unilabs
using the STRATIFY JCV Test, a two-step enzyme-
linked immunosorbent assay (ELISA). The test is
used to detect the presence of antibodies to the
JC Virus in MS patients.	2012-03-21	2012-03-21				H 	          
SJCV	SJCT	POSITIVE for JC Virus Antibodies	2012-03-21	2012-03-21				H 	r         
SJCV	SJRD	20/03/2012	2012-03-21	2012-03-21				H 	NI        
SJCV	SJSD	15/03/2012	2012-03-21	2012-03-21				H 	NI        
SJCV	SJUR	16/03/2012	2012-03-21	2012-03-21				H 	NI        
SJCV	SJCC	The provided blood sample was tested by Unilabs
using the STRATIFY JCV Test, a two-step enzyme-
linked immunosorbent assay (ELISA). The test is
used to detect the presence of antibodies to the
JC Virus in MS patients.	2012-03-21	2012-03-21				H 	          
SJCV	SJCT	NEGATIVE for JC Virus Antibodies	2012-03-21	2012-03-21				H 	r         
SJCV	SJRD	25/12/2012	2012-03-21	2012-03-21				H 	NI        
SJCV	SJSD	22/12/2012	2012-03-21	2012-03-21				H 	NI        
SJCV	SJUR	23/12/2012	2012-03-21	2012-03-21				H 	NI        
1AG	1AG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1BCA	1BCA	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1CG	1CG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1EB	1EB	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1HC	1HC	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1RV	1RV	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1TL	1TL	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1TP	1TP	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1TXG	1TXG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1VZ	1VZ	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
CHIV	CHIV	.{}	2012-03-28					H 	N?/2      
CMGA	CMGA	.{}	2012-03-28					H 	Ir/1      
CMGR	CMGR	.{}	2012-03-28					H 	?/2       
CMMA	CMMA	.{}	2012-03-28					H 	Ir/1      
CMMR	CMMR	.{}	2012-03-28					H 	?/2m      
EBN1	EBN1	.{}	2012-03-28					H 	HIr/2     
EBNA	EBNA	.{}	2012-03-28					H 	?/2       
HBCA	HBCA	.{}	2012-03-28					H 	HIr/1     
HBCO	HBCO	Y	2012-03-28	2012-03-28				H 	NIr?      
HBCR	HBCR	.{}	2012-03-28					H 	?r/2      
HBVA	HBVA	.{}	2012-03-28					H 	HIr/1     
HBVR	HBVR	.{}	2012-03-28					H 	?r/2m     
HCVA	HCVA	.{}	2012-03-28					H 	Ir/1      
HCVR	HCVR	.{}	2012-03-28					H 	?/2m      
HIVA	HIVA	.{}	2012-03-28					H 	Ir/1      
HIVR	HIVR	.{}	2012-03-28					H 	?/2       
SYPA	SYPA	.{}	2012-03-28					H 	?Ir/1     
SYPR	SYPR	.{}	2012-03-28					H 	?r/2m     
TLVA	TLVA	.{}	2012-03-28					H 	Ir/1      
TLVR	TLVR	.{}	2012-03-28					H 	?/2m      
TOXG	TOXG	.{}	2012-03-28					H 	?/2       
TPCO	TPCO	Y	2012-03-28	2012-03-28				H 	IN?       
TXGA	TXGA	.{}	2012-03-28					H 	Ir/1      
VCA1	VCA1	.{}	2012-03-28					H 	HIr/2     
VCA2	VCA2	.{}	2012-03-28					H 	HIr/2     
VCAG	VCAG	.{}	2012-03-28					H 	?/2       
VCAM	VCAM	.{}	2012-03-28					H 	?/2m      
VZGE	VZGE	.{}	2012-03-28					H 	?IN/3r    
VZGR	VZGR	.{}	2012-03-28					H 	?/3r      
VZGV	VZGV	.{}	2012-03-28					H 	INr?/2    
2HC	2HC	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
CVL1	CVL1	.{}	2012-03-28		IU/ml			H 	Hr?/5     
CVL2	CVL2	.{}	2012-03-28					H 	?r/5m     
2HC	2HC	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
CVL1	CVL1	.{}	2012-03-28		IU/ml			H 	Hr?/5     
CVL2	CVL2	.{}	2012-03-28					H 	?r/5m     
QTBG	QTBC	A negative result does not exclude infection. The
performance of this test in immunocompromised
patients has not been fully evaluated. If there is
clinical suspicion of disease caused by
M. tuberculosis, referral to the Infectious
Diseases Team is strongly recommended.	2012-05-01	2012-05-01				I 	?r        
QTBG	QTFR	Mycobacterium tuberculosis infection - NOT likely.	2012-05-01	2012-05-01				I 	?r        
QTBG	QTRT	Negative	2012-05-01	2012-05-01				I 	?         
HBAG	1AG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
HBC 	1BCA	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
CMVS	1CG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
ACVL	1EB	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
HCV 	1HC	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
HIV 	1RV	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
HTLV	1TL	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
SYPS	1TP	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
TXG 	1TXG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
1VG	1VG	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
ACVL	2AN	Cancelled - see comments	2012-03-28	2012-03-28				H 	NA?       
ACVL	ACV1	.{}	2012-03-28					H 	?H/2m     
ACVL	ACVS	.{}	2012-03-28					H 	N?        
HIV 	CHIV	.{}	2012-03-28					H 	N?/2      
CMVS	CMGA	.{}	2012-03-28					H 	Ir/1      
CMVS	CMGR	.{}	2012-03-28					H 	?/2       
CMVS	CMMA	.{}	2012-03-28					H 	Ir/1      
CMVS	CMMR	.{}	2012-03-28					H 	?/2m      
HBC 	HBCA	.{}	2012-03-28					H 	HIr/1     
HBVZ	HBCC	.{}	2012-03-28					H 	Nr?/2     
HBC 	HBCO	Y	2012-03-28	2012-03-28				H 	NIr?      
HBC 	HBCR	.{}	2012-03-28					H 	?r/2      
HBAG	HBVA	.{}	2012-03-28					H 	HIr/1     
HBAG	HBVR	.{}	2012-03-28					H 	?r/2m     
HCV 	HCVA	.{}	2012-03-28					H 	Ir/1      
HCV 	HCVR	.{}	2012-03-28					H 	?/2m      
HIV 	HIVA	.{}	2012-03-28					H 	Ir/1      
HIV 	HIVR	.{}	2012-03-28					H 	?/2       
SYPS	SYPA	.{}	2012-03-28					H 	?Ir/1     
SYPS	SYPR	.{}	2012-03-28					H 	?r/2m     
HTLV	TLVA	.{}	2012-03-28					H 	Ir/1      
HTLV	TLVR	.{}	2012-03-28					H 	?/2m      
TXG 	TOXG	.{}	2012-03-28					H 	?/2       
SYPS	TPCO	Y	2012-03-28	2012-03-28				H 	IN?       
TXG 	TXGA	.{}	2012-03-28					H 	Ir/1      
ACVL	VCA1	.{}	2012-03-28					H 	HIr/2     
ACVL	VCAG	.{}	2012-03-28					H 	?/2       
VZVA	VZVA	.{}	2012-03-28					H 	HI        
VZVR	VZVR	.{}	2012-03-28					H 	?         
ANDT	TDEC	HIV	2012-03-30	2012-03-30				H 	H/2       
HBAG	1AG	Cancelled - see comments	2012-03-30	2012-03-30				H 	NA?       
RUBS	1RS	Cancelled - see comments	2012-03-30	2012-03-30				H 	NA?       
SYPS	1TP	Cancelled - see comments	2012-03-30	2012-03-30				H 	NA?       
HBAG	HBCO	Y	2012-03-30	2012-03-30				H 	NIr?      
HBAG	HBVA	.{}	2012-03-30					H 	HIr/1     
HBAG	HBVR	.{}	2012-03-30					H 	?r/2m     
RUBS	RUGA	.{}	2012-03-30		IU/ml			H 	HIr/1     
RUBS	RUGR	.{}	2012-03-30					H 	?/2       
SYPS	SYPA	.{}	2012-03-30					H 	?Ir/1     
SYPS	SYPR	.{}	2012-03-30					H 	?r/2m     
ANDT	TDEC	.{}	2012-03-30					H 	H/2       
SYPS	TPCO	Y	2012-03-30	2012-03-30				H 	IN?       
HBAG	HBCO	Y	2012-03-30	2012-03-30				H 	NIr?      
HBAG	HBVA	.{ 0.010 }	2012-03-30					H 	HIr/1     
HBAG	HBVR	Not Detected	2012-03-30	2012-03-30				H 	?r/2m     
RUBS	RUGA	234	2012-03-30	2012-03-30	IU/ml			H 	HIr/1     
RUBS	RUGR	Positive	2012-03-30	2012-03-30				H 	?/2       
SYPS	SYPA	0.010	2012-03-30	2012-03-30				H 	?Ir/1     
SYPS	SYPR	Negative	2012-03-30	2012-03-30				H 	?r/2m     
ANDT	TDEC	HIV	2012-03-30	2012-03-30				H 	H/2       
SYPS	TPCO	Y	2012-03-30	2012-03-30				H 	IN?       
UNC 	ADVC	Test not offered.
Please contact a Clinical Virologist to discuss:
Phone 020 344 78986/78995 or 0794 620 2872
for the SpR.	2012-04-12	2012-04-12				H 	HI/1      
UNC 	ADVR	.{}	2012-04-12					H 	HI/1      
SAVC	SAVC	SAMPLE SAVED IN VIROLOGY.	2012-04-12	2012-04-12				H 	?r/2      
VOOH	VOTB	St Elsewhere	2012-04-16	2012-04-16				H 	?         
VOOH	VOTR	Miscellaneous tests negative	2012-04-16	2012-04-16				H 	?         
HBAG	1AG	Cancelled - see comments	2012-04-24	2012-04-24				H 	NA?       
RUBS	1RS	Cancelled - see comments	2012-04-24	2012-04-24				H 	NA?       
SYPS	1TP	Cancelled - see comments	2012-04-24	2012-04-24				H 	NA?       
HBAG	HBCO	Y	2012-04-24	2012-04-24				H 	NIr?      
HBAG	HBVA	.{}	2012-04-24					H 	HIr/1     
HBAG	HBVR	.{}	2012-04-24					H 	?r/2m     
RUBS	RUBC	test entry	2012-04-24	2012-04-24				H 	N?        
RUBS	RUGA	.{}	2012-04-24		IU/ml			H 	HIr/1     
RUBS	RUGR	.{}	2012-04-24					H 	?/2       
SYPS	SYPA	.{}	2012-04-24					H 	?Ir/1     
SYPS	SYPR	.{}	2012-04-24					H 	?r/2m     
ANDT	TDEC	HIV	2012-04-17	2012-04-18				H 	H/2       
SYPS	TPCO	Y	2012-04-24	2012-04-24				H 	IN?       
HDV	HDVT	Not Detected
No evidence of infection.	2012-05-01	2012-05-01				H 	?Hr/4     
HEV	HEGE	Not Detected	2012-05-01	2012-05-01				H 	H?/4      
HEV	HEME	Not Detected	2012-05-01	2012-05-01				H 	H?/4      
PARV	PRVG	Positive	2012-04-25	2012-04-25				H 	?r/2      
PARV	PRVM	Not Detected	2012-04-25	2012-04-25				H 	?r/2m     
RUBS	RUBC	Susceptible to Rubella. Recommend immunisation if
the patient is not pregnant.
Note that acute Rubella infection has not been
excluded.  If this is suspected, please contact us
immediately to arrange for Rubella IgM testing.	2012-04-25	2012-04-25				H 	N?        
RUBS	RUGA	0	2012-04-25	2012-04-25	IU/ml			H 	HIr/1     
RUBS	RUGR	Not Detected	2012-04-25	2012-04-25				H 	?/2       
RUGV	RUGV	0	2012-04-25	2012-04-25	IU/ml			H 	HIr       
VZVS	VZGE	Not Detected	2012-04-25	2012-04-25				H 	?IN/3r    
VZVS	VZGR	.{}	2012-04-25					H 	?/3r      
VZVS	VZGV	.{}	2012-04-25					H 	INr?/2    
HDVP	HDRN	.{}	2012-05-01					H 	?Hrm/20   
HDV	HDVT	Weak Reactive
Further Report to Follow.	2012-05-01	2012-05-01				H 	?Hr/4     
HEV	HEGE	Weak Reactive	2012-05-01	2012-05-01				H 	H?/4      
HEV	HEME	Weak Reactive	2012-05-01	2012-05-01				H 	H?/4      
VZVG	VZVA	2.0	2012-04-25	2012-04-25				H 	HI        
VZVG	VZVR	POSITIVE	2012-04-25	2012-04-25				H 	?         
COSC	COSC	HDVT/HEME/HEGE/	2012-05-01					X 	N         
COSD	COSD	Organisms sent 01/05/2012 12:00	2012-05-01					X 	N         
HDVP	HDRN	.{}	2012-05-01					H 	?Hrm/20   
HDV	HDVT	REACTIVE
Further Report to Follow.	2012-05-01	2012-05-01				H 	?Hr/4     
HEV	HEGE	Positive	2012-05-01	2012-05-01				H 	H?/4      
HEV	HEME	Positive	2012-05-01	2012-05-01				H 	H?/4      
HCVL	CVL1	.{}	2012-05-03		IU/ml			H 	Hr?/5     
HCVL	CVL2	.{}	2012-05-03					H 	?r/5m     
HCVL	CVLC	.{}	2012-05-03					H 	N?        
HCV	HCVA	.{}	2012-05-03					H 	Ir/1      
HCV	HCVR	.{}	2012-05-03					H 	?/2m      
HCV	HCVV	.{}	2012-05-03					H 	I/3       
RUBS	RUGA	200	2012-05-03	2012-05-03	IU/ml			H 	HIr/1     
RUBS	RUGR	Positive	2012-05-03	2012-05-03				H 	?/2       
TDEC	TDEC	HBsAg, HIV, Syphilis	2012-05-03	2012-05-03				H 	H/2       
ALPH	ALPH	.{}	2012-05-08					H 	H/21      
CAM1	CAM1	.{}	2012-05-08					H 	Ir/4      
CAM2	CAM2	.{}	2012-05-08					H 	I/10      
CX1A	CX1A	.{}	2012-05-08					H 	?r/14     
CX1G	CX1G	.{}	2012-05-08					H 	?Ar/14    
CX2G	CX2G	.{}	2012-05-08					H 	?r/14     
CX2M	CX2M	.{}	2012-05-08					H 	?Br/14    
CXIR	CXIR	Rare & Imported Pathogens Laboratory,	2012-05-08	2012-05-08				H 	r?        
CXIS	CXIS	.{}	2012-05-08					H 	I/4       
CXIT	CXIT	.{}	2012-05-08					H 	I/10      
DENG	DENG	.{}	2012-05-08					H 	H?/21     
FLAV	FLAV	.{}	2012-05-08					H 	H?A/21    
HANT	HANT	.{}	2012-05-08					H 	H?/21     
OTSG	OTSG	.{}	2012-05-08					H 	?/21m     
OTSM	OTSM	.{}	2012-05-08					H 	?/21m     
PHLE	PHLE	.{}	2012-05-08					H 	H?/21     
RCA1	RCA1	Rare & Imported Pathogens Laboratory,	2012-05-08	2012-05-08				H 	r?/21     
RICO	RICO	.{}	2012-05-08					H 	?A        
RICR	RICR	Rare & Imported Pathogens Laboratory,	2012-05-08	2012-05-08				H 	r?        
RICS	RICS	.{}	2012-05-08					H 	HI/4?     
RICT	RICT	.{}	2012-05-08					H 	HI/10?    
RIDN	RIDN	.{}	2012-05-08					H 	?/21m     
RIEG	RIEG	.{}	2012-05-08					H 	?/21m     
RIEM	RIEM	.{}	2012-05-08					H 	?/21m     
RISG	RISG	.{}	2012-05-08					H 	?/21m     
RISM	RISM	.{}	2012-05-08					H 	?/21m     
VREF	VREF	SENT	2012-05-08	2012-05-08				H 	I?/4      
ASOR	ASOR	Negative	2012-05-08	2012-05-08				H 	?/3       
BRAB	BRAB	Equivocal	2012-05-08	2012-05-08				H 	?r/14     
BRME	BRME	Negative	2012-05-08	2012-05-08				H 	?r/14     
HEAG	HEAG	Negative	2012-05-08	2012-05-08				H 	A?/3      
MYCT	MYCT	POSITIVE: Titre 640	2012-05-08	2012-05-08				H 	?/2       
ASOR	ASOR	POSITIVE: 300 IU/ml	2012-05-08	2012-05-08				H 	?/3       
BRAB	BRAB	POSITIVE: Titre 40	2012-05-08	2012-05-08				H 	?r/14     
BRME	BRME	POSITIVE: Titre 80	2012-05-08	2012-05-08				H 	?r/14     
COSC	COSC	HEAG/	2012-05-18					X 	N         
COSD	COSD	Organisms sent 18/05/2012 14:28	2012-05-18					X 	N         
HEAG	HEAG	Positive	2012-05-08	2012-05-08				H 	A?/3      
MYCT	MYCT	POSITIVE: Titre 5120	2012-05-08	2012-05-08				H 	?/2       
ASOR	ASOR	POSITIVE: 400 IU/ml	2012-05-08	2012-05-08				H 	?/3       
BRAB	BRAB	POSITIVE: Titre 160	2012-05-08	2012-05-08				H 	?r/14     
BRME	BRME	Negative	2012-05-08	2012-05-08				H 	?r/14     
HEAG	HEAG	Negative	2012-05-08	2012-05-08				H 	A?/3      
MYCT	MYCT	POSITIVE: Titre 20480	2012-05-08	2012-05-08				H 	?/2       
CHIV	CHIV	.{}	2012-05-09					H 	N?/2      
EBN1	EBN1	1.99	2012-05-09	2012-05-09				H 	HIr/2     
EBNA	EBNA	Positive	2012-05-09	2012-05-09				H 	?/2       
EBVC	EBVC	Consistent with a past infection.	2012-05-09	2012-05-09				H 	Nr?       
HBCA	HBCA	.{ 3.880 }	2012-05-09					H 	HIr/1     
HBCO	HBCO	Y	2012-05-09	2012-05-09				H 	NIr?      
HBCR	HBCR	Not Detected	2012-05-09	2012-05-09				H 	?r/2      
HBVA	HBVA	.{ 0.060 }	2012-05-09					H 	HIr/1     
HBVR	HBVR	Not Detected	2012-05-09	2012-05-09				H 	?r/2m     
HCVA	HCVA	0.060	2012-05-09	2012-05-09				H 	Ir/1      
HCVR	HCVR	Not Detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV	2012-05-09	2012-05-09				H 	?/2m      
HIVA	HIVA	0.060	2012-05-09	2012-05-09				H 	Ir/1      
HIVR	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2012-05-09	2012-05-09				H 	?/2       
SYPA	SYPA	0.100	2012-05-09	2012-05-09				H 	?Ir/1     
SYPR	SYPR	Negative	2012-05-09	2012-05-09				H 	?r/2m     
TLVA	TLVA	0.550	2012-05-09	2012-05-09				H 	Ir/1      
TLVR	TLVR	Not Detected
No evidence of infection.	2012-05-09	2012-05-09				H 	?/2m      
TOXG	TOXG	Not Detected	2012-05-09	2012-05-09				H 	?/2       
TOXM	TOXM	Not Detected	2012-05-09	2012-05-09				H 	?/2m      
TPCO	TPCO	Y	2012-05-09	2012-05-09				H 	IN?       
TXGA	TXGA	0.01	2012-05-09	2012-05-09				H 	Ir/1      
TXMA	TXMA	0.03	2012-05-09	2012-05-09				H 	Ir/1      
TXPC	TXPC	No serological evidence of toxoplasma infection.
The patient is susceptible to toxoplasma.
Pregnant and immunosuppressed patients should be
advised of the appropriate precautions to avoid
infections.	2012-05-09	2012-05-09				H 	Nr?       
VCA1	VCA1	0.209	2012-05-09	2012-05-09				H 	HIr/2     
VCA2	VCA2	0.05	2012-05-09	2012-05-09				H 	HIr/2     
VCAG	VCAG	Positive	2012-05-09	2012-05-09				H 	?/2       
VCAM	VCAM	Not Detected	2012-05-09	2012-05-09				H 	?/2m      
VZGE	VZGE	POSITIVE	2012-05-09	2012-05-09				H 	?IN/3r    
VZGR	VZGR	Positive	2012-05-09	2012-05-09				H 	?/3r      
VZGV	VZGV	Not Tested	2012-05-09	2012-05-09				H 	INr?/2    
BCMA	BCMA	.{}	2012-05-09					H 	HIr/2     
HIV 	CHIV	.{}	2012-05-09					H 	N?/2      
COSC	COSC	HBVR/	2012-08-11					X 	N         
COSD	COSD	Organisms sent 11/08/2012 08:56	2012-08-11					X 	N         
CVL1	CVL1	.{ 0 }	2012-05-09		IU/ml			H 	Hr?/5     
CVL2	CVL2	Not Detected	2012-05-09	2012-05-09				H 	?r/5m     
EBN1	EBN1	.{}	2012-05-09					H 	HIr/2     
EBNA	EBNA	.{}	2012-05-09					H 	?/2       
HBC	HBCA	.{ 0.010 }	2012-05-09					H 	HIr/1     
HBC	HBCO	Y	2012-05-09	2012-05-09				H 	NIr?      
HBC	HBCR	Positive	2012-05-09	2012-05-09				H 	?r/2      
HBAG	HBVA	.{ 200.000 }	2012-05-09					H 	HIr/1     
HBAG	HBVR	Positive	2012-05-09	2012-05-09				H 	?r/2m     
HCVA	HCVA	0.050	2012-05-09	2012-05-09				H 	Ir/1      
HCVR	HCVR	Not Detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV
infection, please contact us to discuss further
testing of this sample.	2012-05-09	2012-05-09				H 	?/2m      
HIV 	HIVA	10.000	2012-05-09	2012-05-09				H 	Ir/1      
HIVS	HIVI	HIV-1 POSITIVE	2012-05-09	2012-05-09				H 	IN?/2     
HIV 	HIVR	anti-HIV 1 Detected	2012-05-09	2012-05-09				H 	?/2       
HIVS	HIVV	33.0	2012-05-09	2012-05-09				H 	Ir/2      
SAVC	SAVC	.{}	2012-08-30					H 	?r/2      
SYPA	SYPA	0.030	2012-05-09	2012-05-09				H 	?Ir/1     
SYPR	SYPR	Negative	2012-05-09	2012-05-09				H 	?r/2m     
TLVA	TLVA	0.030	2012-05-09	2012-05-09				H 	Ir/1      
TLVR	TLVR	Not Detected
No evidence of infection.	2012-05-09	2012-05-09				H 	?/2m      
TOXG	TOXG	Not Detected	2012-05-09	2012-05-09				H 	?/2       
TOXM	TOXM	Not Detected	2012-05-09	2012-05-09				H 	?/2m      
TPCO	TPCO	Y	2012-05-09	2012-05-09				H 	IN?       
TXGA	TXGA	0.05	2012-05-09	2012-05-09				H 	Ir/1      
TXMA	TXMA	0.10	2012-05-09	2012-05-09				H 	Ir/1      
TXPC	TXPC	No serological evidence of toxoplasma infection.
The patient is susceptible to toxoplasma.
Pregnant and immunosuppressed patients should be
advised of the appropriate precautions to avoid
infections.	2012-08-11	2012-08-14				H 	Nr?       
VCA1	VCA1	5.50	2012-05-09	2012-05-09				H 	HIr/2     
VCA2	VCA2	0.04	2012-05-09	2012-05-09				H 	HIr/2     
VCAG	VCAG	Positive	2012-05-09	2012-05-09				H 	?/2       
VCAM	VCAM	Not Detected	2012-05-09	2012-05-09				H 	?/2m      
VZGE	VZGE	Not Detected	2012-05-09	2012-05-09				H 	?IN/3r    
VZGR	VZGR	Not Detected	2012-05-09	2012-05-09				H 	?/3r      
VZGV	VZGV	0.06	2012-05-09	2012-05-09				H 	INr?/2    
HIV	CHIV	.{}	2012-05-09					H 	N?/2      
HIVP	H1NA	Not Detected	2012-05-09	2012-05-09				H 	?Hr/6     
HIV2	H2NA	.{ Not Tested }	2012-05-23					H 	?Hr/20    
HIV2	HI2I	.{ Not Tested }	2012-05-23					H 	I?r/20    
HIV	HIVA	5.000	2012-05-09	2012-05-09				H 	Ir/1      
HIVS	HIVI	Negative	2012-05-09	2012-05-09				H 	IN?/2     
HIV	HIVR	Serology results indeterminate. Genome detection
is required.	2012-05-09	2012-05-09				H 	?/2       
HIVS	HIVV	3.0	2012-05-09	2012-05-09				H 	Ir/2      
HIV2	HV21	.{ Not Tested }	2012-05-23		Copies/ml			H 	?Hr/20    
HIV2	HV22	.{ Not Tested }	2012-05-23					H 	r/20      
AHCV	AHCV	Negative	2012-05-11	2012-05-14				H 	r/14      
HCBI	HCBI	Negative	2012-05-11	2012-05-14				H 	Ir/14     
HCOR	HCOR	Negative	2012-05-11	2012-05-14				H 	Ir/14     
HCRN	HCRN	Negative	2012-05-11	2012-05-14				H 	r/14      
HCV2	HCV2	Health Protection Agency,
61 Colindale Avenue, NW9 5HT.	2012-05-11	2012-05-14				H 	r?        
HCV3	HCV3	12/12/12	2012-05-11	2012-05-14				H 	HI/3      
HCV4	HCV4	13/12/12	2012-05-11	2012-05-14				H 	HI        
HIV	CHIV	.{}	2012-05-25					H 	N?/2      
HIV	HIVA	5.000	2012-05-24	2012-05-24				H 	Ir/1      
HIVS	HIVI	Negative	2012-05-24	2012-05-24				H 	IN?/2     
HIV	HIVR	.{}	2012-05-25					H 	?/2       
HIVS	HIVV	5.0	2012-05-24	2012-05-24				H 	Ir/2      
CMVS	1CG	Cancelled - see comments	2012-08-11	2012-08-14				H 	NA?       
CMVM	1CM	Cancelled - see comments	2012-08-11	2012-08-14				H 	NA?       
CHIV	CHIV	.{}	2012-06-01					H 	N?/2      
CMVS	CMGA	.{}	2012-06-01					H 	Ir/1      
CMVS	CMGR	.{}	2012-06-01					H 	?/2       
CMVS	CMMA	.{}	2012-06-01					H 	Ir/1      
CMVS	CMMR	.{}	2012-06-01					H 	?/2m      
CMVS	CMVC	Cancelled by MKIDD	2012-08-11	2012-08-14				H 	N?        
CVL1	CVL1	.{}	2012-06-01		IU/ml			H 	Hr?/5     
CVL2	CVL2	.{}	2012-06-01					H 	?r/5m     
CVLC	CVLC	.{}	2012-06-01					H 	N?        
EBN1	EBN1	.{}	2012-06-01					H 	HIr/2     
EBNA	EBNA	.{}	2012-06-01					H 	?/2       
HBCA	HBCA	.{}	2012-06-01					H 	HIr/1     
HBCO	HBCO	Y	2012-06-01	2012-06-01				H 	NIr?      
HBCR	HBCR	.{}	2012-06-01					H 	?r/2      
HBVA	HBVA	.{}	2012-06-01					H 	HIr/1     
HBVR	HBVR	.{}	2012-06-01					H 	?r/2m     
HCVA	HCVA	.{}	2012-06-01					H 	Ir/1      
HCVR	HCVR	.{}	2012-06-01					H 	?/2m      
HIVA	HIVA	.{}	2012-06-01					H 	Ir/1      
HIVR	HIVR	.{}	2012-06-01					H 	?/2       
SAVC	SAVC	.{}	2012-08-30					H 	?r/2      
SYPA	SYPA	.{}	2012-06-01					H 	?Ir/1     
SYPR	SYPR	.{}	2012-06-01					H 	?r/2m     
TLVA	TLVA	.{}	2012-06-01					H 	Ir/1      
TLVR	TLVR	.{}	2012-06-01					H 	?/2m      
TOXG	TOXG	.{}	2012-06-01					H 	?/2       
TOXM	TOXM	.{}	2012-06-01					H 	?/2m      
TPCO	TPCO	Y	2012-06-01	2012-06-01				H 	IN?       
TXGA	TXGA	.{}	2012-06-01					H 	Ir/1      
TXGV	TXGV	.{}	2012-06-01					H 	IN        
TXMA	TXMA	.{}	2012-06-01					H 	Ir/1      
TXMV	TXMV	.{}	2012-06-01					H 	IN        
VCA1	VCA1	.{}	2012-06-01					H 	HIr/2     
VCA2	VCA2	.{}	2012-06-01					H 	HIr/2     
VCAG	VCAG	.{}	2012-06-01					H 	?/2       
VCAM	VCAM	.{}	2012-06-01					H 	?/2m      
VZGE	VZGE	.{}	2012-06-01					H 	?IN/3r    
VZGR	VZGR	.{}	2012-06-01					H 	?/3r      
VZGV	VZGV	.{}	2012-06-01					H 	INr?/2    
CHIV	CHIV	.{}	2012-06-01					H 	N?/2      
EBN1	EBN1	.{}	2012-06-01					H 	HIr/2     
EBNA	EBNA	.{}	2012-06-01					H 	?/2       
HBCA	HBCA	.{}	2012-06-01					H 	HIr/1     
HBCO	HBCO	Y	2012-06-01	2012-06-01				H 	NIr?      
HBCR	HBCR	.{}	2012-06-01					H 	?r/2      
HBVA	HBVA	.{}	2012-06-01					H 	HIr/1     
HBVR	HBVR	.{}	2012-06-01					H 	?r/2m     
HCVA	HCVA	.{}	2012-06-01					H 	Ir/1      
HCVR	HCVR	.{}	2012-06-01					H 	?/2m      
HIVA	HIVA	.{}	2012-06-01					H 	Ir/1      
HIVR	HIVR	.{}	2012-06-01					H 	?/2       
SYPA	SYPA	.{}	2012-06-01					H 	?Ir/1     
SYPR	SYPR	.{}	2012-06-01					H 	?r/2m     
TLVA	TLVA	.{}	2012-06-01					H 	Ir/1      
TLVR	TLVR	.{}	2012-06-01					H 	?/2m      
TOXG	TOXG	.{}	2012-06-01					H 	?/2       
TOXM	TOXM	.{}	2012-06-01					H 	?/2m      
TPCO	TPCO	Y	2012-06-01	2012-06-01				H 	IN?       
TXGA	TXGA	.{}	2012-06-01					H 	Ir/1      
TXGV	TXGV	.{}	2012-06-01					H 	IN        
TXMA	TXMA	.{}	2012-06-01					H 	Ir/1      
VCA1	VCA1	.{}	2012-06-01					H 	HIr/2     
VCA2	VCA2	.{}	2012-06-01					H 	HIr/2     
VCAG	VCAG	.{}	2012-06-01					H 	?/2       
VCAM	VCAM	.{}	2012-06-01					H 	?/2m      
VZGE	VZGE	.{}	2012-06-01					H 	?IN/3r    
VZGR	VZGR	.{}	2012-06-01					H 	?/3r      
VZGV	VZGV	.{}	2012-06-01					H 	INr?/2    
CHIV	CHIV	.{}	2012-06-01					H 	N?/2      
HBCA	HBCA	.{}	2012-06-01					H 	HIr/1     
HBCO	HBCO	Y	2012-06-01	2012-06-01				H 	NIr?      
HBCR	HBCR	.{}	2012-06-01					H 	?r/2      
HBVA	HBVA	.{}	2012-06-01					H 	HIr/1     
HBVR	HBVR	.{}	2012-06-01					H 	?r/2m     
HCVA	HCVA	.{}	2012-06-01					H 	Ir/1      
HCVR	HCVR	.{}	2012-06-01					H 	?/2m      
HIVA	HIVA	.{}	2012-06-01					H 	Ir/1      
HIVR	HIVR	.{}	2012-06-01					H 	?/2       
SYPA	SYPA	.{}	2012-06-01					H 	?Ir/1     
SYPR	SYPR	.{}	2012-06-01					H 	?r/2m     
TLVA	TLVA	.{}	2012-06-01					H 	Ir/1      
TLVR	TLVR	.{}	2012-06-01					H 	?/2m      
TOXG	TOXG	.{}	2012-06-01					H 	?/2       
TOXM	TOXM	.{}	2012-06-01					H 	?/2m      
TPCO	TPCO	Y	2012-06-01	2012-06-01				H 	IN?       
TXGA	TXGA	.{}	2012-06-01					H 	Ir/1      
TXMA	TXMA	.{}	2012-06-01					H 	Ir/1      
CHIV	CHIV	.{}	2012-06-01					H 	N?/2      
CMGA	CMGA	.{}	2012-06-01					H 	Ir/1      
CMGR	CMGR	.{}	2012-06-01					H 	?/2       
CMMA	CMMA	.{}	2012-06-01					H 	Ir/1      
CMMR	CMMR	.{}	2012-06-01					H 	?/2m      
HBCA	HBCA	.{}	2012-06-01					H 	HIr/1     
HBCO	HBCO	Y	2012-06-01	2012-06-01				H 	NIr?      
HBCR	HBCR	.{}	2012-06-01					H 	?r/2      
HBVA	HBVA	.{}	2012-06-01					H 	HIr/1     
HBVR	HBVR	.{}	2012-06-01					H 	?r/2m     
HCVA	HCVA	.{}	2012-06-01					H 	Ir/1      
HCVR	HCVR	.{}	2012-06-01					H 	?/2m      
HIVA	HIVA	.{}	2012-06-01					H 	Ir/1      
HIVR	HIVR	.{}	2012-06-01					H 	?/2       
SYPA	SYPA	.{}	2012-06-01					H 	?Ir/1     
SYPR	SYPR	.{}	2012-06-01					H 	?r/2m     
TLVA	TLVA	.{}	2012-06-01					H 	Ir/1      
TLVR	TLVR	.{}	2012-06-01					H 	?/2m      
TOXG	TOXG	.{}	2012-06-01					H 	?/2       
TOXM	TOXM	.{}	2012-06-01					H 	?/2m      
TPCO	TPCO	Y	2012-06-01	2012-06-01				H 	IN?       
TXGA	TXGA	.{}	2012-06-01					H 	Ir/1      
TXMA	TXMA	.{}	2012-06-01					H 	Ir/1      
CHIV	CHIV	.{}	2012-06-01					H 	N?/2      
CMGA	CMGA	.{}	2012-06-01					H 	Ir/1      
CMGR	CMGR	.{}	2012-06-01					H 	?/2       
CMMA	CMMA	.{}	2012-06-01					H 	Ir/1      
CMMR	CMMR	.{}	2012-06-01					H 	?/2m      
CVL1	CVL1	.{}	2012-06-01		IU/ml			H 	Hr?/5     
CVL2	CVL2	.{}	2012-06-01					H 	?r/5m     
EBN1	EBN1	.{}	2012-06-01					H 	HIr/2     
EBNA	EBNA	.{}	2012-06-01					H 	?/2       
HBCA	HBCA	.{}	2012-06-01					H 	HIr/1     
HBCO	HBCO	Y	2012-06-01	2012-06-01				H 	NIr?      
HBCR	HBCR	.{}	2012-06-01					H 	?r/2      
HBVA	HBVA	.{}	2012-06-01					H 	HIr/1     
HBVR	HBVR	.{}	2012-06-01					H 	?r/2m     
HCVA	HCVA	.{}	2012-06-01					H 	Ir/1      
HCVR	HCVR	.{}	2012-06-01					H 	?/2m      
HIVA	HIVA	.{}	2012-06-01					H 	Ir/1      
HIVR	HIVR	.{}	2012-06-01					H 	?/2       
SYPA	SYPA	.{}	2012-06-01					H 	?Ir/1     
SYPR	SYPR	.{}	2012-06-01					H 	?r/2m     
TLVA	TLVA	.{}	2012-06-01					H 	Ir/1      
TLVR	TLVR	.{}	2012-06-01					H 	?/2m      
TOXG	TOXG	.{}	2012-06-01					H 	?/2       
TOXM	TOXM	.{}	2012-06-01					H 	?/2m      
TPCO	TPCO	Y	2012-06-01	2012-06-01				H 	IN?       
TXGA	TXGA	.{}	2012-06-01					H 	Ir/1      
TXMA	TXMA	.{}	2012-06-01					H 	Ir/1      
VCA1	VCA1	.{}	2012-06-01					H 	HIr/2     
VCA2	VCA2	.{}	2012-06-01					H 	HIr/2     
VCAG	VCAG	.{}	2012-06-01					H 	?/2       
VCAM	VCAM	.{}	2012-06-01					H 	?/2m      
VZGE	VZGE	.{}	2012-06-01					H 	?IN/3r    
VZGR	VZGR	.{}	2012-06-01					H 	?/3r      
VZGV	VZGV	.{}	2012-06-01					H 	INr?/2    
CHIV	CHIV	.{}	2012-06-01					H 	N?/2      
CMGA	CMGA	.{}	2012-06-01					H 	Ir/1      
CMGR	CMGR	.{}	2012-06-01					H 	?/2       
CMMA	CMMA	.{}	2012-06-01					H 	Ir/1      
CMMR	CMMR	.{}	2012-06-01					H 	?/2m      
EBN1	EBN1	.{}	2012-06-01					H 	HIr/2     
EBNA	EBNA	.{}	2012-06-01					H 	?/2       
HBCA	HBCA	.{}	2012-06-01					H 	HIr/1     
HBCO	HBCO	Y	2012-06-01	2012-06-01				H 	NIr?      
HBCR	HBCR	.{}	2012-06-01					H 	?r/2      
HBVA	HBVA	.{}	2012-06-01					H 	HIr/1     
HBVR	HBVR	.{}	2012-06-01					H 	?r/2m     
HCVA	HCVA	.{}	2012-06-01					H 	Ir/1      
HCVR	HCVR	.{}	2012-06-01					H 	?/2m      
HIVA	HIVA	.{}	2012-06-01					H 	Ir/1      
HIVR	HIVR	.{}	2012-06-01					H 	?/2       
SYPA	SYPA	.{}	2012-06-01					H 	?Ir/1     
SYPR	SYPR	.{}	2012-06-01					H 	?r/2m     
TLVA	TLVA	.{}	2012-06-01					H 	Ir/1      
TLVR	TLVR	.{}	2012-06-01					H 	?/2m      
TOXG	TOXG	.{}	2012-06-01					H 	?/2       
TOXM	TOXM	.{}	2012-06-01					H 	?/2m      
TPCO	TPCO	Y	2012-06-01	2012-06-01				H 	IN?       
TXGA	TXGA	.{}	2012-06-01					H 	Ir/1      
TXMA	TXMA	.{}	2012-06-01					H 	Ir/1      
VCA1	VCA1	.{}	2012-06-01					H 	HIr/2     
VCA2	VCA2	.{}	2012-06-01					H 	HIr/2     
VCAG	VCAG	.{}	2012-06-01					H 	?/2       
VCAM	VCAM	.{}	2012-06-01					H 	?/2m      
VZGE	VZGE	.{}	2012-06-01					H 	?IN/3r    
VZGR	VZGR	.{}	2012-06-01					H 	?/3r      
VZGV	VZGV	.{}	2012-06-01					H 	INr?/2    
CMVS	CMGA	.{}	2012-06-08					H 	Ir/1      
CMVS	CMGR	.{}	2012-06-08					H 	?/2       
CMVS	CMMA	.{}	2012-06-08					H 	Ir/1      
CMVS	CMMR	.{}	2012-06-08					H 	?/2m      
POCH	PCCC	Please note that this test may not detect HIV
infection for up to three months after exposure.	2012-08-07	2012-08-07				H 	?r        
PCCH	PCCH	mkidd	2012-08-07	2012-08-07				H 	I         
POCH	POCR	HIV 1 + 2 antibodies NOT detected.	2012-08-07	2012-08-07				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-07	2012-08-07				H 	?r        
CTEL	CHLA	.{}	2012-07-05					H 	?/14m     
CTEL	CHLG	.{}	2012-07-05					H 	?/14      
CTEL	CHLM	.{}	2012-07-05					H 	?/14m     
CTEL	CTEC	.{}	2012-07-05					H 	N?        
CTEL	SAVE	.{}	2012-07-05					H 	?/2       
VLT	VLRT	.{}	2012-07-10					H 	I         
VLT	VLST	.{}	2012-07-10					H 	I/4       
VLT	VLTA	Cancelled - see comments	2012-07-10	2012-07-11				H 	NA?       
VLT	VLTC	.{ test entry }	2012-07-10					H 	N         
VLT	VLTH	.{}	2012-07-10		ug/ml			H 	/28       
VLT	VLTL	.{}	2012-07-10					H 	?         
VLT	VLTR	.{}	2012-07-10					H 	r?        
VLT	VLTT	.{}	2012-07-10		IU/ml			H 	/28       
VLT	VREF	SENT	2012-07-10	2012-07-11				H 	I?/4      
HCVL	CVL1	.{}	2012-07-17		IU/ml			H 	Hr?/5     
HCVL	CVL2	.{}	2012-07-17					H 	?r/5m     
HCV	HCVA	3.500	2012-07-17	2012-07-17				H 	Ir/1      
HCV	HCVR	Weak Reactive	2012-07-17	2012-07-17				H 	?/2m      
HCVV	HCVV	.{}	2012-07-17					H 	I/3       
POCH	PCCC	Further laboratory testing recommended.
Please review ALL this patient's virology results.	2012-08-08	2012-08-14				H 	?r        
PCCH	PCCH	mkidd	2012-08-07	2012-08-14				H 	I         
POCH	POCR	Invalid	2012-08-07	2012-08-14				H 	?r        
POCH	POCT	Clinic Nurse	2012-08-07	2012-08-14				H 	?r        
SYPS	SYPA	0.020	2012-07-18	2012-07-18				H 	?Ir/1     
SYPS	SYPR	Negative	2012-07-18	2012-07-18				H 	?r/2m     
SYPS	TPCO	Y	2012-07-18	2012-07-18				H 	IN?       
RLYM	20RD	15/04/13	2013-04-18	2013-04-19				H 	I/21?     
RLYM	20SE	12/04/13	2013-04-18	2013-04-19				H 	I/4       
RLYM	BLTG	Negative	2013-04-18	2013-04-19				H 	?H/21m    
RLYM	BLTM	Negative	2013-04-18	2013-04-19				H 	?H/21m    
RLYM	C6EI	Positive	2013-04-18	2013-04-19				H 	?HA/21    
RLYM	LYMC	This is a condensed report. Full details and
results of all assays performed are available.
If required, please contact the Virology
Department to discuss.
Telephone 020 344 78975/78986 for Virology SpR.	2013-04-18	2013-04-19				H 	N?        
RLYM	RLYL	Rare & Imported Pathogens Laboratory,
Porton Down, Wilts. SP4 0JG.	2013-04-18	2013-04-19				H 	r         
RLYM	VREF	SENT	2013-04-18	2013-04-19				H 	I?/4      
EBVS	EBN1	.{}	2014-12-15					H 	HIr/2     
EBVS	EBNA	.{}	2014-12-15					H 	?/2       
EBVS	EBVS	REPORT	2014-12-15	2014-12-16				H 	HNAp1r?   
LYME	LYGA	.{}	2014-12-15					H 	?/2       
LYME	LYMA	.{}	2014-12-15					H 	?/2       
LYME	LYMG	.{}	2014-12-15					H 	Ir/2      
LYME	LYMM	.{}	2014-12-15					H 	Ir/2      
PARV	PRGL	.{}	2014-12-15					H 	I?/2      
PARV	PRML	.{}	2014-12-15					H 	I?/2      
PARV	PRVG	.{}	2014-12-15					H 	?r/2      
PARV	PRVM	.{}	2014-12-15					H 	?r/2m     
EBVS	VCA1	.{}	2014-12-15					H 	HIr/2     
EBVS	VCAG	.{}	2014-12-15					H 	?/2       
VZVS	VZGE	.{}	2014-12-15					H 	?IN/3r    
VZVS	VZGL	.{}	2014-12-15					H 	Ir/2      
VZVS	VZGR	.{}	2014-12-15					H 	?/3r      
VZVS	VZGV	.{}	2014-12-15					H 	INr?/2    
VZVM	VZVM	.{}	2014-12-15					H 	?         
VZVS	VZVS	RESULTS	2014-12-15	2014-12-16				H 	NAHp1?    
VZVS	VZGE	.{}	2014-12-15					H 	?IN/3r    
VZVS	VZGL	.{}	2014-12-15					H 	Ir/2      
VZVS	VZGR	.{}	2014-12-15					H 	?/3r      
VZVS	VZGV	.{}	2014-12-15					H 	INr?/2    
VZVM	VZVM	.{}	2014-12-15					H 	?         
VZVS	VZVS	RESULTS	2014-12-15	2014-12-15				H 	NAHp1?    
EBVS	EBN1	.{}	2014-12-15					H 	HIr/2     
EBVS	EBNA	.{}	2014-12-16					H 	?/2       
EBVS	EBVS	REPORT	2014-12-16	2014-12-16				H 	HNAp1r?   
PARV	PRGL	.{}	2014-12-15					H 	I?/2      
PARV	PRML	.{}	2014-12-15					H 	I?/2      
PARV	PRVG	.{}	2014-12-15					H 	?r/2      
PARV	PRVM	.{}	2014-12-15					H 	?r/2m     
EBVS	VCA1	.{}	2014-12-15					H 	HIr/2     
EBVM	VCA2	.{}	2014-12-15					H 	HIr/2     
EBVS	VCAG	.{}	2014-12-15					H 	?/2       
EBVM	VCAM	.{}	2014-12-15					H 	?/2m      
VZVS	VZGE	.{}	2014-12-15					H 	?IN/3r    
VZVS	VZGL	.{}	2014-12-15					H 	Ir/2      
VZVS	VZGR	.{}	2014-12-15					H 	?/3r      
VZVS	VZGV	.{}	2014-12-15					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-15	2014-12-16				H 	NAHp1?    
EBVS	EBN1	.{}	2014-12-15					H 	HIr/2     
EBVS	EBNA	.{}	2014-12-15					H 	?/2       
EBVS	EBVS	REPORT	2014-12-15	2014-12-16				H 	HNAp1r?   
PARV	PRGL	.{}	2014-12-15					H 	I?/2      
PARV	PRML	.{}	2014-12-15					H 	I?/2      
PARV	PRVG	.{}	2014-12-15					H 	?r/2      
PARV	PRVM	.{}	2014-12-15					H 	?r/2m     
EBVS	VCA1	.{}	2014-12-15					H 	HIr/2     
EBVM	VCA2	.{}	2014-12-15					H 	HIr/2     
EBVS	VCAG	.{}	2014-12-15					H 	?/2       
EBVM	VCAM	.{}	2014-12-15					H 	?/2m      
VZVS	VZGE	.{}	2014-12-15					H 	?IN/3r    
VZVS	VZGL	.{}	2014-12-15					H 	Ir/2      
VZVS	VZGR	.{}	2014-12-15					H 	?/3r      
VZVS	VZGV	.{}	2014-12-15					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-15	2014-12-16				H 	NAHp1?    
EBVS	EBN1	.{}	2014-12-15					H 	HIr/2     
EBVS	EBNA	.{}	2014-12-15					H 	?/2       
EBVS	EBVS	REPORT	2014-12-15	2014-12-16				H 	HNAp1r?   
PARV	PRGL	.{}	2014-12-15					H 	I?/2      
PARV	PRML	.{}	2014-12-15					H 	I?/2      
PARV	PRVG	.{}	2014-12-15					H 	?r/2      
PARV	PRVM	.{}	2014-12-15					H 	?r/2m     
EBVS	VCA1	.{}	2014-12-15					H 	HIr/2     
EBVM	VCA2	.{}	2014-12-15					H 	HIr/2     
EBVS	VCAG	.{}	2014-12-15					H 	?/2       
EBVM	VCAM	.{}	2014-12-15					H 	?/2m      
VZVS	VZGE	.{}	2014-12-15					H 	?IN/3r    
VZVS	VZGL	.{}	2014-12-15					H 	Ir/2      
VZVS	VZGR	.{}	2014-12-15					H 	?/3r      
VZVS	VZGV	.{}	2014-12-15					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-15	2014-12-16				H 	NAHp1?    
EBVS	EBN1	.{}	2014-12-01					H 	HIr/2     
EBVS	EBNA	NOT detected	2014-12-01	2014-12-02				H 	?/2       
EBVS	EBNL	<3.00	2014-12-01	2014-12-02				H 	Ir/2      
EBVS	EBVS	REPORT	2014-12-01	2014-12-02				H 	HNAp1r?   
PARV	PRGL	<0.10	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRML	<0.10	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRVG	NOT detected	2014-12-01	2014-12-02				H 	?r/2      
PARV	PRVM	NOT detected	2014-12-02	2014-12-02				H 	?r/2m     
EBVS	VCA1	.{}	2014-12-01					H 	HIr/2     
EBVS	VCAG	NOT detected	2014-12-01	2014-12-02				H 	?/2       
EBVM	VCAM	NOT detected	2014-12-01	2014-12-02				H 	?/2m      
EBVS	VCGL	<10.0	2014-12-01	2014-12-02				H 	Ir/2      
EBVM	VCML	<10.0	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGE	.{}	2014-12-01					H 	?IN/3r    
VZVS	VZGL	<10.00	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGR	NOT detected	2014-12-01	2014-12-02				H 	?/3r      
VZVS	VZGV	.{}	2014-12-01					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-01	2014-12-02				H 	NAHp1?    
EBVS	EBN1	.{}	2014-12-01					H 	HIr/2     
EBVS	EBNA	NOT detected	2014-12-01	2014-12-02				H 	?/2       
EBVS	EBNL	<3.00	2014-12-01	2014-12-02				H 	Ir/2      
EBVS	EBVS	REPORT	2014-12-01	2014-12-02				H 	HNAp1r?   
PARV	PRGL	<0.10	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRML	<0.10	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRVG	NOT detected	2014-12-01	2014-12-02				H 	?r/2      
PARV	PRVM	NOT detected	2014-12-02	2014-12-02				H 	?r/2m     
EBVS	VCA1	.{}	2014-12-01					H 	HIr/2     
EBVS	VCAG	NOT detected	2014-12-01	2014-12-02				H 	?/2       
EBVM	VCAM	NOT detected	2014-12-01	2014-12-02				H 	?/2m      
EBVS	VCGL	<10.0	2014-12-01	2014-12-02				H 	Ir/2      
EBVM	VCML	<10.0	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGE	.{}	2014-12-01					H 	?IN/3r    
VZVS	VZGL	<10.00	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGR	NOT detected	2014-12-01	2014-12-02				H 	?/3r      
VZVS	VZGV	.{}	2014-12-01					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-01	2014-12-02				H 	NAHp1?    
EBVS	EBN1	.{}	2014-12-01					H 	HIr/2     
EBVS	EBNA	NOT detected	2014-12-01	2014-12-02				H 	?/2       
EBVS	EBNL	<3.00	2014-12-01	2014-12-02				H 	Ir/2      
EBVS	EBVS	REPORT	2014-12-01	2014-12-02				H 	HNAp1r?   
PARV	PRGL	<0.10	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRML	<0.10	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRVG	NOT detected	2014-12-01	2014-12-02				H 	?r/2      
PARV	PRVM	NOT detected	2014-12-02	2014-12-02				H 	?r/2m     
EBVS	VCA1	.{}	2014-12-01					H 	HIr/2     
EBVS	VCAG	NOT detected	2014-12-01	2014-12-02				H 	?/2       
EBVM	VCAM	NOT detected	2014-12-01	2014-12-02				H 	?/2m      
EBVS	VCGL	<10.0	2014-12-01	2014-12-02				H 	Ir/2      
EBVM	VCML	<10.0	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGE	.{}	2014-12-01					H 	?IN/3r    
VZVS	VZGL	<10.00	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGR	NOT detected	2014-12-01	2014-12-02				H 	?/3r      
VZVS	VZGV	.{}	2014-12-01					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-01	2014-12-02				H 	NAHp1?    
ACLA	ACLG	2.2Neg	2011-11-03	2011-11-03	GPLU	0	5	A 	A/10      
ACLA	ACLM	0.5Neg	2011-11-03	2011-11-03	MPLU	0	5	A 	/10       
B2G	B2GG	Cancelled - see comments	2011-12-30	2011-12-30	GPLU	0	3.5	A 	A/14      
B2G	B2GM	Cancelled - see comments	2011-12-30	2011-12-30	MPLU	0	3	A 	/14       
ACLA	ACLG	6.7Neg	2011-11-03	2011-11-03	GPLU	0	5	A 	A/10      
ACLA	ACLM	2.7Neg	2011-11-03	2011-11-03	MPLU	0	5	A 	/10       
B2G	B2GG	Cancelled - see comments	2011-12-30	2011-12-30	GPLU	0	3.5	A 	A/14      
B2G	B2GM	Cancelled - see comments	2011-12-30	2011-12-30	MPLU	0	3	A 	/14       
LSUB	3A	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	x 10^9/L	0.87	2.51	A 	N         
LSUB	3P	Cancelled -  sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	%	57	87	A 	PN        
LSUB	48R	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15		0.54	2.97	A 	          
LSUB	4A	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	x 10^9/L	0.44	1.47	A 	NQ        
LSUB	4C3A	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	x 10^9/L	0.56	1.46	A 	P         
LSUB	4C3P	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	%	31	61	A 	P         
LSUB	4P	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	%	31	64	A 	NP        
LSUB	8A	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	x 10^9/L	0.29	1.05	A 	N         
LSUB	8C3A	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	x 10^9/L	0.25	0.99	A 	          
LSUB	8C3P	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	%	10	36	A 	P         
LSUB	8P	Regret sample for lymphocyte subsets clotted	2011-12-14	2011-12-15	%	16	40	A 	PN        
LSUB	CLY	Regret sample for lymphocyte subsets clotted	2011-12-14					X 	NQ        
LSUB	LY	.{}	2011-12-14		x10^9/L	1.2	3.65	A 	CDSP/0    
LSUB	WCC	.{}	2011-12-14		x10^9/L	3.0	10.0	A 	CWPS/0    
FBCY	CHCU	34.2
Note: reference range change from 04/08/11	2012-06-21	2012-06-21	g/dl	32.0	34.9	A 	NCPS/0    
FBCY	HCTU	0.471	2012-06-21	2012-06-21	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	16.1	2012-06-21	2012-06-21	g/dl	11.5	15.5	A 	NrCP/0    
FBCY	MCHU	30.3	2012-06-21	2012-06-21	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	88.7	2012-06-21	2012-06-21	fL	80	99	A 	CPS/0     
FBCY	MPVU	10.5	2012-06-21	2012-06-21	fL	7	13	A 	CS?/0     
FBCY	PLT	233	2012-06-21	2012-06-21	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	5.31	2012-06-21	2012-06-21	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	12.2	2012-06-21	2012-06-21	%	11.5	15.0	A 	CS/0      
FBCY	WCC	6.40	2012-06-21	2012-06-21	x10^9/L	3.0	10.0	A 	CWPS/0    
COAG	APRA	1.1	2012-06-22	2012-06-22		2.0	3.0	A 	?/1       
COAG	APTT	36	2012-06-22	2012-06-22	secs	22	41	A 	P/1       
FBCZ	BA	.2	2012-06-22	2012-06-22	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	34.2	2012-06-22	2012-06-22	g/dl	32.0	34.9	A 	NCPS/0    
ELU	CREA	104	2012-06-22	2012-06-22	umol/L	49	92	B 	CPr       
CRP	CRP	1.2	2012-06-22	2012-06-22	mg/L	0	5.0	B 	AB        
FBCZ	EO	.5	2012-06-22	2012-06-22	x10^9/L	0.0	0.4	A 	CDSN/0    
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-06-22	2012-06-22	.			B 	          
ELU	H	5	2012-06-22					  	JNr       
FBCY	HCTU	0.471	2012-06-22	2012-06-22	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	16.1	2012-06-22	2012-06-22	g/dl	11.5	15.5	A 	NrCP/0    
ELU	I	No Icterus	2012-06-22					  	JN        
FBCZ	IG	.{}	2012-06-22		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2012-06-22		%			A 	SN/0      
COAG	INR	2.30	2012-06-22	2012-06-22				A 	/1        
ELU	K	3.4	2012-06-22	2012-06-22	mmol/L	3.5	5.1	B 	CP        
ELU	L	19	2012-06-22					  	JN        
FBCZ	LY	24.5%  1.57	2012-06-22	2012-06-22	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	30.3	2012-06-22	2012-06-22	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	88.7	2012-06-22	2012-06-22	fL	80	99	A 	CPS/0     
FBCZ	MO	13.6%  0.87	2012-06-22	2012-06-22	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	10.5	2012-06-22	2012-06-22	fL	7	13	A 	CS?/0     
ELU	NA	140	2012-06-22	2012-06-22	mmol/L	135	145	B 	CP        
FBCZ	NE	61.2%  3.92	2012-06-22	2012-06-22	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	233	2012-06-22	2012-06-22	x10^9/L	150	400	A 	CS/0      
COAG	PT	10.5	2012-06-22	2012-06-22	secs	10.0	12.0	A 	/1        
FBCY	RCC	5.31	2012-06-22	2012-06-22	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	12.2	2012-06-22	2012-06-22	%	11.5	15.0	A 	CS/0      
COAG	TT	13	2012-06-22	2012-06-22	secs	9	15	A 	r/1       
ELU	UREA	4.6	2012-06-22	2012-06-22	mmol/L	1.7	8.3	B 	CP        
FBCY	WCC	6.40	2012-06-22	2012-06-22	x10^9/L	3.0	10.0	A 	CWPS/0    
ELU	ZAGE	43	2012-06-22		y			X 	          
BON	ALB	38	2012-06-22	2012-06-22	g/L	34	50	B 	CP        
BON	ALP	60	2012-06-22	2012-06-22	IU/L	35	104	B 	C         
BON	CA	1.80	2012-06-22	2012-06-22	mmol/L	2.15	2.55	B 	CP        
CK	CK	83	2012-06-22	2012-06-22	IU/L	26	140	B 	          
CL	CL	100	2012-06-22	2012-06-22	mmol/L	98	107	B 	CP        
ESR	ESR	22	2012-06-22	2012-06-22	mm/hr	1	20	A 	C?/0      
MG	MG	1.10	2012-06-22	2012-06-22	mmol/L	0.60	1.00	B 	CP        
OSM	OSMO	290	2012-06-22	2012-06-22	mosmol/kg	285	295	B 	          
PHEN	PHEN	60	2012-06-22	2012-06-22	umol/L	40	80	B 	          
BON	PHOS	2.20	2012-06-22	2012-06-22	mmol/L	0.87	1.45	B 	CP        
TPT	TPT	0.015
0.00-0.04 Unlikely to have acute coronary syndrome
0.05-0.09 Possible ACS, suggest cardiology opinion
>=0.10    Probable ACS	2012-06-22	2012-06-22	ug/L	0	0.01	B 	          
CSFP	CAPP	Slightly bloodstained	2012-06-22	2012-06-22				B 	N         
CGLU	CGLU	1.1	2012-06-22	2012-06-22	mmol/L	2.2	3.9	B 	          
CSFP	CSFT	Lumbar	2012-06-22	2012-06-22				B 	=?        
CSFP	CTP	0.50
Please note amended reference range due to
change in methodology.	2012-06-22	2012-06-22	g/L	0.13	0.40	B 	          
UOSM	UOSM	420	2012-06-22	2012-06-22	mosmol/kg	300	900	B 	          
CK	CK	45	2012-06-27	2012-06-27	IU/L	26	140	B 	          
MPRL	EBP	858	2012-10-15	2012-10-15	mIU/L			B 	QIJ       
MPRL	MPRL	This is a test comment	2012-10-15	2012-10-15				B 	?         
MPRL	PEG1	408	2012-10-15	2012-10-15	mIU/L			B 	NIJ       
MPRL	PEG2	449	2012-10-15	2012-10-15	mIU/L			B 	NIJ       
MPRL	PEGR	88	2012-10-15	2012-10-15	%			B 	QIJ       
PRL	PROL	978	2012-10-15	2012-10-15	mIU/L	102	496	B 	CP        
AHP	AHP	.
(Results may be higher in luteal phase)	2012-11-09		nmol/L	0	6	B 	A         
ELU	CREA	25	2012-06-27	2012-06-27	umol/L	49	92	B 	CPr       
ELU	GFR	55
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to	2012-06-27	2012-06-27	.			B 	          
ELU	K	3.4	2012-06-27	2012-06-27	mmol/L	3.5	5.1	B 	CP        
ELU	NA	140	2012-06-27	2012-06-27	mmol/L	135	145	B 	CP        
ELU	UREA	1.5	2012-06-27	2012-06-27	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	49	2012-06-27		y			X 	          
COSC	COSC	ESCCOL/ENTFAS/	2012-06-21					X 	J-        
COSD	COSD	Organisms sent 21/06/2012 13:23	2012-06-21					X 	J-        
KLA	KLA	SENT TO KIESTRA	2012-06-21					X 	-JNH      
URNM	UCAS	.{}	2012-06-21					M 	?Nr       
URNM	UCAT	.{}	2012-06-21					M 	N         
URNM	UEPC	Scanty	2012-06-21	2012-06-21				M 	?rN       
URNC	UISO	:
Heavy growth of Escherichia coli
Moderate growth of Enterococcus faecalis	1899-12-30	2012-06-21				M 	ABMr?/2aN 
URNM	URBC	Moderate	2012-06-21	2012-06-21				M 	?rN       
URNC	URCC	Y	2012-06-21	2012-06-21				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2012-06-21	2012-06-21				M 	Hp1p2AB?  
URNM	URNM	URINE MICROSCOPY REPORT	2012-06-21	2012-06-21				M 	HXp1p2AB? 
URNC	URST	COMPLETE: 21/06/12	2012-06-21	2012-06-21				M 	N?Ar/2    
URNM	UWBC	Numerous	2012-06-21	2012-06-21				M 	?r/0      
URNM	UYEA	Very Scanty	2012-06-21	2012-06-21				M 	?N        
COSC	COSC	ESCCOL/KLEPNE/	2012-06-22					X 	J-        
COSD	COSD	Organisms sent 22/06/2012 15:17	2012-06-22					X 	J-        
KLA	KLA	SENT TO KIESTRA	2012-06-22					X 	-JNH      
URNM	UCAS	.{}	2012-06-22					M 	?Nr       
URNM	UCAT	.{}	2012-06-22					M 	N         
URNM	UEPC	+-	2012-06-22	2012-06-22				M 	?rN       
URNC	UISO	:
Heavy growth of Escherichia coli
Moderate growth of Klebsiella pneumoniae	1899-12-30	2012-06-22				M 	ABMr?/2aN 
URNM	URBC	+	2012-06-22	2012-06-22				M 	?rN       
URNC	URCC	Y	2012-06-22	2012-06-22				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2012-06-22	2012-06-22				M 	Hp1p2AB?  
URNM	URNM	URINE MICROSCOPY REPORT	2012-06-22	2012-06-22				M 	HXp1p2AB? 
URNC	URST	COMPLETE: 22/06/12	2012-06-22	2012-06-22				M 	N?Ar/2    
URNM	UWBC	++	2012-06-22	2012-06-22				M 	?r/0      
HES	HBA2	2.6	2012-06-25	2012-06-25	%	2.0	3.4	A 	N         
HES	HBF	0.2	2012-06-25	2012-06-25	%			A 	N         
HES	HCON	Possible iron deficiency and/or alpha thalassaemia
carrier. No evidence of sickle or other abnormal
haemoglobin.	2012-06-25	2012-06-25				A 	?p1       
HES	HGBA	Predominant	2012-06-25	2012-06-25	%			A 	?         
HES	HBA2	3.0	2012-06-25	2012-06-25	%	2.0	3.4	A 	N         
HES	HBF	0.6	2012-06-25	2012-06-25	%			A 	N         
HES	HCON	Possible iron deficiency and/or alpha thalassaemia
carrier. No evidence of sickle or other abnormal
haemoglobin.	2012-06-25	2012-06-25				A 	?p1       
HES	HGBA	Predominant	2012-06-25	2012-06-25	%			A 	?         
HES	HBAT	92.1	2012-06-25	2012-06-25	%			A 	N         
HES	HBF	2.7	2012-06-25	2012-06-25	%			A 	N         
HES	HCON	.{}	2012-06-25					A 	?p1       
HES	HGBS	5.2	2012-06-25	2012-06-25	%			A 	N         
LPF	CHDR	2.4	2012-03-29	2012-03-29				B 	          
LPF	CHOL	3.1	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	82	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.15	2012-03-29					X 	N         
ELU	GFR	77
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.6	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.3	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.2	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	1.4	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.9	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.2	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.2	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.8	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	54	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.90	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.3	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	2.2	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.0	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	1	2012-03-29					  	JN        
LPF	LDLU	2.1	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	1.0	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	3.1	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.1	2012-03-29	2012-03-29				B 	          
LPF	CHOL	3.7	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	82	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.15	2012-03-29					X 	N         
ELU	GFR	77
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.4	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.2	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	1.9	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	144	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	1.3	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.7	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.8	2012-03-29	2012-03-29				B 	          
LPF	CHOL	5.7	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	71	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.36	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.8	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.5	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.9	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	12	2012-03-29					  	JN        
LPF	LDLU	3.3	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	137	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	1.9	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.3	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.5	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.5	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	80	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.18	2012-03-29					X 	N         
ELU	GFR	79
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.4	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.8	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.3	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	1	2012-03-29					  	JN        
LPF	LDLU	2.4	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.7	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.2	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.3	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.6	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	73	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.32	2012-03-29					X 	N         
ELU	GFR	88
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.7	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.4	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	7	2012-03-29					  	JN        
LPF	LDLU	2.8	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	139	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.8	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.4	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.0	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.3	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	78	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.22	2012-03-29					X 	N         
ELU	GFR	82
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.9	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	2.1	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.1	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	10	2012-03-29					  	JN        
LPF	LDLU	2.0	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.5	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.9	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.7	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.8	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	90	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.02	2012-03-29					X 	N         
ELU	GFR	68
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.4	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.8	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.5	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	7	2012-03-29					  	JN        
LPF	LDLU	2.6	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	141	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.9	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.4	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.2	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.7	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	54	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.90	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.2	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	2.1	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.1	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	2	2012-03-29					  	JN        
LPF	LDLU	2.3	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.6	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	3.6	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.0	2012-03-29	2012-03-29				B 	          
LPF	CHOL	3.6	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	102	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	0.88	2012-03-29					X 	N         
ELU	GFR	59
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	6.0	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.2	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	0	2012-03-29					  	JN        
LPF	LDLU	2.0	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.8	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.7	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.3	2012-03-29	2012-03-29				B 	          
LPF	CHOL	7.2	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	65	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.52	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.8	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	2.2	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	4.5	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	1.0	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.3	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.2	2012-03-29	2012-03-29				B 	          
LPF	CHOL	5.8	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	75	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.27	2012-03-29					X 	N         
ELU	GFR	85
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.9	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.8	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.5	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	3.6	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	138	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.8	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.7	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.7	2012-03-29	2012-03-29				B 	          
LPF	CHOL	6.2	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	62	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.60	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.5	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	2.3	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	3.6	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.6	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.9	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.3	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.1	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	80	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.18	2012-03-29					X 	N         
ELU	GFR	79
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.5	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.8	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.2	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	8	2012-03-29					  	JN        
LPF	LDLU	2.0	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.6	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.2	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.9	2012-03-29	2012-03-29				B 	          
LPF	CHOL	3.8	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	90	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.02	2012-03-29					X 	N         
ELU	GFR	68
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.0	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.3	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	2.1	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.9	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	7.6	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.3	2012-03-29	2012-03-29				B 	          
LPF	CHOL	3.2	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	78	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.22	2012-03-29					X 	N         
ELU	GFR	82
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.5	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.4	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.2	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	3	2012-03-29					  	JN        
LPF	LDLU	1.3	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	1.0	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	3.5	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	8.6	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.3	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	83	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.13	2012-03-29					X 	N         
ELU	GFR	76
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.1	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	0.5	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	154	2012-03-29					  	JN        
LPF	LDLU	Regret unable to accurately assess LDL
Cholesterol due to high Triglyceride
level.	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	138	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	7.1	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.0	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.7	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.8	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	84	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.11	2012-03-29					X 	N         
ELU	GFR	74
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.6	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.3	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.3	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	2	2012-03-29					  	JN        
LPF	LDLU	3.1	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	144	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.8	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.5	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.1	2012-03-29	2012-03-29				B 	          
LPF	CHOL	6.2	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	67	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.46	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.6	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	2.0	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.3	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	3	2012-03-29					  	JN        
LPF	LDLU	3.8	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.8	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.5	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	3.3	2012-03-29	2012-03-29				B 	          
LPF	CHOL	4.3	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	81	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.16	2012-03-29					X 	N         
ELU	GFR	78
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	5.2	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.3	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.4	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	19	2012-03-29					  	JN        
LPF	LDLU	2.6	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	143	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.8	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.8	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.8	2012-03-29	2012-03-29				B 	          
LPF	CHOL	2.5	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	76	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.25	2012-03-29					X 	N         
ELU	GFR	84
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.9
Reference range applies to fasting samples only.	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	0.9	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.5	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	6	2012-03-29					  	JN        
LPF	LDLU	1.2	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
LPF	NHDL	.	2015-01-31		mmol/L			B 	r         
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	0.9	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	3.3	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
CHAL	CHAL	.	2013-05-17					B 	=?        
CHAL	CHAS	Sent	2012-12-03					B 	?         
LPF	CHDR	3.4	2012-03-29	2012-03-29				B 	          
LPF	CHOL	5.4	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	60	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.67	2012-03-29					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	6.1	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.6	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
ELU	K	4.3	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	4	2012-03-29					  	JN        
LPF	LDLU	3.2	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	142	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
LPF	TRIG	1.3	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.7	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
LPF	CHDR	2.3	2012-03-29	2012-03-29				B 	          
LPF	CHOL	3.9	2012-03-29	2012-03-29	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	78	2012-03-29	2012-03-29	umol/L	49	92	B 	CPr       
ELU	FACR	1.22	2012-03-29					X 	N         
IRON	FE	.	2013-01-29		umol/L	6.6	26.0	B 	CPA       
ELU	GFR	82
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-03-29	2012-03-29	.			B 	          
GLU	GLU	4.9	2012-03-29	2012-03-29	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-03-29					  	JNr       
LPF	HDL	1.7	2012-03-29	2012-03-29	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-03-29					  	JN        
IRON	IBS	.	2013-01-29		%	15	50	B 	B         
ELU	K	4.3	2012-03-29	2012-03-29	mmol/L	3.5	5.1	B 	CP        
ELU	L	3	2012-03-29					  	JN        
LPF	LDLU	1.8	2012-03-29	2012-03-29	mmol/L	0	3.5	B 	          
ELU	NA	140	2012-03-29	2012-03-29	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2012-03-29					X 	N         
IRON	TIBC	.	2013-01-29		umol/L	41	77	B 	          
LPF	TRIG	0.9	2012-03-29	2012-03-29	mmol/L	0.4	2.3	B 	P         
IRON	UIBC	.	2013-01-29		umol/L	20	66	B 	          
ELU	UREA	5.8	2012-03-29	2012-03-29	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-03-29		y			X 	          
VITD	25D2	19	2012-04-30	2012-04-30	nmol/L			B 	rN        
VITD	25D3	14	2012-04-30	2012-04-30	nmol/L			B 	rN        
UCIT	CITR	0.07	2018-02-13	2018-02-19				B 	r         
UCIT	CITX	1.20	2018-02-13	2018-02-19				B 	rN        
24H	CREX	16.5	2018-02-13	2018-02-13				B 	QN        
UOXA	OXCR	30	2018-02-13	2018-02-19				B 	r         
UCIT	UCIT	0.60	2018-02-13	2018-02-19				B 	rPA       
24H	UCR 	8255	2018-02-13	2018-02-13				B 	          
UOXA	UOX 	250	2018-02-13	2018-02-19				B 	rPA       
UOXA	UOXX	500	2018-02-13	2018-02-19				B 	rN        
24H	UT  	24.0	2018-02-13	2018-02-13				B 	P=        
24H	UV  	2000	2018-02-13	2018-02-13				B 	PS=       
VITD	VITD	33
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2012-04-30	2012-04-30	nmol/L	25	120	B 	r         
SAL	SALY	8.4	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	6.1	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	16	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	4.8	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	8.9	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	11.3	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	8.6	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	14.5	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	4.8	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	9.5	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
SAL	SALY	Not Detected	2012-05-17	2012-05-17	mg/L			B 	          
LFT 	ALB	45	2012-11-22	2012-11-22	g/L	34	50	B 	CP        
LFT 	ALP	88	2012-11-22	2012-11-22	IU/L	40	129	B 	C         
LFT 	ALT	30	2012-11-22	2012-11-22	IU/L	10	50	B 	C         
LFT 	BILI	9	2012-11-22	2012-11-22	umol/L	0	137	B 	CPr       
BON 	CA	2.42	2012-11-22	2012-11-22	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.3	2012-11-22	2012-11-22				B 	          
LPF	CHOL	5.0	2012-11-22	2012-11-22	mmol/L	2.5	5.0	B 	PA        
ELU 	CREA	72	2012-11-22	2012-11-22	umol/L	66	112	B 	CPr       
ELU 	FACR	1.34	2012-11-22					X 	N         
ELU 	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-11-22	2012-11-22	.			B 	          
GLU	GLU	4.2	2012-11-22	2012-11-22	mmol/L	3.9	5.8	B 	AB        
LFT 	H	6	2012-11-22					  	JNr       
LPF	HDL	1.5	2012-11-22	2012-11-22	mmol/L	0.9	1.5	B 	          
LFT 	I	17	2012-11-22					  	JN        
ELU 	K	4.4	2012-11-22	2012-11-22	mmol/L	3.5	5.1	B 	CP        
LFT 	L	16	2012-11-22					  	JN        
LPF	LDLU	2.8	2012-11-22	2012-11-22	mmol/L	0	3.5	B 	          
ELU 	NA	143	2012-11-22	2012-11-22	mmol/L	135	145	B 	CP        
BON 	PHOS	1.16	2012-11-22	2012-11-22	mmol/L	0.87	1.45	B 	CP        
RAK1	RAK1	[P1/Rack:ARCHIVE-84/E13|08:47]
[P1/Rack:ARCHIVE-85/E13|10:08]	2012-11-22					X 	NJ        
RAK2	RAK2	[P2/Rack:ARCHIVE-84/E15|08:47]	2012-11-22					X 	NJ        
ELU 	SEX	1.0	2012-11-22					X 	N         
LPF	TRIG	1.6	2012-11-22	2012-11-22	mmol/L	0.4	2.3	B 	P         
ELU 	UREA	4.8	2012-11-22	2012-11-22	mmol/L	1.7	8.3	B 	CP        
ELU 	ZAGE	45	2012-11-22		y			X 	          
HBSS	BCMA	.{P/Rack:Arch/A01|10:43}	2012-11-22					H 	HIr/2     
HBSS	BCMR	.	2012-11-22					H 	?/2m      
HBSS	EABA	1.110	2012-11-22	2012-11-22				H 	HIr/2     
HBSS	EABR	.{ Not Detected }	2012-11-22					H 	?r/2      
HBSS	EAGA	0.094	2012-11-22	2012-11-22				H 	HIr/2     
HBSS	EAGR	.{ Not Detected }	2012-11-22					H 	?/2       
FERR	FERR	171	2012-11-22	2012-11-22	ug/L	30	400	B 	          
FSH	FSH	19.1	2012-11-22	2012-11-22	IU/L	1.5	12.4	B 	          
THY	FT4	15.4	2012-11-22	2012-11-22	pmol/L	12.0	22.0	B 	Cr        
SIND	H	5	2012-11-22					  	JNr       
HBC 	HBCA	.{ 0.006 }	2012-11-22					H 	HIr/1     
HBCC	HBCC	.	2012-11-22					H 	Nr?/2     
HBC 	HBCR	.{ Positive }	2012-11-22					H 	?r/2      
HBS 	HBSA	.{ 81.07 }	2012-11-22					H 	HIr/1     
HBS 	HBSI	.{ Weak Reactive }	2012-11-22					H 	r?/2      
HBS 	HBSR	.{ 83 }	2012-11-22		IU/l			H 	?r/2      
HBAG	HBVA	.{ 52.750 }	2012-11-22					H 	HIr/1     
HBAG	HBVR	.{ Positive }	2012-11-22					H 	?r/2m     
HBVV	HBVV	.	2012-11-22					H 	HI        
SIND	I	17	2012-11-22					  	JN        
SIND	L	14	2012-11-22					  	JN        
LH	LH	12.4	2012-11-22	2012-11-22	IU/L	1.7	8.6	B 	          
PRL 	PROL	520	2012-11-22	2012-11-22	mIU/L	86	324	B 	CP        
RAK1	RAK1	[P1/Rack:ARCHIVE-84/E17|08:47]	2012-11-22					X 	NJ        
THY	TSH	2.45	2012-11-22	2012-11-22	mIU/L	0.27	4.20	B 	Cr        
FBCZ	BA	 4.0%  0.50	2012-05-01	2012-05-01	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	35.6
Note: reference range change from 04/08/11	2012-05-01	2012-05-01	g/dl	32.0	34.9	A 	NCPS/0    
FBCZ	EO	 6.0%  0.74	2012-05-01	2012-05-01	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HCTU	0.345	2012-05-01	2012-05-01	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	15.2	2012-05-01	2012-05-01	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	LY	15.0%  1.86	2012-05-01	2012-05-01	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	36.6	2012-05-01	2012-05-01	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	76.8	2012-05-01	2012-05-01	fL	80	99	A 	CPS/0     
FBCZ	MO	10.0%  1.24	2012-05-01	2012-05-01	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	3.2	2012-05-01	2012-05-01	fL	7	13	A 	CS?/0     
FBCZ	NE	65.0%  8.06	2012-05-01	2012-05-01	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	175	2012-05-01	2012-05-01	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	3.40	2012-05-01	2012-05-01	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	14.2	2012-05-01	2012-05-01	%	11.5	15.0	A 	CS/0      
FBCY	WCC	12.40	2012-05-01	2012-05-01	x10^9/L	3.0	10.0	A 	CWPS/0    
ACLA	ACLG	3.0	2012-05-01	2012-05-01	GPLU	0	5	A 	A/10      
ACLA	ACLM	3.0	2012-05-01	2012-05-01	MPLU	0	5	A 	/10       
APCM	APCM	3.00	2012-05-01	2012-05-01		>2.0		A 	A/14      
THR 	AT3	1.00	2012-05-01	2012-05-01	IU/ml	0.80	1.30	A 	/14       
DRVT	DRV1	30.0	2012-05-01		secs			X 	Pr/14     
DRVT	DRV2	30.0	2012-05-01		secs			X 	NP/14     
DRVT	DRV3	1.0	2012-05-01	2012-05-01		0.90	1.20	A 	Pr/14     
DRVT	DRV4	30.0	2012-05-01		secs			X 	PN/14     
DRVT	DRV5	1.0	2012-05-01	2012-05-01		0.9	1.2	A 	NQ/14     
DRVT	DRV6	30.0	2012-05-01		secs			X 	N/14      
DRVT	DRV7	30.0	2012-05-01		secs			X 	NP/14     
DRVT	DRV8	1.0	2012-05-01	2012-05-01				A 	NP/14     
FIB1	FIB1	1.00	2012-05-01	2012-05-01	g/L			A 	p1/14     
FVL	FVL	G/G Normal	2012-05-01	2012-05-01				A 	/21?H     
THR 	PC	1.00	2012-05-01	2012-05-01	IU/ml	0.7	1.30	A 	P/14      
THR 	PSF	1.0	2012-05-01	2012-05-01	IU/ml			A 	P/14      
ACLA	ACLG	3.0	2012-05-01	2012-05-01	GPLU	0	5	A 	A/10      
ACLA	ACLM	3.0	2012-05-01	2012-05-01	MPLU	0	5	A 	/10       
APCM	APCM	3.00	2012-05-01	2012-05-01		>2.0		A 	A/14      
THR1	AT3	1.00	2012-05-01	2012-05-01	IU/ml	0.80	1.30	A 	/14       
FIB1	FIB1	1.00	2012-05-01	2012-05-01	g/L			A 	p1/14     
PC7 	FVII	1.00	2012-05-01	2012-05-01	IU/ml	0.5	1.5	A 	/14       
FVL	FVL	G/G Normal	2012-05-01	2012-05-01				A 	/21?H     
PSX 	FX	1.0	2012-05-01	2012-05-01	IU/ml			A 	/14       
THR1	PC	1.00	2012-05-01	2012-05-01	IU/ml	0.7	1.30	A 	P/14      
THR1	PC7R	1.00	2012-05-01	2012-05-01		0.76		A 	Q/14      
THR1	PSF	1.0	2012-05-01	2012-05-01	IU/ml			A 	P/14      
THR1	PSXR	1.00	2012-05-01	2012-05-01				A 	Q/14      
TVT 	TVT1	30.0	2012-05-01		secs			X 	P/14      
TVT 	TVT2	30.0	2012-05-01		secs			X 	P/14      
TVT 	TVT3	1.0	2012-05-01	2012-05-01		0.90	1.10	A 	NPQ/14    
TVT 	TVT4	30.0	2012-05-01		secs			X 	PN/14     
TVT 	TVT5	1.0	2012-05-01	2012-05-01		0.90	1.10	A 	N/14      
TVT 	TVT6	30.0	2012-05-01		secs			X 	PN/14     
TVT 	TVT7	30.0	2012-05-01		secs			X 	PN/14     
TVT 	TVT8	1.0	2012-05-01	2012-05-01				A 	N/14      
DRVT	DRV1	30.0	2012-05-01		secs			X 	Pr/14     
DRVT	DRV2	30.0	2012-05-01		secs			X 	NP/14     
DRVT	DRV3	1.0	2012-05-01	2012-05-01		0.90	1.20	A 	Pr/14     
DRVT	DRV4	30.0	2012-05-01		secs			X 	PN/14     
DRVT	DRV5	1.0	2012-05-01	2012-05-01		0.9	1.2	A 	NQ/14     
DRVT	DRV6	30.0	2012-05-01		secs			X 	N/14      
DRVT	DRV7	30.0	2012-05-01		secs			X 	NP/14     
DRVT	DRV8	1.0	2012-05-01	2012-05-01				A 	NP/14     
LUP	ACLG	3.0	2012-05-01	2012-05-01	GPLU	0	5	A 	A/10      
LUP	ACLM	3.0	2012-05-01	2012-05-01	MPLU	0	5	A 	/10       
LUP	DRV1	30.0	2012-05-01		secs			X 	Pr/14     
LUP	DRV2	30.0	2012-05-01		secs			X 	NP/14     
LUP	DRV3	1.0	2012-05-01	2012-05-01		0.90	1.20	A 	Pr/14     
LUP	DRV4	30.0	2012-05-01		secs			X 	PN/14     
LUP	DRV5	1.0	2012-05-01	2012-05-01		0.9	1.2	A 	NQ/14     
LUP	DRV6	30.0	2012-05-01		secs			X 	N/14      
LUP	DRV7	30.0	2012-05-01		secs			X 	NP/14     
LUP	DRV8	1.0	2012-05-01	2012-05-01				A 	NP/14     
TVT	TVT1	30.0	2012-05-01		secs			X 	P/14      
TVT	TVT2	30.0	2012-05-01		secs			X 	P/14      
TVT	TVT3	1.0	2012-05-01	2012-05-01		0.90	1.10	A 	NPQ/14    
TVT	TVT4	30.0	2012-05-01		secs			X 	PN/14     
TVT	TVT5	1.0	2012-05-01	2012-05-01		0.90	1.10	A 	N/14      
TVT	TVT6	30.0	2012-05-01		secs			X 	PN/14     
TVT	TVT7	30.0	2012-05-01		secs			X 	PN/14     
TVT	TVT8	1.0	2012-05-01	2012-05-01				A 	N/14      
LPF	CHDR	2.9	2012-04-03	2012-04-03				B 	          
LPF	CHOL	5.0	2012-04-03	2012-04-03	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	74	2012-04-03	2012-04-03	umol/L	49	92	B 	CPr       
ELU	FACR	1.30	2012-04-03					X 	N         
ELU	GFR	87
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2012-04-03	2012-04-03	.			B 	          
GLU	GLU	5.8	2012-04-03	2012-04-03	mmol/L	3.9	5.8	B 	AB        
ELU	H	No Haemolysis	2012-04-03					  	JNr       
LPF	HDL	1.7	2012-04-03	2012-04-03	mmol/L	1.2	1.7	B 	          
ELU	I	No Icterus	2012-04-03					  	JN        
ELU	K	4.3	2012-04-03	2012-04-03	mmol/L	3.5	5.1	B 	CP        
ELU	L	7	2012-04-03					  	JN        
LPF	LDLU	2.8	2012-04-03	2012-04-03	mmol/L	0	3.5	B 	          
ELU	NA	141	2012-04-03	2012-04-03	mmol/L	135	145	B 	CP        
RAK1	RAK1	[P1/Rack:ARCHIVE-60/E19|15:21]	2012-04-03					X 	NJ        
RAK2	RAK2	[P2/Rack:ARCHIVE-63/E19|16:44]	2012-04-03					X 	NJ        
ELU	SEX	0.742	2012-04-03					X 	N         
LPF	TRIG	1.1	2012-04-03	2012-04-03	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.1	2012-04-03	2012-04-03	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	26	2012-04-03		y			X 	          
HEVP	HERN	Not Detected	2012-04-23	2012-04-23				H 	?rm/20    
HEVP	HEVS	EDBL	2012-04-23	2012-04-23				H 	N?m       
HEVP	HERN	Positive	2012-04-23	2012-04-23				H 	?rm/20    
HEVP	HEVS	EDBL	2012-04-23	2012-04-23				H 	N?m       
HEVP	HERN	test	2012-05-16	2012-05-16				H 	?rm/20    
HEVP	HEVS	EDBL	2012-04-23	2012-04-23				H 	N?m       
HBVL	BVL1	.{ 0 }	2012-05-15		IU/ml			H 	HAr?/5    
HBVL	BVL2	Not Detected	2012-05-15	2012-05-15				H 	?r/5      
HBVL	HBVS	EDBL	2012-05-15	2012-05-15				H 	?rB/5     
CTX	CTX	1.24
Ranges apply to pre-menopausal women only.
Result from Norfolk & Norwich Hospitals	2013-09-20	2013-09-20	ug/L			B 	r/30      
FTDS	FHCG	27.84	2012-09-10	2012-09-10	mIU/ml			B 	          
P1P	P1P	354
Ranges apply to pre-menopausal women only.
Result from Norfolk & Norwich Hospitals	2013-09-20	2013-09-20	ug/L			B 	r/30      
FTDS	PAPA	8.389	2012-09-10	2012-09-10	mIU/ml			B 	          
AHP	AHP	6.0
(Results may be higher in luteal phase)	2012-10-31	2012-11-01	nmol/L	0	6	B 	A         
SYH0	AHPC	18.0
Reference ranges (nmol/L):        Basal   +30 min*
Normal response                              <10
CYP21-defect CAH                   >100     >>200
Late presenting CYP21 CAH         5-200    60->200
CYP21 CAH heterozygote             <10      5-50
(*post 250 ug synacthen)
Results should be interpreted alongside cortisol
response.	2012-10-31	2012-11-01	nmol/L			B 	          
MPRL	AVXY	149	2012-10-31	2012-10-31	mIU/L			B 	QIJ       
SYH0	CORD	238	2012-10-31	2012-10-31	nmol/L			B 	          
MPRL	EBP	298	2012-10-31	2012-10-31	mIU/L			B 	QIJ       
MPRL	MPRL	No significant amount of macroprolactin detected.
The measured prolactin predominantly reflects
bioactive prolactin.	2012-10-15	2012-10-15				B 	?         
MPRL	PEG1	146	2012-10-15	2012-10-15	mIU/L			B 	NIJ       
MPRL	PEG2	151	2012-10-15	2012-10-15	mIU/L			B 	NIJ       
MPRL	PEGR	91	2012-10-31	2012-10-31	%			B 	QIJ       
PRL	PROL	328	2012-10-15	2012-10-15	mIU/L	102	496	B 	CP        
SYH0	STIM	Basal pre ACTH	2012-10-31	2012-10-31				B 	          
VITD	25D2	25	2013-04-25	2013-04-25	nmol/L			B 	rN        
VITD	25D3	<7	2013-04-25	2013-04-25	nmol/L			B 	rN        
3OHB	3HBG	25.24
Note change in units from 1 August 2013
New units (mmol/L) x 1000 = Old units (umol/L)
Result from Great Ormond Street Hospital	2013-08-15	2013-08-15	mmol/L			B 	r         
TGN	6TGN	Cancelled - see comments	2013-04-03	2013-04-03				B 	r/10      
CLOZ	CLOZ	1.10	2013-03-08	2013-03-08	mg/L			B 	r         
HEVY	HEVY	110	2013-04-04	2013-04-04				B 	r         
TGN	MEMP	Cancelled - see comments	2013-04-03	2013-04-03				B 	r/10      
TGN	MTGR	Cancelled - see comments	2013-04-03	2013-04-03				B 	r/10      
CLOZ	NCLO	1.10
A target range for plasma clozapine of
0.35-0.50 mg/L is suggested in treatment of
resistant schizophrenia, but some patients respond
at lower concentrations. The upper limit is
likewise not well defined, but there is an
increased risk of convulsions at higher
doses/plasma concentrations. The measurement of
norclozapine can be useful in monitoring adherence
and concentrations average 70% those of clozapine
during normal therapy.
Results from King's College Hospital.	2013-03-08	2013-03-08	mg/L			B 	r         
NEFA	NEFG	15.64
Result from Great Ormond Street Hospital	2013-08-15	2013-08-15	mmol/L			B 	r         
TCAS	TCAS	1001
Total tricyclic antidepressant results are
semi-quantitative and must only be interpreted in
conjunction with clinical findings. As a guide
therapeutic levels <300 and poisoning >1000ug/L.
If further quantitation is required please contact
the duty biochemist (via x79405) during normal
working hours.
Result from Birmingham Toxicology.	2013-03-08	2013-03-08	ug/L			B 	r         
VITD	VITD	25
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-25	2013-04-25	nmol/L	25	120	B 	r         
VITD	25D2	25	2013-04-25	2013-04-25	nmol/L			B 	rN        
VITD	25D3	25	2013-04-25	2013-04-25	nmol/L			B 	rN        
3OHB	3HBG	1.00
Note change in units from 1 August 2013
New units (mmol/L) x 1000 = Old units (umol/L)
Result from Great Ormond Street Hospital	2013-08-08	2013-08-08	mmol/L			B 	r         
FLEC	FLEC	150
In 95% of cases suppression of ventricular ectopic
contractions occurs with flecainide levels between
200 and 800 ug/L.
Result from Northern General Hospital, Sheffield.
Original paraprotein level changed, referred for
immunofixation.
but not visible on electrophoresis and too faint
to quantitate.
Not routinely offered for myeloma screening.
Negative for immunofixation.	2013-04-04	2013-05-21	ug/L			B 	r         
HEVY	HEVY	100	2013-04-04	2013-04-04				B 	r         
NEFA	NEFG	2.00
Result from Great Ormond Street Hospital	2013-08-08	2013-08-08	mmol/L			B 	r         
VITD	VITD	50
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-25	2013-04-25	nmol/L	25	120	B 	r         
UCOR	UCCR	100	2015-03-31	2015-03-31	nmol/mmol			B 	rN        
UCOR	UCOR	200	2015-03-31	2015-03-31	nmol/L			B 	rP        
RN	UCR	2000	2015-03-31	2015-03-31	umol/L			B 	          
UCOR	UCX	Random urine. Unable to calculate.	2015-03-31	2015-03-31	nmol/24h	0	250	B 	Nr        
24H	CREX	4.0	2015-03-31	2015-03-31	mmol/24h	7.0	21.0	B 	QN        
UCOR	UCOR	200	2015-03-31	2015-03-31	nmol/L			B 	rP        
24H	UCR	2000	2015-03-31	2015-03-31	umol/L			B 	          
UCOR	UCX	400	2015-03-31	2015-03-31	nmol/24h	0	250	B 	Nr        
24H	UT	24.0	2015-03-31	2015-03-31	h			B 	P=        
24H	UV	2000	2015-03-31	2015-03-31	mL			B 	PS=       
24H	CREX	15.6	2015-04-17	2015-04-17	mmol/24h	7.0	21.0	B 	QN        
UCAT	UADR	100	2016-01-25	2016-01-26	nmol/L			B 	r/16      
UCAT	UADX	100	2016-01-25	2016-01-26	nmol/24h			B 	Nr/16     
24H	UCR	13000	2015-04-17	2015-04-17	umol/L			B 	          
UCAT	UDA	100	2016-01-25	2016-01-26	nmol/L			B 	r/16      
UCAT	UDAX	100
Result from St Helier Hospital	2016-01-25	2016-01-26	nmol/24h			B 	Nr/16     
UHIA	UHIA	40	2015-04-17	2015-04-17	umol/L			B 	r         
UHIA	UHIX	48
Result from Royal Free Hospital	2015-04-17	2015-04-17	umol/24h			B 	r         
UCAT	UNOR	100	2016-01-25	2016-01-26	nmol/L			B 	r/16      
UCAT	UNOX	100	2016-01-25	2016-01-26	nmol/24h			B 	Nr/16     
24H	UT	24.0	2015-04-17	2015-04-17	h			B 	P=        
24H	UV	1200	2015-04-17	2015-04-17	mL			B 	PS=       
TRAB	TRAB	1.0
Result from Newcastle	2015-04-22	2015-04-22	IU/L			B 	r/30      
UMET	U3MT	.	2015-04-22		umol/L			B 	r/16      
UMET	U3MX	.	2015-04-22		umol/24h			B 	Nr/16     
24H	UCR	15000	2015-04-17	2015-04-17	umol/L			B 	          
UMET	UMET	.	2015-04-22		umol/L			B 	r/16      
UMET	UMEX	.	2015-04-22		umol/24h			B 	Nr/16     
UMET	UNME	.	2015-04-22		umol/L			B 	r/16      
UMET	UNMX	.	2015-04-22		umol/24h			B 	Nr/16     
24H	UT	.	2015-04-21		h			B 	P=        
24H	UV	24	2015-04-17	2015-04-17	mL			B 	PS=       
ADCR	ADCR	Cancelled - Request entered in error.	2015-04-27	2015-04-29	nmol/mmol	0	15	D 	r         
USP	COMU	Cancelled - Request entered in error.	2015-05-26	2015-05-26				B 	p1A       
DOPR	DOPR	Cancelled - Request entered in error.	2015-04-27	2015-04-29	nmol/mmol		338	D 	r         
IA2	IA2	0.36
Result from King's College Hospital	2015-04-17	2015-04-17	U/mL			B 	r/14      
NADR	NADR	Cancelled - Request entered in error.	2015-04-27	2015-04-29	nmol/mmol		53	D 	r         
UAD	UAD	Cancelled - Request entered in error.	2015-04-27	2015-04-29	nmol/L			D 	          
UDOP	UDOP	Cancelled - Request entered in error.	2015-04-27	2015-04-29	nmol/L			D 	          
USP	UMED	In reference ranges M=Median	2015-05-26	2015-05-26				B 	?         
UNAD	UNAD	Cancelled - Request entered in error.	2015-04-27	2015-04-29	nmol/L			D 	          
USNP	US38	Cancelled - Request entered in error.	2015-05-26	2015-05-26	ug/24h			B 	N         
USNM	US39	Cancelled - Request entered in error.	2015-05-26	2015-05-26	ug/24h			B 	N         
USNA	US4	Cancelled - Request entered in error.	2015-05-26	2015-05-26	ug/24h			B 	N         
USP	USCI	Cancelled - Request entered in error.	2015-05-26	2015-05-26				B 	?         
USP	UST	Cancelled - Request entered in error.	2015-05-26	2015-05-26	hours			B 	P=        
USP	USV	Cancelled - Request entered in error.	2015-05-26	2015-05-26	ml			B 	          
PLAS	C16P	0.160	2015-08-03	2015-08-03				B 	r/16      
PLAS	C18S	0.400
Diagnostic ranges:
Classical Zellweger:
C16/P: <0.025       C18/S: <0.050
Rhizomelic Chondrodysplasia Punctata
C16/P: <0.005       C18/S: <0.010
Result from Sheffield Children's Hospital	2015-08-03	2015-08-03				B 	r/16      
PLAS	COM6	Results are low.	2015-08-03	2015-08-03				B 	r/16      
SIND	H	1	2015-08-03					  	JNr       
SIND	I	1	2015-08-03					  	JN        
SIND	L	1	2015-08-03					  	JN        
NA	NA	140	2015-08-03	2015-08-03	mmol/L	135	145	B 	CP        
PLAS	C16P	0.151	2015-08-03	2015-08-03				B 	r/16      
PLAS	C18S	0.451	2015-08-03	2015-08-03				B 	r/16      
PLAS	COM6	Results are low, but not diagnostic for Zellweger
syndrome.
Diagnostic ranges:
Classical Zellweger:
C16/P: <0.025       C18/S: <0.050
Rhizomelic Chondrodysplasia Punctata
C16/P: <0.005       C18/S: <0.010
Result from Sheffield Children's Hospital	2015-08-03	2015-08-03				B 	r/16      
AGAL	AGAL	10.0
Reference intervals for plasma alpha-galactosidase
Fabry hemizygotes     0   -  0.9
Fabry heterozygotes   0.3 -  7.4
Control range         4.0 - 21.9
Result from Great Ormond Street Hospital	2015-08-05	2015-08-05	nmol/h/mL			B 	r         
AGAL	AGLE	40
Reference intervals for leucocyte alpha-
galactosidase (nmol/hour/mg protein)
Fabry hemizygotes     0.41 - 5.0
Fabry heterozygotes   4.3 - 73
Control range         33 - 134
Blood transfusion within the last 4 weeks may
invalidate the result.
Result from Great Ormond Street Hospital	2016-04-13	2016-04-13	nmol/h/mg			B 	r         
MNI	MNI	Cell Markers Not Indicated.	2012-12-19					A 	Nr        
CM4 	10P	10	2012-12-20	2012-12-20	%			A 	N         
CM1 	117P	0.2	2012-12-20	2012-12-20	%			A 	N         
CM1 	13P	45	2012-12-20	2012-12-20	%			A 	N         
CM2 	19P	23	2012-12-20	2012-12-20	%	4	26	A 	N         
CM2 	20P	11	2012-12-20	2012-12-20	%			A 	N         
CM2 	22P	15	2012-12-20	2012-12-20	%			A 	N         
CM3 	2P	71	2012-12-20	2012-12-20	%			A 	N         
CM1 	33P	59	2012-12-20	2012-12-20	%			A 	N         
CM3 	3411	<0.1	2012-12-20	2012-12-20	%			A 	N         
CM4 	38P	67	2012-12-20	2012-12-20	%			A 	N         
CM3 	5P	11	2012-12-20	2012-12-20	%			A 	N         
CM2 	79B	Cytoplasmic CD79b: 38%	1899-12-30					A 	N         
CM3 	7P	29	2012-12-20	2012-12-20	%			A 	N         
CM1 	BLA	15	2012-12-20	2012-12-20	%			A 	N         
CM3 	C3P	3	2012-12-20	2012-12-20	%			A 	N         
CM2 	CC79	19	2012-12-20	2012-12-20	%			A 	N         
CM4 	CD34	19	2012-12-20	2012-12-20	%			A 	N         
CM1 	CDS	Bone Marrow	2012-12-20	2012-12-20				A 	N?        
CM2 	CKAP	20	2012-12-20	2012-12-20	%			A 	N         
CM2 	CLAM	4	2012-12-20	2012-12-20	%			A 	N         
CM4 	CMCO	CD34+19+10- cells comprise 15% BMMNCs. They are
uniformly CD2+, 50% are CD20+ and 9% are CD38-.
They express neither CD13/CD33 nor cytoplasmic
immunoglobulins. Note that CD34+CD19+ cells do not
stain for TdT in this analysis. Conclusion:
'Precursor' B Lymphoblastic Leukaemia.	2012-12-20	2012-12-20				A 	N?        
CM1 	CMPX	19	2012-12-20	2012-12-20				A 	N         
CM4 	CONS	RG	2012-12-20	2012-12-20				A 	N         
CM4 	DR	35	2012-12-20	2012-12-20	%			A 	N         
CM1 	GATE	Live cell gating by Hoerst 45000 exclusion 87000	2012-12-20	2012-12-20				A 	N         
MPOX	MPOX	Please refer to immunophenotype report.	2012-12-19	2012-12-20				A 	Nr        
CM1 	MPRX	<10%	2012-12-20	2012-12-20				A 	N         
NSE	NSE	Please refer to immunophenotype report.	2012-12-19					A 	Nr        
CM1 	NSPE	Negative	2012-12-20	2012-12-20				A 	N         
CM4 	SETU	AB	2012-12-20					X 	NI        
CM1 	SPE	Negative	2012-12-20	2012-12-20				A 	N         
CM4 	TDTP	Negative	2012-12-20	2012-12-20	%			A 	N         
TISW	BAN	as choc	2012-05-08					X 	Nra?      
TISW	CHOC	3+ white ?sta	2012-05-08					X 	N/2?ra    
COSC	COSC	STAAUR/KLEPNE/NG2/ACIBAU/ACRESP/ACHDEN/ACILWO/	2012-07-13					X 	J-        
COSD	COSD	Organisms sent 13/07/2012 18:50	2012-07-13					X 	J-        
TISC	FCOM	.{}	2013-05-04					M 	I?/3      
TISC	FSTA	INCOMPLETE - LAST UPDATED: 04/05/13	2013-05-04	2013-05-04				M 	?ABr/3    
TISM	GNRF	numerous	2012-07-12	2012-07-12				M 	N?        
STA1	GPC1	POSITIVE	2012-05-08					X 	N?a       
TISM	GPCF	Numerous	2012-05-07	2012-05-07				M 	N?        
STA1	GPD1	POSITIVE	2012-05-08					X 	N?a       
STA1	GPG1	GPC	2012-05-08					X 	N?a       
STA1	GPO1	from CHOC	2012-05-08					X 	N?        
TISM	GPRF	Numerous	2012-07-03	2012-07-12				M 	N?        
STA1	GPS1	POSITIVE	2012-05-08					X 	N?a       
STA1	GPV1	07/05/12 Done	2012-05-08					X 	N?a       
KLA	KLA	SENT TO KIESTRA	2012-04-23					X 	-JNH      
TISW	MAC	as choc	2012-05-08					X 	N/1ra     
MLDI	MLDO	.{}	2012-05-07					X 	r/1       
MLDI	MLDS	.{}	2012-05-07					X 	/1        
TISC	TISC	TISSUE CULTURE REPORT	2012-08-28	2012-08-28				M 	HXp1p2A?r 
TISM	TISM	TISSUE MICROSCOPY REPORT	2012-08-28	2012-08-28				M 	HXp1p2AB?r
TISC	TISO	:
Enrichment culture yields: Achromobacter denitrificans
Direct culture yields: No growth after 2 days incubation	1899-12-30	2013-05-03		35	130	M 	M?/4r     
TISM	WBCF	Numerous	2012-05-07	2012-05-07				M 	?/0       
TISC	FCOM	y	2012-10-05	2012-10-24				M 	I?/3      
TISC	FSTA	COMPLETE: 24/10/12	2012-10-24	2012-10-24				M 	?ABr/3    
TISM	GPCF	None seen	2012-08-28	2012-08-28				M 	N?        
ITRL	ITRR	.{}	2012-10-05		mg/L			M 	/10       
ITRL	ITRS	.{}	2012-10-05					M 	?/10      
ITRL	ITRT	.{}	2012-10-05					M 	?/10      
KLA	KLA	SENT TO KIESTRA	2012-08-28					X 	-JNH      
MREF	MREF	SENT	2012-09-05					X 	/1        
P16S	P16A	xxxxxxxxxxxxxxxxxxxxxxx	2012-08-28	2012-08-28				M 	NA?       
P16I	P16I	.{}	2012-08-31					M 	?         
P16N	P16N	Broad range 16S PCR is a technique designed to
detect DNA from any bacterial species present in
the clinical sample. However, the assay is less
sensitive than molecular tests designed to detect
a single species. A negative result cannot exclude
infection.	2012-08-31	2012-08-31				M 	?r/14     
P16R	P16R	Microbiology, Great Ormond St. Hospital, London	2012-08-31	2012-08-31				M 	rA?/14    
P16S	P16S	Negative	2012-08-31	2012-08-31				M 	?A/14     
P16T	P16T	16S rDNA PCR FOR BACTERIA	2012-08-31	2012-08-31				M 	HXp1p2A   
P18S	P18R	Microbiology, Great Ormond St. Hospital, London	2012-08-28	2012-08-28				M 	r?/14     
P6RD	P6RD	31/08/12	2012-08-31	2012-08-31				M 	I/14      
P6ST	P6ST	31/08/12	2012-08-31	2012-08-31				M 	I/1       
P8ST	P8ST	05/09/12	2012-09-05	2012-10-24				M 	I/1       
PROL	PR05	.{}	2012-10-05					M 	?/10      
PROL	PR07	.{}	2012-10-05		mg/l			M 	/10       
TISC	TCOM	Sent to reference laboratory.	2012-08-28	2012-08-28				M 	N?        
TISC	TISC	TISSUE CULTURE REPORT	2012-09-07	2012-10-24				M 	HXp1p2A?r 
TISM	TISM	TISSUE MICROSCOPY REPORT	2012-09-07	2012-10-24				M 	HXp1p2AB?r
TISC	TISO	.{}	2012-08-28			35	130	M 	M?/4r     
TISC	TPRE	No growth after 2 days.	2012-08-28	2012-08-28				M 	?ANr/3    
VORL	VORR	.{}	2012-10-05		mg/L			M 	/10       
VORL	VORT	.	2012-10-24					M 	?/10      
TISM	WBCF	Moderate	2012-08-28	2012-08-28				M 	?/0       
CERU	CERU	0.58
Please note change to reference range
Effective 08/07/13.	2013-07-08	2013-07-08	g/L	0.20	0.60	B 	AB        
RAK1	RAK1	[P1/Rack:ARCHIVE-211/D01|13:18]	2013-07-08					X 	NJ        
FBCZ	BA	 0.6%  0.04	2013-09-17	2013-09-17	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	33.6	2013-09-17	2013-09-17	g/dl	32.0	34.9	A 	NCPS/0    
FBCZ	EO	 4.5%  0.31	2013-09-17	2013-09-17	x10^9/L	0.0	0.4	A 	CDSN/0    
HES	HBA2	6.0	2013-09-17	2013-09-17	%	2.0	3.4	A 	N         
HES	HBF	0.5	2013-09-17	2013-09-17	%			A 	N         
HES	HCON	Beta Thalassaemia Carrier.	2013-09-17	2013-09-17				A 	?p1       
FBCY	HCTU	0.363	2013-09-17	2013-09-17	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	12.2	2013-09-17	2013-09-17	g/dl	11.5	15.5	A 	NrCP/0    
HES	HGBA	Predominant	2013-09-17	2013-09-17	%			A 	?         
FBCZ	LY	23.0%  1.57	2013-09-17	2013-09-17	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	21.9	2013-09-17	2013-09-17	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	65.2	2013-09-17	2013-09-17	fL	80	99	A 	CPS/0     
FBCZ	MO	 9.2%  0.63	2013-09-17	2013-09-17	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	.{}	2013-09-17		fL	7	13	A 	CS?/0     
FBCZ	NE	62.7%  4.28	2013-09-17	2013-09-17	x10^9/L	2.0	7.5	A 	CDS/0     
NR	NR1	.{}	2013-09-17					X 	SJ/0      
NR	NR2	.{}	2013-09-17					X 	SJ/0      
NR	NRC	.{}	2013-09-17		x10^9/L	0	0.01	A 	SN?/0     
NR	NRP	.{}	2013-09-17					A 	SN/0      
FBCY	PLT	280	2013-09-17	2013-09-17	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	5.70	2013-09-17	2013-09-17	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	16.3	2013-09-17	2013-09-17	%	11.5	15.0	A 	CS/0      
FBCY	WCC	6.82	2013-09-17	2013-09-17	x10^9/L	3.0	10.0	A 	CWPS/0    
FBCZ	BA	 0.2%  0.02	2013-09-17	2013-09-17	x10^9/L	0.0	0.1	A 	CDSN/0    
HESR	CE	Peak in the A and D positions	2013-09-17	2013-09-17				A 	p1        
FBCY	CHCU	34.1	2013-09-17	2013-09-17	g/dl	32.0	34.9	A 	NCPS/0    
FBCZ	EO	 0.6%  0.05	2013-09-17	2013-09-17	x10^9/L	0.0	0.4	A 	CDSN/0    
FOQ	FOQ	Mother B1 Father B1	2013-09-17	2013-09-17				A 	?         
HESR	HCO1	Consistent with Haemoglobin D carrier (Hb AD)
TESTING OF BABY'S FATHER RECOMMENDED.
TEST SAMPLE IGNORE	2013-09-17	2013-09-17				A 	N?p1      
HES	HCON	.{}	2013-09-17					A 	?p1       
FBCY	HCTU	0.393	2013-09-17	2013-09-17	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	13.4	2013-09-17	2013-09-17	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	LY	22.1%  1.78	2013-09-17	2013-09-17	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	29.5	2013-09-17	2013-09-17	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	86.4	2013-09-17	2013-09-17	fL	80	99	A 	CPS/0     
FBCZ	MO	 5.8%  0.47	2013-09-17	2013-09-17	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	10.4	2013-09-17	2013-09-17	fL	7	13	A 	CS?/0     
FBCZ	NE	71.3%  5.74	2013-09-17	2013-09-17	x10^9/L	2.0	7.5	A 	CDS/0     
NR	NR1	.{}	2013-09-17					X 	SJ/0      
NR	NR2	.{}	2013-09-17					X 	SJ/0      
NR	NRC	.{}	2013-09-17		x10^9/L	0	0.01	A 	SN?/0     
NR	NRP	.{}	2013-09-17					A 	SN/0      
FBCY	PLT	307	2013-09-17	2013-09-17	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	4.55	2013-09-17	2013-09-17	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	13.4	2013-09-17	2013-09-17	%	11.5	15.0	A 	CS/0      
ST	ST	Negative
This DOES NOT exclude other Haemoglobinopathies.	2013-09-17	2013-09-17				A 	?/0       
ST	STH	13.4	2013-09-17		g/dl			X 	?/0       
HES	VAR	Peak in the A and D positions	2013-09-17	2013-09-17				A 	Np1       
FBCY	WCC	8.05	2013-09-17	2013-09-17	x10^9/L	3.0	10.0	A 	CWPS/0    
FAFP	FAFP	.	2013-01-23		kIU/L			B 	r         
FALB	FALB	49	2013-01-14	2013-01-14	g/L			B 	r         
FAMY	FAMY	76	2013-01-14	2013-01-14	IU/L			B 	r         
FCEA	FCEA	.	2013-01-23		ug/L			B 	r         
FCHO	FCHO	4.8	2013-01-14	2013-01-14	mmol/L			B 	r         
FCR	FCR	51	2013-01-14	2013-01-14	umol/L			B 	r         
FALB	FH	1	2013-01-14					  	JNr       
FALB	FI	16	2013-01-14					  	JN        
FALB	FL	6	2013-01-14					  	JN        
FLTY	FLTY	Unspecified
(PLEASE NOTE REFERENCE RANGES APPLY TO
SERUM OR URINE ONLY)	2013-01-14	2013-01-14				B 	=?        
FTB	FTB	10	2013-01-14	2013-01-14	umol/L			B 	r         
RAK1	RAK1	[P1/Rack:ARCHIVE-267/A05|16:18]	2013-01-14					X 	NJ        
FHCG	FBHC	.	2013-01-23		IU/L			B 	r         
FELU	FCR	.	2013-01-23		umol/L			B 	r         
FGLU	FGLU	6.1	2013-01-14	2013-01-14	mmol/L			B 	r         
FELU	FH	4	2013-01-14					  	JNr       
FELU	FI	7	2013-01-14					  	JN        
FELU	FK	.	2013-01-23		mmol/L			B 	r         
FELU	FL	10	2013-01-14					  	JN        
FLAC	FLAC	.	2013-01-23		mmol/L			B 	r         
FLDH	FLDH	.	2013-01-23		IU/L			B 	r         
FLTY	FLTY	Unspecified.	2013-01-14	2013-01-14				B 	=?        
FELU	FNA	.	2013-01-23		mmol/L			B 	r         
FTG	FTG	.	2013-01-23		mmol/L			B 	r         
FTP	FTP	.	2013-01-23		g/L			B 	r         
FELU	FU	.	2013-01-23		mmol/L			B 	r         
RAK1	RAK1	[P1/Rack:ARCHIVE-262/A21|12:17]	2013-01-14					X 	NJ        
THY	FT4	.	2013-03-04		pmol/L	12.0	22.0	B 	Cr        
SIND	H	.	2013-03-04					  	JNr       
SIND	I	.	2013-03-04					  	JN        
SIND	L	.	2013-03-04					  	JN        
METS	METS	.	2013-03-11					B 	r/23      
THY	TSH	.	2013-03-04		mIU/L	0.27	4.20	B 	Cr        
VITD	25D2	<7	2013-04-25	2013-04-25	nmol/L			B 	rN        
VITD	25D3	19	2013-04-25	2013-04-25	nmol/L			B 	rN        
BSUL	BSUL	Cancelled - see comments	2013-03-07	2013-03-07	umol/L			B 	r         
BSUL	BTIM	Cancelled - see comments	2013-03-07	2013-03-07		2.3	9.5	B 	r         
CLOZ	CLOZ	1.20
Result from King's College Hospital	2013-02-27	2013-02-27	mg/L			B 	r         
CLOZ	NCLO	0.55
A target range for plasma clozapine of
0.35-0.50 mg/L is suggested in treatment of
resistant schizophrenia, but some patients respond
at lower concentrations. The upper limit is
likewise not well defined, but there is an
increased risk of convulsions at higher
doses/plasma concentrations. The measurement of
norclozapine can be useful in monitoring adherence
and concentrations average 70% those of clozapine
during normal therapy.
A target range for plasma clozapine of
0.35-0.50 mg/L is suggested in treatment of
resistant schizophrenia, but some patients respond
at lower concentrations. The upper limit is
likewise not well defined, but there is an
increased risk of convulsions at higher
doses/plasma concentrations. The measurement of
norclozapine can be useful in monitoring adherence
and concentrations average 70% those of clozapine
during normal therapy.
Results from King's College Hospital.	2013-02-27	2013-02-27	mg/L			B 	r         
VITD	VITD	19
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-25	2013-04-25	nmol/L	25	120	B 	r         
VITD	25D2	<7	2013-04-25	2013-04-25	nmol/L			B 	rN        
VITD	25D3	<7	2013-04-25	2013-04-25	nmol/L			B 	rN        
LFT 	ALB	40	2013-03-07	2013-03-07	g/L	34	50	B 	CP        
LFT 	ALP	50	2013-03-07	2013-03-07	IU/L	35	104	B 	C         
LFT 	ALT	25	2013-03-07	2013-03-07	IU/L	10	35	B 	C         
MPRL	AVXY	.	2013-03-07		mIU/L			B 	QIJ       
LFT 	BILI	8	2013-03-07	2013-03-07	umol/L	0	137	B 	CPr       
BON 	CA	2.35	2013-03-07	2013-03-07	mmol/L	2.15	2.55	B 	CP        
CLOZ	CLOZ	1.50	2013-03-07	2013-03-07	mg/L			B 	r         
ELU 	CREA	90	2013-03-07	2013-03-07	umol/L	49	92	B 	CPr       
MPRL	EBP	.	2013-03-07		mIU/L			B 	QIJ       
ELU 	FACR	1.02	2013-03-07					X 	N         
FSH	FSH	1.0
Ref Range:(Follicular      3.5  -  12.5)
Ref Range:(Mid-cycle       4.7  -  21.5)
Ref Range:(Luteal          1.7  -   7.7)
Ref Range:(Post-menopause 25.8  - 134.8)	2013-03-07	2013-03-07	IU/L			B 	          
THY	FT4	18.0	2013-03-07	2013-03-07	pmol/L	12.0	22.0	B 	Cr        
ELU 	GFR	59
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-03-07	2013-03-07	.			B 	          
HEVY	HEVY	200	2013-04-04	2013-04-04				B 	r         
ELU 	K	5.0	2013-03-07	2013-03-07	mmol/L	3.5	5.1	B 	CP        
LH	LH	1.0
Ref Range:(Follicular      2.4  -  12.6)
Ref Range:(Mid-cycle      14.0  -  95.6)
Ref Range:(Luteal          1.0  -  11.4)
Ref range:(Post-menopause  7.7  -  58.5)	2013-03-07	2013-03-07	IU/L			B 	          
MPRL	MPRL	.	2013-03-07					B 	?         
ELU 	NA	135	2013-03-07	2013-03-07	mmol/L	135	145	B 	CP        
CLOZ	NCLO	0.80
A target range for plasma clozapine of
0.35-0.50 mg/L is suggested in treatment of
resistant schizophrenia, but some patients respond
at lower concentrations. The upper limit is
likewise not well defined, but there is an
increased risk of convulsions at higher
doses/plasma concentrations. The measurement of
norclozapine can be useful in monitoring adherence
and concentrations average 70% those of clozapine
during normal therapy.	2013-03-07	2013-03-07	mg/L			B 	r         
MPRL	PEG1	.	2013-03-07		mIU/L			B 	NIJ       
MPRL	PEG2	.	2013-03-07		mIU/L			B 	NIJ       
MPRL	PEGR	.	2013-03-07		%			B 	QIJ       
BON 	PHOS	1.00	2013-03-07	2013-03-07	mmol/L	0.87	1.45	B 	CP        
PRL 	PROL	1000	2013-03-07	2013-03-07	mIU/L	102	496	B 	CP        
ELU 	SEX	0.742	2013-03-07					X 	N         
TCAS	TCAS	1101
Total tricyclic antidepressant results are
semi-quantitative and must only be interpreted in
conjunction with clinical findings. As a guide
therapeutic levels <300 and poisoning >1000ug/L.
If further quantitation is required please contact
the duty biochemist (via x79405) during normal
working hours.
Result from Birmingham Toxicology.	2013-03-07	2013-03-07	ug/L			B 	r         
THG	TGAB	10	2013-03-07	2013-03-07	IU/mL			B 	r         
THG	THGN	10.0
Tg reference range applies post-ablation/excision.
Note, method change to Immulite XPi from 26/11/12.
There are significant differences from previous
assays. To discuss, contact x72965 or x72954.	2013-03-07	2013-03-07	ug/L			B 	r         
THY	TSH	4.00	2013-03-07	2013-03-07	mIU/L	0.27	4.20	B 	Cr        
ELU 	UREA	15.0	2013-03-07	2013-03-07	mmol/L	1.7	8.3	B 	CP        
VITD	VITD	<7
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-25	2013-04-25	nmol/L	25	120	B 	r         
ELU 	ZAGE	52	2013-03-07		y			X 	          
VITD	25D2	22	2013-04-25	2013-04-25	nmol/L			B 	rN        
VITD	25D3	212	2013-04-25	2013-04-25	nmol/L			B 	rN        
LFT 	ALB	40	2013-03-07	2013-03-07	g/L	34	50	B 	CP        
LFT 	ALP	50	2013-03-07	2013-03-07	IU/L	40	129	B 	C         
LFT 	ALT	25	2013-03-07	2013-03-07	IU/L	10	50	B 	C         
MPRL	AVXY	.	2013-04-25		mIU/L			B 	QIJ       
LFT 	BILI	1	2013-03-07	2013-03-07	umol/L	0	137	B 	CPr       
BON 	CA	2.30	2013-03-07	2013-03-07	mmol/L	2.15	2.55	B 	CP        
BON	CCA 	2.41	2017-10-25	2017-10-25				B 	C         
CLOZ	CLOZ	1.30	2013-03-07	2013-03-07	mg/L			B 	r         
ELU 	CREA	100	2013-03-07	2013-03-07	umol/L	66	112	B 	CPr       
LFT	DBRV	To be reviewed by Duty Biochemist	2017-10-25	2017-10-25				B 	NIJ       
MPRL	EBP	.	2013-04-25		mIU/L			B 	QIJ       
ELU 	FACR	0.90	2013-03-07					X 	N         
FSH	FSH	5.0	2013-03-07	2013-03-07	IU/L	1.5	12.4	B 	          
THY	FT4	15.0	2013-03-07	2013-03-07	pmol/L	12.0	22.0	B 	Cr        
ELU 	GFR	69
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-03-07	2013-03-07	.			B 	          
ELU 	K	5.0	2013-03-07	2013-03-07	mmol/L	3.5	5.1	B 	CP        
LH	LH	5.0	2013-03-07	2013-03-07	IU/L	1.7	8.6	B 	          
MPRL	MPRL	.	2013-03-07					B 	?         
ELU 	NA	135	2013-03-07	2013-03-07	mmol/L	135	145	B 	CP        
CLOZ	NCLO	0.75
A target range for plasma clozapine of
0.35-0.50 mg/L is suggested in treatment of
resistant schizophrenia, but some patients respond
at lower concentrations. The upper limit is
likewise not well defined, but there is an
increased risk of convulsions at higher
doses/plasma concentrations. The measurement of
norclozapine can be useful in monitoring adherence
and concentrations average 70% those of clozapine
during normal therapy.
Results from King's College Hospital.	2013-03-07	2013-03-07	mg/L			B 	r         
MPRL	PEG1	.	2013-03-07		mIU/L			B 	NIJ       
MPRL	PEG2	.	2013-03-07		mIU/L			B 	NIJ       
MPRL	PEGR	.	2013-04-25		%			B 	QIJ       
BON 	PHOS	1.00	2013-03-07	2013-03-07	mmol/L	0.87	1.45	B 	CP        
PRL 	PROL	2000	2013-03-07	2013-03-07	mIU/L	86	324	B 	CP        
PSA	PSA 	5.00
Method used for PSA :Roche Modular	2017-10-25	2017-10-25				B 	          
ELU 	SEX	1.0	2013-03-07					X 	N         
THY	TSH	2.00	2013-03-07	2013-03-07	mIU/L	0.27	4.20	B 	Cr        
ELU 	UREA	8.0	2013-03-07	2013-03-07	mmol/L	1.7	8.3	B 	CP        
VITD	VITD	234
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-25	2013-04-25	nmol/L	25	120	B 	r         
ELU 	ZAGE	58	2013-03-07		y			X 	          
AMIK	AMII	.	2013-02-27					B 	          
AMIK	AMIK	.	2013-02-26		mg/L			B 	          
AMIK	H	.	2013-02-26					  	JNr       
AMIK	I	.	2013-02-26					  	JN        
AMIK	L	.	2013-02-26					  	JN        
UALB	UALB	Urine albumin >4400 mg/L, see urine protein.	2013-07-30	2013-07-30	mg/L			B 	          
RN	UCR	1230	2013-07-30	2013-07-30	umol/L			B 	          
UALB	UMA	Urine albumin/creatinine ratio not indicated.	2013-07-30	2013-07-30	mg/mmol	0.00	2.80	B 	S         
VITD	25D2	<7	2013-04-25	2013-04-25	nmol/L			B 	rN        
VITD	25D3	25	2013-04-25	2013-04-25	nmol/L			B 	rN        
ACTH	ACTH	50.0
Ref.range: <46 ng/L at 9 am	2013-05-16	2013-05-16	ng/l			B 	A/4       
FLG 	AO	A1658	2013-04-05					X 	NJI       
FBCZ	BA	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-05	2013-04-05	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	29.6	2013-04-05	2013-04-05	g/dl	32.0	34.9	A 	NCPS/0    
CTX	CTX	6546.00
Result from Norfolk & Norwich Hospitals	2013-09-20	2013-09-20	ug/L			B 	r/30      
FBCZ	EO	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-05	2013-04-05	x10^9/L	0.0	0.4	A 	CDSN/0    
FLG 	FLG1	Blasts ?	2013-04-05	2013-04-05				A 	NJ-I?     
FLG 	FLG2	Fragment	2013-04-05	2013-04-05				A 	NJ-I?     
FLG 	FLG4	NRBC Abn	2013-04-05	2013-04-05				A 	NJ-I?     
FLG 	FLG7	Abn. Lym	2013-04-05	2013-04-05				A 	NJ-I?     
FLG 	FLG9	NRBC ?
**DO NOT AUTHORISE FBC if "NR" OUTSTANDING**	2013-04-05					A 	NJ-I?     
HBA	GHBI	44
.{test}	2013-09-25	2013-09-25	mmol/mol			B 	          
GH	GHN	10.0	2013-05-16	2013-05-16	ug/L			B 	B         
HBA	HBA	5.5
.{test}	2013-09-25	2013-09-25	% total Hb	4.0	6.0	B 	          
FBCY	HCTU	0.233	2013-04-05	2013-04-05	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	6.9	2013-04-05	2013-04-05	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	IG	.{}	2013-04-05		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2013-04-05		%			A 	SN/0      
FBCZ	LY	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-05	2013-04-05	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	23.1	2013-04-05	2013-04-05	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	77.9	2013-04-05	2013-04-05	fL	80	99	A 	CPS/0     
FBCZ	MO	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-05	2013-04-05	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	11.2	2013-04-05	2013-04-05	fL	7	13	A 	CS?/0     
FBCZ	NE	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-05	2013-04-05	x10^9/L	2.0	7.5	A 	CDS/0     
P1P	P1P	364165
Result from Norfolk & Norwich Hospitals	2013-09-20	2013-09-20	ug/L			B 	r/30      
FBCY	PLT	791	2013-04-05	2013-04-05	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	2.99	2013-04-05	2013-04-05	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	29.0	2013-04-05	2013-04-05	%	11.5	15.0	A 	CS/0      
VITD	VITD	25
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-25	2013-04-25	nmol/L	25	120	B 	r         
FBCY	WCC	14.43	2013-04-05	2013-04-05	x10^9/L	3.0	10.0	A 	CWPS/0    
FLG 	AO	A1663	2013-04-06					X 	NJI       
FBCZ	BA	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-06	2013-04-06	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	28.5	2013-04-06	2013-04-06	g/dl	32.0	34.9	A 	NCPS/0    
FBCZ	EO	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-06	2013-04-06	x10^9/L	0.0	0.4	A 	CDSN/0    
FLG 	FLG2	Fragment	2013-04-06	2013-04-06				A 	NJ-I?     
FLG 	FLG4	WBC Abn
** Check WBC Scattergram and repeat results BEFORE
AUTHORISING **	2013-04-06	2013-04-06				A 	NJ-I?     
FLG 	FLG7	Abn. Lym	2013-04-06	2013-04-06				A 	NJ-I?     
FLG 	FLG9	NRBC ?
**DO NOT AUTHORISE FBC if "NR" OUTSTANDING**	2013-04-06					A 	NJ-I?     
FBCY	HCTU	0.246	2013-04-06	2013-04-06	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	7.0	2013-04-06	2013-04-06	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	IG	.{}	2013-04-06		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2013-04-06		%			A 	SN/0      
FBCZ	LY	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-06	2013-04-06	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	23.3	2013-04-06	2013-04-06	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	81.7	2013-04-06	2013-04-06	fL	80	99	A 	CPS/0     
FBCZ	MO	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-06	2013-04-06	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	12.3	2013-04-06	2013-04-06	fL	7	13	A 	CS?/0     
FBCZ	NE	If WBC >0.5 x10*9/l, blood film will be ordered.	2013-04-06	2013-04-06	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	833	2013-04-06	2013-04-06	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	3.01	2013-04-06	2013-04-06	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	29.5	2013-04-06	2013-04-06	%	11.5	15.0	A 	CS/0      
FBCY	WCC	42.15	2013-04-06	2013-04-06	x10^9/L	3.0	10.0	A 	CWPS/0    
COAT	APRA	Coagulation request entered in error.	2013-05-07	2013-05-07		2.0	3.0	A 	?/1       
COAT	APTT	Coagulation request entered in error.
Note: reference range change from 18/02/2013	2013-05-07	2013-05-07	secs	22	41	A 	P/1       
DDIT	DDIT	0.93	2013-05-07	2013-05-07	mg/l FEU			A 	pI        
COAT	FIB	Coagulation request entered in error.	2013-05-07	2013-05-07	g/L			A 	p1/1      
COAT	INR	Coagulation request entered in error.	2013-05-07	2013-05-07				A 	/1        
COAT	PT	Cancelled - Coagulation request entered in error.	2013-05-07	2013-05-07	secs	10.0	12.0	A 	/1        
DDIT	TDDI	930	2013-05-07	2013-05-07	ug/l FEU			A 	sr/1      
LUP	ACLG	Cancelled - see comments	2013-05-07	2013-05-10	GPLU	0	5	A 	A/10      
LUP	ACLM	Cancelled - see comments	2013-05-07	2013-05-10	MPLU	0	5	A 	/10       
FBCY	CHCU	Request entered in error	2013-05-07	2013-05-07	g/dl	32.0	34.9	A 	NCPS/0    
LUP	DRV1	Cancelled - see comments	2013-05-07		secs			X 	Pr/14     
LUP	DRV2	Cancelled - see comments	2013-05-07		secs			X 	NP/14     
LUP	DRV3	Cancelled - see comments	2013-05-07	2013-05-10		0.90	1.20	A 	Pr/14     
LUP	DRV4	Cancelled - see comments	2013-05-07		secs			X 	PN/14     
LUP	DRV5	Cancelled - see comments	2013-05-07	2013-05-10		0.9	1.2	A 	NQ/14     
LUP	DRV6	Cancelled - see comments	2013-05-07		secs			X 	N/14      
LUP	DRV7	Cancelled - see comments	2013-05-07		secs			X 	NP/14     
LUP	DRV8	Cancelled - see comments	2013-05-07	2013-05-10				A 	NP/14     
FBCY	HCTU	Request entered in error	2013-05-07	2013-05-07	L/L	0.37	0.50	A 	CPS/0     
FBCY	HGB	Request entered in error	2013-05-07	2013-05-07	g/dl	13.0	17.0	A 	NrCP/0    
FBCZ	IG	Request entered in error	2013-05-07	2013-05-07	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Request entered in error	2013-05-07	2013-05-07	%			A 	SN/0      
PT	INR	Coagulation request entered in error.	2013-05-07	2013-05-07				A 	/1        
FBCZ	LY	Request entered in error	2013-05-07	2013-05-07	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	Request entered in error	2013-05-07	2013-05-07	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Request entered in error	2013-05-07	2013-05-07	fL	80	99	A 	CPS/0     
FBCZ	MO	Request entered in error	2013-05-07	2013-05-07	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Request entered in error	2013-05-07	2013-05-07	fL	7	13	A 	CS?/0     
FBCZ	NE	Request entered in error	2013-05-07	2013-05-07	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Request entered in error	2013-05-07	2013-05-07	x10^9/L	150	400	A 	CS/0      
PSF	PSF	Cancelled - see comments	2013-05-07	2013-05-10	IU/ml			A 	P/14      
PT	PT	Cancelled - Coagulation request entered in error.	2013-05-07	2013-05-07	secs	10.0	12.0	A 	/1        
FBCY	RCC	Request entered in error	2013-05-07	2013-05-07	x10^12/L	4.4	5.8	A 	P/0       
FBCY	RDWU	Request entered in error	2013-05-07	2013-05-07	%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - FBC Request entered in error	2013-05-07	2013-05-07	x10^9/L	3.0	10.0	A 	CWPS/0    
LUP	ACLG	Cancelled-test orders too old	2013-06-03	2013-06-03	GPLU	0	5	A 	A/10      
LUP	ACLM	Cancelled-test orders too old	2013-06-03	2013-06-03	MPLU	0	5	A 	/10       
LUP	DRV1	Cancelled-test orders too old	2013-06-03		secs			X 	Pr/14     
LUP	DRV2	Cancelled-test orders too old	2013-06-03		secs			X 	NP/14     
LUP	DRV3	Cancelled-test orders too old	2013-06-03	2013-06-03		0.90	1.20	A 	Pr/14     
LUP	DRV4	Cancelled-test orders too old	2013-06-03		secs			X 	PN/14     
LUP	DRV5	Cancelled-test orders too old	2013-06-03	2013-06-03		0.9	1.2	A 	NQ/14     
LUP	DRV6	Cancelled-test orders too old	2013-06-03		secs			X 	N/14      
LUP	DRV7	Cancelled-test orders too old	2013-06-03		secs			X 	NP/14     
LUP	DRV8	Cancelled-test orders too old	2013-06-03	2013-06-03				A 	NP/14     
COAT	APRA	1.2	2013-05-19	2013-05-19		2.0	3.0	A 	?/1       
COAT	APTT	38
Note: reference range change from 18/02/2013	2013-05-19	2013-05-19	secs	22	41	A 	P/1       
COAT	FIB	5.70	2013-05-19	2013-05-19	g/L			A 	p1/1      
COAT	INR	1.08	2013-05-19	2013-05-19				A 	/1        
COAT	PT	12.2	2013-05-19	2013-05-19	secs	10.0	12.0	A 	/1        
AR	AR	Normal sequence	2013-04-10	2013-04-10				B 	r         
GEN1	GEN1	Normal sequence	2013-04-10	2013-04-10				B 	r         
HY11	HY11	Normal sequence	2013-04-10	2013-04-10				B 	r         
PH1A	PH1A	c.508G>A p.Gly170Arg
See detailed report attached.	2013-04-10	2013-04-10				B 	r         
PH1B	PH1B	.	2013-04-10					B 	r         
PH2A	PH2A	Normal sequence	2013-04-10	2013-04-10				B 	r         
PH2B	PH2B	Normal sequence	2013-04-10	2013-04-10				B 	r         
PH3A	PH3A	Normal sequence	2013-04-10	2013-04-10				B 	r         
PH3B	PH3B	Normal sequence	2013-04-10	2013-04-10				B 	r         
SCO1	SCO1	Normal sequence	2013-04-10	2013-04-10				B 	r         
SL4A	SL4A	Normal sequence	2013-04-10	2013-04-10				B 	r         
SRD2	SRD2	Normal sequence	2013-04-10	2013-04-10				B 	r         
TT	TT	19
Note: reference range change from 13/06/2013	2013-06-13	2013-06-13	secs	9	15	A 	r/1       
ACLA	ACLG	IT TEST. Not required.	2013-08-14	2013-08-14	GPLU	0	5	A 	A/10      
ACLA	ACLM	IT TEST. Not required.	2013-08-14	2013-08-14	MPLU	0	5	A 	/10       
THR 	AT3	IT TEST. Not required.
Note: reference range change from 02/07/2013	2013-08-14	2013-08-14	IU/ml	0.80	1.30	A 	/14       
DRVT	DRV1	2.0	2013-07-29		secs			X 	Pr/14     
DRVT	DRV2	1.2	2013-07-29		secs			X 	NP/14     
DRVT	DRV3	1.67	2013-08-14	2013-08-14		0.90	1.20	A 	Pr/14     
FVL	FVL	.	2013-08-14					A 	/21?H     
THR 	PC	IT TEST. Not required.
Note: reference range change from 02/07/2013	2013-08-14	2013-08-14	IU/ml	0.7	1.30	A 	P/14      
PGM	PGM	IT TEST. Not required.	2013-08-14	2013-08-14				A 	/21?H     
THR 	PSF	IT TEST. Not required.
Note: reference range change from 02/07/2013	2013-08-14	2013-08-14	IU/ml			A 	P/14      
ACLA	ACLG	IT TEST. Not required.	2013-08-14	2013-08-14	GPLU	0	5	A 	A/10      
ACLA	ACLM	IT TEST. Not required.	2013-08-14	2013-08-14	MPLU	0	5	A 	/10       
THR1	AT3	2.00
Note: reference range change from 02/07/2013	2013-07-29	2013-08-08	IU/ml	0.80	1.30	A 	/14       
FVII	FVII	3.00	2013-07-29	2013-08-08	IU/ml	0.5	1.5	A 	/14       
FVL	FVL	.	2013-08-14					A 	/21?H     
FX  	FX	5.00	2013-07-29	2013-08-08	IU/ml			A 	/14       
THR1	PC	3.00
Note: reference range change from 02/07/2013	2013-07-29	2013-08-08	IU/ml	0.7	1.30	A 	P/14      
THR1	PC7R	1.00	2013-07-29	2013-08-08		0.76		A 	Q/14      
PGM	PGM	IT TEST. Not required.	2013-08-14	2013-08-14				A 	/21?H     
THR1	PSF	6.00
Note: reference range change from 02/07/2013	2013-07-29	2013-08-08	IU/ml			A 	P/14      
THR1	PSXR	1.20	2013-07-29	2013-08-08				A 	Q/14      
TVT 	TVT1	2.0	2013-07-29		secs			X 	P/14      
TVT 	TVT2	1.5	2013-07-29		secs			X 	P/14      
TVT 	TVT3	1.33	2013-07-29	2013-08-08		0.90	1.10	A 	NPQ/14    
ACLA	ACLG	25.0
Moderate Positive	2013-07-01	2013-07-29	GPLU	0	5	A 	A/10      
ACLA	ACLM	25.0
Moderate Positive	2013-07-01	2013-07-29	MPLU	0	5	A 	/10       
THR 	AT3	23.00
Note: reference range change from 02/07/2013	2013-07-01	2013-07-29	IU/ml	0.80	1.30	A 	/14       
DNAP	DNAP	BLANK	2013-07-01					X 	          
DRVT	DRV1	5.0	2013-07-01		secs			X 	Pr/14     
DRVT	DRV2	4.0	2013-07-01		secs			X 	NP/14     
DRVT	DRV3	1.25	2013-07-02	2013-07-29		0.90	1.20	A 	Pr/14     
FVL	FVL	APCRM screen negative. FVL test not performed.	2013-07-01	2013-07-29				A 	/21?H     
THR 	PC	31.00
Note: reference range change from 02/07/2013	2013-07-01	2013-07-29	IU/ml	0.7	1.30	A 	P/14      
PGM	PGM	Blank	2013-07-01	2013-07-29				A 	/21?H     
THR 	PSF	2.00
Note: reference range change from 02/07/2013	2013-07-01	2013-07-29	IU/ml			A 	P/14      
CHIM	CHIM	.{}	2013-08-06					A 	?         
GATA	GATA	.{}	2013-08-06					A 	?         
GATA	RE11	Sample sent to Paediatric Malignancy Unit at Great
Ormond Street for analysis.	2013-07-08					X 	?         
CHIM	RE12	Sample sent to Molecular Diagnosis Laboratory,
Royal Free Hospital.
Please phone 02078302314 for enquiries.	2013-07-08					X 	?         
CA	ALB	45	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.40	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	2.2	2013-09-24	2013-09-24				B 	          
LPF	CHOL	5.8	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	66	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	1.49	2013-09-24					X 	N         
ELU	GFR	86
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.6	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	1	2013-09-24					  	JNr       
LPF	HDL	2.6	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	14	2013-09-24					  	JN        
ELU	K	4.4	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	7	2013-09-24					  	JN        
LPF	LDLU	2.9	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	141	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.09	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.5	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D12|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	0.6	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.9	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	50	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.53	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.3	2013-09-24	2013-09-24				B 	          
LPF	CHOL	5.6	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	93	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.99	2013-09-24					X 	N         
ELU	GFR	57
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.2	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	3	2013-09-24					  	JNr       
LPF	HDL	1.7	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	19	2013-09-24					  	JN        
ELU	K	4.7	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	11	2013-09-24					  	JN        
LPF	LDLU	3.3	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	140	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.29	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.7	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D16|18:18]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.4	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	4.0	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	46	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.47	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	4.9	2013-09-24	2013-09-24				B 	          
LPF	CHOL	6.8	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	70	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	1.39	2013-09-24					X 	N         
ELU	GFR	81
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	5.3	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	3	2013-09-24					  	JNr       
LPF	HDL	1.4	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	20	2013-09-24					  	JN        
ELU	K	4.1	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	20	2013-09-24					  	JN        
LPF	LDLU	4.7	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	141	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.25	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.0	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C14|18:16]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.6	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.9	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
LFT 	ALB	54	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
LFT 	ALP	55	2013-09-24	2013-09-24	IU/L	35	104	B 	C         
LFT 	ALT	16	2013-09-24	2013-09-24	IU/L	10	35	B 	C         
LFT 	BILI	15	2013-09-24	2013-09-24	umol/L	0	137	B 	CPr       
CA	CA	2.42	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	4.4	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.8	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU 	CREA	64	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU 	FACR	1.54	2013-09-24					X 	N         
ELU 	GFR	89
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.4	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
LFT 	H	5	2013-09-24					  	JNr       
LPF	HDL	1.1	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
LFT 	I	25	2013-09-24					  	JN        
ELU 	K	3.9	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
LFT 	L	9	2013-09-24					  	JN        
LPF	LDLU	3.2	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU 	NA	141	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.47	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	2.5	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D11|18:17]	2013-09-24					X 	NJ        
ELU 	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.1	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU 	UREA	3.6	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU 	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	48	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.36	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	2.5	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.3	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	78	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	1.22	2013-09-24					X 	N         
ELU	GFR	71
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.3	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	2	2013-09-24					  	JNr       
LPF	HDL	1.7	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	16	2013-09-24					  	JN        
ELU	K	4.2	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	14	2013-09-24					  	JN        
LPF	LDLU	2.3	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	140	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.36	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	2.5	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D15|18:18]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	0.6	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.4	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	50	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.54	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	2.8	2013-09-24	2013-09-24				B 	          
LPF	CHOL	5.5	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	98	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.93	2013-09-24					X 	N         
ELU	GFR	54
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.8	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	11	2013-09-24					  	JNr       
LPF	HDL	2.0	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	19	2013-09-24					  	JN        
ELU	K	4.2	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	9	2013-09-24					  	JN        
LPF	LDLU	3.1	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	142	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.38	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	2.5	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C09|18:16]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	0.9	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	6.7	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	48	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.39	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	2.0	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.0	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	79	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	1.20	2013-09-24					X 	N         
ELU	GFR	70
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.8	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	13	2013-09-24					  	JNr       
LPF	HDL	2.0	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	15	2013-09-24					  	JN        
ELU	K	4.2	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	3	2013-09-24					  	JN        
LPF	LDLU	1.7	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	142	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.14	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.3	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D04|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	0.6	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	5.5	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	48	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.48	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	5.6	2013-09-24	2013-09-24				B 	          
LPF	CHOL	5.6	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	369	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.20	2013-09-24					X 	N         
ELU	GFR	12
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	6.4	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	5	2013-09-24					  	JNr       
LPF	HDL	1.0	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	13	2013-09-24					  	JN        
ELU	K	4.7	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	23	2013-09-24					  	JN        
LPF	LDLU	3.4	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	143	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.54	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	5.4	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C17|18:16]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	2.7	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	26.7	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	40	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.30	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	7.1	2013-09-24	2013-09-24				B 	          
LPF	CHOL	7.1	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	351	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.21	2013-09-24					X 	N         
ELU	GFR	12
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	6.6	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	6	2013-09-24					  	JNr       
LPF	HDL	1.0	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	8	2013-09-24					  	JN        
ELU	K	4.3	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	88	2013-09-24					  	JN        
LPF	LDLU	5.7	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	140	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.03	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	6.9	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D09|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	0.9	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	11.4	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	48	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.55	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	2.3	2013-09-24	2013-09-24				B 	          
LPF	CHOL	3.6	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	247	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.31	2013-09-24					X 	N         
ELU	GFR	18
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	5.9	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	9	2013-09-24					  	JNr       
LPF	HDL	1.6	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	10	2013-09-24					  	JN        
ELU	K	4.8	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	8	2013-09-24					  	JN        
LPF	LDLU	1.5	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	139	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.31	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	6.4	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D10|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.1	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	16.5	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	40	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.46	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	5.5	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.4	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	293	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.26	2013-09-24					X 	N         
ELU	GFR	15
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.4	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	4	2013-09-24					  	JNr       
LPF	HDL	0.8	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	16	2013-09-24					  	JN        
ELU	K	5.3	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	8	2013-09-24					  	JN        
LPF	LDLU	2.7	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	145	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.06	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	19.0	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C24|18:16]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	2.0	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	23.8	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	46	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.36	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.2	2013-09-24	2013-09-24				B 	          
LPF	CHOL	5.5	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	210	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.38	2013-09-24					X 	N         
ELU	GFR	22
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	6.0	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	7	2013-09-24					  	JNr       
LPF	HDL	1.7	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	10	2013-09-24					  	JN        
ELU	K	4.5	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	18	2013-09-24					  	JN        
LPF	LDLU	3.0	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	139	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.21	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	9.6	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D06|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.8	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	8.3	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	41	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.70	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	8.3	2013-09-24	2013-09-24				B 	          
LPF	CHOL	6.6	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	342	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.21	2013-09-24					X 	N         
ELU	GFR	12
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.0	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	7	2013-09-24					  	JNr       
LPF	HDL	0.8	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	15	2013-09-24					  	JN        
ELU	K	4.4	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	53	2013-09-24					  	JN        
LPF	LDLU	4.7	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	138	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.06	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	26.2	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C30|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	2.5	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	23.8	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	42	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.34	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.0	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.8	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	382	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.19	2013-09-24					X 	N         
ELU	GFR	11
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.3	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	0	2013-09-24					  	JNr       
LPF	HDL	1.6	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	12	2013-09-24					  	JN        
ELU	K	4.8	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	109	2013-09-24					  	JN        
LPF	LDLU	2.3	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	139	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.31	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	27.2	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D01|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.9	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	19.1	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	50	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.51	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	2.9	2013-09-24	2013-09-24				B 	          
LPF	CHOL	2.9	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	479	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.14	2013-09-24					X 	N         
ELU	GFR	8
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.9	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	3	2013-09-24					  	JNr       
LPF	HDL	1.0	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	15	2013-09-24					  	JN        
ELU	K	5.6	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	8	2013-09-24					  	JN        
LPF	LDLU	1.4	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	143	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.14	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	13.9	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C15|18:16]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.1	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	16.6	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	39	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.10	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.0	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.5	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	427	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.16	2013-09-24					X 	N         
ELU	GFR	9
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.5	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	11	2013-09-24					  	JNr       
LPF	HDL	1.5	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	10	2013-09-24					  	JN        
ELU	K	5.6	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	9	2013-09-24					  	JN        
LPF	LDLU	2.3	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	140	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.95	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	25.4	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/C29|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	1.5	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	20.0	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	37	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.26	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.1	2013-09-24	2013-09-24				B 	          
LPF	CHOL	6.1	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	242	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.32	2013-09-24					X 	N         
ELU	GFR	19
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	6.0	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	3	2013-09-24					  	JNr       
LPF	HDL	2.0	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	14	2013-09-24					  	JN        
ELU	K	4.7	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	82	2013-09-24					  	JN        
LPF	LDLU	2.6	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	138	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.04	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	52.7	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D14|18:18]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	3.2	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	14.1	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	43	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.19	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
LPF	CHDR	3.4	2013-09-24	2013-09-24				B 	          
LPF	CHOL	4.1	2013-09-24	2013-09-24	mmol/L	2.5	5.0	B 	PA        
ELU	CREA	248	2013-09-24	2013-09-24	umol/L	49	92	B 	CPr       
ELU	FACR	0.31	2013-09-24					X 	N         
ELU	GFR	18
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2013-09-24	2013-09-24	.			B 	          
GLU	GLU	4.5	2013-09-24	2013-09-24	mmol/L	3.9	5.8	B 	AB        
ELU	H	1	2013-09-24					  	JNr       
LPF	HDL	1.2	2013-09-24	2013-09-24	mmol/L	1.2	1.7	B 	          
ELU	I	14	2013-09-24					  	JN        
ELU	K	4.1	2013-09-24	2013-09-24	mmol/L	3.5	5.1	B 	CP        
ELU	L	10	2013-09-24					  	JN        
LPF	LDLU	2.5	2013-09-24	2013-09-24	mmol/L	0	3.5	B 	          
ELU	NA	141	2013-09-24	2013-09-24	mmol/L	135	145	B 	CP        
P	PHOS	1.03	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	66.7	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
RAK2	RAK2	[P2/Rack:ARCHIVE-295/D05|18:17]	2013-09-24					X 	NJ        
ELU	SEX	0.742	2013-09-24					X 	N         
LPF	TRIG	0.9	2013-09-24	2013-09-24	mmol/L	0.4	2.3	B 	P         
ELU	UREA	12.0	2013-09-24	2013-09-24	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2013-09-24		y			X 	          
CA	ALB	45	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.43	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	4	2013-09-24					  	JNr       
SIND	I	15	2013-09-24					  	JN        
SIND	L	21	2013-09-24					  	JN        
P	PHOS	1.63	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.3	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	43	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.38	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	7	2013-09-24					  	JNr       
SIND	I	13	2013-09-24					  	JN        
SIND	L	3	2013-09-24					  	JN        
P	PHOS	1.10	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.9	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	46	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.51	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	3	2013-09-24					  	JNr       
SIND	I	42	2013-09-24					  	JN        
SIND	L	4	2013-09-24					  	JN        
P	PHOS	1.43	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.6	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	48	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.45	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	2	2013-09-24					  	JNr       
SIND	I	19	2013-09-24					  	JN        
SIND	L	6	2013-09-24					  	JN        
P	PHOS	1.12	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.6	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	50	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.53	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	7	2013-09-24					  	JNr       
SIND	I	35	2013-09-24					  	JN        
SIND	L	8	2013-09-24					  	JN        
P	PHOS	0.64	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.0	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	49	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.49	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	3	2013-09-24					  	JNr       
SIND	I	29	2013-09-24					  	JN        
SIND	L	2	2013-09-24					  	JN        
P	PHOS	0.99	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	5.5	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	41	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.28	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	1	2013-09-24					  	JNr       
SIND	I	12	2013-09-24					  	JN        
SIND	L	8	2013-09-24					  	JN        
P	PHOS	1.02	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	8.1	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	45	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.44	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	4	2013-09-24					  	JNr       
SIND	I	15	2013-09-24					  	JN        
SIND	L	4	2013-09-24					  	JN        
P	PHOS	1.02	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	2.0	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	52	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.52	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	27	2013-09-24					  	JNr       
SIND	I	25	2013-09-24					  	JN        
SIND	L	3	2013-09-24					  	JN        
P	PHOS	1.21	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.1	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	47	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.41	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	21	2013-09-24					  	JNr       
SIND	I	22	2013-09-24					  	JN        
SIND	L	6	2013-09-24					  	JN        
P	PHOS	1.32	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.5	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	51	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.59	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	3	2013-09-24					  	JNr       
SIND	I	17	2013-09-24					  	JN        
SIND	L	7	2013-09-24					  	JN        
P	PHOS	1.72	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.0	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	46	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.39	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	2	2013-09-24					  	JNr       
SIND	I	27	2013-09-24					  	JN        
SIND	L	7	2013-09-24					  	JN        
P	PHOS	1.03	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.7	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	51	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.55	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	7	2013-09-24					  	JNr       
SIND	I	22	2013-09-24					  	JN        
SIND	L	7	2013-09-24					  	JN        
P	PHOS	1.20	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	2.8	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	46	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.37	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	14	2013-09-24					  	JNr       
SIND	I	8	2013-09-24					  	JN        
SIND	L	263	2013-09-24					  	JN        
P	PHOS	1.66	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	5.2	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	50	2013-09-24	2013-09-24	g/L	34	50	B 	CP        
CA	CA	2.46	2013-09-24	2013-09-24	mmol/L	2.15	2.55	B 	CP        
SIND	H	2	2013-09-24					  	JNr       
SIND	I	18	2013-09-24					  	JN        
SIND	L	11	2013-09-24					  	JN        
P	PHOS	1.11	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	4.0	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
CA	ALB	50	2013-11-25	2013-11-25	g/L	34	50	B 	CP        
CA	CA	2.49	2013-11-25	2013-11-25	mmol/L	2.15	2.55	B 	CP        
FLAM	CCA	2.41	2013-11-25	2013-11-25	mmol/L	2.15	2.55	B 	C         
SIND	H	2	2013-09-24					  	JNr       
SIND	I	46	2013-09-24					  	JN        
IGF	IGF1	0.1
Note: new reference ranges.
Assay changed to DiaSorin Liaison from 18/12/12.	2013-11-22	2013-11-22	nmol/L	11.3	30.9	B 	          
SIND	L	6	2013-09-24					  	JN        
P	PHOS	1.05	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.3	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
TRAB	TRAB	1.5
Result from Newcastle	2013-11-20	2013-11-20	IU/L			B 	r/30      
ADAA	ADAA	Negative
Result from Royal Devon & Exeter	2014-01-13	2014-01-13				B 	r         
ADAL	ADAL	5.9
A detectable anti-TNF trough level (immediately
pre-dose) is associated with a higher rate of
clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-13	2014-01-13	mg/L			B 	r         
CA	ALB	30	2013-11-22	2013-11-22	g/L	34	50	B 	CP        
CA	CA	2.80	2013-11-22	2013-11-22	mmol/L	2.15	2.55	B 	CP        
CA	CCA	3.10	2013-11-22	2013-11-22	mmol/L	2.15	2.55	B 	C         
SIND	H	7	2013-09-24					  	JNr       
SIND	I	14	2013-09-24					  	JN        
INFA	INFA	POSITIVE
Result from Royal Devon & Exeter	2014-01-13	2014-01-13				B 	r         
INFL	INFL	100
A detectable anti-TNF trough level (immediately
pre-dose) is associated with a higher rate of
clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-13	2014-01-13	mg/L			B 	r         
SIND	L	8	2013-09-24					  	JN        
P	PHOS	1.47	2013-09-24	2013-09-24	mmol/L	0.87	1.45	B 	CP        
PTH	PTH	3.8	2013-09-24	2013-09-24	pmol/L	1.6	6.9	B 	          
SAA	SAA	21.0
In cases of amyloidosis:
SAA <10mg/L: Amyloid deposits stable or gradually
regress in virtually all patients - no increase in
anti-inflammatory treatment is required.
SAA 10-25mg/L: Amyloid deposits stable in most
patients - further monitoring without changes in
therapy may be appropriate.
SAA >50mg/L: Amyloid deposits accumulate in most
patients, and more intensive or alternative
treatment should be considered.
Result from Royal Free Hospital.	2013-11-12	2013-11-12	mg/L			B 	r         
UAAS	UAAS	2.20
Reference ranges:
Controls (age <6m)     <4.0 mmol/mol creatinine
Controls (6-12m)       <2.5 mmol/mol creatinine
Controls (>12m)        <2.0 mmol/mol creatinine
Patients proven to have antiquitin mutations on
both alleles           2.4-100 mmol/mol creatinine
Analysis has been done purely on a research basis.
Result from UCL Institute of Child Health.	2013-10-02	2013-10-02	mmol/molCr			B 	r         
USP	COMU	An interpretative comment will be inserted here.
Please provide any relevant clinical details to
facilitate this.
Dr Francis Lam - Date reported: 2 Nov 2013
For further advice please contact Dr. Gill Rumsby
(02034472955) or Dr Francis Lam (02034472965).	2013-12-02	2013-12-02				B 	p1A       
USP	UMED	In reference ranges M=Median	2013-12-02	2013-12-02				B 	?         
USAA	US1	300	2013-12-02	2013-12-02	ug/24h			B 	N         
USAP	US17	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAA	US2	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US20	1000	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US21	500	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US22	500	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US23	500	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US24	500	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US26	200	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US27	500	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US28	500	2013-12-02	2013-12-02	ug/24h			B 	N         
USAA	US3	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAM	US31	4200	2013-12-02	2013-12-02	ug/24h			B 	N         
USAA	US4	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAA	US5	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAP	US7	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAP	US8	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USAP	US9	100	2013-12-02	2013-12-02	ug/24h			B 	N         
USP	USCI	Any provided clinical information will be entered
here.	2013-12-02	2013-12-02				B 	?         
USP	USCR	5000	2013-12-02	2013-12-02	umol/L			B 	N         
USP	UST	24	2013-12-02	2013-12-02	hours			B 	P=        
USP	USV	3000	2013-12-02	2013-12-02	ml			B 	          
USP	USX	15.0	2013-12-02	2013-12-02	mmol/24h			B 	rQN       
ADAL	ADAL	6.0
A detectable anti-TNF trough level
(immediately pre-dose) is associated with a
higher rate of clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-10	2014-01-10	mg/L			B 	r         
INFL	INFL	5.9
A detectable anti-TNF trough level
(immediately pre-dose) is associated with a
higher rate of clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-10	2014-01-10	mg/L			B 	r         
ADAL	ADAL	85
A detectable anti-TNF trough level
(immediately pre-dose) is associated with a
higher rate of clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-10	2014-01-10	mg/L			B 	r         
INFL	INFL	3.2
A detectable anti-TNF trough level
(immediately pre-dose) is associated with a
higher rate of clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-10	2014-01-10	mg/L			B 	r         
ADAL	ADAL	19.5
A detectable anti-TNF trough level
(immediately pre-dose) is associated with a
higher rate of clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-10	2014-01-10	mg/L			B 	r         
INFL	INFL	55
A detectable anti-TNF trough level
(immediately pre-dose) is associated with a
higher rate of clinical and endoscopic remission.
Result from Royal Devon & Exeter	2014-01-10	2014-01-10	mg/L			B 	r         
24H	CREX	10.0	2014-04-14	2014-04-14	mmol/24h	7.0	21.0	B 	QN        
UURA	UACR	120	2014-04-14	2014-04-14	umol/mmol	150	500	B 	rN        
24H	UCR	5000	2014-04-14	2014-04-14	umol/L			B 	          
24H	UT	24.0	2014-04-14	2014-04-14	h			B 	P=        
UURA	UUAM	0.60
Note change in units as of 14/4/14
New units mmol/L x 1000 = old units umol/L	2014-04-14	2014-04-14	mmol/L			B 	rP        
UURA	UUAX	1.2	2014-04-14	2014-04-14	mmol/24h	1.2	5.9	B 	rN        
24H	UV	2000	2014-04-14	2014-04-14	mL			B 	PS=       
METS	METS	Metanephrine = 100
Normetanephrine = 500
3MT = 50
Result from Freeman Hospital, Newcastle-upon-Tyne	2014-01-21	2014-01-21				B 	r/23      
PES	A1G	5.0	2014-02-24	2014-02-24	%	1.7	3.8	X 	P         
PES	A1GG	4.0	2014-02-24	2014-02-24	g/L	1.3	2.7	X 	Q         
PES	A2G	10.0	2014-02-24	2014-02-24	%	8.1	15.3	X 	P         
PES	A2GG	8.0	2014-02-24	2014-02-24	g/L	6.1	11.3	X 	Q         
PES	ALBG	44.0	2014-02-24	2014-02-24	g/L	33.3	54.1	X 	Q         
PES	ALBP	55.0	2014-02-24	2014-02-24	%	51.8	67.1	X 	P         
PES	B1G	5.0	2014-02-24	2014-02-24	%	6.0	9.9	X 	P         
PES	B1GG	4.0	2014-02-24	2014-02-24	g/L	4.1	7.7	X 	Q         
PES	B2G	5.0	2014-02-24	2014-02-24	%			X 	P         
PES	B2GL	4.0	2014-02-24	2014-02-24	g/L	1.2	5.6	X 	Q         
PES	GG	20.0	2014-02-24	2014-02-24	%	8.9	20.0	X 	P         
PES	GGG	16.0	2014-02-24	2014-02-24	g/L	6.1	15.0	X 	Q         
PES	PCOM	Discrete band in the gamma region.
Method changed on 24/02/14 from gel to capillary
electrophoresis. New reference ranges apply.	2014-02-24	2014-02-24				B 	A         
PES	PPR	4
Method changed on 24/02/14 from gel to capillary
electrophoresis. Paraproteins average 2 g/L higher
(80% between 1 g/L lower and 5 g/L higher).
IgA PP more affected than IgG or IgM.	2014-02-24	2014-02-24	g/L	0		B 	N         
PES	PPRP	5	2014-02-24		%			X 	N         
PES	PROT	80	2014-02-24	2014-02-24	g/L	63	83	B 	CP        
BON	ALB	40	2014-03-02	2014-03-02	g/L	34	50	B 	CP        
ALDO	ALDO	400
Aldosterone:renin =
Adult reference ranges:
Recumbent 100 - 500 pmol/L
Ambulant  600 - 1200 pmol/L	2014-04-08	2014-04-11	pmol/l	100	500	B 	A         
BON	ALP	50	2014-03-02	2014-03-02	IU/L	35	104	B 	C         
BON	CA	2.50	2014-03-02	2014-03-02	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.61	2014-03-02	2014-03-02	mmol/L	2.15	2.55	B 	C         
ELU	CREA	90	2014-03-02	2014-03-02	umol/L	49	92	B 	CPr       
ELU	FACR	1.02	2014-03-02					X 	N         
ELU	GFR	59
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2014-03-02	2014-03-02	.			B 	          
ELU	H	1	2014-03-02					  	JNr       
ELU	I	1	2014-03-02					  	JN        
ELU	K	4.0	2014-03-02	2014-03-02	mmol/L	3.5	5.1	B 	CP        
ELU	L	1	2014-03-02					  	JN        
ELU	NA	145	2014-03-02	2014-03-02	mmol/L	135	145	B 	CP        
BON	PHOS	1.10	2014-03-02	2014-03-02	mmol/L	0.87	1.45	B 	CP        
REN	REN	1.00
Adult reference ranges:
Recumbent 0.5 - 2.2 nmol/L/h
Ambulant  1.2 - 4.4 nmol/L/h	2014-04-08	2014-04-11	nmol/h/L	1.1	2.7	B 	          
ELU	SEX	0.742	2014-03-02					X 	N         
ELU	UREA	5.0	2014-03-02	2014-03-02	mmol/L	1.7	8.3	B 	CP        
VPA	VALM	50
Therapeutic efficacy may be achievable at
concentrations lower than the therapeutic
reference range.
NOTE CHANGE IN UNITS FROM 13/08/12
New units mg/L = 0.14 x old units umol/L	2014-07-04	2014-07-04	mg/L			B 	          
ELU	ZAGE	53	2014-03-02		y			X 	          
BON	ALB	40	2014-04-04	2014-04-04	g/L	34	50	B 	CP        
BON	ALP	1	2014-04-04	2014-04-04	IU/L	35	104	B 	C         
AND	AND	5.0
Reference ranges are for adults.	2014-06-02	2014-06-02	nmol/L	1.0	11.5	B 	A         
BON	CA	0.05	2014-04-04	2014-04-04	mmol/L	2.15	2.55	B 	CP        
BON	CCA	0.16	2014-04-04	2014-04-04	mmol/L	2.15	2.55	B 	C         
ELU	CREA	75	2014-04-04	2014-04-04	umol/L	49	92	B 	CPr       
ELU	FACR	1.27	2014-04-04					X 	N         
ELU	GFR	74
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2014-04-04	2014-04-04	.			B 	          
GH	GHN	1.0	2014-06-02	2014-06-02	ug/L			B 	B         
ELU	K	13.8	2014-04-04	2014-04-04	mmol/L	3.5	5.1	B 	CP        
ELU	NA	135	2014-04-04	2014-04-04	mmol/L	135	145	B 	CP        
BON	PHOS	1.00	2014-04-04	2014-04-04	mmol/L	0.87	1.45	B 	CP        
ELU	SEX	0.742	2014-04-04					X 	N         
ELU	UREA	5.0	2014-04-04	2014-04-04	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2014-04-04		y			X 	          
BON	ALB	40	2014-04-04	2014-04-04	g/L	34	50	B 	CP        
BON	ALP	Unsuitable due to EDTA contamination	2014-04-04	2014-04-04	IU/L	35	104	B 	C         
AMH	AMH	Cancelled - see comments	2014-07-07	2014-07-07	pmol/L			B 	r         
AMIO	AMIO	1.0	2014-05-30	2014-05-30	mg/L	0.5	2.0	B 	r/16      
BON	CA	Unsuitable due to EDTA contamination	2014-04-04	2014-04-04	mmol/L	2.15	2.55	B 	CP        
BON	CCA	Unable to calculate.	2014-04-04	2014-04-04	mmol/L	2.15	2.55	B 	C         
ELU	CREA	75	2014-04-04	2014-04-04	umol/L	49	92	B 	CPr       
AMIO	DMAM	1.0
Result from St Helier Hospital	2014-05-30	2014-05-30	mg/L	0.5	2.0	B 	r/16      
ELU	FACR	1.27	2014-04-04					X 	N         
ELU	GFR	74
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2014-04-04	2014-04-04	.			B 	          
IGF	IGF1	10.0
Note: new reference ranges.
Assay changed to DiaSorin Liaison from 18/12/12.	2014-05-30	2014-05-30	nmol/L	11.3	30.9	B 	          
INAB	INAB	1.2
Result from Royal Surrey Hospital	2014-05-30	2014-05-30				B 	r         
ELU	K	Unsuitable due to EDTA contamination	2014-04-04	2014-04-04	mmol/L	3.5	5.1	B 	CP        
ELU	NA	135	2014-04-04	2014-04-04	mmol/L	135	145	B 	CP        
BON	PHOS	1.00	2014-04-04	2014-04-04	mmol/L	0.87	1.45	B 	CP        
ELU	SEX	0.742	2014-04-04					X 	N         
ELU	UREA	5.0	2014-04-04	2014-04-04	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2014-04-04		y			X 	          
ASUB	ASUB	5
Reference ranges:
Males                                 <1.0 IU/L
Females, pre-menopausal               <1.0 IU/L
Females, post-menopausal or mid-cycle <3.0 IU/L
Result from Queen Elizabeth Hospital, Birmingham	2014-06-08	2014-06-09	IU/L			B 	r         
ELF	ELF	9.5
ELF score > or = 9.5 indicates high risk of
advanced fibrosis. Refer to secondary care, as per
Camden and Islington CCG pathway.
Result from North Middlesex Hospital.	2014-04-22	2014-04-22				B 	?r        
GCT	GCT	7.8
Reference range applies to 1 hour post 50g glucose
in non-fasting 28 weeks ante-natal patients only.	2014-04-22	2014-04-22	mmol/L			B 	          
SIND	H	.	2014-07-03					  	JNr       
SIND	I	.	2014-07-03					  	JN        
IGF	IGF1	30.0
Note: new reference ranges.
Assay changed to DiaSorin Liaison from 18/12/12.	2014-05-02	2014-05-02	nmol/L	11.3	30.9	B 	          
SIND	L	.	2014-07-03					  	JN        
LAXA	LAXA	Neg
Result from City Hospital, Birmingham	2014-06-24	2014-06-25				B 	r         
THG	TGAB	79	2014-07-03	2014-07-03	IU/mL			B 	r         
THGR	THG	<5.0
UCLH and Birmingham Tg results concordant - assay
interference does NOT appear to be present.
Endogenous antibodies to Tg may interfere in its
measurement. Interpret Tg in Tg-Ab positive sera
with caution.
Result from QEH, Birmingham.	2014-07-03	2014-07-03	ug/L	0	5	B 	r/23      
THG	THGN	<0.9
Anti-Tg >40 IU/mL: interference in thyroglobulin
assay may be present. Await results of parallel
thyroglobulin analysis at UCLH and Birmingham.
Tg reference range applies post-ablation/excision.
Note, method change to Immulite XPi from 26/11/12.
There are significant differences from previous
assays. To discuss, contact x72972 or x72954.	2014-07-03	2014-07-03	ug/L			B 	r         
AMH	AMH	50.00
Ovarian Fertility Potential:
Optimal Fertility           : 40.04 - 67.90 pmol/L
Satisfactory Fertility      : 21.98 - 40.03 pmol/L
Low Fertility               :  3.08 - 21.97 pmol/L
Very Low/Undetectable       :         <3.07 pmol/L
Levels greater than 67.90 pmol/L are suggestive of
polycystic ovarian disease or granulosa cell
tumours.	2014-07-01	2014-07-01	pmol/L			B 	r         
AND	AND	>35.0
Reference ranges are for adults.
Reference range updated 19/06/14
in line with manufacturer's guidance.	2014-06-24	2014-06-24	nmol/L	1.0	11.5	B 	A         
ASUB	ASUB	55
Reference ranges:
Males                                 <1.0 IU/L
Females, pre-menopausal               <1.0 IU/L
Females, post-menopausal or mid-cycle <3.0 IU/L
Result from Queen Elizabeth Hospital, Birmingham	2014-06-24	2014-07-01	IU/L			B 	r         
SCDX	BVL1	.{}	2014-10-24		IU/ml			H 	HAr?/5    
SCDX	BVL2	.{}	2014-10-24					H 	?r/5      
SCDX	CMGR	.{}	2014-10-24					H 	?/2       
SCDX	CMMR	.{}	2014-10-24					H 	?/2m      
SCDX	CMMV	.{}	2014-10-24					H 	Ir        
SCDX	CVL1	.{}	2014-10-24		IU/ml			H 	Hr?/5     
SCDX	CVL2	.{}	2014-10-24					H 	?r/5m     
SCDX	EBNA	.{}	2014-10-24					H 	?/2       
GCT	GCT	6.2
Reference range applies to 1 hour post 50g glucose
in non-fasting 28 weeks ante-natal patients only.	2014-04-22	2014-04-22	mmol/L			B 	          
UTET	GTET	10
Result from Great Ormond Street Hospital	2014-06-02	2014-06-02	umol/L			B 	r         
SCDX	HBCR	.{}	2014-10-24					H 	?r/2      
SCDX	HBVR	.{}	2014-10-24					H 	?r/2m     
SCDX	HCVR	.{}	2014-10-24					H 	?/2m      
SCDX	HIVR	.{}	2014-10-24					H 	?/2       
SCDX	HVL1	.{}	2014-10-24		Copies/ml			H 	HAr?/5    
SCDX	HVL2	.{}	2014-10-24					H 	?r/5      
IGF	IGF1	999.0
Note: new reference ranges.
Assay changed to DiaSorin Liaison from 18/12/12.	2014-05-02	2014-05-02	nmol/L	11.3	30.9	B 	          
LAXA	LAXA	Ok
Result from City Hospital, Birmingham	2014-07-01	2014-07-01				B 	r         
MYPA	MYPA	5
Result from Analytical Unit, St Georges'	2014-05-13	2014-05-13	mg/L			B 	r         
RAK2	RAK2	[P2/Rack:ARCHIVE-32/B02|14:39]	2014-04-22					X 	NJ        
SCDX	SCDS	COMPLETE REPORT	2014-10-24	2014-10-24				H 	Hr?       
SCDY	SCSS	END OF SCD SCREEN REPORT	2014-10-24	2014-10-24				H 	NA?       
SCDY	SYPR	.{}	2014-10-24					H 	?r/2m     
THRB	THRB	this is a test
Result from Addenbrookes Hospital, Cambridge	2014-08-04	2014-08-04				B 	r         
SCDY	TLVR	.{}	2014-10-24					H 	?/2m      
SCDY	TOXG	.{}	2014-10-24					H 	?/2       
SCDY	TOXM	.{}	2014-10-24					H 	?/2m      
UTET	URGT	5
Units: umol/mmol Creatinine
Result from Great Ormond Street Hospital	2014-06-02	2014-06-02				B 	r         
VPA	VALM	300
Therapeutic efficacy may be achievable at
concentrations lower than the therapeutic
reference range.
NOTE CHANGE IN UNITS FROM 13/08/12
New units mg/L = 0.14 x old units umol/L	2014-07-03	2014-07-03	mg/L			B 	          
SCDX	VCAG	.{}	2014-10-24					H 	?/2       
SCDX	VCAM	.{}	2014-10-24					H 	?/2m      
SCDY	VZGR	.{}	2014-10-24					H 	?/3r      
ACTH	ACTH	.
Ref.range: <46 ng/L at 9 am	2014-08-29		ng/l			B 	A/4       
AHP	AHP	Cancelled - see comments	2014-08-28	2014-08-28	nmol/L	0	6	B 	A         
ALDO	ALDO	Cancelled - see comments
This is a test	2014-08-28	2014-08-28	pmol/l	100	500	B 	A         
REN	REN	Cancelled - this is a test	2014-09-05	2014-09-05	nmol/h/L	1.1	2.7	B 	          
AHP	AHP	Cancelled - see comments	2015-01-27	2015-01-27	nmol/L	0	6	B 	A         
CA	ALB	<2	2014-12-08	2014-12-08	g/L	34	50	B 	CP        
CA	CA	2.28	2014-12-08	2014-12-08	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Albumin too low to calculate.	2014-12-08	2014-12-08	mmol/L	2.15	2.55	B 	C         
SIND	H	2	2014-12-08					  	JNr       
SIND	I	0	2014-12-08					  	JN        
SIND	L	0	2014-12-08					  	JN        
PTH	PTH	0.8	2014-12-08	2014-12-08	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-184/A13|19:52]	2014-12-08					X 	NJ        
USP	COMU	Cancelled - see comments
TEST	2015-08-24	2015-08-24				B 	p1A       
GT0	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
GT0	GT0 	5.0	2017-10-29	2017-10-29				B 	          
USP	UMED	In reference ranges M=Median	2015-08-24	2015-08-24				B 	?         
USP	USCI	Cancelled - see comments	2015-08-24	2015-08-24				B 	?         
USP	UST	12	2015-08-24	2015-08-24	hours			B 	P=        
USP	USV	Cancelled - see comments	2015-08-24	2015-08-24	ml			B 	          
HMGC	HMGC	positive
Result from Oxford Immunology	2015-11-02	2015-11-02				B 	r/16      
UADS	UADS	Cancelled - Request entered in error.	2015-11-27	2015-11-27				B 	r         
HG	HG	100.0
Test
Result from Centre for Clinical Science,
University of Surrey	2015-12-09	2015-12-11	nmol/L	0	30	B 	r/16      
24H	CREX	6.6	2015-12-09	2015-12-09	mmol/24h	7.0	21.0	B 	QN        
24H	UCR	5000	2015-12-09	2015-12-09	umol/L			B 	          
UCOP	UCRX	Cancelled	2016-08-09	2016-08-25				B 	r/16      
UCOP	UCUR	Cancelled	2016-08-09	2016-08-25				B 	r/16      
24H	UT	22.6
Please note urine collection NOT 24hours.	2015-12-09	2015-12-09	h			B 	P=        
24H	UV	1250	2015-12-09	2015-12-09	mL			B 	PS=       
ACHR	ACHR	test	2015-12-11	2015-12-11	nmol/l	0	0.45	I 	?Aar      
ACHR	ACRE	Royal Free Hospital	2015-12-11	2015-12-11				I 	rA?       
SY60	CORD	test
Normal response: >/= 415 nmol/L at any time	2017-10-29	2017-10-29				B 	          
SY60	STIM	test	2017-10-29	2017-10-29				B 	          
ACHR	ACHR	Cancelled - see comments
Test request.	2015-12-15	2015-12-15	nmol/l	0	0.45	I 	?Aar      
ACHR	ACRE	Royal Free Hospital	2015-12-14	2015-12-15				I 	rA?       
SY60	CORD	TEST
Normal response: >/= 415 nmol/L at any time	2017-10-29	2017-10-29				B 	          
PROG	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
PROG	PROG	Cancelled - see comments
Test	2015-12-17	2015-12-17	nmol/L			B 	          
SY60	STIM	TEST	2017-10-29	2017-10-29				B 	          
FCAL	FCAL	1088
<60 ug/g: within ref range - ?IBS / quiescent IBD.
60 - 150 ug/g: marginally elevated - consider
causes such as infection, polyps, GI tract
malignancy, NSAIDS - suggest repeat initially.
>150 ug/g: suggestive of IBD.
Known IBD: interpret results in clinical context.
Result from King's College Hospital	2015-12-30	2015-12-30	ug/g			B 	r/10      
AMH	AMHR	5.0
Note method change to Roche AMH 02/02/15. Results
on average 25% lower than previous method (Beckman
Gen II).
Female reference ranges (10th - 90th percentiles):
20 - 29 years:   13.1 - 53.8 pmol/L
30 - 34 years:    6.8 - 47.8 pmol/L
35 - 39 years:    5.5 - 37.4 pmol/L
40 - 44 years:    0.7 - 21.2 pmol/L
45 - 50 years:    0.3 - 14.7 pmol/L
Levels are known to be higher in PCOS.
Approximate guide for assessing ovarian reserve in
women 18 - 44 years. Antral follicle count (AFC):
AFC 0 - 7;  AMH   <4.9     pmol/L
AFC 8 - 15; AMH 4.9 - 16.2 pmol/L
AFC    >15; AMH   >16.2    pmol/L
To discuss, contact x72954 or x72972.	2016-01-07	2016-01-07	pmol/L			B 	          
SY60	CORD	Cancelled - see comments	2017-10-29	2017-10-29				B 	          
HBA	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
HBA	GHBI	42	2017-10-05	2017-10-05				B 	          
GT0	GT0 	TEST	2017-10-29	2017-10-29				B 	          
HBA	HBA 	6.0	2017-10-05	2017-10-05				B 	          
SY60	STIM	Cancelled - see comments	2017-10-29	2017-10-29				B 	          
AND	AND	25.0	2016-01-14	2016-01-14	nmol/L	1.0	11.5	B 	A         
AND	H	1	2016-01-14					  	JNr       
AND	I	1	2016-01-14					  	JN        
AND	L	1	2016-01-14					  	JN        
AMH	AMHR	35.0
Note method change to Roche AMH 02/02/15. Results
on average 25% lower than previous method (Beckman
Gen II).
Female reference ranges (10th - 90th percentiles):
20 - 29 years:   13.1 - 53.8 pmol/L
30 - 34 years:    6.8 - 47.8 pmol/L
35 - 39 years:    5.5 - 37.4 pmol/L
40 - 44 years:    0.7 - 21.2 pmol/L
45 - 50 years:    0.3 - 14.7 pmol/L
Levels are known to be higher in PCOS.
Approximate guide for assessing ovarian reserve in
women 18 - 44 years. Antral follicle count (AFC):
AFC 0 - 7;  AMH   <4.9     pmol/L
AFC 8 - 15; AMH 4.9 - 16.2 pmol/L
AFC    >15; AMH   >16.2    pmol/L
To discuss, contact x72954 or x72972.	2016-01-13	2016-01-13	pmol/L			B 	          
AMH	AMHR	411.0
Reference range represents 5th-95th centile	2016-01-13	2016-01-13	pmol/L			B 	          
AND	AND	25.0
Reference ranges are for adults.	2016-01-14	2016-01-14	nmol/L	1.0	11.5	B 	A         
AND	H	1	2016-01-14					  	JNr       
AND	I	1	2016-01-14					  	JN        
AND	L	1	2016-01-14					  	JN        
CHAL	CHAL	Test	2016-03-04	2016-03-04				B 	=?        
CHAL	CHAS	Test	2016-03-04					B 	?         
HG	HG	50.0
Result from Centre for Clinical Science,
University of Surrey	2016-03-04	2016-03-07	nmol/L	0	30	B 	r/16      
SIND	H	.	2016-03-26					  	JNr       
SIND	I	.	2016-03-26					  	JN        
SIND	L	.	2016-03-26					  	JN        
PROG	PROG	Cancelled - see comments	2016-03-26	2016-03-26	nmol/L			B 	          
FRUC	FRUN	500
Reference range is for non-diabetics.
Fructosamine CANNOT be used to diagnose diabetes:
for diagnosis, use fasting glucose and/or GTT.
People with diabetes can have results within the
reference range.
Analysed at Northwick Park Hospital	2016-03-23	2016-03-23	umol/L			B 	r/3       
FLEC	FLEC	199
In 95% of cases suppression of ventricular ectopic
contractions occurs with flecainide levels between
200 and 800 ug/L. There is some evidence to
suggest there is significant risk of arrhythmias
when levels exceed 800 ug/L.
Result from Alder Hey, Liverpool.	2016-03-29	2016-03-29	ug/L			B 	r         
AQ4	AQ4	Negative
AQ4 is the major disease autoantigen in NMO. AQ4
antibodies are found in >80% of NMO patients and
in ~50% of patients with longitudinally extensive
transverse myelitis. They are infrequent in
patients with optic neuritis without spinal cord
involvement.
Result from Oxford Immunology	2016-04-04	2016-04-04				F 	?r        
C1EF	CINF	94
From 18/09/15, reference range updated to 70-150%
Result from Sheffield Northern General	2016-04-04	2016-04-04	%	40	150	B 	r/7       
C1EF	CINF	93
From 18/09/15, reference range updated to 70-150%
Result from Sheffield Northern General	2016-04-04	2016-04-04	%	40	150	B 	r/7       
DPD	DPD	Patient genotyped for four DYPD mutations
associated with 5FU toxicity.
No DYPD mutations were found.
DPD deficiency is unlikely to be a cause of severe
toxicity to 5FU therapy.
Result from Purine Lab, Guy's and St Thomas'	2016-04-04	2016-04-04				B 	r/28      
DPD	DPD	Patient genotyped for four DPYD mutations
associated with 5FU toxicity.
No DPYD mutations were found.
DPD deficiency is unlikely to be a cause of severe
toxicity to 5FU therapy.
Result from Purine Lab, Guy's and St Thomas'	2016-04-04	2016-04-04				B 	r/28      
AMOG	AMOG	Positive
Result from Oxford Immunology	2016-04-05	2016-04-05				B 	r/28      
MOG	CAST	Serum	2016-05-04	2016-05-04				F 	?AB       
MOG	MOGA	positive	2016-04-07	2016-04-07				F 	?AB       
INIB	INIB	300
Post-menopausal <5 ng/L
Day 3 of cycle <273 ng/L
Adult female <341 ng/L
Please note new reference ranges for inhibin B
following a change of assay to Beckman Coulter Gen
II in December 2010. Patient results are
approximately 50% higher than previously.
The new units of ng/L are numerically identical to
the previous units of pg/mL.
Results from Charing Cross Hospital.	2016-04-08	2016-04-08	ng/L			B 	r/23      
LPF	CHDR	2.5	2016-04-26	2016-04-26				B 	          
LPF	CHOL	5.0	2016-04-26	2016-04-26	mmol/L	2.5	5.0	B 	PA        
SIND	H	1	2016-04-26					  	JNr       
LPF	HDL	2.0	2016-04-26	2016-04-26	mmol/L	1.2	1.7	B 	          
SIND	I	1	2016-04-26					  	JN        
SIND	L	1	2016-04-26					  	JN        
LPF	LDLU	Regret unable to accurately assess LDL
Cholesterol due to high Triglyceride
level.	2016-04-26	2016-04-26	mmol/L	0	3.5	B 	          
LPF	NHDL	3.0	2016-04-26	2016-04-26	mmol/L			B 	r         
LPF	TRIG	14.9
Moderate hypertriglyceridaemia. Review secondary
causes and repeat fasting within two weeks.
Consider referral if abnormality persists.	2016-04-26	2016-04-26	mmol/L	0.4	2.3	B 	P         
CYCA	CYCA	299
Reference Range: 100 - 300 ug/L
Please note change in platform effective 19/09/17.
Please contact the duty biochemist to discuss
if necessary.	2017-09-19	2017-09-19				B 	          
SULP	SSUL	Negative
The following sulphonylureas have been screened
for: Chlorpropamide; Glibenclamide; Gliclazide;
Glimepiride; Glipizide; Tolazamide and Tolbutamide
Result from Royal Surrey Hospital	2016-05-16	2016-05-16				B 	r         
TPMT	TPGT	.	2017-09-11					B 	N         
TPMT	TPMT	.	2017-09-11					B 	r/7       
SULP	USUL	Cancelled - see comments	2016-05-16	2016-05-16				B 	r         
SULP	SSUL	Cancelled - see comments	2016-05-16	2016-05-16				B 	r         
TAC	TAC 	15.0
Method used for Tacrolimus:Architect CMIA	2017-09-06	2017-09-06				B 	          
SULP	USUL	Negative
The following sulphonylureas have been screened
for: Chlorpropamide; Glibenclamide; Gliclazide;
Glimepiride; Glipizide; Tolazamide and Tolbutamide
Result from Royal Surrey Hospital	2016-05-16	2016-05-16				B 	r         
FRUC	FRU2	Cancelled	2016-06-02	2016-06-10	umol/L			B 	NI-J      
FRUC	FRUN	Cancelled	2016-06-02	2016-06-10	umol/L			B 	r/3       
FRUC	FRU2	Cancelled	2016-06-02	2016-06-10	umol/L			B 	NI-J      
FRUC	FRUN	Cancelled	2016-06-02	2016-06-10	umol/L			B 	r/3       
FRUC	FRU2	.	2016-06-15		umol/L			B 	NI-J      
FRUC	FRUN	400
Reference range is for non-diabetics.
Fructosamine CANNOT be used to diagnose diabetes:
for diagnosis, use fasting glucose and/or GTT.
People with diabetes can have results within the
reference range.
Analysed at Northwick Park Hospital	2016-06-15	2016-06-15	umol/L			B 	r/3       
TMP	CREA	100	2016-07-29	2016-07-29	umol/L	66	112	B 	CPr       
GFR	FACR	0.90	2016-07-29					X 	N         
GFR	GFR	71
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-07-29	2016-07-29	.			B 	          
SIND	H	.	2016-07-29					  	JNr       
SIND	I	.	2016-07-29					  	JN        
SIND	L	.	2016-07-29					  	JN        
TMP	PHOS	1.00	2016-07-29	2016-07-29	mmol/L	0.87	1.45	B 	CP        
GFR	SEX	1.0	2016-07-29					X 	N         
TMP	TMP1	.	2016-07-29		mmol/L			B 	N         
TMP	TMP2	0.96	2016-07-29	2016-07-29	mmol/L			B 	N         
TMP	TMPF	0.280	2016-07-29					  	NJ        
TMP	TRP	0.90	2016-07-29	2016-07-29				B 	r         
RN	UCR	5000	2016-07-29	2016-07-29	umol/L			B 	          
TMP	UP	5.0	2016-07-29	2016-07-29	mmol/L			B 	P         
GFR	ZAGE	49	2016-07-29		y			X 	          
GAD	GADE	1	2016-08-25	2016-08-25				F 	AB        
GAD	GADI	Negative	2016-08-25	2016-08-25				F 	?AB       
IA2	IA2 	0.00
Result from King''s College Hospital	2016-08-25	2016-08-25				B 	r/14      
INAB	INSA	0.1
Result from King''s College Hospital	2016-08-25	2016-08-25				B 	r/14      
FECA	ALB 	45	2016-10-13	2016-10-13				B 	CP        
FECA	CA  	2.50	2016-10-13	2016-10-13				B 	CP        
FECA	CACR	0.40	2016-10-13	2016-10-13				B 	QN        
FECA	CCA 	2.51	2016-10-13	2016-10-13				B 	C         
FECA	CREA	100	2016-10-13	2016-10-13				B 	CPr       
FECA	FECA	0.016
In cases of hypercalcaemia, a fractional excretion
of calcium:
<0.010   Suggestive of FHH
>0.020   Suggestive of PHPT	2016-10-13	2016-10-13				B 	N         
GFR	GFR 	.
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-10-13					B 	          
FECA	UCA9	2.00	2016-10-13	2016-10-13				B 	P         
RN	UCR 	5000	2016-10-13	2016-10-13				B 	          
GFR	ZAGE	.	2016-10-13					X 	          
AAP	A1AT	0.10	2017-08-18	2017-08-18				B 	AB        
AA1	AA1 	10.00
Result from Royal Free Hospital	2017-08-18	2017-08-18				B 	r         
AAP	AAP 	test
Result from Royal Free Hospital	2017-08-18	2017-08-18				B 	r         
ALPI	ALPI	test	2017-08-18	2017-08-18				B 	r         
APB	APB 	10.00
Result from Royal Free Hospital	2017-08-18	2017-08-18				B 	r         
CORT	CORT	50
Reference range 6-10 am: 133 - 537 nmol/L	2017-08-02	2017-08-02				B 	          
CORT	DBRV	To be reviewed by Duty Biochemist	2017-08-02	2017-08-02				B 	NIJ       
PB	PHBM	10	2017-08-17	2017-08-17				B 	          
SAA	SAA 	10.0
In cases of amyloidosis:
SAA <10mg/L: Amyloid deposits stable or gradually
regress in virtually all patients - no increase in
anti-inflammatory treatment is required.
SAA 10-25mg/L: Amyloid deposits stable in most
patients - further monitoring without changes in
therapy may be appropriate.
SAA >50mg/L: Amyloid deposits accumulate in most
patients, and more intensive or alternative
treatment should be considered.
Results should be interpreted with the CRP result.
Result from Royal Free Hospital.	2017-08-18	2017-08-18				B 	r         
SIRO	SIRO	15.0
By Mass Spectrometry (LC-MS/MS)
Results from Harefield Hospital	2017-08-22	2017-08-22				B 	r         
TAC	TAC 	10.0
Method used for Tacrolimus:Architect CMIA	2017-08-22	2017-08-22				B 	          
THG	TGAB	500	2017-08-22	2017-08-22				B 	r         
THG	THGN	10.0
Tg reference range applies post-ablation/excision.
For interpretative advice please contact the
Duty Biochemist on dutybiochemist@uclh.nhs.uk	2017-08-22	2017-08-22				B 	r         
TPMT	TPGT	TEST
Result from City Hospital, Birmingham	2017-08-18	2017-08-18				B 	N         
TPMT	TPMT	90
Deficient    <10 mU/L
Low        20-67 mU/L
Normal    68-150 mU/L
High         >150 mU/L
Recent blood transfusions may mask a deficient
TPMT result.
Result from City Hospital, Birmingham	2017-08-18	2017-08-18				B 	r/7       
BON	ALB 	40	2017-09-21	2017-09-21				B 	CP        
BON	ALP 	50	2017-09-21	2017-09-21				B 	C         
ALPI	BALP	10	2017-10-10	2017-10-10				B 	          
BON	CA  	2.00	2017-09-21	2017-09-21				B 	CP        
BON	CCA 	2.11	2017-09-21	2017-09-21				B 	C         
24H	CREX	10.0	2017-09-27	2017-09-27				B 	QN        
PHM	DHG 	50	2018-01-05	2018-01-05				B 	rP        
PHM	DHGR	5.0	2018-01-05	2018-01-05				B 	r         
PHM	DHGX	50	2018-01-05	2018-01-05				B 	rN        
ALPI	FALP	100	2017-10-10	2017-10-10				B 	          
PHM	HOG 	50	2018-01-05	2018-01-05				B 	rPNIJ     
PHM	HOGR	5	2018-01-05	2018-01-05				B 	rNIJ      
PHM	HOGX	50	2018-01-05	2018-01-05				B 	rNIJ      
ALPI	IALP	10	2017-10-10	2017-10-10				B 	          
ALPI	LALP	100	2017-10-10	2017-10-10				B 	          
ALPI	PALP	10	2017-10-10	2017-10-10				B 	          
PHM	PHMC	Test comment
Note change in methodology to LC-MS/MS from GC-MS
and updated interpretative cut-off for
DHG:creatinine. HOG no longer routinely reported.
For queries: felicity.stokes@hslpathology.com	2018-01-05	2018-01-05				B 	          
BON	PHOS	1.00
.{This is a test}	2017-09-21	2017-09-21				B 	CP        
UCOR	SEND	.	2018-01-08					B 	I?J       
TPMT	TPMT	test
Deficient    <10 mU/L
Low        20-67 mU/L
Normal    68-150 mU/L
High         >150 mU/L
Recent blood transfusions may mask a deficient
TPMT result.
Result from City Hospital, Birmingham	2017-10-03	2017-10-05				B 	r/7       
UCOR	UCCR	150.00	2017-09-27	2017-09-27				B 	rN        
UCOR	UCOR	150	2017-09-27	2017-09-27				B 	rP        
24H	UCR 	10000
Note dilute urine: results may be misleading	2017-09-27	2017-09-27				B 	          
UCOR	UCX 	150
Please note change in reference interval and
methodology to LC-MS/MS effective 08/09/17.
Result from Queen Elizabeth Hospital, Birmingham.	2017-09-27	2017-09-27				B 	Nr        
PHM	UGC 	50	2018-01-05	2018-01-05				B 	rPA       
PHM	UGCR	5	2018-01-05	2018-01-05				B 	r         
PHM	UGCX	50	2018-01-05	2018-01-05				B 	rN        
PHM	UGR 	50	2018-01-05	2018-01-05				B 	rP        
PHM	UGRR	5	2018-01-05	2018-01-05				B 	r         
PHM	UGRX	50	2018-01-05	2018-01-05				B 	rN        
24H	UT  	24.0	2017-09-27	2017-09-27				B 	P=        
24H	UV  	1000	2017-09-27	2017-09-27				B 	PS=       
FECA	ALB 	30	2017-10-17	2017-10-17				B 	CP        
FECA	CA  	2.14	2017-10-17	2017-10-17				B 	CP        
FECA	CACR	0.78	2017-10-17	2017-10-17				B 	QN        
FECA	CCA 	2.44	2017-10-17	2017-10-17				B 	C         
SY60	CORD	test
Normal response: >/= 415 nmol/L at any time	2017-10-29	2017-10-29				B 	          
FECA	CREA	91	2017-10-17	2017-10-17				B 	CPr       
FECA	FECA	0.033
In cases of hypercalcaemia, a fractional excretion
of calcium:
<0.010   Suggestive of FHH
>0.020   Suggestive of PHPT	2017-10-17	2017-10-17				B 	N         
SIRO	SIRO	test
Assay performed in-house from 19/09/17.
Please contact the duty biochemist to discuss
if necessary	2017-10-17	2017-10-17				B 	r         
SY60	STIM	test	2017-10-29	2017-10-29				B 	          
FECA	UCA9	2.25	2017-10-17	2017-10-17				B 	P         
FECA	UCR 	2898	2017-10-17	2017-10-17				B 	          
VITD	VITD	50
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Please note method change to Roche immunoassay
effective 07/10/17. Results are comparable to the
previous LC-MS/MS method, except with patients on
vitamin D2 supplementation where results may be
lower. Manufacturer guidance states 92% detection
of 25-hydroxyvitamin D2. Please contact the duty
biochemist to discuss if necessary.	2017-10-12	2017-10-12				B 	r         
AS	AS  	test
Result from Centre for Clinical Science,
University of Surrey	2017-10-31	2017-10-31				B 	r/16      
UCAL	CAX 	2.0	2017-11-02	2017-11-02				B 	QN        
24H	CREX	10.0	2017-11-02	2017-11-02				B 	QN        
AS	SEND	test	2017-10-31	2017-10-31				B 	I?J       
UCAL	UCA9	2.00	2017-11-02	2017-11-02				B 	P         
24H	UCR 	10000	2017-11-02	2017-11-02				B 	          
24H	UT  	24.0	2017-11-02	2017-11-02				B 	P=        
24H	UV  	1000	2017-11-02	2017-11-02				B 	PS=       
CR	CREA	Cancelled - see comments	2017-11-01	2017-11-01				B 	CPr       
VMA	HVAC	test
Result from Great Ormond Street Hospital	2017-10-31	2017-10-31				B 	r/7       
VMA	SEND	test	2017-10-31	2017-10-31				B 	I?J       
UCTH	UCTH	TEST	2017-10-31	2017-10-31				B 	r         
VMA	VMAC	test	2017-10-31	2017-10-31				B 	r/7       
INSG	INSG	<10
Insulin at Guildford = pmol/L (divide by 7 to give
result in mIU/L, the units used at UCLH).
Guildford use Mecodia assay - detects all forms,
quoted cross-reactivities: aspart 80%, lispro 89%
determir 22%, glargine 44%, glulisine 100%.
Result from Guildford.	2016-04-15	2016-04-15	pmol/L			B 	r         
VITD	25D2	<7	2013-04-24	2013-04-24	nmol/L			B 	rN        
VITD	25D3	75	2013-04-24	2013-04-24	nmol/L			B 	rN        
AT	A1AT	<0.20	2013-12-27	2013-12-27	g/L			B 	AB        
VITD	VITD	75
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2013-04-24	2013-04-24	nmol/L	25	120	B 	r         
FLAM	ALB	39	2013-11-21	2013-11-21	g/L	34	50	B 	CP        
FLAM	CA	2.40	2013-11-21	2013-11-21	mmol/L	2.15	2.55	B 	CP        
FLAM	CCA	2.53	2013-11-21	2013-11-21	mmol/L	2.15	2.55	B 	C         
SIND	H	1	2013-11-21					  	JNr       
SIND	I	1	2013-11-21					  	JN        
SFLC	KAPA	31.0	2013-01-30	2013-01-30	mg/L			B 	r         
SFLC	KLRA	3.88
Analysed at UCLH using SPAplus Freelite. Results
may differ from those using the Royal Free method.
Occasional monoclonal proteins react atypically in
the assay and give erroneous results.
Contact x72950 to discuss if discrepancy suspected	2013-01-30	2013-01-30				B 	r         
SIND	L	1	2013-11-21					  	JN        
SFLC	LAMB	8.0	2013-01-30	2013-01-30	mg/L			B 	r         
FPHT	FPHT	20.0
Note:as of 13/8/12 test units have changed to mg/L	2014-11-11	2014-11-12	mg/L			P 	Ap1       
FZNS	FZNS	20.0
Note:as of 13/8/12 test units have changed to mg/L	2014-11-11	2014-11-12	mg/L			P 	Ap1       
HOXS	HOX1	17
The measured saliva concentration is equivalent to
a blood concentration of.	2014-11-12	2014-11-13	mg/L			P 	Np1r      
HOXS	HOXS	10.0
Note:as of 13/8/12 test units have changed to mg/L
During therapy with Oxcarbazepine
monitoring of only the active metabolite
10-Hydroxycarbazepine is recommended	2014-11-12	2014-11-13	mg/L			P 	Ap1       
HOXS	OXCD	10	2014-11-12	2014-11-13				P 	A?=       
HOXS	OXCT	0900	2014-11-12	2014-11-13				P 	?=        
FPHT	PHT2	200
The measured free concentration is equivalent to
this total concentration.	2014-11-11	2014-11-12	mg/L			P 	Np1r      
FPHT	PHTD	10	2014-11-11	2014-11-12				P 	A?=       
FPHT	PHTT	0900	2014-11-11	2014-11-12				P 	?=        
VPAS	VPA1	100
The measured saliva concentration is equivalent to
a blood concentration of.	2014-11-12	2014-11-13	mg/L			P 	Np1r      
VPAS	VPAD	10	2014-11-12	2014-11-13				P 	A?=       
VPAS	VPAS	10.0
Note:as of 13/8/12 test units have changed to mg/L	2014-11-12	2014-11-13	mg/L			P 	Ap1       
VPAS	VPAT	900	2014-11-12	2014-11-13				P 	?=        
FZNS	ZNS2	200
The measured free concentration is equivalent to
this total concentration.	2014-11-11	2014-11-12	mg/L			P 	Np1r      
FZNS	ZNSD	10	2014-11-11	2014-11-12				P 	A?=       
FZNS	ZNST	0900	2014-11-11	2014-11-12				P 	?=        
CL	CL	98	2014-03-11	2014-03-11	mmol/L	98	107	B 	CP        
CR	CREA	84	2014-03-11	2014-03-11	umol/L	49	92	B 	CPr       
SIND	H	10	2014-03-11					  	JNr       
SIND	I	10	2014-03-11					  	JN        
K	K	4.6	2014-03-11	2014-03-11	mmol/L	3.5	5.1	B 	CP        
SIND	L	10	2014-03-11					  	JN        
NA	NA	126	2014-03-11	2014-03-11	mmol/L	135	145	B 	CP        
U	UREA	5.0	2014-03-11	2014-03-11	mmol/L	1.7	8.3	B 	CP        
SCDX	BVL1	.{ 0 }	2014-08-04		IU/ml			H 	HAr?/5    
SCDX	BVL2	Not Detected	2014-08-04	2014-08-04				H 	?r/5      
SCDW	CMGA	6	2014-08-11	2014-08-11				H 	Ir/1      
SCDX	CMGR	Positive	2014-08-11	2014-08-11				H 	?/2       
CMGV	CMGV	10	2014-08-11	2014-08-11				H 	Ir        
SCDW	CMMA	0.2	2014-08-04	2014-08-04				H 	Ir/1      
SCDX	CMMR	Not Detected	2014-08-04	2014-08-04				H 	?/2m      
SCDX	CMMV	.{}	2014-08-04					H 	Ir        
SCDX	CVL1	.{ 0 }	2014-08-04		IU/ml			H 	Hr?/5     
SCDX	CVL2	Not Detected	2014-08-04	2014-08-04				H 	?r/5m     
SCDW	EBN1	0.1	2014-08-04	2014-08-04				H 	HIr/2     
SCDX	EBNA	Weak Reactive	2014-08-04	2014-08-04				H 	?/2       
SCDW	HBCA	.{ 0.200 }	2014-08-04					H 	HIr/1     
SCDX	HBCR	Positive	2014-08-04	2014-08-04				H 	?r/2      
SCDW	HBVA	.{ 0.200 }	2014-08-04					H 	HIr/1     
SCDX	HBVR	Not Detected	2014-08-04	2014-08-04				H 	?r/2m     
SCDW	HCVA	0.100	2014-08-04	2014-08-04				H 	Ir/1      
SCDX	HCVR	Not Detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV
infection, please contact us to discuss further
testing of this sample.	2014-08-04	2014-08-04				H 	?/2m      
SCDW	HCVV	.{}	2014-08-04					H 	I/3       
SCDW	HIVA	0.100	2014-08-04	2014-08-04				H 	Ir/1      
SCDX	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2014-08-04	2014-08-04				H 	?/2       
SCDX	HVL1	.{ 0 }	2014-08-04		Copies/ml			H 	HAr?/5    
SCDX	HVL2	Not Detected (<50 Copies/ml)	2014-08-04	2014-08-04				H 	?r/5      
SCDI	SAVI	Sample saved in Virology.	2014-08-04	2014-08-04				H 	I?/0      
SCDX	SCDS	COMPLETE REPORT	2014-08-04	2014-08-04				H 	Hr?       
SCDY	SCSS	END OF SCD SCREEN REPORT	2014-08-04	2014-08-04				H 	NA?       
SCDW	SYPA	0.100	2014-08-04	2014-08-04				H 	?Ir/1     
SCDY	SYPR	Negative	2014-08-04	2014-08-04				H 	?r/2m     
SCDW	TLVA	0.100	2014-08-04	2014-08-04				H 	Ir/1      
SCDY	TLVR	Not Detected
No evidence of infection.	2014-08-04	2014-08-04				H 	?/2m      
SCDY	TOXG	Not Detected	2014-08-04	2014-08-04				H 	?/2       
SCDY	TOXM	Not Detected	2014-08-04	2014-08-04				H 	?/2m      
SCDW	TXGA	0.1	2014-08-04	2014-08-04				H 	Ir/1      
SCDW	TXMA	0.2	2014-08-04	2014-08-04				H 	Ir/1      
SCDW	TXMV	.{}	2014-08-04					H 	IN        
SCDW	VCA1	0.1	2014-08-04	2014-08-04				H 	HIr/2     
SCDW	VCA2	0.1	2014-08-04	2014-08-04				H 	HIr/2     
SCDX	VCAG	Weak Reactive	2014-08-04	2014-08-04				H 	?/2       
SCDX	VCAM	Not Detected	2014-08-04	2014-08-04				H 	?/2m      
SCDW	VZGE	Not Detected	2014-08-04	2014-08-04				H 	?IN/3r    
SCDY	VZGR	Not Detected	2014-08-04	2014-08-04				H 	?/3r      
SCDW	VZGV	Not Tested	2014-08-04	2014-08-04				H 	INr?/2    
EPOU	EPOU	4.5
Serum erythropoietin below the reference range but
maybe normal if the haemoglobin is within limits.	2014-01-06	2014-01-06	IU/L			A 	/7        
EPOU	EPOU	10.0
Serum erythropoietin within reference range for
normal haemoglobin.	2014-01-06	2014-01-06	IU/L			A 	/7        
ELU	CREA	100	2014-01-31	2014-01-31	umol/L	49	92	B 	CPr       
ELU	GFR	45
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2014-01-31	2014-01-31	.			B 	          
GFRC	GFRC	eGFR < 60 ml/min/1.73m^2. No previous eGFR results
on record. If new, confirm with repeat within 2
weeks or sooner if AKI suspected.	2014-01-31	2014-01-31				B 	          
SIND	H	0	2014-01-22					  	JNr       
SIND	I	0	2014-01-22					  	JN        
ELU	K	4.5	2014-01-31	2014-01-31	mmol/L	3.5	5.1	B 	CP        
SIND	L	3	2014-01-22					  	JN        
ELU	NA	140	2014-01-31	2014-01-31	mmol/L	135	145	B 	CP        
PTH	PTH	1.8	2014-01-22	2014-01-22	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-129/B09|18:52]	2014-01-22					X 	NJ        
ELU	UREA	8.0	2014-01-31	2014-01-31	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	53	2014-01-31		y			X 	          
SIND	H	0	2014-01-22					  	JNr       
SIND	I	0	2014-01-22					  	JN        
SIND	L	2	2014-01-22					  	JN        
PTH	PTH	4.7	2014-01-22	2014-01-22	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-129/D10|19:00]	2014-01-22					X 	NJ        
SIND	H	0	2014-01-22					  	JNr       
SIND	I	0	2014-01-22					  	JN        
SIND	L	3	2014-01-22					  	JN        
PTH	PTH	10.3	2014-01-22	2014-01-22	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-129/D14|19:00]	2014-01-22					X 	NJ        
VITD	25D2	50
This line should not be suppressed
.{test of suppression of comments}	2014-03-02	2014-07-16	nmol/L			B 	rN        
VITD	25D3	50
.{test of suppression of comments	2014-03-02	2014-03-02	nmol/L			B 	rN        
ALDO	ALDO	500
Adult reference ranges:
Recumbent 100 - 500 pmol/L
Ambulant  600 - 1200 pmol/L	2014-02-21	2014-02-21	pmol/l	100	500	B 	A         
SIND	H	0	2014-01-22					  	JNr       
SIND	I	0	2014-01-22					  	JN        
SIND	L	1	2014-01-22					  	JN        
PTH	PTH	28.4	2014-01-22	2014-01-22	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-128/D08|18:43]	2014-01-22					X 	NJ        
VITD	VITD	100
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2014-03-02	2014-03-02	nmol/L	25	120	B 	r         
METS	3MT	120	2014-02-20	2014-02-20	pmol/L			B 	r         
SIND	H	0	2014-01-22					  	JNr       
SIND	I	0	2014-01-22					  	JN        
SIND	L	0	2014-01-22					  	JN        
METS	META	400	2014-02-20	2014-02-20	pmol/L			B 	r         
METS	METC	Borderline increase in plasma normetanephrine, but
not in the range normally associated with
phaeochromocytoma. Recommend repeat plasma
metanephrines with patient in supine position for
30mins, excluding any interfering drugs, eg.
antidepressants and antihypertensives (especially
beta-blockers and non-selective alpha-adrenoceptor
blockers). Please provide a full drug history on
the request form.
To discuss, contact Dr Anne Dawnay (x72954) or Dr
Francis Lam (x72965).	2016-03-02	2016-03-02				B 	r         
METS	NMET	1900	2014-02-20	2014-02-20	pmol/L			B 	r         
PTH	PTH	72.5	2014-01-22	2014-01-22	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-133/C04|20:09]	2014-01-22					X 	NJ        
METS	3MT	<100	2014-02-20	2014-02-20	pmol/L			B 	r         
AND	AND	>20.0
Reference ranges are for adults.	2014-02-08	2014-02-08	nmol/L	1.0	11.5	B 	A         
ELF	ELF	testtest
Result from North Middlesex Hospital.	2014-03-14	2014-03-14				B 	?r        
SIND	H	0	2014-01-22					  	JNr       
SIND	I	0	2014-01-22					  	JN        
SIND	L	1	2014-01-22					  	JN        
METS	META	200	2014-02-20	2014-02-20	pmol/L			B 	r         
METS	METC	TEST
To discuss, contact Dr Anne Dawnay (x72954) or Dr
Sarah Pitkin (x72963).
Note: plasma metanephrines analysed at UCLH by
tandem mass spectrometry from 1st January 2014.	2014-03-14	2014-03-14				B 	r         
METS	NMET	500	2014-02-20	2014-02-20	pmol/L			B 	r         
PTH	PTH	237.3	2014-01-22	2014-01-22	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-128/C27|18:43]	2014-01-22					X 	NJ        
REN	REN	2.22
Adult reference ranges:
Recumbent 0.5 - 2.2 nmol/L/h
Ambulant  1.2 - 4.4 nmol/L/h	2014-02-21	2014-02-21	nmol/h/L	1.1	2.7	B 	          
AHP	AHP	Cancelled - see comments	2014-07-23	2014-07-23	nmol/L	0	6	B 	A         
ELU	CREA	Cancelled - see comments	2014-07-23	2014-07-23	umol/L	49	92	B 	CPr       
ELU	GFR	Cancelled - see comments	2014-07-23	2014-07-23	.			B 	          
ELU	K	Cancelled - see comments	2014-07-23	2014-07-23	mmol/L	3.5	5.1	B 	CP        
ELU	NA	Cancelled - see comments	2014-07-23	2014-07-23	mmol/L	135	145	B 	CP        
ELU	UREA	Cancelled - see comments	2014-07-23	2014-07-23	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	54	2014-07-22		y			X 	          
CA	ALB	<2	2014-07-23	2014-07-23	g/L	34	50	B 	CP        
CA	CA	0.50	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Albumin too low to calculate.	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	C         
SIND	H	0	2014-07-23					  	JNr       
SIND	I	0	2014-07-23					  	JN        
SIND	L	2	2014-07-23					  	JN        
RAK1	RAK1	[P1/Rack:ARCHIVE-67/C01|17:13]	2014-07-23					X 	NJ        
CA	ALB	<2	2014-07-23	2014-07-23	g/L	34	50	B 	CP        
CA	CA	1.04	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Albumin too low to calculate.	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	C         
SIND	H	1	2014-07-23					  	JNr       
SIND	I	1	2014-07-23					  	JN        
SIND	L	0	2014-07-23					  	JN        
RAK1	RAK1	[P1/Rack:ARCHIVE-67/B30|17:13]	2014-07-23					X 	NJ        
CA	ALB	Cancelled - see comments
Not required	2014-07-23	2014-07-23	g/L	34	50	B 	CP        
CA	CA	1.96	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Unable to calculate.	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	C         
SIND	H	0	2014-07-23					  	JNr       
SIND	I	0	2014-07-23					  	JN        
SIND	L	0	2014-07-23					  	JN        
RAK1	RAK1	[P1/Rack:ARCHIVE-67/C02|17:13]	2014-07-23					X 	NJ        
CA	ALB	<2
Not required	2014-07-23	2014-07-23	g/L	34	50	B 	CP        
CA	CA	2.45	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Albumin too low to calculate.	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	C         
CHAL	CHAL	test	2014-08-08	2014-08-08				B 	=?        
CHAL	CHAS	test	2014-08-08					B 	?         
SIND	H	1	2014-07-23					  	JNr       
SIND	I	0	2014-07-23					  	JN        
SIND	L	0	2014-07-23					  	JN        
RAK1	RAK1	[P1/Rack:ARCHIVE-67/B26|17:13]	2014-07-23					X 	NJ        
CA	ALB	<2	2014-07-23	2014-07-23	g/L	34	50	B 	CP        
AMH	AMH	6.00
Ovarian Fertility Potential:
Optimal Fertility           : 40.04 - 67.90 pmol/L
Satisfactory Fertility      : 21.98 - 40.03 pmol/L
Low Fertility               :  3.08 - 21.97 pmol/L
Very Low/Undetectable       :         <3.07 pmol/L
Levels greater than 67.90 pmol/L are suggestive of
polycystic ovarian disease or granulosa cell
tumours.
Note: test performed in-house from 17/06/14.
Reference ranges may be different from previous.	2014-08-06	2014-08-06	pmol/L			B 	r         
CA	CA	2.97	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Albumin too low to calculate.	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	C         
SIND	H	1	2014-07-23					  	JNr       
SIND	I	1	2014-07-23					  	JN        
SIND	L	0	2014-07-23					  	JN        
RAK1	RAK1	[P1/Rack:ARCHIVE-67/B25|17:13]	2014-07-23					X 	NJ        
CA	ALB	<2	2014-07-23	2014-07-23	g/L	34	50	B 	CP        
AMH	AMH	5.00
Ovarian Fertility Potential:
Optimal Fertility           : 40.04 - 67.90 pmol/L
Satisfactory Fertility      : 21.98 - 40.03 pmol/L
Low Fertility               :  3.08 - 21.97 pmol/L
Very Low/Undetectable       :         <3.07 pmol/L
Levels greater than 67.90 pmol/L are suggestive of
polycystic ovarian disease or granulosa cell
tumours.
Note: test performed in-house from 17/06/14.
Reference ranges may be different from previous.	2014-08-05	2014-08-05	pmol/L			B 	r         
CA	CA	4.86	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	CP        
CA	CCA	Albumin too low to calculate.	2014-07-23	2014-07-23	mmol/L	2.15	2.55	B 	C         
SIND	H	0	2014-07-23					  	JNr       
SIND	I	0	2014-07-23					  	JN        
SIND	L	0	2014-07-23					  	JN        
LTG	LTG	test
Note:as of 13/8/12 test units have changed to mg/L	2014-08-18	2014-08-18	mg/L			P 	Ap1       
LTG	LTGD	test	2014-08-18	2014-08-18				P 	A?=       
LTG	LTGT	test	2014-08-18	2014-08-18				P 	?=        
RAK1	RAK1	[P1/Rack:ARCHIVE-67/C03|17:13]	2014-07-23					X 	NJ        
UALB	UALB	<3	2014-08-18	2014-08-18	mg/L			B 	          
RN	UCR	5000	2014-08-18	2014-08-18	umol/L			B 	          
UALB	UMA	Unable to calculate ACR as urine albumin
undetectable.	2014-08-18	2014-08-18	mg/mmol	0.00	2.80	B 	S         
TGN	6TGN	700
Units: pmol/8x10^8 RBC
Red cell TGN above the therapeutic range (>450).
Dose reduction is advisable if TGN levels are
>550, depending on clinical situation. If patient
is not responding to therapy, consider alternative
immunosuppressant therapies.
Repeat TGN measurement 4-6 weeks after any change
in therapy.
Results from Purine Unit, Guy's and St Thomas'	2014-10-02	2014-10-02				B 	r/10      
GCT	GCT	Icteric sample, unsuitable for analysis
Reference range applies to 1 hour post 50g glucose
in non-fasting 28 weeks ante-natal patients only.	2014-09-09	2014-09-09	mmol/L			B 	          
SIND	H	10	2014-09-09					  	JNr       
SIND	I	5000	2014-09-09					  	JN        
SIND	L	10	2014-09-09					  	JN        
TGN	MEMP	100
Units: pmol/8x10^8 RBC
Results from Purine Unit, Guy's and St Thomas'	2014-10-02	2014-10-02				B 	r/10      
TGN	MTGR	0	2014-10-02	2014-10-02				B 	r/10      
RAK2	RAK2	[P2/Rack:ARCHIVE-28/B21|14:00]	2014-09-09					X 	NJ        
SHBG	SHBG	Icteric sample, unsuitable for analysis
Please note change to reference range
effective 05/08/13.	2014-09-15	2014-09-15	nmol/L	20	122	B 	P         
SIND	H	23	2014-09-23					  	JNr       
SIND	I	14	2014-09-23					  	JN        
SIND	L	17	2014-09-23					  	JN        
PTH	PTH	74.5	2014-09-24	2014-09-24	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-36/D29|11:03]	2014-09-24					X 	NJ        
SIND	H	21	2014-09-23					  	JNr       
SIND	I	12	2014-09-23					  	JN        
SIND	L	12	2014-09-23					  	JN        
PTH	PTH	53.7	2014-09-24	2014-09-24	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-36/E01|11:03]	2014-09-24					X 	NJ        
SIND	H	22	2014-09-23					  	JNr       
SIND	I	12	2014-09-23					  	JN        
SIND	L	11	2014-09-23					  	JN        
PTH	PTH	15.4	2014-09-24	2014-09-24	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-36/D28|11:03]	2014-09-24					X 	NJ        
SIND	H	28	2014-09-23					  	JNr       
SIND	I	11	2014-09-23					  	JN        
SIND	L	9	2014-09-23					  	JN        
PTH	PTH	9.6	2014-09-24	2014-09-24	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-36/D24|11:02]	2014-09-24					X 	NJ        
LPF	CHDR	3.3	2014-11-26	2014-11-26				B 	          
LPF	CHOL	5.0	2014-11-26	2014-11-26	mmol/L	2.5	5.0	B 	PA        
SIND	H	9	2014-09-23					  	JNr       
LPF	HDL	1.5	2014-11-26	2014-11-26	mmol/L	1.2	1.7	B 	          
SIND	I	11	2014-09-23					  	JN        
SIND	L	11	2014-09-23					  	JN        
LPF	LDLU	2.6	2014-11-26	2014-11-26	mmol/L	0	3.5	B 	          
TST	NHDL	3.5	2014-11-26	2014-11-26	mmol/L			B 	r         
PTH	PTH	7.1	2014-09-24	2014-09-24	pmol/L	1.6	6.9	B 	          
RAK1	RAK1	[P1/Rack:ARCHIVE-36/D30|11:03]	2014-09-24					X 	NJ        
LPF	TRIG	2.0	2014-11-26	2014-11-26	mmol/L	0.4	2.3	B 	P         
ALDO	ALDO	<53
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2014-11-20	2014-11-20	pmol/l	100	500	B 	A         
LPF	CHDR	2.7	2014-11-26	2014-11-26				B 	          
LPF	CHOL	4.0	2014-11-26	2014-11-26	mmol/L	2.5	5.0	B 	PA        
LPF	HDL	1.5	2014-11-26	2014-11-26	mmol/L	1.2	1.7	B 	          
LPF	LDLU	1.6	2014-11-26	2014-11-26	mmol/L	0	3.5	B 	          
TST	NHDL	2.5	2014-11-26	2014-11-26	mmol/L			B 	r         
LPF	TRIG	2.0	2014-11-26	2014-11-26	mmol/L	0.4	2.3	B 	P         
ALDO	ALDO	Cancelled - see comments	2014-11-05	2014-11-05	pmol/l	100	500	B 	A         
LPF	CHDR	3.3	2014-11-26	2014-11-26				B 	          
LPF	CHOL	5.0	2014-11-26	2014-11-26	mmol/L	2.5	5.0	B 	PA        
LPF	HDL	1.5	2014-11-26	2014-11-26	mmol/L	1.2	1.7	B 	          
LPF	LDLU	2.6	2014-11-26	2014-11-26	mmol/L	0	3.5	B 	          
TST	NHDL	3.5	2014-11-26	2014-11-26	mmol/L			B 	r         
LPF	TRIG	2.0	2014-11-26	2014-11-26	mmol/L	0.4	2.3	B 	P         
ALDO	ALDO	Cancelled - see comments	2014-11-05	2014-11-05	pmol/l	100	500	B 	A         
LPF	CHDR	2.7	2014-11-26	2014-11-26				B 	          
LPF	CHOL	4.0	2014-11-26	2014-11-26	mmol/L	2.5	5.0	B 	PA        
GLU	GLU	4.7
Reference range applies to fasting samples only.	2014-11-18	2014-11-18	mmol/L	3.9	5.8	B 	AB        
LPF	HDL	1.5	2014-11-26	2014-11-26	mmol/L	1.2	1.7	B 	          
LPF	LDLU	1.6	2014-11-26	2014-11-26	mmol/L	0	3.5	B 	          
TST	NHDL	2.5	2014-11-26	2014-11-26	mmol/L			B 	r         
LPF	TRIG	2.0	2014-11-26	2014-11-26	mmol/L	0.4	2.3	B 	P         
ALDO	ALDO	149
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2014-11-03	2014-11-04	pmol/l	100	500	B 	A         
LPF	CHDR	1.7	2014-11-24	2014-11-24				B 	          
LPF	CHOL	5.0	2014-11-24	2014-11-24	mmol/L	2.5	5.0	B 	PA        
LPF	HDL	3.0	2014-11-24	2014-11-24	mmol/L	1.2	1.7	B 	          
LPF	LDLU	1.1	2014-11-24	2014-11-24	mmol/L	0	3.5	B 	          
TST	NHDL	Cancelled - see comments	2014-11-26	2014-11-26	mmol/L			B 	r         
REN	REN	7.71
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   0.50 - 3.90 nmol/L/h
Upright  2.20 - 7.70 nmol/L/h	2014-11-03	2014-11-04	nmol/h/L	1.1	2.7	B 	          
LPF	TRIG	2.0	2014-11-24	2014-11-24	mmol/L	0.4	2.3	B 	P         
24H	CREX	7.5	2015-06-12	2015-06-12	mmol/24h	7.0	21.0	B 	QN        
24H	UCR	5000	2015-06-12	2015-06-12	umol/L			B 	          
UCOP	UCRX	1.5
Result from Royal Free Hospital
From 15/06/15, samples for trace element analysis
are sent to the Royal Free Hospital.
Note change in reference range.	2015-06-12	2015-06-12	umol/24h			B 	r/16      
UCOP	UCUR	1.0
Result from Royal Free Hospital	2015-06-12	2015-06-12	umol/L			B 	r/16      
24H	UT	24.0	2015-06-12	2015-06-12	h			B 	P=        
24H	UV	1500	2015-06-12	2015-06-12	mL			B 	PS=       
CU	CURF	11.0
Result from Royal Free Hospital
From 15/06/15, samples for trace element analysis
are sent to the Royal Free Hospital.
Note change in reference range.	2015-06-15	2015-06-15	umol/L			B 	r/16      
SE	SERF	1.5
Result from Royal Free Hospital
From 15/06/15, samples for trace element analysis
are sent to the Royal Free Hospital.
Note change in reference range.	2015-06-15	2015-06-15	umol/L			B 	r/16      
VMA	HVAC	20
Result from Great Ormond Street Hospital	2015-05-29	2015-05-29	umol/mmol			B 	r/7       
VMA	VMAC	15	2015-05-29	2015-05-29	umol/mmol			B 	r/7       
FGF	FGF	100
Result from Norfolk & Norwich Hospitals	2015-06-01	2015-06-01	HRU/mL			B 	r/30      
FLG	AO	A1658	2014-10-06					X 	NJI       
FBCZ	BA	 0.2%  0.02	2014-10-06	2014-10-06	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	 0.8%  0.08	2014-10-06	2014-10-06	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HBGL	129	2014-10-06	2014-10-06	g/L			A 	rCP/0     
FBCY	HCTU	0.405	2014-10-06	2014-10-06	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	.{}	2014-10-06		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2014-10-06		%			A 	SN/0      
FBCZ	LY	14.6%  1.44	2014-10-06	2014-10-06	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	319	2014-10-06	2014-10-06	g/L			A 	CPS/0     
FBCY	MCHU	27.5	2014-10-06	2014-10-06	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	86.4	2014-10-06	2014-10-06	fL	80	99	A 	CPS/0     
FBCZ	MO	 7.3%  0.72	2014-10-06	2014-10-06	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	11.3	2014-10-06	2014-10-06	fL	7	13	A 	CS?/0     
FBCZ	NE	77.1%  7.58	2014-10-06	2014-10-06	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	332	2014-10-06	2014-10-06	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	4.69	2014-10-06	2014-10-06	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	13.9	2014-10-06	2014-10-06	%	11.5	15.0	A 	CS/0      
FBCY	WCC	9.83	2014-10-06	2014-10-06	x10^9/L	3.0	10.0	A 	CWPS/0    
CL	CL	105	2014-10-09	2014-10-09	mmol/L	98	107	B 	CP        
CR	CREA	97	2014-10-09	2014-10-09	umol/L	49	92	B 	CPr       
SIND	H	9	2014-10-09					  	JNr       
HCV	HCVV	.{}	2014-10-09					H 	I/3       
SIND	I	20	2014-10-09					  	JN        
K	K	5.0	2014-10-09	2014-10-09	mmol/L	3.5	5.1	B 	CP        
SIND	L	10	2014-10-09					  	JN        
NA	NA	149	2014-10-09	2014-10-09	mmol/L	135	145	B 	CP        
U	UREA	6.2	2014-10-09	2014-10-09	mmol/L	1.7	8.3	B 	CP        
PES	A1G	7.0	2015-01-13	2015-01-13	%	1.7	3.8	X 	P         
PES	A1GG	4.9	2015-01-13	2015-01-13	g/L	1.3	2.7	X 	Q         
PES	A2G	15.0	2015-01-13	2015-01-13	%	8.1	15.3	X 	P         
PES	A2GG	10.5	2015-01-13	2015-01-13	g/L	6.1	11.3	X 	Q         
PES	ALBG	46.2	2015-01-13	2015-01-13	g/L	33.3	54.1	X 	Q         
PES	ALBP	66.0	2015-01-13	2015-01-13	%	51.8	67.1	X 	P         
PES	B1G	8.0	2015-01-13	2015-01-13	%	6.0	9.9	X 	P         
PES	B1GG	5.6	2015-01-13	2015-01-13	g/L	4.1	7.7	X 	Q         
PES	B2G	8.0	2015-01-13	2015-01-13	%			X 	P         
PES	B2GL	5.6	2015-01-13	2015-01-13	g/L	1.2	5.6	X 	Q         
PES	GG	24.0	2015-01-13	2015-01-13	%	8.9	20.0	X 	P         
PES	GGG	16.8	2015-01-13	2015-01-13	g/L	6.1	15.0	X 	Q         
HBA	GHBI	45	2015-01-13	2015-01-13	mmol/mol			B 	          
HBA	HBA	7.0	2015-01-13	2015-01-13	% total Hb	4.0	6.0	B 	          
PES	PCOM	Comment
Method changed on 24/02/14 from gel to capillary
electrophoresis. New reference ranges apply.	2015-01-13	2015-01-13				B 	A         
PES	PROT	70	2015-01-13	2015-01-13	g/L	63	83	B 	CP        
LFT	ALB	Cancelled - see comments	2014-09-12	2014-09-12	g/L	34	50	B 	CP        
LFT	ALP	Cancelled - Please see comment above.	2014-09-12	2014-09-12	IU/L	35	104	B 	C         
LFT	ALT	Cancelled - Please see comment above.	2014-09-12	2014-09-12	IU/L	10	35	B 	C         
LFT	BILI	Cancelled - Please see comment above.	2014-09-12	2014-09-12	umol/L	0	137	B 	CPr       
ELU	CREA	Cancelled - Please see comment above.	2014-09-12	2014-09-12	umol/L	49	92	B 	CPr       
ELU	GFR	Cancelled - Please see comment above.	2014-09-12	2014-09-12	.			B 	          
ELU	H	.	2014-09-12					  	JNr       
HAVS	HAGA	.{}	2014-09-08					H 	Ir/1      
HAVS	HAGR	.{}	2014-09-08					H 	?/2       
HAVM	HAMA	.{}	2014-09-08					H 	Ir/1      
HAVM	HAMR	.{}	2014-09-08					H 	?/1m      
ELU	I	.	2014-09-12					  	JN        
ELU	K	Cancelled - Please see comment above.	2014-09-12	2014-09-12	mmol/L	3.5	5.1	B 	CP        
ELU	L	.	2014-09-12					  	JN        
ELU	NA	Cancelled - Please see comment above.	2014-09-12	2014-09-12	mmol/L	135	145	B 	CP        
ELU	UREA	Cancelled - Please see comment above.	2014-09-12	2014-09-12	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	33	2014-09-05		y			X 	          
FLG 	AO	A1031	2014-09-02					X 	NJI       
FBCZ	BA	 0.5%  0.04	2014-09-02	2014-09-02	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	 1.2%  0.09	2014-09-02	2014-09-02	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HBGL	124	2014-09-02	2014-09-02	g/L			A 	rCP/0     
FBCY	HCTU	0.377	2014-09-02	2014-09-02	L/L	0.33	0.45	A 	CPS/0     
FBCZ	LY	38.9%  3.03	2014-09-02	2014-09-02	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	329	2014-09-02	2014-09-02	g/L			A 	CPS/0     
FBCY	MCHU	32.5	2014-09-02	2014-09-02	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	99.0	2014-09-02	2014-09-02	fL	80	99	A 	CPS/0     
FBCZ	MO	 9.6%  0.75	2014-09-02	2014-09-02	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	9.6	2014-09-02	2014-09-02	fL	7	13	A 	CS?/0     
FBCZ	NE	49.8%  3.88	2014-09-02	2014-09-02	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	332	2014-09-02	2014-09-02	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	3.81	2014-09-02	2014-09-02	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	15.6	2014-09-02	2014-09-02	%	11.5	15.0	A 	CS/0      
FBCY	WCC	7.79	2014-09-02	2014-09-02	x10^9/L	3.0	10.0	A 	CWPS/0    
VITD	25D2	<7	2014-12-19	2014-12-22	nmol/L			B 	rN        
VITD	25D3	27	2014-12-19	2014-12-22	nmol/L			B 	rN        
HBA	GHBI	44	2014-12-19	2014-12-19	mmol/mol			B 	          
HBA	HBA	6.2	2014-12-19	2014-12-19	% total Hb	4.0	6.0	B 	          
VITD	VITD	27
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2014-12-19	2014-12-22	nmol/L	25	120	B 	r         
CR	CREA	37	2014-10-13	2014-10-13	umol/L	28	52	B 	CPr       
CR	CREA	41	2014-10-13	2014-10-13	umol/L	28	52	B 	CPr       
FLG 	AO	A1663	2014-09-29					X 	NJI       
FBCZ	BA	 0.3%  0.02	2014-09-29	2014-09-29	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	 2.1%  0.14	2014-09-29	2014-09-29	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HBGL	104	2014-09-29	2014-09-29	g/L			A 	rCP/0     
FBCY	HCTU	0.302	2014-09-29	2014-09-29	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	.{}	2014-09-29		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2014-09-29		%			A 	SN/0      
FBCZ	LY	21.5%  1.45	2014-09-29	2014-09-29	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	344	2014-09-29	2014-09-29	g/L			A 	CPS/0     
FBCY	MCHU	31.0	2014-09-29	2014-09-29	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	90.1	2014-09-29	2014-09-29	fL	80	99	A 	CPS/0     
FBCZ	MO	 8.0%  0.54	2014-09-29	2014-09-29	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	10.5	2014-09-29	2014-09-29	fL	7	13	A 	CS?/0     
FBCZ	NE	68.1%  4.59	2014-09-29	2014-09-29	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	211	2014-09-29	2014-09-29	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	3.35	2014-09-29	2014-09-29	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	13.1	2014-09-29	2014-09-29	%	11.5	15.0	A 	CS/0      
FBCY	WCC	6.74	2014-09-29	2014-09-29	x10^9/L	3.0	10.0	A 	CWPS/0    
COAT	APRA	No citrate sample for Coagulation received.	2014-07-04	2014-07-04		2.0	3.0	A 	?/1       
COAT	APTT	No citrate sample for Coagulation received.	2014-07-04	2014-07-04	secs	22	41	A 	P/1       
COAT	FIB	No citrate sample for Coagulation received.	2014-07-04	2014-07-04	g/L			A 	p1/1      
COAT	INR	No citrate sample for Coagulation received.	2014-07-04	2014-07-04				A 	/1        
COAT	PT	Cancelled - No citrate sample for Coagulation	2014-07-04	2014-07-04	secs	10.0	12.0	A 	/1        
ALT	ALT	33	2014-11-25	2014-11-25	IU/L	10	35	B 	C         
FLG	AO	A2573	2014-06-23					X 	NJI       
FBCZ	BA	 0.1%  0.03	2014-06-23		x10^9/L	0.0	0.1	A 	CDSN/0    
LPF	CHDR	3.0	2014-11-19	2014-11-19				B 	          
LPF	CHOL	fail	2014-11-25	2014-11-25	mmol/L	2.5	5.0	B 	PA        
FBCZ	EO	 1.2%  0.39	2014-06-23		x10^9/L	0.0	0.4	A 	CDSN/0    
FLG	FLG9	NRBC ?	2014-06-23					A 	NJ-I?     
FBCY	HBGL	97
Please note change of units	2014-06-23		g/L			A 	rCP/0     
FBCY	HCTU	0.333	2014-06-23		L/L	0.33	0.45	A 	CPS/0     
LPF	HDL	1.5	2014-11-19	2014-11-19	mmol/L	1.2	1.7	B 	          
FBCZ	IG	.{}	2014-06-23		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2014-06-23		%			A 	SN/0      
LPF	LDLU	2.1	2014-11-19	2014-11-19	mmol/L	0	3.5	B 	          
FBCZ	LY	 3.1%  1.00	2014-06-23		x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	291
Please note change of units	2014-06-23		g/L			A 	CPS/0     
FBCY	MCHU	23.2	2014-06-23		pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	79.5	2014-06-23		fL	80	99	A 	CPS/0     
FBCZ	MO	 4.8%  1.55	2014-06-23		x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	9.1	2014-06-23		fL	7	13	A 	CS?/0     
FBCZ	NE	90.8% 29.28	2014-06-23		x10^9/L	2.0	7.5	A 	CDS/0     
TST	NHDL	3.0	2014-11-19	2014-11-19	mmol/L			B 	r         
FBCY	PLT	523	2014-06-23		x10^9/L	150	400	A 	CS/0      
FBCY	RCC	4.19	2014-06-23		x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	19.2	2014-06-23		%	11.5	15.0	A 	CS/0      
LPF	TRIG	2.0	2014-11-19	2014-11-19	mmol/L	0.4	2.3	B 	P         
FBCY	WCC	32.25	2014-06-23		x10^9/L	3.0	10.0	A 	CWPS/0    
HCVA	HCVA	.	2014-06-04					H 	Ir/1      
HCVR	HCVR	.	2014-06-04					H 	?/2m      
HCVV	HCVV	.{}	2014-06-04					H 	I/3       
IGF	IGF1	.
Note: new reference ranges.
Assay changed to DiaSorin Liaison from 18/12/12.	2014-06-04		nmol/L	15.0	39.9	B 	          
CHCU	CHCU	Request entered in error	2014-05-09	2014-05-09	g/dl	32.0	34.9	A 	NCPS/0    
FBCY	HBGL	Request entered in error
Please note change of units	2014-05-09	2014-05-09	g/L			A 	rCP/0     
FBCY	HCTU	Request entered in error	2014-05-09	2014-05-09	L/L	0.33	0.45	A 	CPS/0     
HGB	HGB	Request entered in error	2014-05-09	2014-05-09	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	IG	Request entered in error	2014-05-09	2014-05-09	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Request entered in error	2014-05-09	2014-05-09	%			A 	SN/0      
FBCZ	LY	Request entered in error	2014-05-09	2014-05-09	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Request entered in error
Please note change of units	2014-05-09	2014-05-09	g/L			A 	CPS/0     
FBCY	MCHU	Request entered in error	2014-05-09	2014-05-09	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Request entered in error	2014-05-09	2014-05-09	fL	80	99	A 	CPS/0     
FBCZ	MO	Request entered in error	2014-05-09	2014-05-09	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Request entered in error	2014-05-09	2014-05-09	fL	7	13	A 	CS?/0     
FBCZ	NE	Request entered in error	2014-05-09	2014-05-09	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Request entered in error	2014-05-09	2014-05-09	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Request entered in error	2014-05-09	2014-05-09	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Request entered in error	2014-05-09	2014-05-09	%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - FBC Request entered in error	2014-05-09	2014-05-09	x10^9/L	3.0	10.0	A 	CWPS/0    
FLG 	AO	A1658	2014-05-07					X 	NJI       
FBCZ	BA	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-05-07	2014-05-07	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-05-07	2014-05-07	x10^9/L	0.0	0.4	A 	CDSN/0    
FLG 	FLG1	Blasts ?	2014-05-07	2014-05-07				A 	NJ-I?     
FLG 	FLG9	NRBC ?	2014-05-07	2014-05-07				A 	NJ-I?     
HBGL	HBGL	87
Please note change of units	2014-05-07	2014-05-07	g/L			A 	rCP/0     
FBCY	HCTU	0.311	2014-05-07	2014-05-07	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	.{}	2014-05-07		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2014-05-07		%			A 	SN/0      
FBCZ	LY	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-05-07	2014-05-07	x10^9/L	1.2	3.65	A 	CDSP/0    
MCGL	MCGL	280
Please note change of units	2014-05-07	2014-05-07	g/L			A 	CPS/0     
FBCY	MCHU	27.4	2014-05-07	2014-05-07	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	98.1	2014-05-07	2014-05-07	fL	80	99	A 	CPS/0     
FBCZ	MO	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-05-07	2014-05-07	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	12.3	2014-05-07	2014-05-07	fL	7	13	A 	CS?/0     
FBCZ	NE	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-05-07	2014-05-07	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	161	2014-05-07	2014-05-07	x10^9/L	150	400	A 	CS/0      
FBCY	RAKH	1.111	2014-05-07					X 	NJ        
FBCY	RCC	3.17	2014-05-07	2014-05-07	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	15.4	2014-05-07	2014-05-07	%	11.5	15.0	A 	CS/0      
FBCY	WCC	6.39	2014-05-07	2014-05-07	x10^9/L	3.0	10.0	A 	CWPS/0    
TSTF	BA	 1.0%  0.08
THIS IS A TEST PATIENT.
Please disregard these results.	2014-05-03	2014-05-04	x10^9/L	0.0	0.1	A 	CDSN/0    
DIFF	DIFF	.	2014-05-03					X 	          
TSTF	EO	 4.0%  0.32	2014-05-03	2014-05-04	x10^9/L	0.0	0.4	A 	CDSN/0    
GF	GF	*POSITIVE*	2014-05-03	2014-05-04				A 	?/0       
TSTF	HBGL	130
Please note change of units	2014-05-03	2014-05-04	g/L			A 	rCP/0     
TSTF	HCTU	0.400	2014-05-03	2014-05-04	L/L	0.33	0.45	A 	CPS/0     
TSTF	LY	40.0%  3.20	2014-05-03	2014-05-04	x10^9/L	1.2	3.65	A 	CDSP/0    
TSTF	MCGL	350
Please note change of units	2014-05-03	2014-05-04	g/L			A 	CPS/0     
TSTF	MCHU	27.0	2014-05-03	2014-05-04	pg	27.0	33.5	A 	CPS/0     
TSTF	MCVU	82.0	2014-05-03	2014-05-04	fL	80	99	A 	CPS/0     
TSTF	MO	 5.0%  0.40	2014-05-03	2014-05-04	x10^9/L	0.2	1.0	A 	CDS/0     
TSTF	MPVU	12.0	2014-05-03	2014-05-04	fL	7	13	A 	CS?/0     
TSTF	NE	50.0%  4.00	2014-05-03	2014-05-04	x10^9/L	2.0	7.5	A 	CDS/0     
TSTF	PLT	270	2014-05-03	2014-05-04	x10^9/L	150	400	A 	CS/0      
TSTF	RCC	4.90	2014-05-03	2014-05-04	x10^12/L	3.95	5.15	A 	P/0       
TSTF	RDWU	12.5	2014-05-03	2014-05-04	%	11.5	15.0	A 	CS/0      
TSTF	WCC	8.00	2014-05-03	2014-05-04	x10^9/L	3.0	10.0	A 	CWPS/0    
TSTF	BA	 1.0%  0.08	2014-05-02	2014-05-02	x10^9/L	0.0	0.1	A 	CDSN/0    
TSTF	EO	 4.0%  0.32	2014-05-02	2014-05-02	x10^9/L	0.0	0.4	A 	CDSN/0    
TSTF	HBGL	155	2014-05-02	2014-05-02	g/L			A 	rCP/0     
TSTF	HCTU	0.450	2014-05-02	2014-05-02	L/L	0.37	0.50	A 	CPS/0     
TSTF	LY	40.0%  3.20	2014-05-02	2014-05-02	x10^9/L	1.2	3.65	A 	CDSP/0    
TSTF	MCGL	355	2014-05-02	2014-05-02	g/L			A 	CPS/0     
TSTF	MCHU	28.0	2014-05-02	2014-05-02	pg	27.0	33.5	A 	CPS/0     
TSTF	MCVU	82.0	2014-05-02	2014-05-02	fL	80	99	A 	CPS/0     
TSTF	MO	 5.0%  0.40	2014-05-02	2014-05-02	x10^9/L	0.2	1.0	A 	CDS/0     
TSTF	MPVU	12.0	2014-05-02	2014-05-02	fL	7	13	A 	CS?/0     
TSTF	NE	50.0%  4.00	2014-05-02	2014-05-02	x10^9/L	2.0	7.5	A 	CDS/0     
TSTF	PLT	270	2014-05-02	2014-05-02	x10^9/L	150	400	A 	CS/0      
TSTF	RCC	4.50	2014-05-02	2014-05-02	x10^12/L	4.4	5.8	A 	P/0       
TSTF	RDWU	12.5	2014-05-02	2014-05-02	%	11.5	15.0	A 	CS/0      
TSTF	WCC	8.00	2014-05-02	2014-05-02	x10^9/L	3.0	10.0	A 	CWPS/0    
FBCZ	BA	 1.0%  0.08	2014-05-02	2014-05-02	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	35.0	2014-05-02	2014-05-02	g/dl	32.0	34.9	A 	NCPS/0    
FBCZ	EO	 4.0%  0.33	2014-05-02	2014-05-02	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HCTU	0.440	2014-05-02	2014-05-02	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	14.5	2014-05-02	2014-05-02	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	LY	40.0%  3.28	2014-05-02	2014-05-02	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	27.0	2014-05-02	2014-05-02	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	83.0	2014-05-02	2014-05-02	fL	80	99	A 	CPS/0     
FBCZ	MO	 5.0%  0.41	2014-05-02	2014-05-02	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	12.0	2014-05-02	2014-05-02	fL	7	13	A 	CS?/0     
FBCZ	NE	50.0%  4.10	2014-05-02	2014-05-02	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	270	2014-05-02	2014-05-02	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	4.50	2014-05-02	2014-05-02	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	12.5	2014-05-02	2014-05-02	%	11.5	15.0	A 	CS/0      
FBCY	WCC	8.20	2014-05-02	2014-05-02	x10^9/L	3.0	10.0	A 	CWPS/0    
TSTF	BA	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-04-28	2014-04-28	x10^9/L	0.0	0.1	A 	CDSN/0    
TSTF	EO	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-04-28	2014-04-28	x10^9/L	0.0	0.4	A 	CDSN/0    
TSTF	HBGL	143	2014-04-28	2014-04-28	g/L			A 	rCP/0     
TSTF	HCTU	0.506	2014-04-28	2014-04-28	L/L	0.33	0.45	A 	CPS/0     
TSTF	LY	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-04-28	2014-04-28	x10^9/L	1.2	3.65	A 	CDSP/0    
TSTF	MCGL	283	2014-04-28	2014-04-28	g/L			A 	CPS/0     
TSTF	MCHU	32.6	2014-04-28	2014-04-28	pg	27.0	33.5	A 	CPS/0     
TSTF	MCVU	115.3	2014-04-28	2014-04-28	fL	80	99	A 	CPS/0     
TSTF	MO	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-04-28	2014-04-28	x10^9/L	0.2	1.0	A 	CDS/0     
TSTF	MPVU	14.1	2014-04-28	2014-04-28	fL	7	13	A 	CS?/0     
TSTF	NE	If WBC >0.5 x10*9/l, blood film will be ordered.	2014-04-28	2014-04-28	x10^9/L	2.0	7.5	A 	CDS/0     
TSTF	PLT	199	2014-04-28	2014-04-28	x10^9/L	150	400	A 	CS/0      
TSTF	RCC	4.39	2014-04-28	2014-04-28	x10^12/L	3.95	5.15	A 	P/0       
TSTF	RDWU	16.4	2014-04-28	2014-04-28	%	11.5	15.0	A 	CS/0      
TSTF	WCC	11.98	2014-04-28	2014-04-28	x10^9/L	3.0	10.0	A 	CWPS/0    
CL	CL	100	2014-03-11	2014-12-03	mmol/L	98	107	B 	CP        
CR	CREA	82	2014-03-11	2014-12-03	umol/L	49	92	B 	CPr       
HBA	GHBI	40	2014-12-03	2014-12-03	mmol/mol			B 	          
SIND	H	10	2014-03-11					  	JNr       
HBA	HBA	5.0	2014-12-03	2014-12-03	% total Hb	4.0	6.0	B 	          
SIND	I	10	2014-03-11					  	JN        
K	K	4.5	2014-03-11	2014-12-03	mmol/L	3.5	5.1	B 	CP        
SIND	L	10	2014-03-11					  	JN        
NA	NA	125	2014-03-11	2014-12-03	mmol/L	135	145	B 	CP        
U	UREA	5.0	2014-03-11	2014-12-03	mmol/L	1.7	8.3	B 	CP        
FLG	AO	A1663	2014-02-25					X 	NJI       
FBCZ	BA	 0.4%  0.03	2014-02-25	2014-02-25	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	25.9	2014-02-25	2014-02-25	g/dl	32.0	34.9	A 	NCPS/0    
LPF	CHDR	2.7	2014-11-27	2014-11-27				B 	          
LPF	CHOL	4.0	2014-11-27	2014-11-27	mmol/L	2.5	5.0	B 	PA        
FBCZ	EO	.{}	2014-02-25		x10^9/L	0.0	0.4	A 	CDSN/0    
FLG	FLG9	NRBC ?
**DO NOT AUTHORISE FBC if "NR" OUTSTANDING**	2014-02-25					A 	NJ-I?     
FBCY	HBGL	.	2014-11-27		g/L			A 	rCP/0     
FBCY	HCTU	0.463	2014-02-25	2014-02-25	L/L	0.33	0.45	A 	CPS/0     
LPF	HDL	1.5	2014-11-27	2014-11-27	mmol/L	1.2	1.7	B 	          
FBCY	HGB	12.0	2014-02-25	2014-02-25	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	IG	.{}	2014-02-25		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2014-02-25		%			A 	SN/0      
LPF	LDLU	1.6	2014-11-27	2014-11-27	mmol/L	0	3.5	B 	          
FBCZ	LY	.{}	2014-02-25		x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	.	2014-11-27		g/L			A 	CPS/0     
FBCY	MCHU	22.5	2014-02-25	2014-02-25	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	86.7	2014-02-25	2014-02-25	fL	80	99	A 	CPS/0     
FBCZ	MO	.{}	2014-02-25		x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	12.4	2014-02-25	2014-02-25	fL	7	13	A 	CS?/0     
FBCZ	NE	.{}	2014-02-25		x10^9/L	2.0	7.5	A 	CDS/0     
LPF	NHDL	2.5	2014-11-27	2014-11-27	mmol/L			B 	r         
FBCY	PLT	273	2014-02-25	2014-02-25	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	5.34	2014-02-25	2014-02-25	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	16.0	2014-02-25	2014-02-25	%	11.5	15.0	A 	CS/0      
LPF	TRIG	2.0	2014-11-27	2014-11-27	mmol/L	0.4	2.3	B 	P         
FBCY	WCC	8.21	2014-02-25	2014-02-25	x10^9/L	3.0	10.0	A 	CWPS/0    
HBA	GHBI	35	2015-12-23	2015-12-23	mmol/mol			B 	          
HBA	HBA	5.3	2015-12-23	2015-12-23	% total Hb	4.0	6.0	B 	          
GH	GHN	Cancelled - see comments	2015-03-24	2015-03-24	ug/L			B 	B         
FPSA	PSA	Cancelled - see comments	2015-04-07	2015-04-07	ug/L			B 	          
FPSA	PSAF	Cancelled - see comments	2015-04-07	2015-04-07	ug/L			B 	          
SPCO	SPCO	Octreotide Challenge Test	2015-03-24	2015-03-24				B 	          
STIM	STIM	0 mins	2015-03-24	2015-03-24				B 	          
UHIA	UHIA	Cancelled - see comments	2015-03-31	2015-03-31	umol/L			B 	r         
UHIA	UHIX	Cancelled - see comments	2015-04-07	2015-04-08	umol/24h			B 	r         
ACTH	ACTH	100.0
Ref.range: <46 ng/L at 9 am	2015-02-26	2015-02-26	ng/l			B 	A/4       
COSC	COSC	SYPR/	2015-03-16					X 	N         
COSD	COSD	Organisms sent 16/03/2015 09:38	2015-03-16					X 	N         
GLAB	GLAI	.	2015-02-23					I 	?         
GLAB	GLGA	.	2015-02-23					I 	?Ar       
GLAB	GLGG	.	2015-02-23					I 	?Ar       
GLAB	GLGI	.	2015-02-23					I 	?         
HIVS	HIVI	.{}	2015-03-10					H 	IN?/2     
HIVS	HIVV	.{}	2015-03-10					H 	Ir/2      
NA	NA	.	2015-02-27		mmol/L	135	145	B 	CP        
OSM	OSMO	.	2015-02-27		mosmol/kg	285	295	B 	          
STS	RPR	Not tested	2015-03-13	2015-03-16				H 	?Hr/2m    
SAVE	SAVC	.{}	2015-03-05					H 	?r/2      
SAVE	SAVE	.{}	2015-03-05					H 	?/2       
SAVE	SV65	.{}	2015-03-05					H 	?/2       
STS	SYPA	2.100	2015-02-22	2015-02-23				H 	?Ir/1     
STS	SYPR	.{ POSITIVE }	2015-02-22					H 	?r/2m     
STS	TPC	.{ No Comment }	2015-03-12					H 	?/2       
STS	TPPA	Not Tested	2015-03-13	2015-03-16				H 	?Hr/2m    
TSH	TSH	.	2015-02-27		mIU/L	0.27	4.20	B 	Cr        
UOSM	UOSM	.	2015-02-27		mosmol/kg	300	900	B 	          
HBA	GHBI	Cancelled - see comments	2015-02-23	2015-02-23	mmol/mol			B 	          
HBA	HBA	Cancelled - see comments	2015-02-23	2015-02-23	% total Hb	4.0	6.0	B 	          
UALB	UALB	Cancelled - see comments	2015-02-23	2015-02-23	mg/L			B 	          
UALB	UMA	Cancelled - see comments	2015-02-23	2015-02-23	mg/mmol	0.00	2.80	B 	S         
STS	RPR	Not tested	2015-03-12	2015-03-16				H 	?Hr/2m    
STS	SYPA	10.000	2015-02-20	2015-02-20				H 	?Ir/1     
STS	SYPR	.{ POSITIVE }	2015-02-20					H 	?r/2m     
STS	TPC	Regret insufficient sample for analysis.	2015-03-12	2015-03-16				H 	?/2       
STS	TPPA	Cancelled	2015-03-12	2015-03-16				H 	?Hr/2m    
EBVS	EBN1	.	2015-04-27					H 	HIr/2     
EBVS	EBNA	.	2015-04-27					H 	?/2       
EBVS	EBVS	REPORT	2015-04-27	2015-04-28				H 	HNAp1r?   
EBVS	VCA1	.	2015-04-27					H 	HIr/2     
EBVS	VCAG	.	2015-04-27					H 	?/2       
FLG	AO	A1663	2015-01-21					X 	NJI       
FBCZ	BA	 0.7%  0.04	2015-01-21	2015-01-21	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	 7.1%  0.43	2015-01-21	2015-01-21	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HBGL	145	2015-01-21	2015-01-21	g/L			A 	rCP/0     
FBCY	HCTU	0.475	2015-01-21	2015-01-21	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	.{}	2015-01-21		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2015-01-21		%			A 	SN/0      
FBCZ	LY	36.3%  2.19	2015-01-21	2015-01-21	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	305	2015-01-21	2015-01-21	g/L			A 	CPS/0     
FBCY	MCHU	31.9	2015-01-21	2015-01-21	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	104.6	2015-01-21	2015-01-21	fL	80	99	A 	CPS/0     
FBCZ	MO	 1.7%  0.10	2015-01-21	2015-01-21	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	11.8	2015-01-21	2015-01-21	fL	7	13	A 	CS?/0     
FBCZ	NE	54.2%  3.27	2015-01-21	2015-01-21	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	220	2015-01-21	2015-01-21	x10^9/L	150	400	A 	CS/0      
FBCY	RAKH	2.27	2015-01-21					X 	NJ        
FBCY	RCC	4.54	2015-01-21	2015-01-21	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	13.9	2015-01-21	2015-01-21	%	11.5	15.0	A 	CS/0      
FBCY	WCC	6.03	2015-01-21	2015-01-21	x10^9/L	3.0	10.0	A 	CWPS/0    
ALDO	ALDO	2310
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2015-01-27	2015-01-27	pmol/l	100	500	B 	A         
ALDO	ALDO	286
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2015-01-27	2015-01-27	pmol/l	100	500	B 	A         
ALDO	ALDO	2110
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2015-01-27	2015-01-27	pmol/l	100	500	B 	A         
ALDO	ALDO	1810
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2015-01-27	2015-01-27	pmol/l	100	500	B 	A         
ALDO	ALDO	1230
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2015-01-27	2015-01-27	pmol/l	100	500	B 	A         
ALDO	ALDO	708
***Please note: change in assay from 3/11/14***
*******New reference ranges apply*******
Adult reference ranges:
Supine   150 - 550 pmol/L
Upright  250 - 950 pmol/L	2015-01-27	2015-01-27	pmol/l	100	500	B 	A         
PRED	COMS	300
By Mass Spectrometry (LC-MS/MS)
Results from Harefield Hospital	2015-03-19	2015-03-19	nmol/L			B 	r/16      
PRED	PRMS	4000
By Mass Spectrometry (LC-MS/MS)
Results from Harefield Hospital	2015-03-19	2015-03-19	nmol/L			B 	r/16      
PRED	PRTI	4 hours
ACTH is labile and its measurement requires an
EDTA (purple top tube) sample to be sent to the
lab immediately on ice. Samples for FBC cannot
also be used for ACTH.
Haemolysis may falsely lower the plasma ACTH
concentration due to degradation by intracellular
proteases. Please interpret with caution.	2015-03-19	2015-03-24				B 	=         
UHIA	UHIA	10	2015-03-31	2015-03-31	umol/L			B 	r         
UHIA	UHIX	42	2015-03-31	2015-03-31	umol/24h			B 	r         
24H	CREX	12.5	2015-03-31	2015-03-31	mmol/24h	7.0	21.0	B 	QN        
24H	UCR	5000	2015-03-31	2015-03-31	umol/L			B 	          
UHIA	UHIA	18	2015-03-31	2015-03-31	umol/L			B 	r         
UHIA	UHIX	45	2015-03-31	2015-03-31	umol/24h			B 	r         
24H	UT	24.0	2015-03-31	2015-03-31	h			B 	P=        
24H	UV	2500	2015-03-31	2015-03-31	mL			B 	PS=       
24H	CREX	12.5	2015-03-31	2015-03-31	mmol/24h	7.0	21.0	B 	QN        
24H	UCR	5000	2015-03-31	2015-03-31	umol/L			B 	          
UHIA	UHIA	50	2015-03-31	2015-03-31	umol/L			B 	r         
UHIA	UHIX	125	2015-03-31	2015-03-31	umol/24h			B 	r         
24H	UT	24.0	2015-03-31	2015-03-31	h			B 	P=        
24H	UV	2500	2015-03-31	2015-03-31	mL			B 	PS=       
TST	SRHU	Cancelled - Request entered in error.	2015-11-17	2015-11-17	mmol/L			B 	          
USP	COMU	Test
Dr Francis Lam - Date reported: 20/11/15
For further advice please contact Dr Gill Rumsby
(02034472955), Dr Francis Lam (02034472965) or
Oliver Clifford-Mobley (02034472961).	2015-11-20	2015-11-20				B 	p1A       
USP	UMED	In reference ranges M=Median	2015-11-20	2015-11-20				B 	?         
USAM	US27	100	2015-11-20	2015-11-20	ug/24h			B 	N         
USAA	US3	100	2015-11-20	2015-11-20	ug/24h			B 	N         
USAP	US8	100	2015-11-20	2015-11-20	ug/24h			B 	N         
USP	USCI	No clinical details provided.	2015-11-20	2015-11-20				B 	?         
USP	UST	24	2015-11-20	2015-11-20	hours			B 	P=        
USP	USV	1000	2015-11-20	2015-11-20	ml			B 	          
PITT	GHCN	4.0	2016-02-01	2016-02-01	ug/L			B 	          
PITT	STIM	20' pre dose	2016-01-29	2016-01-30				B 	          
ITT0	CORD	500
Note method change to Roche Gen II assay 21/09/15.
Results >200 nmol/L average 26% lower.
New reference range: 6-10 am: 172 to 497 nmol/L.	2016-02-01	2016-02-01	nmol/L			B 	          
ITT0	GHCN	2.0	2016-02-01	2016-02-01	ug/L			B 	          
ITT0	GLUD	2.0	2016-02-01	2016-02-01	mmol/L			B 	          
SIND	H	.	2016-02-01					  	JNr       
SIND	I	.	2016-02-01					  	JN        
SIND	L	.	2016-02-01					  	JN        
ITT0	STIM	Basal pre insulin	2016-01-29	2016-01-30				B 	          
GL10	GLUD	2.0	2016-02-01	2016-02-01	mmol/L			B 	          
GL10	STIM	10' post dose	2016-01-29	2016-01-30				B 	          
GL15	GLUD	2.0	2016-02-01	2016-02-01	mmol/L			B 	          
GL15	STIM	15' post dose	2016-01-29	2016-01-30				B 	          
DIG	DIGM	1.0
Target range 0.5 - 1.0 ug/L in heart failure
Please note change in reference range effective
01/02/16.	2016-01-31	2016-01-31	ug/L			B 	          
ITT2	GLUD	2.0	2016-02-01	2016-02-01	mmol/L			B 	          
ITT2	STIM	20' post dose	2016-01-29	2016-01-30				B 	          
GL25	GLUD	2.0	2016-02-01	2016-02-01	mmol/L			B 	          
GL25	STIM	25' post dose	2016-02-01	2016-02-01				B 	          
ITT3	CORD	200
Note method change to Roche Gen II assay 21/09/15.
New cut-off applies. Normal response:
a cortisol >= 415 nmol/L at any time.	2016-02-01	2016-02-01	nmol/L			B 	          
ITT3	GHCN	4.0	2016-02-01	2016-02-01	ug/L			B 	          
ITT3	GLUD	2.0	2016-02-01	2016-02-01	mmol/L			B 	          
SIND	H	.	2016-02-01					  	JNr       
SIND	I	.	2016-02-01					  	JN        
SIND	L	.	2016-02-01					  	JN        
ITT3	STIM	30' post dose	2016-02-01	2016-02-01				B 	          
PRED	COMS	23	2015-03-18	2015-03-18	nmol/L			B 	r/16      
PRED	PRMS	226
Result from Harefield Hospital	2015-03-18	2015-03-18	nmol/L			B 	r/16      
PRED	PRTI	6	2015-03-18	2015-03-18				B 	=         
PRED	COMS	Cancelled - Request entered in error.	2015-03-19	2015-03-19	nmol/L			B 	r/16      
SIND	H	Cancelled - Request entered in error.	2015-03-19					  	JNr       
SIND	I	Cancelled - Request entered in error.	2015-03-19					  	JN        
SIND	L	Cancelled - Request entered in error.	2015-03-19					  	JN        
NA	NA	Cancelled - Request entered in error.	2015-03-19	2015-03-20	mmol/L	135	145	B 	CP        
PRED	PRMS	Cancelled - Request entered in error.	2015-03-19	2015-03-19	nmol/L			B 	r/16      
PRED	PRTI	Cancelled - Request entered in error.	2015-03-19	2015-03-19				B 	=         
CCR	CCR	.	2015-06-24		mL/min	71	151	B 	          
UCIT	CITR	0.25	2015-11-17	2015-11-17	mmol/mmol			B 	r         
UCIT	CITX	2.00	2015-05-05	2015-05-05	mmol/24hr	1.3	6	B 	rN        
CCR	CREA	Cancelled - see comments	2015-06-24	2015-06-24	umol/L	49	92	B 	CPr       
24H	CREX	8.0
Note reference range applies only to adults	2015-11-17	2015-11-17	mmol/24h	7.0	21.0	B 	QN        
GFR	FACR	.	2015-06-24					X 	N         
GFR	GFR	Cancelled - see comments	2015-06-24	2015-06-24	.			B 	          
SIND	H	Cancelled - see comments	2015-06-24					  	JNr       
SIND	I	Cancelled - see comments	2015-06-24					  	JN        
SIND	L	Cancelled - see comments	2015-06-24					  	JN        
UOXA	OXCR	250
Please note: change in reference range 01/10/2014	2015-11-17	2015-11-17	umol/mmol	1	38	B 	r         
GFR	SEX	.	2015-06-24					X 	N         
UCIT	UCIT	1.00	2015-05-05	2015-05-05	mmol/L			B 	rPA       
24H	UCR	4000	2015-11-17	2015-11-17	umol/L			B 	          
UOXA	UOX	1000	2015-05-05	2015-05-05	umol/L			B 	rPA       
UOXA	UOXX	2000
(Note:Adult reference range. Correct for body
surface area in children)	2015-05-05	2015-05-05	umol/24h	100	460	B 	rN        
24H	UT	24.0	2015-05-05	2015-05-05	h			B 	P=        
24H	UV	2000	2015-05-05	2015-05-05	mL			B 	PS=       
GFR	ZAGE	.	2015-06-24		y			X 	          
RUBM	RUMA	0.4	2015-09-03	2015-09-03				H 	HIr/1     
RUBM	RUMR	Not Detected	2015-09-03	2015-09-03				H 	?/2m      
SIND	H	12	2015-09-01					  	JNr       
SIND	I	17	2015-09-01					  	JN        
SIND	L	3	2015-09-01					  	JN        
TSH	TSH	1.36	2015-09-01	2015-09-01	mIU/L	0.27	4.20	B 	Cr        
BVLR	BVLR	.{}	2016-08-22					H 	Ir?       
CVLR	CVLR	.{}	2016-08-22					H 	Ir?       
HVLR	HVLR	.{}	2016-08-22					H 	Ir?       
ELU	CREA	31	2015-11-04	2015-11-04	umol/L	49	92	B 	CPr       
ELU	FACR	3.80	2015-11-04					X 	N         
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2015-11-04	2015-11-04	.			B 	          
ELU	H	5	2015-11-04					  	JNr       
ELU	I	11	2015-11-04					  	JN        
ELU	K	3.0	2015-11-04	2015-11-04	mmol/L	3.5	5.1	B 	CP        
ELU	L	0	2015-11-04					  	JN        
ELU	NA	137	2015-11-04	2015-11-04	mmol/L	135	145	B 	CP        
ELU	SEX	0.742	2015-11-04					X 	N         
ELU	UREA	2.9	2015-11-04	2015-11-04	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	34	2015-11-04		y			X 	          
IGRA	QTBC	.	2016-02-02					I 	?r        
IGRA	QTFR	.	2016-02-02					I 	?r        
IGRA	QTRT	.	2016-02-02					I 	?         
IGRA	QTRV	Insufficient	2016-02-02	2016-02-02	IU/mL			I 	Ir        
FBCY	HBGL	Request entered in error	2016-02-01	2016-02-01	g/L			A 	rCP/0     
FBCY	HCTU	Request entered in error	2016-02-01	2016-02-01	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Request entered in error	2016-02-01	2016-02-01	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Request entered in error	2016-02-01	2016-02-01	%			A 	SN/0      
FBCZ	LY	Request entered in error	2016-02-01	2016-02-01	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Request entered in error	2016-02-01	2016-02-01	g/L			A 	CPS/0     
FBCY	MCHU	Request entered in error	2016-02-01	2016-02-01	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Request entered in error	2016-02-01	2016-02-01	fL	80	99	A 	CPS/0     
FBCZ	MO	Request entered in error	2016-02-01	2016-02-01	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Request entered in error	2016-02-01	2016-02-01	fL	7	13	A 	CS?/0     
FBCZ	NE	Request entered in error	2016-02-01	2016-02-01	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Request entered in error	2016-02-01	2016-02-01	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Request entered in error	2016-02-01	2016-02-01	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Request entered in error	2016-02-01	2016-02-01	%	11.5	15.0	A 	CS/0      
RETC	REP	Cancelled - Request entered in error	2016-02-01	2016-02-01	%	0.38	2.64	A 	/0        
RETC	RET	Request entered in error	2016-02-01	2016-02-01	x 10^9/L	20	100	A 	P/0       
FBCY	WCC	Cancelled - FBC Request entered in error	2016-02-01	2016-02-01	x10^9/L	3.0	10.0	A 	CWPS/0    
COAT	APRA	Coagulation request entered in error.	2016-02-01	2016-02-01		2.0	3.0	A 	?/1       
COAT	APTT	Coagulation request entered in error.	2016-02-01	2016-02-01	secs	22	41	A 	P/1       
COAT	FIB	Coagulation request entered in error.	2016-02-01	2016-02-01	g/L			A 	p1/1      
COAT	INR	Coagulation request entered in error.	2016-02-01	2016-02-01				A 	/1        
COAT	PT	Cancelled - Coagulation request entered in error.	2016-02-01	2016-02-01	secs	10.0	12.0	A 	/1        
FBCY	HBGL	.	2016-02-03		g/L			A 	rCP/0     
FBCY	HCTU	.	2016-02-03		L/L	0.33	0.45	A 	CPS/0     
FBCZ	LY	.	2016-02-03		x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	.	2016-02-03		g/L			A 	CPS/0     
FBCY	MCHU	.	2016-02-03		pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	.	2016-02-03		fL	80	99	A 	CPS/0     
FBCZ	MO	.	2016-02-03		x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	.	2016-02-03		fL	7	13	A 	CS?/0     
FBCZ	NE	.	2016-02-03		x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	.	2016-02-03		x10^9/L	150	400	A 	CS/0      
FBCY	RCC	.	2016-02-03		x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	.	2016-02-03		%	11.5	15.0	A 	CS/0      
FBCY	WCC	.	2016-02-03		x10^9/L	3.0	10.0	A 	CWPS/0    
FBCY	HBGL	.	2016-02-03		g/L			A 	rCP/0     
FBCY	HCTU	.	2016-02-03		L/L	0.33	0.45	A 	CPS/0     
FBCZ	LY	.	2016-02-03		x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	.	2016-02-03		g/L			A 	CPS/0     
FBCY	MCHU	.	2016-02-03		pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	.	2016-02-03		fL	80	99	A 	CPS/0     
FBCZ	MO	.	2016-02-03		x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	.	2016-02-03		fL	7	13	A 	CS?/0     
FBCZ	NE	.	2016-02-03		x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	.	2016-02-03		x10^9/L	150	400	A 	CS/0      
FBCY	RCC	.	2016-02-03		x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	.	2016-02-03		%	11.5	15.0	A 	CS/0      
RET	REP	.	2016-02-03		%	0.38	2.64	A 	/0        
RET	RET	.	2016-02-03		x 10^9/L	20	100	A 	P/0       
FBCY	WCC	.	2016-02-03		x10^9/L	3.0	10.0	A 	CWPS/0    
COAT	APRA	.	2016-02-03			2.0	3.0	A 	?/1       
COAT	APTT	.	2016-02-03		secs	22	41	A 	P/1       
COAT	FIB	.	2016-02-03		g/L			A 	p1/1      
COAT	INR	.	2016-02-03					A 	/1        
COAT	PT	.	2016-02-03		secs	10.0	12.0	A 	/1        
COAT	PTM	.	2016-02-03		secs	10.0	12.0	A 	N         
BVLR	BVLR	.{}	2016-08-22					H 	Ir?       
CVLR	CVLR	.{}	2016-08-22					H 	Ir?       
HVLR	HVLR	.{}	2016-08-22					H 	Ir?       
FBCY	HBGL	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	g/L			A 	rCP/0     
FBCY	HCTU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	%			A 	SN/0      
FBCZ	LY	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	g/L			A 	CPS/0     
FBCY	MCHU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	fL	80	99	A 	CPS/0     
FBCZ	MO	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	fL	7	13	A 	CS?/0     
FBCZ	NE	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	3.0	10.0	A 	CWPS/0    
FBCY	HBGL	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	g/L			A 	rCP/0     
FBCY	HCTU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	%			A 	SN/0      
FBCZ	LY	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	g/L			A 	CPS/0     
FBCY	MCHU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	fL	80	99	A 	CPS/0     
FBCZ	MO	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	fL	7	13	A 	CS?/0     
FBCZ	NE	Sample for differential clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	%	11.5	15.0	A 	CS/0      
RETC	REP	Sample for reticulocyte count clotted.	2016-02-10	2016-02-10	%	0.38	2.64	A 	/0        
RETC	RET	Sample for reticulocyte count clotted.	2016-02-10	2016-02-10	x 10^9/L	20	100	A 	P/0       
FBCY	WCC	Cancelled - Sample for FBC clotted, please repeat.	2016-02-10	2016-02-10	x10^9/L	3.0	10.0	A 	CWPS/0    
CSFP	CSFT	.	2015-04-28					B 	=?        
CSFP	CTP	1.43	2015-04-28	2015-04-28	g/L	0.13	0.40	B 	          
TPT	H	0	2015-04-28					  	JNr       
TPT	HTRT	<3
Please note change in reporting units to ng/L
Old units ug/L x 1000 = new units ng/L
Effective 01/12/2014.	2015-04-28	2015-04-28	ng/L			B 	          
TPT	I	18	2015-04-28					  	JN        
TPT	L	10	2015-04-28					  	JN        
NA	NA	140	2015-09-01	2015-09-01	mmol/L	135	145	B 	CP        
SY30	CORD	450
Note method change to Roche Gen II assay 21/09/15.
New cut-off applies. Normal response:
a cortisol >= 415 nmol/L at any time.	2015-09-21		nmol/L			B 	          
SY30	STIM	Basal pre ACTH	2015-09-21					B 	          
CORD	CORD	144
Note method change to Roche Gen II assay 21/09/15.
New cut-off applies. Normal response:
a cortisol >= 415 nmol/L at any time.	2015-09-21	2015-09-21	nmol/L			B 	          
SIND	H	5	2015-09-21					  	JNr       
SIND	I	14	2015-09-21					  	JN        
SIND	L	22	2015-09-21					  	JN        
CORT	CORT	201
Note method change to Roche Gen II assay 21/09/15.
Results >200 nmol/L average 26% lower.
New reference range: 6-10 am: 172 to 497 nmol/L.	2015-09-21	2015-09-21	nmol/l			B 	          
SIND	H	4	2015-09-21					  	JNr       
SIND	I	31	2015-09-21					  	JN        
SIND	L	16	2015-09-21					  	JN        
MPL	MPL	REPORT	2015-06-12	2015-06-12				H 	HNr?p1p2AB
MPL	MYCT	.	2015-06-12					H 	?/2       
MPL	MYGR	Negative	2015-06-12	2015-06-12				H 	?Nr/2     
MPL	MYGV	<0.100	2015-06-12	2015-06-12				H 	?NI/2     
MPL	MYMR	Negative	2015-06-12	2015-06-12				H 	?Nr/2     
MPL	MYMV	<0.10	2015-06-12	2015-06-12				H 	?NI/2     
U	UREA	5.0	2015-05-05	2015-05-05	mmol/L	1.7	8.3	B 	CP        
FBCY	HBGL	Request entered in error	2015-02-18	2015-02-18	g/L			A 	rCP/0     
FBCY	HCTU	Request entered in error	2015-02-18	2015-02-18	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Request entered in error	2015-02-18	2015-02-18	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Request entered in error	2015-02-18	2015-02-18	%			A 	SN/0      
FBCZ	LY	Request entered in error	2015-02-18	2015-02-18	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Request entered in error	2015-02-18	2015-02-18	g/L			A 	CPS/0     
FBCY	MCHU	Request entered in error	2015-02-18	2015-02-18	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Request entered in error	2015-02-18	2015-02-18	fL	80	99	A 	CPS/0     
FBCZ	MO	Request entered in error	2015-02-18	2015-02-18	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Request entered in error	2015-02-18	2015-02-18	fL	7	13	A 	CS?/0     
FBCZ	NE	Request entered in error	2015-02-18	2015-02-18	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Request entered in error	2015-02-18	2015-02-18	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Request entered in error	2015-02-18	2015-02-18	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Request entered in error	2015-02-18	2015-02-18	%	11.5	15.0	A 	CS/0      
HTLV	TLVA	Cancelled - Request entered in error.	2015-02-23	2015-02-24				H 	Ir/1      
HTLV	TLVR	Repeat to confirm.	2015-02-22	2015-02-23				H 	?/2m      
FBCY	WCC	Cancelled - FBC Request entered in error	2015-02-18	2015-02-18	x10^9/L	3.0	10.0	A 	CWPS/0    
FBCY	HBGL	Request entered in error	2015-10-21	2015-10-21	g/L			A 	rCP/0     
FBCY	HCTU	Request entered in error	2015-10-21	2015-10-21	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Request entered in error	2015-10-21	2015-10-21	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Request entered in error	2015-10-21	2015-10-21	%			A 	SN/0      
FBCZ	LY	Request entered in error	2015-10-21	2015-10-21	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Request entered in error	2015-10-21	2015-10-21	g/L			A 	CPS/0     
FBCY	MCHU	Request entered in error	2015-10-21	2015-10-21	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Request entered in error	2015-10-21	2015-10-21	fL	80	99	A 	CPS/0     
FBCZ	MO	Request entered in error	2015-10-21	2015-10-21	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Request entered in error	2015-10-21	2015-10-21	fL	7	13	A 	CS?/0     
FBCZ	NE	Request entered in error	2015-10-21	2015-10-21	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Request entered in error	2015-10-21	2015-10-21	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Request entered in error	2015-10-21	2015-10-21	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Request entered in error	2015-10-21	2015-10-21	%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - FBC Request entered in error	2015-10-21	2015-10-21	x10^9/L	3.0	10.0	A 	CWPS/0    
ETH	ETHN	<10
For guidance the driving limit is <800 mg/L
Please note change of units effective 30/06/15	2015-06-30	2015-06-30	mg/L			B 	?         
AKIF	AKIF	?AKI - creatinine increase >50% from previous.
Please review creatinine results urgently.
Consider nephrotoxic drugs, obstruction, hydration
and infection. www.londonaki.net/clinical	2015-02-13	2015-02-13				B 	r?        
AKT	AKT	3	2015-02-13	2015-02-13				B 	NIJ-      
CR	CREA	180
?AKI - creatinine increase >50% from previous.
www.londonaki.net/clinical	2015-02-13	2015-02-13	umol/L	49	92	B 	CPr       
GFR	FACR	1.18	2015-02-06					X 	N         
GFR	GFR	75
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2015-02-06	2015-02-06	.			B 	          
NA	NA	140	2015-02-09	2015-02-10	mmol/L	135	145	B 	CP        
GFR	SEX	0.742	2015-02-06					X 	N         
GFR	ZAGE	34	2015-02-05		y			X 	          
METS	3MT	.	2015-08-17		pmol/L			B 	r         
AKI	AKI	3	2015-01-29	2015-01-29				B 	?         
AKIF	AKIF	.	2015-01-31					B 	r?        
AKT	AKT	3	2015-01-29	2015-01-29				B 	NIJ-      
APRA	APRA	1.2	2015-10-04	2015-10-04		2.0	3.0	A 	?/1       
APTT	APTT	38	2015-10-04	2015-10-04	secs	22	41	A 	P/1       
FBCZ	BA	 1.0%  0.11	2015-10-04	2015-10-04	x10^9/L	0.0	0.1	A 	CDSN/0    
CM3	C3P	NOTE: At high concentrations of paracetamol, one
of its metabolites and therapeutic levels of
N-acetylcysteine may cause falsely low results of
creatinine (measured enzymatically), lactate,
triglycerides, cholesterol, HDL and urate.	1899-12-30					A 	N         
CCR	CCR	.	2015-02-09		mL/min	71	151	B 	          
CORD	CORD	.	2015-09-24		nmol/L			B 	          
CR	CREA	100	2015-02-09		umol/L	49	92	B 	CPr       
FBCZ	EO	 4.0%  0.44	2015-10-04	2015-10-04	x10^9/L	0.0	0.4	A 	CDSN/0    
GFR	FACR	0.18	2015-01-29					X 	N         
FIB	FIB	4.20	2015-10-04	2015-10-04	g/L			A 	p1/1      
GFR	GFR	11
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2015-01-29	2015-01-29	.			B 	          
SIND	H	.	2015-04-16					  	JNr       
FBCY	HBGL	160	2015-10-04	2015-10-04	g/L			A 	rCP/0     
FBCY	HCTU	0.500	2015-10-04	2015-10-04	L/L	0.33	0.45	A 	CPS/0     
SIND	I	.	2015-04-16					  	JN        
INR	INR	1.10	2015-10-04	2015-10-04				A 	/1        
SIND	L	.	2015-04-16					  	JN        
LPA	LPA2	.	2015-04-16		nmol/L			B 	          
FBCZ	LY	40.0%  4.40	2015-10-04	2015-10-04	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	365	2015-10-04	2015-10-04	g/L			A 	CPS/0     
FBCY	MCHU	34.0	2015-10-04	2015-10-04	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	100.0	2015-10-04	2015-10-04	fL	80	99	A 	CPS/0     
METS	META	142	2015-07-31	2015-10-04	pmol/L			B 	r         
METS	METC	.	2015-08-17					B 	r         
FBCZ	MO	 5.0%  0.55	2015-10-04	2015-10-04	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	14.0	2015-10-04	2015-10-04	fL	7	13	A 	CS?/0     
NA	NA	140	2015-02-09	2015-02-09	mmol/L	135	145	B 	CP        
FBCZ	NE	50.0%  5.50	2015-10-04	2015-10-04	x10^9/L	2.0	7.5	A 	CDS/0     
METS	NMET	.	2015-08-17		pmol/L			B 	r         
FBCY	PLT	410	2015-10-04	2015-10-04	x10^9/L	150	400	A 	CS/0      
PCET	PMOL	31
NOTE: At high concentrations of paracetamol, one
of its metabolites and therapeutic levels of
N-acetylcysteine may cause falsely low results of
creatinine (measured enzymatically), lactate,
triglycerides, cholesterol, HDL and urate.	2015-08-17	2015-10-04	mg/L	10	30	B 	          
PT	PT	13.0	2015-10-04	2015-10-04	secs	10.0	12.0	A 	/1        
FBCY	RCC	6.00	2015-10-04	2015-10-04	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	16.0	2015-10-04	2015-10-04	%	11.5	15.0	A 	CS/0      
STS	RPR	.{}	2015-03-27					H 	?Hr/2m    
GFR	SEX	0.742	2015-01-29					X 	N         
STS	SYPA	0.060	2015-03-27					H 	?Ir/1     
STS	SYPR	Negative	2015-03-27					H 	?r/2m     
STS	TPC	.{}	2015-03-27					H 	?/2       
STS	TPPA	.{}	2015-03-27					H 	?Hr/2m    
VWFC	VWFC	.{0.80}	2015-10-21		IU/ml			A 	/14       
FBCY	WCC	11.00	2015-10-04	2015-10-04	x10^9/L	3.0	10.0	A 	CWPS/0    
GFR	ZAGE	34	2015-01-29		y			X 	          
CAAQ	CALA	37	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CARG	33	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CCIT	6	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CCY2	not detected	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CGLN	509	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CGLT	3	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CGLY	6	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CHIS	14	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CILE	4	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CLEU	9	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CLYS	14	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CMET	3	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CORN	4	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CPHE	9	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CPRO	not detected	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CSER	60	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CTAW	8	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CTHR	34	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CTYR	10	2016-02-23	2016-02-23	umol/L			D 	          
CAAQ	CVAL	15	2016-02-23	2016-02-23	umol/L			D 	          
AMIQ	PALA	475	2016-02-23	2016-02-23	umol/L	225	560	D 	N         
AMIQ	PALL	3	2016-02-23	2016-02-23	umol/L		1	D 	N         
AMIQ	PARG	58	2016-02-23	2016-02-23	umol/L	330	126	D 	N         
AMIQ	PASA	160	2016-02-23	2016-02-23	umol/L		1	D 	N         
AMIQ	PCIT	23	2016-02-23	2016-02-23	umol/L	8	50	D 	N         
AMIQ	PCY2	22	2016-02-23	2016-02-23	umol/L	22	56	D 	N         
AMIQ	PGLN	872	2016-02-23	2016-02-23	umol/L	480	820	D 	N         
AMIQ	PGLT	55	2016-02-23	2016-02-23	umol/L	30	80	D 	N         
AMIQ	PGLY	295	2016-02-23	2016-02-23	umol/L	103	340	D 	          
AMIQ	PHC1	10	2016-02-23	2016-02-23	umol/L	5	12	D 	N         
AMIQ	PHC2	not detected	2016-02-23	2016-02-23	umol/L		1	D 	N         
AMIQ	PHIS	105	2016-02-23	2016-02-23	umol/L	38	160	D 	N         
AMIQ	PILE	67	2016-02-23	2016-02-23	umol/L	31	115	D 	N         
AMIQ	PLEU	95	2016-02-23	2016-02-23	umol/L	72	297	D 	N         
AMIQ	PLYS	264	2016-02-23	2016-02-23	umol/L	82	315	D 	N         
AMIQ	PMET	41	2016-02-23	2016-02-23	umol/L	13	40	D 	N         
AMIQ	PORN	108	2016-02-23	2016-02-23	umol/L	20	114	D 	N         
AMIQ	PPHE	73	2016-02-23	2016-02-23	umol/L	33	81	D 	N         
AMIQ	PPRO	339	2016-02-23	2016-02-23	umol/L	83	380	D 	N         
AMIQ	PSER	169	2016-02-23	2016-02-23	umol/L	46	194	D 	N         
AMIQ	PTAW	192	2016-02-23	2016-02-23	umol/L	25	252	D 	N         
AMIQ	PTHR	323	2016-02-23	2016-02-23	umol/L	38	221	D 	N         
AMIQ	PTYR	104	2016-02-23	2016-02-23	umol/L	35	95	D 	N         
AMIQ	PVAL	187	2016-02-23	2016-02-23	umol/L	137	462	D 	N         
CAA2	RALA	0.08	2016-02-23	2016-02-23				D 	N         
CAA2	RARG	0.57	2016-02-23	2016-02-23				D 	N         
CAA2	RCIT	0.26	2016-02-23	2016-02-23				D 	N         
CAA2	RGLN	0.58	2016-02-23	2016-02-23				D 	N         
CAA2	RGLT	0.05	2016-02-23	2016-02-23				D 	N         
CAA2	RGLY	0.02	2016-02-23	2016-02-23				D 	N         
CAA2	RHIS	0.13	2016-02-23	2016-02-23				D 	N         
CAA2	RILE	0.06	2016-02-23	2016-02-23				D 	N         
CAA2	RLEU	0.09	2016-02-23	2016-02-23				D 	N         
CAA2	RLYS	0.05	2016-02-23	2016-02-23				D 	N         
CAA2	RMET	0.07	2016-02-23	2016-02-23				D 	N         
CAA2	RORN	0.04	2016-02-23	2016-02-23				D 	N         
CAA2	RPHE	0.12	2016-02-23	2016-02-23				D 	N         
CAA2	RSER	0.36	2016-02-23	2016-02-23				D 	N         
CAA2	RTAW	0.04	2016-02-23	2016-02-23				D 	N         
CAA2	RTHR	0.11	2016-02-23	2016-02-23				D 	N         
CAA2	RTYR	0.10	2016-02-23	2016-02-23				D 	N         
CAA2	RVAL	0.08	2016-02-23	2016-02-23				D 	N         
SIND	H	.	2016-01-11					  	JNr       
SIND	I	.	2016-01-11					  	JN        
SIND	L	.	2016-01-11					  	JN        
PROG	PROG	Cancelled - Request entered in error.	2016-01-11	2016-01-11	nmol/L			B 	          
FLG	AO	A1731	2016-02-14					X 	NJI       
FBCZ	BA	 0.1%  0.02	2016-02-14	2016-02-14	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	 0.2%  0.03	2016-02-14	2016-02-14	x10^9/L	0.0	0.4	A 	CDSN/0    
ESR	ESR	12	2016-02-14	2016-02-14	mm/hr	1	7	A 	C?/0      
FLG	FLG9	NRBC ?	2016-02-14	2016-02-14				A 	NJ-I?     
FBCY	HBGL	106	2016-02-14	2016-02-14	g/L			A 	rCP/0     
FBCY	HCTU	0.352	2016-02-14	2016-02-14	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	.{}	2016-02-14		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2016-02-14		%			A 	SN/0      
FBCZ	LY	 3.4%  0.58	2016-02-14	2016-02-14	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	301	2016-02-14	2016-02-14	g/L			A 	CPS/0     
FBCY	MCHU	26.8	2016-02-14	2016-02-14	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	89.1	2016-02-14	2016-02-14	fL	80	99	A 	CPS/0     
FBCZ	MO	 9.0%  1.54	2016-02-14	2016-02-14	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	13.5	2016-02-14	2016-02-14	fL	7	13	A 	CS?/0     
FBCZ	NE	87.3% 14.97	2016-02-14	2016-02-14	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	233	2016-02-14	2016-02-14	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	3.95	2016-02-14	2016-02-14	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	14.6	2016-02-14	2016-02-14	%	11.5	15.0	A 	CS/0      
RET	REP	2.00	2016-02-14	2016-02-14	%	0.38	2.64	A 	/0        
RET	RET	300.00	2016-02-14	2016-02-14	x 10^9/L	20	100	A 	P/0       
FBCY	WCC	17.15	2016-02-14	2016-02-14	x10^9/L	3.0	10.0	A 	CWPS/0    
COAT	APRA	1.1	2016-02-15	2016-02-15		2.0	3.0	A 	?/1       
COAT	APTT	35	2016-02-14	2016-02-15	secs	22	41	A 	P/1       
COAT	FIB	2.00	2016-02-14	2016-02-15	g/L			A 	p1/1      
COAT	INR	1.00	2016-02-14	2016-02-15				A 	/1        
COAT	PT	10.0	2016-02-14	2016-02-15	secs	10.0	12.0	A 	/1        
PES	A1G	.	2016-03-24		%	1.7	3.8	X 	P         
PES	A1GG	.	2016-03-30		g/L	1.3	2.7	X 	Q         
PES	A2G	.	2016-03-24		%	8.1	15.3	X 	P         
PES	A2GG	.	2016-03-30		g/L	6.1	11.3	X 	Q         
PES	ALBG	.	2016-03-30		g/L	33.3	54.1	X 	Q         
PES	ALBP	Cancelled - see comments	2016-03-30	2016-03-30	%	51.8	67.1	X 	P         
PES	B1G	.	2016-03-24		%	6.0	9.9	X 	P         
PES	B1GG	.	2016-03-30		g/L	4.1	7.7	X 	Q         
PES	B2G	.	2016-03-24		%			X 	P         
PES	B2GL	.	2016-03-30		g/L	1.2	5.6	X 	Q         
PES	GG	.	2016-03-24		%	8.9	20.0	X 	P         
PES	GGG	.	2016-03-30		g/L	6.1	15.0	X 	Q         
SFLC	KAPA	.	2016-03-24		mg/L			B 	r         
SFLC	KLRA	.	2016-03-24					B 	r         
SFLC	LAMB	.	2016-03-24		mg/L			B 	r         
PES	PCOM	.	2016-03-24					B 	A         
PES	PPR	.	2016-03-24		g/L	0		B 	N         
PES	PPRP	.	2016-03-24		%			X 	N         
PES	PROT	.	2016-03-24		g/L	63	83	B 	CP        
ELU	CREA	Cancelled - Request entered in error.	2016-04-20	2016-04-20	umol/L	49	92	B 	CPr       
ELU	FACR	.	2016-04-20					X 	N         
ELU	GFR	Cancelled - Request entered in error.	2016-04-20	2016-04-20	.			B 	          
ELU	H	.	2016-04-20					  	JNr       
ELU	I	.	2016-04-20					  	JN        
ELU	K	Cancelled - Request entered in error.	2016-04-20	2016-04-20	mmol/L	3.5	5.1	B 	CP        
ELU	L	.	2016-04-20					  	JN        
ELU	NA	Cancelled - Request entered in error.	2016-04-20	2016-04-20	mmol/L	135	145	B 	CP        
ELU	UREA	Cancelled - Request entered in error.	2016-04-20	2016-04-20	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	35	2016-04-13		y			X 	          
COAT	APRA	Coagulation request entered in error.	2016-04-29	2016-04-30		2.0	3.0	A 	?/1       
COAT	APTT	Coagulation request entered in error.	2016-04-29	2016-04-30	secs	22	41	A 	P/1       
ESR	ESR	26	2016-04-27	2016-04-28	mm/hr	1	7	A 	C?/0      
COAT	FIB	Coagulation request entered in error.	2016-04-29	2016-04-30	g/L			A 	p1/1      
FBCY	HBGL	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	g/L			A 	rCP/0     
FBCY	HCTU	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Sample for differential clotted, please repeat.	2016-04-30	2016-04-30	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Sample for differential clotted, please repeat.	2016-04-30	2016-04-30	%			A 	SN/0      
COAT	INR	Coagulation request entered in error.	2016-04-29	2016-04-30				A 	/1        
FBCZ	LY	Sample for differential clotted, please repeat.	2016-04-30	2016-04-30	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	g/L			A 	CPS/0     
FBCY	MCHU	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	fL	80	99	A 	CPS/0     
FBCZ	MO	Sample for differential clotted, please repeat.	2016-04-30	2016-04-30	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	fL	7	13	A 	CS?/0     
FBCZ	NE	Sample for differential clotted, please repeat.	2016-04-30	2016-04-30	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	x10^9/L	150	400	A 	CS/0      
COAT	PT	Cancelled - Coagulation request entered in error.	2016-04-29	2016-04-30	secs	10.0	12.0	A 	/1        
FBCY	RCC	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - Sample for FBC clotted, please repeat.	2016-04-30	2016-04-30	x10^9/L	3.0	10.0	A 	CWPS/0    
FLG	AO	Interrli	2016-04-26					X 	NJI       
ESR	ESR	TMB	2016-04-26	2016-04-26	mm/hr	1	7	A 	C?/0      
FBCY	HBGL	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	g/L			A 	rCP/0     
FBCY	HCTU	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	Insufficient Sample for differential.	2016-04-30	2016-04-30	x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	Insufficient Sample for differential.	2016-04-30	2016-04-30	%			A 	SN/0      
FBCZ	LY	Insufficient Sample for differential.	2016-04-30	2016-04-30	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	g/L			A 	CPS/0     
FBCY	MCHU	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	fL	80	99	A 	CPS/0     
FBCZ	MO	Insufficient Sample for differential.	2016-04-30	2016-04-30	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	fL	7	13	A 	CS?/0     
FBCZ	NE	Insufficient Sample for differential.	2016-04-30	2016-04-30	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Insufficient sample for FBC. Please repeat.	2016-04-30	2016-04-30	%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - Insufficient sample for FBC.	2016-04-30	2016-04-30	x10^9/L	3.0	10.0	A 	CWPS/0    
INSG	INSG	10
Insulin at Guildford = pmol/L (divide by 7 to give
result in mIU/L, the units used at UCLH).
Guildford use Mecodia assay - detects all forms,
quoted cross-reactivities: aspart 80%, lispro 89%
determir 22%, glargine 44%, glulisine 100%.
Result from Guildford.	2016-04-15	2016-04-15	pmol/L			B 	r         
CIT3	A1AT	1.98	2016-05-08	2016-05-08	g/L			B 	AB        
CIT3	ACE	<4	2016-05-08	2016-05-08	U/L			B 	A         
CIT3	ALB	36	2016-05-08	2016-05-08	g/L	34	50	B 	CP        
CIT3	ALP	40	2016-05-08	2016-05-08	IU/L	35	104	B 	C         
CIT3	ALT	16	2016-05-08	2016-05-08	IU/L	10	35	B 	C         
CIT3	AMIK	<0.8	2016-05-08	2016-05-08	mg/L			B 	          
CIT3	AMMO	116	2016-05-08	2016-05-08	umol/L	11	32	B 	AB        
CIT3	AMY	33	2016-05-08	2016-05-08	IU/L	28	100	B 	AB        
CIT3	AST	30	2016-05-08	2016-05-08	IU/L	0	31	B 	C         
CIT3	B2M	1.5	2016-05-08	2016-05-08	mg/L	0	2.3	B 	AB        
CIT3	BILI	5	2016-05-08	2016-05-08	umol/L	0	137	B 	CPr       
CIT3	C3	1.24	2016-05-08	2016-05-08	g/L	0.90	1.80	B 	A         
CIT3	C4	0.29	2016-05-08	2016-05-08	g/L	0.10	0.40	B 	          
CIT3	CA	2.10	2016-05-08	2016-05-08	mmol/L	2.15	2.55	B 	CP        
CIT3	CARM	<1	2016-05-08	2016-05-08	mg/L			B 	          
CIT3	CBIL	3	2016-05-08	2016-05-08	umol/L	0	5	B 	          
CIT3	CERU	0.23	2016-05-08	2016-05-08	g/L	0.20	0.60	B 	AB        
CIT3	CHOL	4.6	2016-05-08	2016-05-08	mmol/L	2.5	5.0	B 	PA        
CIT3	CK	1166	2016-05-08	2016-05-08	IU/L	26	140	B 	          
CIT3	CL	102	2016-05-08	2016-05-08	mmol/L	98	107	B 	CP        
CIT4	CREA	70	2016-05-08	2016-05-08	umol/L	49	92	B 	CPr       
CIT4	CRP	115.4	2016-05-08	2016-05-08	mg/L	0	5.0	B 	AB        
CIT4	CRQ	72	2016-05-08	2016-05-08	umol/L	45	84	B 	          
CIT4	ETHN	<100
For guidance the driving limit is <800 mg/L
Please note change of units effective 30/06/15	2016-05-08	2016-05-08	mg/L			B 	?         
GFR	FACR	1.39	2016-05-08					X 	N         
CIT4	FE	5.1	2016-05-08	2016-05-08	umol/L	6.6	26.0	B 	CPA       
CIT4	GENT	Cancelled - Request entered in error.	2016-05-09	2016-05-09	mg/L			B 	r         
GFR	GFR	88
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-05-08	2016-05-08	.			B 	          
CIT4	GGT	15	2016-05-08	2016-05-08	IU/L	6	42	B 	C         
CIT4	GLU	4.7
Reference range applies to fasting samples only.	2016-05-08	2016-05-08	mmol/L	3.9	5.8	B 	AB        
CIT4	H	3	2016-05-08					  	JNr       
CIT4	HAPT	1.6	2016-05-08	2016-05-08	g/L	0.3	2.0	B 	A         
CIT4	HCO3	25	2016-05-08	2016-05-08	mmol/L	22	29	B 	CP        
CIT4	HCRP	235.5	2016-05-08	2016-05-08	mg/L	0	5.0	B 	          
CIT4	HDL	1.5	2016-05-08	2016-05-08	mmol/L	1.2	1.7	B 	          
CIT4	I	14	2016-05-08					  	JN        
CIT4	IGA	1.37	2016-05-08	2016-05-08	g/L	0.7	4.0	B 	S         
CIT4	IGG	8.06	2016-05-08	2016-05-08	g/L	7.0	16.0	B 	AS        
CIT4	IGM	1.07	2016-05-08	2016-05-08	g/L	0.4	2.3	B 	BS        
CIT4	K	4.6	2016-05-08	2016-05-08	mmol/L	3.5	5.1	B 	CP        
CIT4	L	8	2016-05-08					  	JN        
CIT4	LACT	1.66	2016-05-08	2016-05-08	mmol/L	0.50	1.65	B 	          
CIT5	LDH	188	2016-05-08	2016-05-08	IU/L	240	480	B 	C         
CIT5	LIPA	20	2016-05-08	2016-05-08	U/L	13	60	B 	          
CIT5	LITH	<0.05	2016-05-08	2016-05-08	mmol/L	0.6	1.0	B 	          
CIT5	LPA2	36
Note new assay in use from 09/04/15. The assay
has been restandardised and measures the number of
Lp(a)particles independent of size heterogeneity.
A result of >75nmol/L is considered to reflect
increased risk (Framingham data).	2016-05-08	2016-05-08	nmol/L			B 	          
CIT5	MG	0.76	2016-05-08	2016-05-08	mmol/L	0.60	1.00	B 	CP        
CIT5	MTX	<0.04
(<0.1 after 48 hrs)	2016-05-08	2016-05-08	umol/L			B 	A$        
CIT5	NA	140	2016-05-08	2016-05-08	mmol/L	135	145	B 	CP        
CIT5	PHBM	<1	2016-05-08	2016-05-08	mg/L			B 	          
CIT5	PHEM	<1	2016-05-08	2016-05-08	mg/L			B 	          
CIT5	PHOS	0.82	2016-05-08	2016-05-08	mmol/L	0.87	1.45	B 	CP        
CIT5	PMOL	4.6	2016-05-08	2016-05-08	mg/L	10	30	B 	          
CIT5	PROT	56	2016-05-08	2016-05-08	g/L	63	83	B 	CP        
CIT5	RF	17.6
Please note amended reference range due to
change in methodology.	2016-05-08	2016-05-08	IU/mL			I 	?A        
CIT5	SALY	Not Detected	2016-05-08	2016-05-08	mg/L			B 	          
GFR	SEX	0.742	2016-05-08					X 	N         
CIT5	THEM	<0.8	2016-05-08	2016-05-08	mg/L			B 	          
CIT5	TRIG	1.5	2016-05-08	2016-05-08	mmol/L	0.4	2.3	B 	P         
CIT5	UA	146	2016-05-08	2016-05-08	umol/L	175	363	B 	CP        
CIT5	UIBC	43.0	2016-05-08	2016-05-08	umol/L	20	66	B 	          
CIT5	UREA	3.2	2016-05-08	2016-05-08	mmol/L	1.7	8.3	B 	CP        
CIT6	VALM	<3
Therapeutic efficacy may be achievable at
concentrations lower than the therapeutic
reference range.	2016-05-08	2016-05-08	mg/L			B 	          
CIT6	VANC	<1.7	2016-05-08	2016-05-08	mg/L			B 	          
GFR	ZAGE	35	2016-05-08		y			X 	          
CIT6	ZINC	31.5	2016-05-08	2016-05-08	umol/L	11	24	B 	          
CIT7	BARB	Negative	2016-05-08	2016-05-08				B 	r?        
CIT7	BENS	Negative	2016-05-08	2016-05-08				B 	r?        
CIT7	COKE	Negative	2016-05-08	2016-05-08				B 	r?        
CIT7	METD	Negative	2016-05-08	2016-05-08				B 	Ar?       
CIT7	OPIA	POSITIVE	2016-05-08	2016-05-08				B 	r?        
CIT7	TAMP	Negative	2016-05-08	2016-05-08				B 	r?        
CIT7	UALB	109	2016-05-08	2016-05-08	mg/L			B 	          
CIT7	UAMY	11	2016-05-08	2016-05-08	IU/L	0	460	B 	A         
CIT7	UCA9	<0.20	2016-05-08	2016-05-08	mmol/L			B 	P         
CIT7	UCAN	Cancelled - Request entered in error.	2016-05-09	2016-05-09				B 	r?        
CIT7	UCL	29	2016-05-08	2016-05-08	mmol/L			B 	AS        
CIT7	UCR	1606	2016-05-08	2016-05-08	umol/L			B 	          
CIT7	UK	8	2016-05-08	2016-05-08	mmol/L			B 	P         
CIT7	UMAG	1.4	2016-05-08	2016-05-08	mmol/L			B 	P         
CIT7	UNA	44	2016-05-08	2016-05-08	mmol/L			B 	PS        
CIT7	UP	2.8	2016-05-08	2016-05-08	mmol/L			B 	P         
CIT7	UTP	0.29	2016-05-08	2016-05-08	g/L	0	0.10	B 	P         
CIT7	UUAM	0.49	2016-05-08	2016-05-08	mmol/L			B 	rP        
CIT7	UUU	55.1	2016-05-08	2016-05-08	mmol/L			B 	P         
CIT8	FALB	33
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	g/L			B 	r         
CIT8	FAMY	59
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	IU/L			B 	r         
CIT8	FCHO	3.9
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	mmol/L			B 	r         
CIT8	FCR	28
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	umol/L			B 	r         
CIT8	FGLU	4.7
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-09	mmol/L			B 	r         
CIT8	FH	3	2016-05-08					  	JNr       
CIT8	FI	10	2016-05-08					  	JN        
CIT8	FK	4.3
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	mmol/L			B 	r         
CIT8	FL	8	2016-05-08					  	JN        
CIT8	FLAC	2.62
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-09	mmol/L			B 	r         
CIT8	FLDH	122
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	IU/L			B 	r         
CIT8	FNA	138
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	mmol/L			B 	r         
CIT8	FTB	5
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	umol/L			B 	r         
CIT8	FTG	1.7
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	mmol/L			B 	r         
CIT8	FTP	59
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	g/L			B 	r         
CIT8	FU	3.7
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2016-05-08	2016-05-08	mmol/L			B 	r         
CSFP	CGLU	6.4	2016-05-08	2016-05-08	mmol/L	2.2	3.9	B 	          
CSFP	CSFT	.	2016-05-08					B 	=?        
CSFP	CTP	1.86	2016-05-08	2016-05-08	g/L	0.13	0.40	B 	          
CIE1	AFP	3.4
Method used for AFP: Roche Modular	2016-05-09	2016-05-09	kIU/L	0	6	B 	          
CIE1	AMHR	49.7
Note method change to Roche AMH 02/02/15. Results
on average 25% lower than previous method (Beckman
Gen II).
Female reference ranges (10th - 90th percentiles):
20 - 29 years:   13.1 - 53.8 pmol/L
30 - 34 years:    6.8 - 47.8 pmol/L
35 - 39 years:    5.5 - 37.4 pmol/L
40 - 44 years:    0.7 - 21.2 pmol/L
45 - 50 years:    0.3 - 14.7 pmol/L
Levels are known to be higher in PCOS.
Approximate guide for assessing ovarian reserve in
women 18 - 44 years. Antral follicle count (AFC):
AFC 0 - 7;  AMH   <4.9     pmol/L
AFC 8 - 15; AMH 4.9 - 16.2 pmol/L
AFC    >15; AMH   >16.2    pmol/L
To discuss, contact x72954 or x72972.	2016-05-08	2016-05-08	pmol/L			B 	          
CIE1	BNP	14	2016-05-09	2016-05-09	pmol/L			B 	AB        
CIE1	C125	8
Method used for CA125 :Roche Modular	2016-05-09	2016-05-09	kIU/L	0	35	B 	          
CIE1	C153	16
Method used for CA153 :Roche Modular	2016-05-09	2016-05-09	kIU/L	0	25	B 	          
CIE1	C199	16
Method used for CA199 :Roche Modular	2016-05-09	2016-05-09	kIU/L	0	27	B 	          
CIE1	CEA	3.9
Method used for CEA: Roche Modular	2016-05-09	2016-05-09	ug/L	0	3.4	B 	          
CIE1	CKMB	1	2016-05-09	2016-05-09	ug/L	0.0	2.9	B 	          
CIE1	CORT	16	2016-05-09	2016-05-09	nmol/l			B 	          
CIE1	DHEA	1.3	2016-05-09	2016-05-09	umol/L	0.3	11.0	B 	          
CIE1	DIGM	Cancelled - Request entered in error.	2016-05-09	2016-05-09	ug/L			B 	          
CIE1	EABA	1.850	2016-05-09	2016-05-09				H 	HIr/2     
CIE1	EAGA	0.135	2016-05-09	2016-05-09				H 	HIr/2     
CIE1	FERR	44	2016-05-08	2016-05-09	ug/L	13	150	B 	          
CIE1	FHCG	Cancelled - Request entered in error.	2016-05-09	2016-05-10	mIU/ml			B 	          
CIE1	FSH	17.3
Ref Range:(Follicular      3.5  -  12.5)
Ref Range:(Mid-cycle       4.7  -  21.5)
Ref Range:(Luteal          1.7  -   7.7)
Ref Range:(Post-menopause 25.8  - 134.8)	2016-05-08	2016-05-09	IU/L			B 	          
CIE1	FT3	4.2	2016-05-09	2016-05-09	pmol/L	4.0	6.8	B 	C         
CIE1	FT4	18.1	2016-05-08	2016-05-09	pmol/L	12.0	22.0	B 	Cr        
SIND	H	4	2016-05-08					  	JNr       
CIE1	HAGA	60.00	2016-05-09	2016-05-09				H 	Ir/1      
CIE1	HAMA	0.379	2016-05-09	2016-05-09				H 	Ir/1      
CIE2	HBCA	1.940	2016-05-08	2016-05-08				H 	HIr/1     
CIE2	HBSA	.{ 2.00 }	2016-05-08					H 	HIr/1     
CIE2	HBVA	0.422	2016-05-08	2016-05-08				H 	HIr/1     
CIE2	HCG	<1.0	2016-05-08	2016-05-09	IU/L	0	3	B 	          
CIE2	HCVA	0.034	2016-05-08	2016-05-08				H 	Ir/1      
CIE2	HIVA	0.141	2016-05-08	2016-05-08				H 	Ir/1      
CIE2	HTRT	<3
Please note change in reporting units to ng/L
Old units ug/L x 1000 = new units ng/L
Effective 01/12/2014.	2016-05-08	2016-05-09	ng/L			B 	          
SIND	I	24	2016-05-08					  	JN        
CIE2	IGE	2	2016-05-09	2016-05-09	kIU/L	0	100	B 	A         
CIE2	INSU	Cancelled - Request entered in error.	2016-05-09	2016-05-09	mIU/L	2.6	24.9	B 	          
SIND	L	6	2016-05-08					  	JN        
CIE2	LH	1.5
Ref Range:(Follicular      2.4  -  12.6)
Ref Range:(Mid-cycle      14.0  -  95.6)
Ref Range:(Luteal          1.0  -  11.4)
Ref range:(Post-menopause  7.7  -  58.5)	2016-05-08	2016-05-09	IU/L			B 	          
CIE2	OEST	3377
Note method change from 09/02/15.
Results expected to differ by <25%.
New reference ranges apply:
Ref Range:(Follicular       98  -  571 )
Ref Range:(Mid-cycle       177  -  1153)
Ref Range:(Luteal          122  -  1094)
Ref Range:(Post-menopause  <183        )	2016-05-08	2016-05-09	pmol/L			B 	CP        
CIE2	PAPA	Cancelled - Request entered in error.	2016-05-09	2016-05-10	mIU/ml			B 	          
CIE2	PROG	0.6
Ref Range:(Follicular      0.6  -   4.7)
Ref Range:(Periovulatory   2.4  -   9.4)
Ref Range:(Luteal          5.3  -  86.0)
Ref Range:(Post-menopause  0.3  -   2.5)	2016-05-08	2016-05-09	nmol/L			B 	          
CIE2	PROL	485	2016-05-08	2016-05-09	mIU/L	102	496	B 	CP        
CIE2	PSA	<0.01
Method used for PSA :Roche Modular	2016-05-08	2016-05-09	ug/L			B 	          
CIE2	PSAF	0.01	2016-05-08	2016-05-09	ug/L			B 	          
CIE2	PTH	2.1	2016-05-09	2016-05-09	pmol/L	1.6	6.9	B 	          
CIE2	RUGA	126.20	2016-05-08	2016-05-08	IU/ml			H 	HIr/1     
CIE2	SFOL	>20.0
Folate result assumes no folic acid supplement
on day of sampling	2016-05-08	2016-05-09	ng/mL	2.3	17.6	B 	          
CIE3	SHBG	59	2016-05-09	2016-05-09	nmol/L	20	122	B 	P         
CIE3	TEST	<0.4	2016-05-08	2016-05-09	nmol/L	0	1.8	B 	CP        
CIE3	TGAB	Cancelled - Request entered in error.	2016-05-09		IU/mL			B 	r         
CIE3	TPO	5
Please note amended reference range due to
change in methodology.	2016-05-09	2016-05-09	IU/mL			I 	Ara       
CIE3	TSH	1.67	2016-05-08	2016-05-09	mIU/L	0.27	4.20	B 	Cr        
CIE3	VB12	726
Note amended reference range due to change to
Gen II assay.	2016-05-08	2016-05-09	pg/mL	191	663	B 	          
CIT2	BCMA	0.05	2016-05-08	2016-05-08				H 	HIr/2     
CIT2	CMGA	56	2016-05-08	2016-05-08				H 	Ir/1      
CIT2	CMMA	0.14	2016-05-08	2016-05-08				H 	Ir/1      
CIT2	CYCA	Cancelled - Request entered in error.	2016-05-09	2016-05-09	ug/l			B 	          
CIT2	HBQR	<0.05	2016-05-08	2016-05-08	IU/ml			H 	H/2       
CIT2	HCAR	<3.0	2016-05-08	2016-05-08				H 	Ir?       
CIT2	RUMA	0.4	2016-05-08	2016-05-08				H 	HIr/1     
CIT2	SYPA	0.060	2016-05-08	2016-05-08				H 	?Ir/1     
CIT2	TAC	Cancelled - Request entered in error.	2016-05-09	2016-05-09	ug/L			B 	          
CIT2	TLVA	0.180	2016-05-08	2016-05-08				H 	Ir/1      
CIT2	TXGA	0.1	2016-05-08	2016-05-08				H 	Ir/1      
CIT2	TXMA	0.23	2016-05-08	2016-05-08				H 	Ir/1      
CIE1	AFP	3.6
Method used for AFP: Roche Modular	2016-05-08	2016-05-09	kIU/L	0	6	B 	          
CIE1	AMHR	Cancelled - Request entered in error.	2016-05-09		pmol/L			B 	          
CIE1	BNP	14
Heart Failure Unlikely: <47 pmol/L
Raised Levels:           47 - 236 pmol/L
High Levels:            >236 pmol/L
NCL Network & NICE guidelines: see information
for GPs at www.uclh.nhs.uk/biochemistry	2016-05-09	2016-05-09	pmol/L			B 	AB        
CIE1	C125	9
Method used for CA125 :Roche Modular	2016-05-08	2016-05-09	kIU/L	0	35	B 	          
CIE1	C153	21
Method used for CA153 :Roche Modular	2016-05-08	2016-05-09	kIU/L	0	25	B 	          
CIE1	C199	5
Method used for CA199 :Roche Modular	2016-05-08	2016-05-09	kIU/L	0	27	B 	          
CIE1	CEA	1.8
Method used for CEA: Roche Modular	2016-05-08	2016-05-09	ug/L	0	3.4	B 	          
CIE1	CKMB	3	2016-05-08	2016-05-09	ug/L	0.0	2.9	B 	          
CIE1	CORT	252
Note amendment to reference range 03/02/16
Following recommendation from kit manufacturer.
New reference range 6-10 am: 133 to 537 nmol/L.	2016-05-08	2016-05-09	nmol/l			B 	          
CIE1	DHEA	1.1	2016-05-08	2016-05-08	umol/L	0.3	11.0	B 	          
CIE1	DIGM	Cancelled - Request entered in error.	2016-05-09	2016-05-09	ug/L			B 	          
CIE1	EABA	1.710	2016-05-08	2016-05-08				H 	HIr/2     
CIE1	EAGA	0.122	2016-05-08	2016-05-08				H 	HIr/2     
CIE1	FERR	155	2016-05-08	2016-05-09	ug/L	13	150	B 	          
CIE1	FHCG	Cancelled - Request entered in error.	2016-05-09	2016-05-10	mIU/ml			B 	          
CIE1	FSH	79.9
Ref Range:(Follicular      3.5  -  12.5)
Ref Range:(Mid-cycle       4.7  -  21.5)
Ref Range:(Luteal          1.7  -   7.7)
Ref Range:(Post-menopause 25.8  - 134.8)	2016-05-08	2016-05-09	IU/L			B 	          
CIE1	FT3	4.8	2016-05-08	2016-05-09	pmol/L	4.0	6.8	B 	C         
CIE1	FT4	12.7	2016-05-08	2016-05-09	pmol/L	12.0	22.0	B 	Cr        
SIND	H	4	2016-05-08					  	JNr       
CIE1	HAGA	60.00	2016-05-08	2016-05-08				H 	Ir/1      
CIE1	HAMA	0.267	2016-05-08	2016-05-08				H 	Ir/1      
CIE2	HBCA	2.020	2016-05-08	2016-05-08				H 	HIr/1     
CIE2	HBSA	.{ 2.00 }	2016-05-08					H 	HIr/1     
CIE2	HBVA	0.499	2016-05-08	2016-05-08				H 	HIr/1     
CIE2	HCG	2.7	2016-05-08	2016-05-09	IU/L	0	3	B 	          
CIE2	HCVA	0.031	2016-05-08	2016-05-08				H 	Ir/1      
CIE2	HIVA	0.161	2016-05-08	2016-05-08				H 	Ir/1      
CIE2	HTRT	8
Please note change in reporting units to ng/L
Old units ug/L x 1000 = new units ng/L
Effective 01/12/2014.	2016-05-08	2016-05-09	ng/L			B 	          
SIND	I	15	2016-05-08					  	JN        
CIE2	IGE	34	2016-05-08	2016-05-09	kIU/L	0	100	B 	A         
CIE2	INSU	3.6
Insulin assayed by Roche Modular: unlikely to
detect insulin lispro, aspart, glulisine, determir
or glargine but some cross-reactivity with
glargine metabolite M1.	2016-05-08	2016-05-09	mIU/L	2.6	24.9	B 	          
SIND	L	4	2016-05-08					  	JN        
CIE2	LH	30.9
Ref Range:(Follicular      2.4  -  12.6)
Ref Range:(Mid-cycle      14.0  -  95.6)
Ref Range:(Luteal          1.0  -  11.4)
Ref range:(Post-menopause  7.7  -  58.5)	2016-05-08	2016-05-09	IU/L			B 	          
CIE2	OEST	<44
Note method change from 09/02/15.
Results expected to differ by <25%.
New reference ranges apply:
Ref Range:(Follicular       98  -  571 )
Ref Range:(Mid-cycle       177  -  1153)
Ref Range:(Luteal          122  -  1094)
Ref Range:(Post-menopause  <183        )	2016-05-08	2016-05-09	pmol/L			B 	CP        
CIE2	PAPA	<0.020	2016-05-08	2016-05-09	mIU/ml			B 	          
CIE2	PROG	<0.5
Ref Range:(Follicular      0.6  -   4.7)
Ref Range:(Periovulatory   2.4  -   9.4)
Ref Range:(Luteal          5.3  -  86.0)
Ref Range:(Post-menopause  0.3  -   2.5)	2016-05-08	2016-05-09	nmol/L			B 	          
CIE2	PROL	258	2016-05-08	2016-05-09	mIU/L	102	496	B 	CP        
CIE2	PSA	<0.01
Method used for PSA :Roche Modular	2016-05-08	2016-05-09	ug/L			B 	          
CIE2	PSAF	Cancelled - Request entered in error.	2016-05-09	2016-05-09	ug/L			B 	          
CIE2	PTH	2.0	2016-05-08	2016-05-09	pmol/L	1.6	6.9	B 	          
CIE2	RUGA	500.00	2016-05-08	2016-05-08	IU/ml			H 	HIr/1     
CIE2	SFOL	8.0
Folate result assumes no folic acid supplement
on day of sampling	2016-05-08	2016-05-09	ng/mL	2.3	17.6	B 	          
CIE3	SHBG	39	2016-05-08	2016-05-09	nmol/L	20	122	B 	P         
CIE3	TEST	Cancelled - Request entered in error.	2016-05-09	2016-05-09	nmol/L	0	1.8	B 	CP        
CIE3	TGAB	435	2016-05-08		IU/mL			B 	r         
CIE3	TPO	89
Please note amended reference range due to
change in methodology.	2016-05-08	2016-05-09	IU/mL			I 	Ara       
CIE3	TSH	3.60	2016-05-08	2016-05-09	mIU/L	0.27	4.20	B 	Cr        
CIE3	VB12	339
Note amended reference range due to change to
Gen II assay.	2016-05-08	2016-05-09	pg/mL	191	663	B 	          
ATAG	ATAG	.	2016-07-01		IU/ml	0.8	1.3	A 	?/90      
FIB	FIB	0.80	2016-06-30	2016-06-30	g/L			A 	p1/1      
FIBA	FIBA	.	2016-07-01		g/L	1.5	4.0	A 	?p1/90    
FVL	FVL	Test performed at The Doctors Laboratory.
60 Whitfield Street  London   W1T 4EU.
PCR testing performed using the Elucigene Kit.
see Haemstaisis comment for results	2016-06-30	2016-06-30				A 	/21?H     
HHCM	HHCM	~
Result:
-------
Factor II prothrombin mutation c.*97G>A: NOT present
Factor V Leiden c.1601G>A mutation: 	 NOT present
MTHFR mutation c.C665T:                  PRESENT [HETEROZYGOTE]
-
Comment:
--------
This patient is a carrier [heterozygous] of the MTHFR c.C665T
mutation. Heterozygous carriers generally do not have an
increased risk of venous or arterial thrombosis. This mutation
is present in about 40% of the Caucasian population and
recent publications suggest there is growing evidence
that MTHFR polymorphism testing has minimal clinical utility
[Hickey et al ACMG Practice Guideline; Genetics in Medicine
2013:15[2]:153-156.
-
Other inherited and acquired risk factors also affect the
risk of developing venous thromboembolism.
-
Assay:
This PCR assay has been performed using the Elucigene
TRP kit to analyse the c.*97G>A mutation [also known
as G20210A] in the Prothrombin gene, the c.1601G>A
[p.Arg534Gln] Factor V [Leiden] mutation [also known as
G1691A] and the c.C665T [p.Ala222Val] MTHFR mutation
[also known as c.C677T].
-
Prothrombin gene Accession number NC_000011.9.
Factor V gene Accession number NG_011806.
MTHFR gene accession number NM_005957.3.
-
			     [For lab use only: TRP13]	2016-06-30	2016-06-30				A 	/1        
MTHF	MTHF	~	2016-06-30	2016-06-30				A 	/21?H     
PGM	PGM	~	2016-06-30	2016-06-30				A 	/21?H     
FVL	FVL	Sample sent to TDL Genetics for testing. Please
see Haemostaisis Genetic report for results	2016-07-05					A 	/21?H     
BACD	BACD	85
Phoned to ward	2016-06-20	2016-06-20	umol/L	0	14	B 	          
CAL	CCOL	Off white/cream and orange	2016-06-20	2016-06-20				B 	r?        
CAL	CCON	Soft	2016-06-20	2016-06-20				B 	r?        
UCIT	CITR	0.67	2016-06-20	2016-06-20	mmol/mmol			B 	r         
UCIT	CITX	24.00	2016-06-20	2016-06-20	mmol/24hr	1.3	6	B 	rN        
CAL	CMAC	Whole stone	2016-06-20	2016-06-20				B 	r?        
CAL	CMIC	Crystalline and granular	2016-06-20	2016-06-20				B 	r?        
CAL	COMC	Result not consistent with known PH1,2,3.	2016-06-20	2016-06-20				B 	rN        
24H	CREX	36.0	2016-06-20	2016-06-20	mmol/24h	7.0	21.0	B 	QN        
CAL	CSS	Unstated	2016-06-20	2016-06-20				B 	r?=       
CAL	CUA	100	2016-06-20	2016-06-20	%			B 	rN        
PHM	DHG	999	2016-06-20	2016-06-20	umol/L			B 	rP        
PHM	DHGR	111	2016-06-20	2016-06-20	umol/mmol			B 	r         
PHM	DHGX	3996	2016-06-20	2016-06-20	umol/24h			B 	rN        
GEN1	GEN1	Abnormal genotype	2016-06-20	2016-06-20				B 	r         
PHM	HOG	100	2016-06-20	2016-06-20	umol/L			B 	rPNIJ     
PHM	HOGR	11	2016-06-20	2016-06-20	umol/mmol			B 	rNIJ      
PHM	HOGX	400	2016-06-20	2016-06-20	umol/24h			B 	rNIJ      
OXAL	OXAL	55
(<10 NON FASTING)
known PH 1,2 and 3	2016-06-20	2016-06-20	umol/L			B 	A/8       
UOXA	OXCR	56
If no secondary cause of hyperoxaluria present,
consider primary hyperoxaluria.
For interpretative advice please contact
Dr.G.Rumsby (Tel:020 3447 2955) or
Oliver Clifford-Mobley (Tel:020 3447 2961)
or via the address given above	2016-06-20	2016-06-20	umol/mmol	1	38	B 	r         
PHM	PHMC	Elevated urine glycolate in the presence of
hyperoxaluria is suggestive of primary
hyperoxaluria type 1. Suggest repeat to confirm
and consider genetic testing.
Elevated urine glycerate in the presence of
hyperoxaluria is suggestive of primary
hyperoxaluria type 2. Recommend genetic testing.
Elevated urine HOG and/or DHG in the presence of
hyperoxaluria is suggestive of primary
hyperoxaluria type 3. Recommend genetic testing.	2016-06-20	2016-06-20				B 	          
UCIT	UCIT	6.00	2016-06-20	2016-06-20	mmol/L			B 	rPA       
24H	UCR	9000	2016-06-20	2016-06-20	umol/L			B 	          
UCYS	UCYS	Positive	2016-06-20	2016-06-20				B 	?Ar       
PHM	UGC	3231	2016-06-20	2016-06-20	umol/L			B 	rPA       
PHM	UGCR	359	2016-06-20	2016-06-20	umol/mmol			B 	r         
PHM	UGCX	12924	2016-06-20	2016-06-20	umol/24h	140	620	B 	rN        
PHM	UGR	4790.6	2016-06-20	2016-06-20	umol/L			B 	rP        
PHM	UGRR	532	2016-06-20	2016-06-20	umol/mmol			B 	r         
PHM	UGRX	19162	2016-06-20	2016-06-20	umol/24h			B 	rN        
UOXA	UOX	500	2016-06-20	2016-06-20	umol/L			B 	rPA       
UOXA	UOXX	2000	2016-06-20	2016-06-20	umol/24h	100	460	B 	rN        
24H	UT	24.0	2016-06-20	2016-06-20	h			B 	P=        
24H	UV	4000	2016-06-20	2016-06-20	mL			B 	PS=       
CAL	WT	2000	2016-06-20	2016-06-20	mg			B 	r         
BACD	BACD	5	2016-06-20	2016-06-20	umol/L	0	14	B 	          
CAL	CAOX	100
consisting of	2016-06-20	2016-06-20	%			B 	rN        
CAL	CCOL	Brown	2016-06-20	2016-06-20				B 	r?        
CAL	CCON	Hard	2016-06-20	2016-06-20				B 	r?        
UCIT	CITR	0.17	2016-06-20	2016-06-20	mmol/mmol			B 	r         
UCIT	CITX	2.00	2016-06-20	2016-06-20	mmol/24hr	1.3	6	B 	rN        
CAL	CMAC	Crushings/Fragments	2016-06-20	2016-06-20				B 	r?        
CAL	CMIC	Crystalline	2016-06-20	2016-06-20				B 	r?        
CAL	COXD	45	2016-06-20	2016-06-20	%			B 	rN        
CAL	COXM	55	2016-06-20	2016-06-20	%			B 	rN        
24H	CREX	12.0	2016-06-20	2016-06-20	mmol/24h	7.0	21.0	B 	QN        
CAL	CSS	Urinary stone	2016-06-20	2016-06-20				B 	r?=       
PHM	DHG	Not Detected	2016-06-20	2016-06-20	umol/L			B 	rP        
PHM	DHGR	Unable to calculate.	2016-06-20	2016-06-20	umol/mmol			B 	r         
PHM	DHGX	Unable to calculate.	2016-06-20	2016-06-20	umol/24h			B 	rN        
GEN1	GEN1	Normal genotype	2016-06-20	2016-06-20				B 	r         
PHM	HOG	<10	2016-06-20	2016-06-20	umol/L			B 	rPNIJ     
PHM	HOGR	Unable to calculate.	2016-06-20	2016-06-20	umol/mmol			B 	rNIJ      
PHM	HOGX	Unable to calculate.	2016-06-20	2016-06-20	umol/24h			B 	rNIJ      
OXAL	OXAL	2
(<10 NON FASTING)	2016-06-20	2016-06-20	umol/L			B 	A/8       
UOXA	OXCR	17	2016-06-20	2016-06-20	umol/mmol	1	38	B 	r         
PHM	PHMC	All PH metabolites normal. Primary hyperoxaluria
types 2 and 3 are unlikely. In the presence of
hyperoxaluria normal glycolate does not exclude
PH1. Genetic testing is available.	2016-06-20	2016-06-20				B 	          
UCIT	UCIT	1.00	2016-06-20	2016-06-20	mmol/L			B 	rPA       
24H	UCR	6000	2016-06-20	2016-06-20	umol/L			B 	          
UCYS	UCYS	Negative	2016-06-20	2016-06-20				B 	?Ar       
PHM	UGC	85	2016-06-20	2016-06-20	umol/L			B 	rPA       
PHM	UGCR	14	2016-06-20	2016-06-20	umol/mmol			B 	r         
PHM	UGCX	170	2016-06-20	2016-06-20	umol/24h	140	620	B 	rN        
PHM	UGR	30	2016-06-20	2016-06-20	umol/L			B 	rP        
PHM	UGRR	5	2016-06-20	2016-06-20	umol/mmol			B 	r         
PHM	UGRX	60	2016-06-20	2016-06-20	umol/24h			B 	rN        
UOXA	UOX	100	2016-06-20	2016-06-20	umol/L			B 	rPA       
UOXA	UOXX	200	2016-06-20	2016-06-20	umol/24h	100	460	B 	rN        
24H	UT	24.0	2016-06-20	2016-06-20	h			B 	P=        
24H	UV	2000	2016-06-20	2016-06-20	mL			B 	PS=       
CAL	WT	10	2016-06-20	2016-06-20	mg			B 	r         
FLG	AO	A2573	2016-08-09					X 	NJI       
FBCZ	BA	 0.2%  0.01	2016-08-09	2016-08-09	x10^9/L	0.0	0.1	A 	CDSN/0    
DIFF	DIFF	See differential results.	2016-08-10					X 	          
FBCZ	EO	 1.2%  0.06	2016-08-09	2016-08-09	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCZ	FCOM	test	2016-08-10	2016-08-10				A 	K?Nr      
FBCY	HBGL	97	2016-08-09	2016-08-09	g/L			A 	rCP/0     
FBCY	HCTU	0.333	2016-08-09	2016-08-09	L/L	0.33	0.45	A 	CPS/0     
FBCZ	IG	.{}	2016-08-09		x10^9/l	0.00	0.01	A 	SN/0      
FBCZ	IGP	.{}	2016-08-09		%			A 	SN/0      
FBCZ	LY	27.2%  1.40	2016-08-09	2016-08-09	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	291	2016-08-09	2016-08-09	g/L			A 	CPS/0     
FBCY	MCHU	21.4	2016-08-09	2016-08-09	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	73.3	2016-08-09	2016-08-09	fL	80	99	A 	CPS/0     
FBCZ	MO	 6.4%  0.33	2016-08-09	2016-08-09	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	9.6	2016-08-09	2016-08-09	fL	7	13	A 	CS?/0     
FBCZ	NE	65.0%  3.35	2016-08-09	2016-08-09	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	361	2016-08-09	2016-08-09	x10^9/L	150	400	A 	CS/0      
PVIS	PVIS	1.80	2016-08-10	2016-08-11	mPa	1.50	1.72	A 	p1/4      
FBCY	RCC	4.54	2016-08-09	2016-08-09	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	18.9	2016-08-09	2016-08-09	%	11.5	15.0	A 	CS/0      
FBCY	WCC	5.15	2016-08-09	2016-08-09	x10^9/L	3.0	10.0	A 	CWPS/0    
BNP	BNPN	4000
Please note change of units from pmol/L to ng/L
from 19/09/2016.
NT-proBNP >2000 ng/L - high levels; refer to
rapid access heart failure clinic to be seen
within 2 weeks. To discuss further, please contact
UCLH.heartfailure@nhs.net
Please note ng/L is the same as pg/ml
this is a test sample	2016-09-23	2016-09-23				B 	AB        
DRVT	DRV1	46.1	2016-05-27		secs			X 	Pr/14     
DRVT	DRV4	41.0	2016-05-27		secs			X 	PN/14     
DRVT	DRV6	34.4	2016-05-27		secs			X 	N/14      
LSUB	3A  	.	2016-08-27					A 	N         
LSUB	3P  	.	2016-08-27					A 	PN        
LSUB	48R 	.	2016-08-27					A 	          
LSUB	4A  	.	2016-08-27					A 	NQ        
LSUB	4C3A	.	2016-08-27					A 	P         
LSUB	4C3P	.	2016-08-27					A 	P         
LSUB	4P  	.	2016-08-27					A 	NP        
LSUB	8A  	.	2016-08-27					A 	N         
LSUB	8C3A	.	2016-08-27					A 	          
LSUB	8C3P	.	2016-08-27					A 	P         
LSUB	8P  	.	2016-08-27					A 	PN        
LSUB	CLY 	.	2016-08-27					X 	NQ        
LY  	LY  	No EDTA sample received for FBC and differential.	2016-08-26	2016-08-27				A 	CDSP/0    
WCC 	WCC 	Cancelled - No EDTA sample received for FBC.	2016-08-26	2016-08-27				A 	CWPS/0    
BNP	BNPN	Cancelled - see comments	2016-12-04	2016-12-04				B 	AB        
HBA	GHBI	35	2017-01-18	2017-01-18				B 	          
HBA	HBA 	5.5	2017-01-18	2017-01-18				B 	          
SIND	H   	Cancelled - Request entered in error.	2016-10-09					  	JNr       
SIND	I   	Cancelled - Request entered in error.	2016-10-09					  	JN        
SIND	L   	Cancelled - Request entered in error.	2016-10-09					  	JN        
NA	NA  	Cancelled - Request entered in error.	2016-10-09	2016-10-09				B 	CP        
HIVL	HIVL	REPORT	2016-08-11	2016-08-11				H 	HABp1Nr?  
HIVL	HVL1	<50	2016-08-11		Copies/ml			H 	HAr?/5    
HIVL	HVL2	Not Detected (<50 Copies/ml)	2016-08-11					H 	?r/5      
HIVL	HVLH	1.68	2016-08-11					H 	Ir?/5     
HIVL	HVLP	None in past 300 days	2016-08-11					H 	NI?       
HIVL	HVLS	EDTA	2016-08-11	2016-08-11				H 	?rB/5     
HES	HCON	.	2016-08-16					A 	?p1       
HES	HGBC	30.0	2016-08-16					A 	N         
HES	HGBS	3.1	2016-08-16					A 	N         
HES	HGSC	33.1	2016-08-16					A 	N         
CD19	C19P	.	2016-08-31					A 	/2        
CD19	CD19	.	2016-08-31					A 	/2        
LUP	ACLG	.	2016-11-09					A 	A/10      
LUP	ACLM	.	2016-11-09					A 	/10       
DNAE	DNAE	.	2016-11-15					I 	Ar        
LUP	DRV1	.	2016-06-15		secs			X 	Pr/14     
LUP	DRV3	.	2016-06-15			0.90	1.20	A 	Pr/14     
LUP	DRVO	Please note change in Lupus anticoagulant
methodology and reporting, effective 07/06/2016.	1899-12-30					A 	NPQ?/14   
F13C	F13C	.	2016-05-19		IU/ml	0.70	1.40	A 	          
F8	F8	.	2016-05-19		IU/ml			A 	/14       
FII	FII	.	2016-05-19		IU/ml	0.5	1.5	A 	/14       
PSFN	PSFN	.	2016-06-15		IU/ml	0.50	1.20	A 	r/90      
F8	F8	0.63	2016-05-09	2016-05-11	IU/ml			A 	/14       
FIX	FIX	0.545	2016-05-09	2016-05-11	IU/ml			A 	/14       
FXI	FXI	0.59	2016-05-09	2016-05-11	IU/ml	0.5	1.5	A 	/14       
FXII	FXII	0.66	2016-05-09	2016-05-11	IU/ml	52	164	A 	/14       
VWAG	VWAG	0.67	2016-05-09	2016-05-11	IU/ml	0.50	2.00	A 	/14       
VWFC	VWFC	0.63	2016-04-21	2016-04-21	IU/ml			A 	/14       
LFT	ALB	.	2016-04-01		g/L	34	50	B 	CP        
LFT	ALP	100	2016-04-01	2016-04-01	IU/L	35	104	B 	C         
LFT	ALT	34	2016-04-01	2016-04-01	IU/L	10	35	B 	C         
LFT	BILI	19	2016-04-01	2016-04-01	umol/L	0	137	B 	CPr       
LFT	ALB	.	2016-04-01		g/L	34	50	B 	CP        
LFT	ALP	.	2016-04-01		IU/L	35	104	B 	C         
LFT	ALT	.	2016-04-01		IU/L	10	35	B 	C         
LFT	BILI	18	2016-04-01	2016-04-01	umol/L	0	137	B 	CPr       
LFT	ALB	Cancelled - Request entered in error.	2016-08-14	2016-08-14	g/L	34	50	B 	CP        
LFT	ALP	Cancelled - Request entered in error.	2016-08-14	2016-08-14	IU/L	35	104	B 	C         
LFT	ALT	Cancelled - Request entered in error.	2016-08-14	2016-08-14	IU/L	10	35	B 	C         
LFT	BILI	Cancelled - Request entered in error.	2016-08-14	2016-08-14	umol/L	0	137	B 	CPr       
BON	CA	Cancelled - Request entered in error.	2016-08-14	2016-08-14	mmol/L	2.15	2.55	B 	CP        
BON	CCA	Unable to calculate.	2016-08-14	2016-08-14	mmol/L	2.15	2.55	B 	C         
HIV	CHIV	.{}	2016-06-21					H 	N?/2      
ELU	CREA	Cancelled - Request entered in error.	2016-08-14	2016-08-14	umol/L	49	92	B 	CPr       
CRYO	CRYO	POSITIVE	2016-03-04	2016-03-04				B 	?/8       
ELU	GFR	.
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-08-14		.			B 	          
LFT	H	.	2016-08-14					  	JNr       
HBVZ	HBCC	.{}	2016-06-21					H 	Nr?/2     
HBAG	HBCO	Y	2016-06-21	2016-06-21				H 	NIr?      
HBAG	HBVA	.{}	2016-06-21					H 	HIr/1     
HBAG	HBVR	.{}	2016-06-21					H 	?r/2m     
HIV	HIVA	.{}	2016-06-21					H 	Ir/1      
HIV	HIVR	.{}	2016-06-21					H 	?/2       
LFT	I	.	2016-08-14					  	JN        
ELU	K	Cancelled - Request entered in error.	2016-08-14	2016-08-14	mmol/L	3.5	5.1	B 	CP        
LFT	L	.	2016-08-14					  	JN        
ELU	NA	Cancelled - Request entered in error.	2016-08-14	2016-08-14	mmol/L	135	145	B 	CP        
PCOM	PCOM	.	2016-03-04					B 	A         
BON	PHOS	Cancelled - Request entered in error.	2016-08-14	2016-08-14	mmol/L	0.87	1.45	B 	CP        
STS	RPR	.{}	2016-06-08					H 	?Hr/2m    
SAVC	SAVC	.{}	2016-06-21					H 	?r/2      
SAVE	SAVE	Cancelled	2016-06-21	2016-06-21				H 	?/2       
SV65	SV65	.{}	2016-06-21					H 	?/2       
STS	SYPA	.{}	2016-06-21					H 	?Ir/1     
STS	SYPR	.{}	2016-06-21					H 	?r/2m     
STS	TPC	.{}	2016-06-08					H 	?/2       
STS	TPPA	.{}	2016-06-08					H 	?Hr/2m    
TPX	TPX	Not calculated. Random urine specimen received	2016-06-03	2016-06-03	g/24h	0	0.15	B 	QN        
UCPR	UCPR	100000	2016-06-03	2016-06-03	mg/mmol	0	13	B 	QN        
UCR	UCR	1000	2016-06-03	2016-06-03	umol/L			B 	          
ELU	UREA	Cancelled - Request entered in error.	2016-08-14	2016-08-14	mmol/L	1.7	8.3	B 	CP        
UTP	UTP	100.00	2016-06-03	2016-06-03	g/L	0	0.10	B 	P         
ELU	ZAGE	35	2016-07-19		y			X 	          
AKIF	AKIF	?AKI - creatinine increase >50% from previous.
Please review creatinine results urgently.
Consider nephrotoxic drugs, obstruction, hydration
and infection. www.londonaki.net/clinical	2016-03-03	2016-03-03				B 	r?        
AKIW	AKIW	Stage 1
Rise in creatinine may indicate AKI stage 1.
Please review creatinine results. Consider sepsis/
dehydration/toxicity/obstruction/renal disease.
For information: www.londonaki.net/clinical	2016-03-03						
AKT	AKT	3	2016-03-03	2016-03-03				B 	NIJ-      
CR	CREA	256
?AKI - creatinine increase >50% from previous.
www.londonaki.net/clinical	2016-03-03	2016-03-03	umol/L	49	92	B 	CPr       
GFR	FACR	0.30	2016-03-03					X 	N         
GFR	GFR	19
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-03-03	2016-03-03	.			B 	          
GFR	SEX	0.742	2016-03-03					X 	N         
GFR	ZAGE	35	2016-03-03		y			X 	          
CAA1	CALA	.	2016-12-21					D 	          
CAA1	CARG	.	2016-12-21					D 	          
CAA1	CCIT	.	2016-12-21					D 	          
CAA1	CCY2	.	2016-12-21					D 	          
CAA1	CGLN	.	2016-12-21					D 	          
CAA1	CGLT	.	2016-12-21					D 	          
CAA1	CHIS	.	2016-12-21					D 	          
CAA1	CILE	.	2016-12-21					D 	          
CAA1	CLEU	.	2016-12-21					D 	          
CAA1	CLYS	.	2016-12-21					D 	          
CAA1	CMET	.	2016-12-21					D 	          
CAA1	CORN	.	2016-12-21					D 	          
CAA1	CPHE	.	2016-12-21					D 	          
CAA1	CPRO	.	2016-12-21					D 	          
CAA1	CSER	.	2016-12-21					D 	          
CAA1	CTAW	.	2016-12-21					D 	          
CAA1	CTHR	.	2016-12-21					D 	          
CAA1	CTYR	.	2016-12-21					D 	          
CAA1	CVAL	.	2016-12-21					D 	          
LSUB	48R	1.2	2016-02-15	2016-02-16		0.54	2.97	A 	          
LSUB	4C3A	0.628	2016-02-15	2016-02-16	x 10^9/L	0.56	1.46	A 	P         
LSUB	4C3P	42.6	2016-02-15	2016-02-16	%	31	61	A 	P         
LSUB	8C3A	0.508	2016-02-15	2016-02-16	x 10^9/L	0.25	0.99	A 	          
LSUB	8C3P	34.5	2016-02-15	2016-02-16	%	10	36	A 	P         
CD19	C19P	12.96	2016-02-15	2016-02-16	%			A 	/2        
CD19	CD19	0.165	2016-02-15	2016-02-16	x10^9/L	0.11	0.69	A 	/2        
LSUB	3A	.	2016-02-19		x 10^9/L	0.87	2.51	A 	N         
LSUB	3P	.	2016-02-19		%	57	87	A 	PN        
LSUB	48R	0.7	2016-02-10	2016-02-12		0.54	2.97	A 	          
LSUB	4A	0.35	2016-07-07	2016-07-11	x 10^9/L	0.44	1.47	A 	NQ        
LSUB	4C3A	0.346	2016-02-10	2016-02-12	x 10^9/L	0.56	1.46	A 	P         
LSUB	4C3P	34.9	2016-02-10	2016-02-12	%	31	61	A 	P         
LSUB	4P	.	2016-02-19		%	31	64	A 	NP        
LSUB	8A	.	2016-02-19		x 10^9/L	0.29	1.05	A 	N         
LSUB	8C3A	0.503	2016-02-10	2016-02-12	x 10^9/L	0.25	0.99	A 	          
LSUB	8C3P	50.8	2016-02-10	2016-02-12	%	10	36	A 	P         
LSUB	8P	.	2016-02-19		%	16	40	A 	PN        
A13A	A13A	16.0	2017-12-12	2017-12-12				A 	          
NUCL	ADP	.	2016-07-07		nM/10^9 pl	19	38	A 	P/90      
NUCL	ADPR	.	2016-07-07		nM/10^9 pl	18	28	A 	NP        
THR1	AT3 	.	2016-09-09					A 	/14       
NUCL	ATPR	.	2016-07-07		nM/10^9 pl	8	20	A 	NP        
NUCL	ATPT	.	2016-07-07		nM/10^9 pl	41	61	A 	NP        
CD19	C19P	2.98	2016-02-10	2016-02-12	%			A 	/2        
CD19	CD19	0.010	2016-02-11	2016-02-12	x10^9/L	0.11	0.69	A 	/2        
HIV	CHIV	.{}	2016-05-10					H 	N?/2      
LSUB	CLY	0.35	2016-02-11					X 	NQ        
LUP	DRVO	Please note change in Lupus anticoagulant
methodology and reporting, effective 07/06/2016.	2016-08-24	2016-08-24				A 	NPQ?/14   
FVL	FVL	Test performed at The Doctors Laboratory.
60 Whitfield Street  London   W1T 4EU.
PCR testing performed using the Elucigene Kit.
Result:
-------
Factor II prothrombin mutation c.*97G>A: NOT present
Factor V Leiden c.1601G>A mutation: 	 NOT present
MTHFR mutation c.C665T:                  PRESENT [HETEROZYGOTE]
-
Comment:
--------
This patient is a carrier [heterozygous] of the MTHFR c.C665T
mutation. Heterozygous carriers generally do not have an
increased risk of venous or arterial thrombosis. This mutation
is present in about 40% of the Caucasian population and
recent publications suggest there is growing evidence
that MTHFR polymorphism testing has minimal clinical utility
[Hickey et al ACMG Practice Guideline; Genetics in Medicine
2013:15[2]:153-156.
-
Other inherited and acquired risk factors also affect the
risk of developing venous thromboembolism.
-
Assay:
This PCR assay has been performed using the Elucigene
TRP kit to analyse the c.*97G>A mutation [also known
as G20210A] in the Prothrombin gene, the c.1601G>A
[p.Arg534Gln] Factor V [Leiden] mutation [also known as
G1691A] and the c.C665T [p.Ala222Val] MTHFR mutation
[also known as c.C677T].
-
Prothrombin gene Accession number NC_000011.9.
Factor V gene Accession number NG_011806.
MTHFR gene accession number NM_005957.3.
-
			     [For lab use only: TRP13]	2016-06-30	2016-06-30				A 	/21?H     
HIVS	GEEN	HIV-1 POSITIVE	2016-05-10	2016-05-10				H 	I?/2      
HIV	HIVA	.{}	2016-05-10					H 	Ir/1      
HIVS	HIVI	.{}	2016-05-10					H 	IN?/2     
HIV	HIVR	.{}	2016-05-10					H 	?/2       
HIVS	HIVV	.{}	2016-05-10					H 	Ir/2      
HPIA	HPIA	1.0	2016-07-07	2016-07-07	% of ref.	0	26	A 	p1/14     
LSUB	LY	 3.5%  0.35	2016-02-11	2016-02-11	x10^9/L	1.2	3.65	A 	CDSP/0    
MTHF	MTHF	see mask	2016-06-30	2016-06-30				A 	/21?H     
PGM	PGM	see mask	2016-06-30	2016-06-30				A 	/21?H     
NUCL	PRPP	.	2016-07-07					  	JN?r      
SFOL	SFOL	16.0
Folate result assumes no folic acid supplement
on day of sampling
~
Please note change in reference range following
restandardisation of method. Results are expected
to be ~20% lower across the measuring range and
~50% lower at the lower end of the measuring range	2016-05-15	2016-05-15	ng/mL	2.3	17.6	B 	          
LSUB	WCC	10.00	2016-02-11	2016-02-11	x10^9/L	3.0	10.0	A 	CWPS/0    
BC	BC  	BLOOD CULTURE REPORT	2016-11-24	2016-11-29				M 	HXp1p2AB?r
BCW	BCA 	446580298630	2016-11-29					X 	N         
BCW	BCAN	No growth after 5 days	2016-11-29					X 	Nr/5      
BCW	BCO 	449294243467	2016-11-29					X 	N         
BC	BCST	COMPLETE: 29/11/16	2016-11-29	2016-11-29				M 	?NA       
BC	BISO	.{}	2016-11-29					M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2016-11-29	2016-11-29				M 	N?ra      
BC	CFIN	Y	2016-11-29	2016-11-29				M 	?I/6      
BCW	NCON	No growth after 5 days	2016-11-29					X 	Nr/5      
BC	BC  	BLOOD CULTURE REPORT	2016-11-24	2016-11-29				M 	HXp1p2AB?r
BCW	BCA 	446580298483	2016-11-29					X 	N         
BCW	BCAN	No growth after 5 days	2016-11-29					X 	Nr/5      
BCW	BCO 	449294243669	2016-11-29					X 	N         
BC	BCST	COMPLETE: 29/11/16	2016-11-29	2016-11-29				M 	?NA       
BC	BISO	.{}	2016-11-29					M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2016-11-29	2016-11-29				M 	N?ra      
BC	CFIN	Y	2016-11-29	2016-11-29				M 	?I/6      
BCW	NCON	No growth after 5 days	2016-11-29					X 	Nr/5      
BC	BC  	BLOOD CULTURE REPORT	2016-11-24	2016-11-30				M 	HXp1p2AB?r
BCW	BCA 	446580298482	2016-11-30					X 	N         
BCW	BCAN	No growth after 5 days	2016-11-30					X 	Nr/5      
BCW	BCO 	449294243466	2016-11-30					X 	N         
BC	BCST	COMPLETE: 30/11/16	2016-11-30	2016-11-30				M 	?NA       
BC	BISO	.{}	2016-11-30					M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2016-11-30	2016-11-30				M 	N?ra      
BC	CFIN	Y	2016-11-30	2016-11-30				M 	?I/6      
BCW	NCON	No growth after 5 days	2016-11-30					X 	Nr/5      
BC	BC  	BLOOD CULTURE REPORT	2016-11-24	2016-11-30				M 	HXp1p2AB?r
BCW	BCA 	446580298627	2016-11-30					X 	N         
BCW	BCAN	No growth after 5 days	2016-11-30					X 	Nr/5      
BCW	BCO 	449294243675	2016-11-30					X 	N         
BC	BCST	COMPLETE: 30/11/16	2016-11-30	2016-11-30				M 	?NA       
BC	BISO	.{}	2016-11-30					M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2016-11-30	2016-11-30				M 	N?ra      
BC	CFIN	Y	2016-11-30	2016-11-30				M 	?I/6      
BCW	NCON	No growth after 5 days	2016-11-30					X 	Nr/5      
BC	BC  	BLOOD CULTURE REPORT	2016-11-22	2016-11-28				M 	HXp1p2AB?r
BCW	BCA 	446580298706	2016-11-28					X 	N         
BCW	BCAN	No growth after 5 days	2016-11-28					X 	Nr/5      
BCW	BCO 	449289846074	2016-11-28					X 	N         
BC	BCST	COMPLETE: 28/11/16	2016-11-28	2016-11-28				M 	?NA       
BC	BISO	.{}	2016-11-28					M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2016-11-28	2016-11-28				M 	N?ra      
BC	CFIN	Y	2016-11-28	2016-11-28				M 	?I/6      
BCW	NCON	No growth after 5 days	2016-11-28					X 	Nr/5      
BC	BC  	BLOOD CULTURE REPORT	2016-11-22	2016-11-28				M 	HXp1p2AB?r
BCW	BCA 	446580298705	2016-11-28					X 	N         
BCW	BCAN	No growth after 5 days	2016-11-28					X 	Nr/5      
BCW	BCO 	449294243371	2016-11-28					X 	N         
BC	BCST	COMPLETE: 28/11/16	2016-11-28	2016-11-28				M 	?NA       
BC	BISO	.{}	2016-11-28					M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2016-11-28	2016-11-28				M 	N?ra      
BC	CFIN	Y	2016-11-28	2016-11-28				M 	?I/6      
BCW	NCON	No growth after 5 days	2016-11-28					X 	Nr/5      
AMSC	AMSC	ACHXYL/	2016-06-10					X 	J-        
AMSD	AMSD	Organisms sent 10/06/2016 10:57	2016-06-10					X 	J-        
COSC	COSC	ACHXYL/	2016-06-10					X 	J-        
COSD	COSD	Organisms sent 10/06/2016 10:23	2016-06-10					X 	J-        
KLA	KLA	SENT TO KIESTRA	2016-06-10					X 	-JNH      
URNC	UISO	:
     Achromobacter xylosoxidans	1899-12-30	2016-06-10				M 	ABMr?/2aN 
URNC	UPRE	.{}	2016-06-10					M 	?ar       
URNC	URCC	y	2016-06-10	2016-06-10				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-06-10	2016-06-10				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 10/06/16	2016-06-10	2016-06-10				M 	N?Ar/2    
AMSC	AMSC	ACHXYL/	2016-06-10					X 	J-        
AMSD	AMSD	Organisms sent 10/06/2016 10:57	2016-06-10					X 	J-        
KLA	KLA	SENT TO KIESTRA	2016-06-10					X 	-JNH      
URNC	UISO	:
     Achromobacter xylosoxidans	1899-12-30	2016-06-10				M 	ABMr?/2aN 
URNC	UPRE	.{}	2016-06-10					M 	?ar       
URNC	URCC	Y	2016-06-10	2016-06-10				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-06-10	2016-06-10				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 10/06/16	2016-06-10	2016-06-10				M 	N?Ar/2    
LPCR	LRE2	LEISHMANIA AETHIOPICA DNA detected	2016-10-20	2016-10-20				P 	?Ah/20m   
CGNT	CPRP	.{}	2016-09-15					X 	N?r       
CGNT	GCAC	.{}	2018-02-26					X 	N?r       
1433	1433	Negative	2017-06-20	2017-06-20				F 	?AB       
OCB	COCB	Negative	2017-06-20	2017-06-20				F 	?Ah       
OCB	OCBC	Something else completely	2017-06-20	2017-06-20				F 	N?A       
OCB	SOCB	Negative	2017-06-20	2017-06-20				F 	?N        
1433	1433	Negative	2017-06-20	2017-06-20				F 	?AB       
OCB	COCB	Negative	2017-06-20	2017-06-20				F 	?Ah       
OCB	OCBC	Some sort of comment	2017-06-20	2017-06-20				F 	N?A       
OCB	SOCB	Negative	2017-06-20	2017-06-20				F 	?N        
CAL	CCOL	Black	2017-01-11	2017-01-11				B 	r?        
CAL	CCON	Hard	2017-01-11	2017-01-11				B 	r?        
CAL	CMAC	Crushings/Fragments	2017-01-11	2017-01-11				B 	r?        
CAL	CMIC	Amorphous	2017-01-11	2017-01-11				B 	r?        
CAL	COMC	No common renal stone constituents detected.
FTIR spectrum consistent with organic material,
predominantly protein.
Spot test positive for blood	2017-01-11	2017-01-11				B 	rN        
CAL	CSS 	Unstated	2017-01-11	2017-01-11				B 	r?=       
CAL	WT  	<1	2017-01-11	2017-01-11				B 	r         
CAL	CAOX	95
consisting of	2017-01-11	2017-01-11				B 	rN        
CAL	CCOL	Off white/cream and brown	2017-01-11	2017-01-11				B 	r?        
CAL	CCON	Hard	2017-01-11	2017-01-11				B 	r?        
CAL	CMAC	Multiple whole stones and crushings/fragments	2017-01-11	2017-01-11				B 	r?        
CAL	CMIC	Smooth nodular	2017-01-11	2017-01-11				B 	r?        
CAL	COXD	15	2017-01-11	2017-01-11				B 	rN        
CAL	COXM	85	2017-01-11	2017-01-11				B 	rN        
CAL	CSS 	Urinary stone	2017-01-11	2017-01-11				B 	r?=       
CAL	WT  	52	2017-01-11	2017-01-11				B 	r         
CAL	CCAP	35	2017-01-11	2017-01-11				B 	rN        
CAL	CCOL	Off white/cream	2017-01-11	2017-01-11				B 	r?        
CAL	CCON	Hard	2017-01-11	2017-01-11				B 	r?        
CAL	CMAC	Whole stone and crushings/fragments	2017-01-11	2017-01-11				B 	r?        
CAL	CMAP	65	2017-01-11	2017-01-11				B 	rN        
CAL	CMIC	Granular	2017-01-11	2017-01-11				B 	r?        
CAL	CSS 	Bladder stone	2017-01-11	2017-01-11				B 	r?=       
CAL	WT  	1503	2017-01-11	2017-01-11				B 	r         
CAL	CAOX	15	2017-01-11	2017-01-11				B 	rN        
CAL	CCOL	Orange	2017-01-11	2017-01-11				B 	r?        
CAL	CCON	Hard	2017-01-11	2017-01-11				B 	r?        
CAL	CMAC	Whole stone	2017-01-11	2017-01-11				B 	r?        
CAL	CMIC	Crystalline and granular	2017-01-11	2017-01-11				B 	r?        
CAL	CSS 	Left ureteric stone	2017-01-11	2017-01-11				B 	r?=       
CAL	CUA 	85	2017-01-11	2017-01-11				B 	rN        
CAL	WT  	56	2017-01-11	2017-01-11				B 	r         
FGLU	FGLU	Cancelled - Entered in error. Not required.
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2017-02-28	2017-02-28				B 	r         
SIND	H   	74	2017-03-01					  	JNr       
SIND	I   	21	2017-03-01					  	JN        
K	K   	4.4	2017-03-01	2017-03-01				B 	CP        
SIND	L   	19	2017-03-01					  	JN        
NA	NA  	146	2017-03-01	2017-03-01				B 	CP        
SFOL	SFOL	<2.0
Note new reference range effective 03/04/2017.
Folate deficiency is likely in presence of
macrocytosis and anaemia and supplementation
recommended.
In absence of clinical symptoms repeat sample
and/or trial therapeutic supplementation.	2017-04-03	2017-04-03				B 	          
SFOL	SFOL	12.2
Note new reference range effective 03/04/2017.
If no change in dietary habits,a normal serum
folate makes folate deficiency unlikely.	2017-04-03	2017-04-03				B 	          
UPOR	PBGS	Negative
This test screens for porphyria during an acute
neurovisceral attack and may be negative during
remission.	2017-11-14	2017-11-14				B 	?         
RN	UCR 	5000	2017-11-14	2017-11-14				B 	          
UPOR	UPOC	Urine porphyrin and PBG screens negative. Sample
will be saved for 3 months, contact laboratory if
more sensitive analysis required (e.g. if strong
clinical suspicion).	2017-11-14	2017-11-14				B 	N         
UPOR	UPOS	Not present in excess.
This test screens for porphyrias with symptomatic
cutaneous lesions excluding acute photosensitivity
Where there is a high index of clinical suspicion
please contact the lab to refer for more sensitive
analysis.	2017-11-14	2017-11-14				B 	?         
HDV	1HD 	Cancelled - see comments	2017-03-02	2017-03-02				H 	NA?       
HBVL	BVL1	631	2017-02-28	2017-02-28				H 	HAr?/5    
HBVL	BVL2	.{ POSITIVE }	2017-02-28					H 	?r/5      
HBVL	BVLH	2.8	2017-02-28	2017-02-28				H 	Ir?       
HBVL	BVLP	.{ None in past 300 days }	2017-02-28					H 	NI?       
HBVL	HBVL	REPORT	2017-02-28	2017-02-28				H 	HABp1Nr?  
HBVL	HBVS	EDTA	2017-02-28	2017-02-28				H 	?rB/5     
HDV	HDVT	EDTA sample is unsuitable for anti-HDV testing.
Please send a clotted blood or SST sample.	2017-03-02	2017-03-02				H 	?Hr/4     
RAK 	RAK 	[Discarded 09/03/2017|12:14]	2017-03-09					X 	NJ        
COSC	COSC	HBVR/	2017-02-28					X 	N         
COSD	COSD	Organisms sent 28/02/2017 17:26	2017-02-28					X 	N         
HBMS	EABA	0.003	2017-02-28	2017-02-28				H 	HIr/2     
HBMS	EABR	POSITIVE	2017-02-28	2017-02-28				H 	?r/2      
HBMS	EAGA	0.101	2017-02-28	2017-02-28				H 	HIr/2     
HBMS	EAGR	NOT detected	2017-02-28	2017-02-28				H 	?/2       
HBMS	HBCC	.{}	2017-02-28					H 	Nr?/2     
HBMS	HBCO	Y	2017-02-28	2017-02-28				H 	NIr?      
HBMS	HBVA	2554.000	2017-02-28	2017-02-28				H 	HIr/1     
HBMS	HBVR	Positive	2017-02-28	2017-02-28				H 	?r/2m     
RAK 	RAK 	[Discarded 10/03/2017|14:50]	2017-03-10					X 	NJ        
AFP	AFP 	.{.}	2017-10-26					B 	          
LFT	ALB 	45	2017-02-27	2017-02-27				B 	CP        
LFT	ALP 	39	2017-02-27	2017-02-27				B 	C         
LFT	ALT 	13	2017-02-27	2017-02-27				B 	C         
LFT	BILI	4	2017-02-27	2017-02-27				B 	CPr       
BON	CA  	2.35	2017-02-27	2017-02-27				B 	CP        
BON	CCA 	2.36	2017-02-27	2017-02-27				B 	C         
ELU	CREA	74	2017-02-27	2017-02-27				B 	CPr       
ELU	FACR	1.30	2017-02-27					X 	N         
ELU	GFR 	76
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2017-02-27	2017-02-27				B 	          
LFT	H   	7	2017-02-27					  	JNr       
FBCY	HBGL	Request entered in error	2017-02-27	2017-02-27				A 	rCP/0     
FBCY	HCTU	Request entered in error	2017-02-27	2017-02-27				A 	CPS/0     
LFT	I   	16	2017-02-27					  	JN        
FBCZ	IG  	Request entered in error	2017-02-27	2017-02-27				A 	SN/0      
FBCZ	IGP 	Request entered in error	2017-02-27	2017-02-27				A 	SN/0      
ELU	K   	4.2	2017-02-27	2017-02-27				B 	CP        
LFT	L   	10	2017-02-27					  	JN        
FBCZ	LY  	Request entered in error	2017-02-27	2017-02-27				A 	CDSP/0    
FBCY	MCGL	Request entered in error	2017-02-27	2017-02-27				A 	CPS/0     
FBCY	MCHU	Request entered in error	2017-02-27	2017-02-27				A 	CPS/0     
FBCY	MCVU	Request entered in error	2017-02-27	2017-02-27				A 	CPS/0     
FBCZ	MO  	Request entered in error	2017-02-27	2017-02-27				A 	CDS/0     
FBCY	MPVU	Request entered in error	2017-02-27	2017-02-27				A 	CS?/0     
ELU	NA  	142	2017-02-27	2017-02-27				B 	CP        
FBCZ	NE  	Request entered in error	2017-02-27	2017-02-27				A 	CDS/0     
BON	PHOS	1.15	2017-02-27	2017-02-27				B 	CP        
FBCY	PLT 	Request entered in error	2017-02-27	2017-02-27				A 	CS/0      
FBCY	RCC 	Request entered in error	2017-02-27	2017-02-27				A 	P/0       
FBCY	RDWU	Request entered in error	2017-02-27	2017-02-27				A 	CS/0      
ELU	SEX 	0.742	2017-02-27					X 	N         
ELU	UREA	7.2	2017-02-27	2017-02-27				B 	CP        
FBCY	WCC 	Cancelled - FBC Request entered in error	2017-02-27	2017-02-27				A 	CWPS/0    
ELU	ZAGE	52	2017-02-27					X 	          
PES	A1G 	3.7	2017-04-07					X 	P         
PES	A1GG	2.7	2017-04-07					X 	Q         
PES	A2G 	9.1	2017-04-07					X 	P         
PES	A2GG	6.6	2017-04-07					X 	Q         
PES	ALBG	46.5	2017-04-07					X 	Q         
PES	ALBP	64.6	2017-04-07					X 	P         
PES	B1G 	5.5	2017-04-07					X 	P         
PES	B1GG	4.0	2017-04-07					X 	Q         
PES	B2G 	4.4	2017-04-07					X 	P         
PES	B2GL	3.2	2017-04-07					X 	Q         
PES	GG  	12.7	2017-04-07					X 	P         
PES	GGG 	9.1	2017-04-07					X 	Q         
PES	PCOM	No significant abnormality	2017-04-07	2017-04-07				B 	A         
PES	PPR 	no abnormal band visible	2017-04-07	2017-04-07				B 	N         
PES	PROT	72	2017-04-07	2017-04-07				B 	CP        
UCIT	CITR	0.19	2017-05-18	2017-05-18				B 	r         
UCIT	CITX	2.60	2017-05-18	2017-05-18				B 	rN        
24H	CREX	14.0	2017-05-18	2017-05-18				B 	QN        
PHM	DHG 	30	2017-05-19	2017-05-19				B 	rP        
PHM	DHGR	4.3	2017-05-19	2017-05-19				B 	r         
PHM	DHGX	60	2017-05-19	2017-05-19				B 	rN        
PHM	HOG 	20	2017-05-19	2017-05-19				B 	rPNIJ     
PHM	HOGR	3	2017-05-19	2017-05-19				B 	rNIJ      
PHM	HOGX	40	2017-05-19	2017-05-19				B 	rNIJ      
UOXA	OXCR	36	2017-05-18	2017-05-18				B 	r         
PHM	PHMC	OC5-DB-02 report example	2017-05-18	2017-05-18				B 	          
UCIT	UCIT	1.30	2017-05-18	2017-05-18				B 	rPA       
24H	UCR 	7000	2017-05-18	2017-05-18				B 	          
PHM	UGC 	150	2017-05-18	2017-05-18				B 	rPA       
PHM	UGCR	21	2017-05-18	2017-05-18				B 	r         
PHM	UGCX	300	2017-05-18	2017-05-18				B 	rN        
PHM	UGR 	.{10	2017-05-19					B 	rP        
UOXA	UOX 	250	2017-05-18	2017-05-18				B 	rPA       
UOXA	UOXX	500	2017-05-18	2017-05-18				B 	rN        
UPHM	UPHM	7.0	2017-05-18	2017-05-18				B 	          
24H	UT  	24.0	2017-05-18	2017-05-18				B 	P=        
24H	UV  	2000	2017-05-18	2017-05-18				B 	PS=       
24H	CREX	.	2017-06-09					B 	QN        
PHM	DHG 	Cancelled - see comments	2017-06-09	2017-06-09				B 	rP        
PHM	DHGR	.	2017-06-09					B 	r         
PHM	HOG 	Cancelled - see comments	2017-06-09	2017-06-09				B 	rPNIJ     
PHM	HOGR	.	2017-06-09					B 	rNIJ      
PHM	HOGX	Unable to calculate.	2017-06-09					B 	rNIJ      
PHM	PHMC	Cancelled - see comments: TEST	2017-06-09	2017-06-09				B 	          
24H	UCR 	.	2017-06-09					B 	          
PHM	UGC 	Cancelled - see comments	2017-06-09	2017-06-09				B 	rPA       
PHM	UGCR	.	2017-06-09					B 	r         
PHM	UGR 	Cancelled - see comments	2017-06-09	2017-06-09				B 	rP        
PHM	UGRR	.	2017-06-09					B 	r         
PHM	UGRX	Cancelled - see comments	2017-06-09	2017-06-09				B 	rN        
24H	UT  	Cancelled - see comments	2017-06-09	2017-06-09				B 	P=        
24H	UV  	Cancelled - see comments	2017-06-09	2017-06-09				B 	PS=       
AMH	AMHR	20.0
Female ref ranges(2.5th - 97.5th percentiles):
20 - 24 years:    8.7 - 83.6 pmol/L
25 - 29 years:    6.4 - 70.3 pmol/L
30 - 34 years:    4.1 - 58.0 pmol/L
35 - 39 years:    1.1 - 53.5 pmol/L
40 - 44 years:    0.2 - 39.1 pmol/L
45 - 50 years:    0.1 - 19.3 pmol/L
Levels are known to be higher in PCOS.
Approximate guide for assessing ovarian reserve in
women 18 - 44 years. Antral follicle count (AFC):
AFC 0 - 7;  AMH   <4.9     pmol/L
AFC 8 - 15; AMH 4.9 - 16.2 pmol/L
AFC    >15; AMH   >16.2    pmol/L
Please note from 01/05/17 adjusted ranges reflect
the availability of an increased dataset.
For interpretative advice please contact the
Duty Biochemist on dutybiochemist@uclh.nhs.uk	2017-08-18					B 	          
HBA	GHBI	42
.{test	2017-08-01	2017-08-01				B 	          
HBA	HBA 	.	2017-08-01					B 	          
OXAL	OXAL	20
(<10 NON FASTING)	2017-09-05	2017-09-05				B 	A/8       
THG	TGAB	50	2017-08-22	2017-08-22				B 	r         
THG	THGN	50.0
Tg reference range applies post-ablation/excision.
For interpretative advice please contact the
Duty Biochemist on dutybiochemist@uclh.nhs.uk	2017-08-22	2017-08-25				B 	r         
LSUB	3A  	.	2017-09-21					A 	N         
LSUB	3P  	.	2017-09-21					A 	PN        
LSUB	48R 	.	2017-09-21					A 	          
LSUB	4A  	.	2017-09-21					A 	NQ        
LSUB	4C3A	.	2017-09-21					A 	P         
LSUB	4C3P	.	2017-09-21					A 	P         
LSUB	4P  	.	2017-09-21					A 	NP        
LSUB	8A  	.	2017-09-21					A 	N         
LSUB	8C3A	.	2017-09-21					A 	          
LSUB	8C3P	.	2017-09-21					A 	P         
LSUB	8P  	.	2017-09-21					A 	PN        
FLG	AO  	A1663	2017-09-21					X 	NJI       
FBCZ	BA  	 2.0%  0.17	2018-02-07	2018-02-07				A 	CDSN/0    
FBCZ	BLAA	.	2017-09-21					A 	DSN       
CD19	C19P	.	2017-09-21					A 	/2        
CD19	CD19	.	2017-09-21					A 	/2        
LSUB	CLY 	1.57	2018-02-07					X 	NQ        
CDNK	CNKA	.	2017-09-21					A 	/2        
CDNK	CNKP	.	2017-09-21					A 	/2        
FBCZ	EO  	 2.0%  0.17	2018-02-07	2018-02-07				A 	CDSN/0    
FBCZ	FCOM	Howell-Jolly bodies present.	2018-02-07	2018-02-07				A 	K?Nr      
FBCY	HBGL	134	2017-09-21	2017-09-22				A 	rCP/0     
FBCY	HCTU	0.433	2017-09-21	2017-09-22				A 	CPS/0     
FBCZ	IG  	.{}	2017-09-21					A 	SN/0      
FBCZ	IGP 	.{}	2017-09-21					A 	SN/0      
FBCZ	LY  	18.0%  1.57	2018-02-07	2018-02-07				A 	CDSP/0    
FBCY	MCGL	309	2017-09-21	2017-09-22				A 	CPS/0     
FBCY	MCHU	33.5	2017-09-21	2017-09-22				A 	CPS/0     
FBCY	MCVU	108.3	2017-09-21	2017-09-22				A 	CPS/0     
FBCZ	MET 	.	2017-09-21					A 	DSN       
FBCZ	MO  	 9.0%  0.78	2018-02-07	2018-02-07				A 	CDS/0     
FBCY	MPVU	13.3	2017-09-21	2017-09-22				A 	CS?/0     
FBCZ	MYEA	.	2017-09-21					A 	DSN       
FBCZ	NE  	69.0%  6.00	2018-02-07	2018-02-07				A 	CDS/0     
FBCY	NRB 	 5.7%  0.52	2018-02-07	2018-02-07				A 	SND       
FBCY	PLT 	254	2017-09-21	2017-09-22				A 	CS/0      
FBCZ	PROA	.	2017-09-21					A 	DSN       
FBCY	RAKH	3.37	2017-09-21					X 	NJ        
FBCY	RCC 	4.00	2017-09-21	2017-09-22				A 	P/0       
FBCY	RDWU	13.1	2017-09-21	2017-09-22				A 	CS/0      
WBCP	WBCP	9.22	2018-02-07					X 	N-J       
FBCY	WCC 	8.70
WBC adjusted for NRBC.	2018-02-07	2018-02-07				A 	CWPS/0    
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	7.76	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	11.03	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	4.42	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	13.36	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	6.28	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	8.27	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	11.10	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	9.98	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	7.95	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	8.31	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	9.49	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	9.54	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	7.08	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	13.71	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	12.59	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	19.31	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	7.18	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
ADAL	ADAL	test
A detectable anti-TNF trough level (immediately
pre-dose) is associated with a higher rate of
clinical and endoscopic remission.
Result from Royal Devon & Exeter	2017-11-17	2017-11-17				B 	r         
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	9.01	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
ADAL	SEND	CANC	2017-11-17	2017-11-17				B 	I?J       
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	13.42	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
SFLC	KAPA	.	2018-03-05					B 	r         
SFLC	KLRA	Unable to calculate.
Occasional monoclonal proteins react atypically
in the assay and give erroneous results. Please
contact the lab to discuss if discrepancy
suspected.	2018-03-01	2018-03-09				B 	r         
SFLC	LAMB	.	2018-03-05					B 	r         
IGS	DBRV	To be reviewed by Duty Biochemist	2017-10-25	2017-10-25				B 	NIJ       
FRUC	FRU2	.	2017-10-25					B 	NI-J      
FRUC	FRUN	300
Reference range is for non-diabetics.
Fructosamine CANNOT be used to diagnose diabetes:
for diagnosis, use fasting glucose and/or GTT.
People with diabetes can have results within the
reference range.
Analysed at Northwick Park Hospital	2017-10-25	2017-10-25				B 	r/3       
IGS	IGA 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	S         
IGS	IGG 	9.16	2017-10-21	2017-10-21				B 	AS        
IGS	IGM 	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	BS        
PSA	PSA 	5.00
Method used for PSA :Roche Modular	2017-10-25	2017-10-25				B 	          
SIRO	SIRO	<2.0
Assay performed in-house from 19/09/17.
Please contact the duty biochemist to discuss
if necessary	2017-10-26	2017-10-26				B 	r         
ADAL	ADAL	test
A detectable anti-TNF trough level (immediately
pre-dose) is associated with a higher rate of
clinical and endoscopic remission.
Result from Royal Devon & Exeter	2017-11-17	2017-11-17				B 	r         
AHP	AHP 	1.7
Analysed by LC-MS/MS
Please note method change to LC-MS/MS
effective 03/10/17. Results are comparable to
previous GC-MS method.	2017-10-03	2017-10-03				B 	A         
ADAL	SEND	SEND	2017-11-17	2017-11-17				B 	I?J       
AMIO	AMIO	Cancelled - see comments	2017-10-29	2017-10-29				B 	r/16      
CSFP	CGLU	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	          
CSFP	CSFT	CSF	2017-10-20	2017-10-20				B 	=?        
CSFP	CTP 	0.43	2017-10-21	2017-10-21				B 	          
CSFP	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
AMIO	DMAM	Cancelled - see comments	2017-10-29	2017-10-29				B 	r/16      
SEND	SEND	test	2017-10-29	2017-10-29				B 	I?J       
AMI	AMI 	Cancelled - see comments	2017-10-29	2017-10-29				B 	r/30      
CSFP	CGLU	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	          
CSFP	CSFT	csf	2017-10-20	2017-10-20				B 	=?        
CSFP	CTP 	0.41	2017-10-21	2017-10-21				B 	          
CSFP	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
SEND	SEND	test	2017-10-29	2017-10-29				B 	I?J       
ALU	ALU 	test
<0.4 umol/L (<10 ug/L) in subjects without CRF
<2.2 umol/L (<60 ug/L) low toxicity in CRF
Result from Centre for Clinical Science,
University of Surrey	2017-10-29	2017-10-29				B 	r/30      
CSFP	CGLU	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	          
CSFP	CSFT	csf	2017-10-20	2017-10-20				B 	=?        
CSFP	CTP 	0.42	2017-10-21	2017-10-21				B 	          
CSFP	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
SEND	SEND	Send	2017-10-29	2017-10-29				B 	I?J       
AEP	AEP 	test
Result from Royal Free Hospital	2017-10-29	2017-10-29				B 	r/56      
CSFP	CGLU	Cancelled - Request entered in error.	2017-10-20	2017-10-20				B 	          
CSFP	CSFT	csf	2017-10-20	2017-10-20				B 	=?        
CSFP	CTP 	0.42	2017-10-21	2017-10-21				B 	          
CSFP	DBRV	To be reviewed by Duty Biochemist	2017-10-29	2017-10-29				B 	NIJ       
SEND	SEND	Send	2017-10-29	2017-10-29				B 	I?J       
BACD	BACD	Cancelled	2017-11-15	2017-11-15				B 	          
CAL	CCOL	Cancelled	2017-11-15	2017-11-15				B 	r?        
CAL	CCON	Cancelled	2017-11-15	2017-11-15				B 	r?        
UCIT	CITR	Cancelled	2017-11-15	2017-11-15				B 	r         
CAL	CMAC	Cancelled	2017-11-15	2017-11-15				B 	r?        
CAL	CMIC	Cancelled	2017-11-15	2017-11-15				B 	r?        
CAL	CSS 	Cancelled	2017-11-15	2017-11-15				B 	r?=       
UOXA	OXCR	Cancelled	2017-11-15	2017-11-15				B 	r         
SWET	SW  	Cancelled	2017-11-15	2017-11-15				B 	          
SWET	SWCL	Cancelled	2017-11-15	2017-11-15				B 	          
SWET	SWSS	Cancelled	2017-11-15	2017-11-15				B 	=         
UCIT	UCIT	Cancelled	2017-11-15	2017-11-15				B 	rPA       
24H	UCR 	Cancelled	2017-11-15	2017-11-15				B 	          
UCYS	UCYS	Cancelled	2017-11-15	2017-11-15				B 	?Ar       
UOXA	UOX 	Cancelled	2017-11-15	2017-11-15				B 	rPA       
24H	UT  	Cancelled	2017-11-15	2017-11-15				B 	P=        
24H	UV  	Cancelled	2017-11-15	2017-11-15				B 	PS=       
CAL	WT  	Cancelled	2017-11-15	2017-11-15				B 	r         
BACD	BACD	10	2017-11-15	2017-11-16				B 	          
CAL	CAOX	100
consisting of	2017-11-15	2017-11-16				B 	rN        
CAL	CCOL	Brown	2017-11-15	2017-11-16				B 	r?        
CAL	CCON	Hard	2017-11-15	2017-11-16				B 	r?        
UCIT	CITR	Not calculated: Analyte below lower limit of
detection.
Low citrate. Please exclude the possibility of
distal renal tubular acidosis, bacterial
contamination (UTI) or malabsorptive disorders in
this patient	2017-11-16	2017-11-16				B 	r         
UCIT	CITX	Unable to calculate.	2017-11-16	2017-11-16				B 	rN        
CAL	CMAC	Whole stone	2017-11-15	2017-11-16				B 	r?        
CAL	CMIC	Crystalline	2017-11-15	2017-11-16				B 	r?        
CAL	CNOT	Calculus analysis is a semi-quantitative method
and percentages represent the approximate
composition of mixtures of minerals.
Minor components <10% are not numerically
reported because of imprecision at this level.	2017-11-15	2017-11-16				B 	          
CAL	COXD	50	2017-11-15	2017-11-16				B 	rN        
CAL	COXM	50	2017-11-15	2017-11-16				B 	rN        
24H	CREX	12.0	2017-11-15	2017-11-15				B 	QN        
CAL	CSS 	Urinary stone	2017-11-15	2017-11-16				B 	r?=       
OXAL	OXAL	10
(<10 NON FASTING)	2017-11-16	2017-11-16				B 	A/8       
UOXA	OXCR	83	2017-11-16	2017-11-16				B 	r         
SWET	SW  	90	2017-11-15	2017-11-16				B 	          
SWET	SWCL	15
Normal, with low probability of CF     <40 mmol/L
Suggestive but not diagnostic of CF  40-60 mmol/L
Supports the diagnosis of CF           >60 mmol/L	2017-11-15	2017-11-16				B 	          
SWET	SWSS	Right arm	2017-11-15	2017-11-16				B 	=         
UCIT	UCIT	<0.1	2017-11-16	2017-11-16				B 	rPA       
24H	UCR 	6000	2017-11-15	2017-11-15				B 	          
UCYS	UCYS	Negative	2017-11-16	2017-11-16				B 	?Ar       
UOXA	UOX 	500	2017-11-16	2017-11-16				B 	rPA       
UOXA	UOXX	1000	2017-11-16	2017-11-16				B 	rN        
24H	UT  	24.0	2017-11-15	2017-11-15				B 	P=        
24H	UV  	2000	2017-11-15	2017-11-15				B 	PS=       
CAL	WT  	100	2017-11-15	2017-11-16				B 	r         
25D2	25D2	25	2017-10-11	2017-10-11				B 	rN        
25D3	25D3	25	2017-10-11	2017-10-11				B 	rN        
ALPI	ALP 	200	2017-10-10	2017-10-10				B 	C         
ALPI	BALP	85	2017-10-10	2017-10-10				B 	          
SY0	CORD	test
Reference range 6-10 am: 133 - 537 nmol/L	2017-10-30	2017-10-30				B 	          
SY0	DBRV	To be reviewed by Duty Biochemist	2017-10-30	2017-10-30				B 	NIJ       
ALPI	FALP	15	2017-10-10	2017-10-10				B 	          
ALPI	H   	1	2017-10-10					  	JNr       
ALPI	I   	1	2017-10-10					  	JN        
ALPI	IALP	Not detected	2017-10-10	2017-10-10				B 	          
ALPI	L   	1	2017-10-10					  	JN        
ALPI	LALP	100	2017-10-10	2017-10-10				B 	          
ALPI	PALP	Not detected	2017-10-10	2017-10-10				B 	          
SY0	STIM	test	2017-10-30	2017-10-30				B 	          
VITD	VITD	50
ASSAY DOES NOT DETECT ALFACALCIDOL OR CALCITRIOL.
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Total 25-hydroxy vitamin D is the sum of D2 & D3.	2017-10-11	2017-10-11				B 	r         
PND	ADE1	.	2017-12-04					A 	?         
PND	ADER	.	2017-12-04					A 	?         
PND	AML1	.	2017-12-04					A 	?         
PND	AMLR	.	2017-12-04					A 	?         
PND	ARE1	.	2017-12-04					A 	?         
PND	ARER	.	2017-12-04					A 	?         
PND	ASE1	.	2017-12-04					A 	?         
PND	ASER	.	2017-12-04					A 	?         
PND	BAR1	.	2017-12-04					A 	?         
PND	BAR2	.	2017-12-04					A 	?         
PND	BGA1	.	2017-12-04					A 	?         
PND	BGAR	.	2017-12-04					A 	?         
PND	BML1	.	2017-12-04					A 	?         
PND	BMLR	.	2017-12-04					A 	?         
PND	BSE1	.	2017-12-04					A 	?         
PND	BSE2	.	2017-12-04					A 	?         
PND	CREV	.	2017-12-04					X 	H         
PND	DDE2	.	2017-12-04					A 	?         
PND	DDER	.	2017-12-04					A 	?         
PND	EXB 	.	2017-12-04					X 	-IH       
PND	FDNA	.	2017-12-04					X 	H=        
PND	GAPP	sometings	2017-12-04	2017-12-27				A 	@1Ap1p2   
PND	HBGL	.	2017-12-04					A 	rCP/0     
PND	HCON	.{}	2017-12-07					A 	?p1       
PND	HCTU	.	2017-12-04					A 	CPS/0     
PND	HGBA	.	2017-12-04					A 	?         
PND	MATR	.	2017-12-04					A 	?         
PND	MCGL	.	2017-12-04					A 	CPS/0     
PND	MCHU	.	2017-12-04					A 	CPS/0     
PND	MCVU	.	2017-12-04					A 	CPS/0     
PND	MPVU	.	2017-12-04					A 	CS?/0     
PND	NRB 	.	2017-12-04					A 	SND       
PND	PDNA	.	2017-12-04					X 	H=        
PND	PLT 	.	2017-12-04					A 	CS/0      
PND	PNDF	.	2017-12-04					A 	?p1       
PND	PNDM	.	2017-12-04					A 	?         
PND	RCC 	.	2017-12-04					A 	P/0       
PND	RDWU	.	2017-12-04					A 	CS/0      
PND	REN1	.	2017-12-04					A 	?         
PND	RENR	.	2017-12-04					A 	?         
VITD	VITD	44
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Please note method change to Roche immunoassay
effective 07/10/17. Results are comparable to the
previous LC-MS/MS method, except with patients on
vitamin D2 supplementation where results may be
lower. Manufacturer guidance states 92% detection
of 25-hydroxyvitamin D2. Please contact the duty
biochemist to discuss if necessary.	2017-10-11	2017-10-11				B 	r         
PND	WCC 	.	2017-12-04					A 	CWPS/0    
PND	XMN2	.	2017-12-04					A 	?         
PND	XMNR	.	2017-12-04					A 	?         
VITD	VITD	46
Deficient                <25 nmol/L
Insufficient           25-50 nmol/L
Consider reducing dose  >200 nmol/L
Please note method change to Roche immunoassay
effective 07/10/17. Results are comparable to the
previous LC-MS/MS method, except with patients on
vitamin D2 supplementation where results may be
lower. Manufacturer guidance states 92% detection
of 25-hydroxyvitamin D2. Please contact the duty
biochemist to discuss if necessary.	2017-10-11	2017-10-11				B 	r         
RESP	ADVP	Sample sent to TDL Genetics for testing. Please
see Haemostaisis Genetic report for results	2017-01-06	2017-01-06				H 	?H/2m     
SIND	ALB 	.{.}	2017-10-26					B 	CP        
SIND	ALP 	.{.}	2017-10-26					B 	C         
SIND	ALT 	.{.}	2017-10-26					B 	C         
SIND	BILI	.{.}	2017-10-26					B 	CPr       
RESP	CORP	.{}	2017-11-10					H 	?H/2m     
RESP	FLAP	Assay performed with the Gen-Probe Lifecodes
HLA-SSO Typing kits based on Luminex xMAP
technology and with the Olerup SSP HLA-B*57 kit
supplied by Qiagen.	2017-01-06	2017-01-06				H 	?H/2m     
RESP	FLBP	Please note this test is no longer in use.
Do NOT book in this request, instead refer
any malaria request to Parasitology Department.	2017-01-06	2017-01-06				H 	?H/2m     
G6PD	G6SC	.{}	2017-11-09					A 	?Hr       
RESP	MPVP	Sample sent to TDL Genetics for testing. Please
see Haemostaisis Genetic report for results	2017-01-06	2017-01-06				H 	?H/2m     
NA	NA  	.	2017-05-30					B 	CP        
RESP	PARE	.{}	2017-11-10					H 	?H/2m     
RESP	PFLP	The thrombophilia genetics testing has been
performed by PCR using the Elucigene TRP kit at
TDL Genetics.	2017-01-06	2017-01-06				H 	?Hr/2m    
RESP	RESP	REPORT	2017-01-06	2017-01-06				H 	NAHp1?r   
RESP	RHIP	.{}	2017-11-10					H 	?H/2m     
RESP	RSVP	The thrombophilia genetics testing has been
performed by PCR using the Elucigene TRP kit at
TDL Genetics.	2017-01-06	2017-01-06				H 	?H/2m     
AMSC	AMSC	Organisms sent 12/06/2017 18:05	2017-06-12					X 	J-        
AMSD	AMSD	MRSA/	2017-06-12					X 	J-        
COSC	COSC	MRSA/	2017-06-12					X 	J-        
COSD	COSD	Organisms sent 12/06/2017 17:20	2017-06-12					X 	J-        
MRSC	FSTH	COMPLETE: 16/06/17	2017-06-16	2017-06-16				M 	?r/3      
MRSC	HCOM	y	2017-06-12	2017-06-12				M 	I?/3      
ICN	ICNA	Please disregard	2017-06-12					X 	/1        
ICN	ICNN	This is a test patient	2017-06-12					X 	?/1       
ICN	ICNP	.	2017-06-13					G 	@1N?I     
ICN	ICNS	Nil action required	2017-06-13					X 	/1        
MRSC	MISO	:	2017-06-12	2017-06-12				M 	Mr/3      
MRSC	MRCC	This isolate shows high-level resistance to
Mupirocin. When using the MRSA suppression
protocol replace Mupirocin nasal ointment with
Naseptin nasal cream (if nut allergy or
chlorhexidine allergy contact Microbiology for
alternatives).	2017-06-16	2017-06-16				M 	N?        
MRSC	MRCM	The patient should be regarded as MRSA positive
for the next 6 months for the purpose of isolation
and surgical prophylaxis. It is not necessary to
re-test for the next 6 months. Please refer to the
MRSA screening protocol.	2017-06-12	2017-06-12				M 	N?        
MRSC	MRSC	MRSA CULTURE REPORT	2017-06-12	2017-06-12				M 	Hp1p2A?r  
MRSP	MRSP	INTERNAL RESULT	2017-06-12					X 	HI        
DPC	65ST	Nail	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  15/02/18	2018-02-15					X 	N?H-Ja    
DPC	67S2	.	2017-10-03					X 	NHJ-?a    
DERM	68FE	Negative: Dermatophytes NOT detected	2018-02-15	2018-02-15				M 	?         
DERM	COMG	Y	2018-02-15	2018-02-15				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2018-02-15	2018-02-15				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2018-02-15	2018-02-15				M 	p1p2A?r   
DERM	DORG	.{}	2018-02-15					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	Yeasts and non-dermatophytes NOT isolated	2018-02-15	2018-02-15				M 	?ABN      
DPC	EIR 	NO	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2018-02-15	2018-02-15				M 	HAp1p2r   
FUNM	FUNM	Please see PCR result	2018-02-15	2018-02-15				M 	?/1       
DERM	GSTA	COMPLETE: 15/02/18	2018-02-15	2018-02-15				M 	?r        
DPC	IC  	27	2018-01-09					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Nail	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  15/02/18	2018-02-15					X 	N?H-Ja    
DPC	67S2	.	2017-10-03					X 	NHJ-?a    
DERM	68FE	POSITIVE for Trichophyton rubrum complex.	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2018-02-15	2018-02-15				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2018-02-15	2018-02-15				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2018-02-15					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	Yeasts and non-dermatophytes NOT isolated	2018-02-15	2018-02-15				M 	?ABN      
DPC	EIR 	NO	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Please see PCR result	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 15/02/18	2018-02-15	2018-02-15				M 	?r        
DPC	IC  	27	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	27	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Nail	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  09/01/18	2018-01-09					X 	N?H-Ja    
DPC	67S2	.	2017-10-03					X 	NHJ-?a    
DERM	68FE	POSITIVE for Trichophyton interdigitale complex.	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2018-01-09	2018-01-09				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2017-10-03	2017-10-03				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2018-01-09					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	Yeasts and non-dermatophytes NOT isolated	2018-01-09	2018-01-09				M 	?ABN      
DPC	EIR 	NO	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Please see PCR result	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 09/01/18	2018-01-09	2018-01-09				M 	?r        
DPC	IC  	27	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	24	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Nail	2017-10-03					X 	HJ-?      
DPC	67S2	.	2017-10-03					X 	NHJ-?a    
DERM	68FE	POSITIVE for Trichophyton rubrum and
Trichophyton interdigitale mixed infection	2017-10-03	2017-10-03				M 	?         
DERM	COMG	y	2017-10-03	2017-10-03				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2017-10-03	2017-10-03				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	Trichophyton rubrum and Trichophyton interdigitale	2017-10-03	2017-10-03				M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	Culture for Non-dermatophyte fungi ongoing.	2017-10-03	2017-10-03				M 	?ABN      
DPC	EIR 	NO	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Please see PCR result	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 03/10/17	2017-10-03	2017-10-03				M 	?r        
DPC	IC  	0	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	27	2017-10-03					X 	HNIJ-     
DPC	TRUB	27	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Nail	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  03/10/17	2017-10-03					X 	N?H-Ja    
DPC	67S2	No Growth Day 14  03/10/17	2017-10-03					X 	NHJ-?a    
DERM	68FE	PCR Inhibited. Please see microscopy and culture	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2017-10-03	2017-10-03				M 	?I/15     
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2017-10-03					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	No fungal growth after 14 days incubation	2017-10-03	2017-10-03				M 	?ABN      
DPC	EIR 	Inhibited extend culture	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Fungal elements NOT seen.	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 03/10/17	2017-10-03	2017-10-03				M 	?r        
DPC	IC  	0	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Skin	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  03/10/17	2017-10-03					X 	N?H-Ja    
DPC	67S2	No Growth Day 14  09/01/18	2018-01-09					X 	NHJ-?a    
DERM	68FE	POSITIVE for Microsporium sp.	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2018-01-09	2018-01-09				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2017-10-03	2017-10-03				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2018-01-09					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	No fungal growth after 14 days incubation	2018-01-09	2018-01-09				M 	?ABN      
DPC	EIR 	YES	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Fungal elements SEEN.	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 09/01/18	2018-01-09	2018-01-09				M 	?r        
DPC	IC  	27	2017-10-03					X 	HNIJ-     
DPC	MIC 	27	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Skin	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  15/02/18	2018-02-15					X 	N?H-Ja    
DPC	67S2	No Growth Day 14  15/02/18	2018-02-15					X 	NHJ-?a    
DERM	68FE	POSITIVE for Trichophyton violacium.	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2017-10-03	2017-10-03				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2017-10-03	2017-10-03				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2017-10-03					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	No fungal growth after 14 days incubation	2017-10-03	2017-10-03				M 	?ABN      
DPC	EIR 	YES	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Fungal elements SEEN.	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 03/10/17	2017-10-03	2017-10-03				M 	?r        
DPC	IC  	0	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	27	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	27	2017-10-03					X 	HNIJ-     
DPC	65ST	Skin	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  15/02/18	2018-02-15					X 	N?H-Ja    
DPC	67S2	No Growth Day 14  15/02/18	2018-02-15					X 	NHJ-?a    
DERM	68FE	POSITIVE for Trichopyton tonsurans.	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2017-10-03	2017-10-03				M 	?I/15     
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2017-10-03					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	No fungal growth after 14 days incubation	2017-10-03	2017-10-03				M 	?ABN      
DPC	EIR 	YES	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Fungal elements SEEN.	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 03/10/17	2017-10-03	2017-10-03				M 	?r        
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	27	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Skin	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  15/02/18	2018-02-15					X 	N?H-Ja    
DPC	67S2	No Growth Day 14  15/02/18	2018-02-15					X 	NHJ-?a    
DERM	68FE	PCR Inhibited. Please see microscopy and culture	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2017-10-03	2017-10-03				M 	?I/15     
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2017-10-03					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	No fungal growth after 14 days incubation	2017-10-03	2017-10-03				M 	?ABN      
DPC	EIR 	Inhibited extend culture	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Fungal elements NOT seen.	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 03/10/17	2017-10-03	2017-10-03				M 	?r        
DPC	IC  	0	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	0	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
DPC	65ST	Skin	2017-10-03					X 	HJ-?      
DPC	67S1	No Growth Day 7  15/02/18	2018-02-15					X 	N?H-Ja    
DPC	67S2	No Growth Day 14  15/02/18	2018-02-15					X 	NHJ-?a    
DERM	68FE	POSITIVE for Trichopyton tonsurans.	2017-10-03	2017-10-03				M 	?         
DERM	COMG	Y	2017-10-03	2017-10-03				M 	?I/15     
DERM	DC01	Please note the detection of dermatophytes has
moved from culture and microscopy to PCR.
PCR is a more rapid and accurate technique for the
diagnosis of dermatophyte infection	2017-10-03	2017-10-03				M 	N?        
DERM	DERM	FUNGAL CULTURE REPORT	2017-10-03	2017-10-03				M 	p1p2A?r   
DERM	DORG	.{}	2017-10-03					M 	M?/20     
DPC	DPC 	03/10/17	2017-10-03					X 	HJ-       
DERM	DPRE	No fungal growth after 14 days incubation	2017-10-03	2017-10-03				M 	?ABN      
DPC	EIR 	YES	2017-10-03					X 	HNIJ-     
FUNM	FUMT	FUNGAL MICROSCOPY REPORT	2017-10-03	2017-10-03				M 	HAp1p2r   
FUNM	FUNM	Fungal elements SEEN.	2017-10-03	2017-10-03				M 	?/1       
DERM	GSTA	COMPLETE: 03/10/17	2017-10-03	2017-10-03				M 	?r        
DPC	IC  	0	2017-10-03					X 	HNIJ-     
DPC	MIC 	0	2017-10-03					X 	HNIJ-     
DPC	TMEN	0	2017-10-03					X 	HNIJ-     
DPC	TRUB	0	2017-10-03					X 	HNIJ-     
DPC	TTON	27	2017-10-03					X 	HNIJ-     
DPC	TVIO	0	2017-10-03					X 	HNIJ-     
XBDG	XBDC	Test line 2	2017-09-27	2017-09-27				M 	          
XBDG	XBDE	Test line 3	2017-09-27	2017-09-27				M 	N         
XBDG	XBDR	Test line 1	2017-09-27	2017-09-27				M 	/14?      
SGAL	GACO	Y	2017-11-22					M 	?I-r      
SGAL	GALE	Negative	2017-11-22					M 	?Ar/4     
SGAL	GALI	0.9	2017-11-22					M 	Ar        
SGAL	GAST	COMPLETE: 22/11/17	2017-11-22					M 	N?B       
SGAL	SMTP	Bronchial alveolar lavage	2017-11-22	2017-11-22				M 	?Hr       
SGAL	GACO	Y	2017-11-22					M 	?I-r      
SGAL	GALE	Negative	2017-11-22					M 	?Ar/4     
SGAL	GALI	0.4	2017-11-22					M 	Ar        
SGAL	GAST	COMPLETE: 22/11/17	2017-11-22					M 	N?B       
SGAL	SMTP	Serum	2017-11-22	2017-11-22				M 	?Hr       
SGAL	GACO	y	2017-11-22	2017-11-22				M 	?I-r      
SGAL	GALE	Equivocal	2017-11-22	2017-11-22				M 	?Ar/4     
SGAL	GALI	0.8	2017-11-22	2017-11-22				M 	Ar        
SGAL	GALP	1.1	2017-11-22					M 	HNIaJ-r   
SGAL	GAST	COMPLETE: 22/11/17	2017-11-22	2017-11-22				M 	N?B       
SGAL	SMTP	Bronchial alveolar lavage	2017-11-22	2017-11-22				M 	?Hr       
SGAL	GACO	y	2017-11-22	2017-11-22				M 	?I-r      
SGAL	GALE	Equivocal	2017-11-22	2017-11-22				M 	?Ar/4     
SGAL	GALI	0.4	2017-11-22	2017-11-22				M 	Ar        
SGAL	GALP	0.6	2017-11-22	2017-11-22				M 	HNIaJ-r   
SGAL	GAST	COMPLETE: 22/11/17	2017-11-22	2017-11-22				M 	N?B       
SGAL	SMTP	Serum	2017-11-22	2017-11-22				M 	?Hr       
SGAL	GACO	y	2017-11-22	2017-11-22				M 	?I-r      
SGAL	GALE	Positive	2017-11-22	2017-11-22				M 	?Ar/4     
SGAL	GALI	1.1	2017-11-22	2017-11-22				M 	Ar        
SGAL	GALP	1.1	2017-11-22	2017-11-22				M 	HNIaJ-r   
SGAL	GAST	COMPLETE: 22/11/17	2017-11-22	2017-11-22				M 	N?B       
SGAL	SMTP	Bronchial alveolar lavage	2017-11-22	2017-11-22				M 	?Hr       
SGAL	GACO	y	2017-11-22	2017-11-22				M 	?I-r      
SGAL	GALE	Positive	2017-11-22	2017-11-22				M 	?Ar/4     
SGAL	GALI	0.6	2017-11-22	2017-11-22				M 	Ar        
SGAL	GALP	0.6	2017-11-22	2017-11-22				M 	HNIaJ-r   
SGAL	GAST	COMPLETE: 22/11/17	2017-11-22	2017-11-22				M 	N?B       
SGAL	SMTP	Serum	2017-11-22	2017-11-22				M 	?Hr       
UMPA	67UP	No significant growth	2018-03-12	2018-03-12	          			M 	HIJ-?r    
USI	SILB	.	2018-03-12		          			X 	HI-       
USI	SILC	.	2018-03-12		          			X 	HI-       
URNC	UISO	.{}	2018-03-12		          			M 	ABMr?/2aN 
URNC	UPRE	No significant growth.	2018-03-12	2018-03-12	          			M 	?ar       
GENG	GECC		1899-12-30					M 	N?        
GENG	GEEC		1899-12-30					M 	N?        
GENG	GERC		1899-12-30					M 	N?        
GENG	GEWC	Moderate	2018-04-06	2018-04-06				M 	?         
GENG	GHAY	Grade 1 (normal)
Normal flora. No evidence of Bacterial Vaginosis.	2018-04-06	2018-04-06				M 	N?r       
GENG	GYMA		1899-12-30					M 	NAp1?     
GENG	GYNM		1899-12-30					M 	HXp1p2A?r 
GENG	GECC		1899-12-30					M 	N?        
GENG	GEEC		1899-12-30					M 	N?        
GENG	GERC		1899-12-30					M 	N?        
GENG	GEWC	Moderate	2018-04-06	2018-04-06				M 	?         
GENG	GHAY	Grade 2 (intermediate)
Mixed flora, intermediate between normal flora and
bacterial vaginosis. Assess with clinical criteria
and send repeat sample to confirm if necessary.	2018-04-06	2018-04-06				M 	N?r       
GENG	GYMA		1899-12-30					M 	NAp1?     
GENG	GYNM		1899-12-30					M 	HXp1p2A?r 
GENG	GECC		1899-12-30					M 	N?        
GENG	GEEC		1899-12-30					M 	N?        
GENG	GERC		1899-12-30					M 	N?        
GENG	GEWC	Moderate	2018-04-06	2018-04-06				M 	?         
GENG	GHAY	Grade 3 (abnormal)
Microscopy suggestive of Bacterial Vaginosis.	2018-04-06	2018-04-06				M 	N?r       
GENG	GYMA		1899-12-30					M 	NAp1?     
GENG	GYNM		1899-12-30					M 	HXp1p2A?r 
GENG	GECC		1899-12-30					M 	N?        
GENG	GEEC		1899-12-30					M 	N?        
GENG	GERC		1899-12-30					M 	N?        
GENG	GEWC	.{}	2018-04-06					M 	?         
GENG	GHAY		1899-12-30					M 	N?r       
GENG	GYMA	Cancelled - see comments	2018-04-06	2018-04-06				M 	NAp1?     
GENG	GYNM	CANCELLED	2018-04-06	2018-04-06				M 	HXp1p2A?r 
GENG	GECC		1899-12-30					M 	N?        
GENG	GEEC		1899-12-30					M 	N?        
GENG	GERC		1899-12-30					M 	N?        
GENG	GEWC	Moderate	2018-04-06	2018-04-06				M 	?         
GENG	GHAY	Grade I (Normal flora only) No indication of
bacterial vaginosis	2018-04-06	2018-04-06				M 	N?r       
GENG	GYMA		1899-12-30					M 	NAp1?     
GENG	GYNM		1899-12-30					M 	HXp1p2A?r 
FAW2	CAM 	.{}	2017-09-08					X 	?r/2      
CDIF	CDAP	.{}	2017-09-08					M 	Br?/1     
CDIF	CDCM	Entered in error.	2017-09-08	2017-09-08				M 	NA?r      
CDIF	CDIA	Cancelled - see comments	2017-09-08	2017-09-08				M 	NA?r      
CDIF	CDIF	CANCELLED	2017-09-08	2017-09-08				M 	HXp1p2AB?r
CDIF	CGDH	.{}	2017-09-08					M 	?r/1      
COSC	COSC	.{}	2017-09-09					X 	J-        
COSD	COSD	.{}	2017-09-09					X 	J-        
CDIF	CRQ7	No	2017-09-06					X 	N         
CDIF	CT14	No	2017-09-06					X 	N         
CDIF	CTOX	.{}	2017-09-08					M 	?r/1      
ETCI	ETCI	.{}	2017-09-08					X 	?/3       
FAEC	FACC	y	2017-09-08	2017-09-08				M 	?Ir/3     
FAEC	FAEA	.{}	2017-09-08					M 	?Br/1     
FAEC	FAEC	FAECES CULTURE REPORT	2017-09-06	2017-09-08				M 	HXp1p2AB?r
FAEC	FAST	COMPLETE: 08/09/17	2017-09-08	2017-09-08				M 	?Ar/3     
FAEC	FCMT	This is a test	2017-09-08	2017-09-08				M 	N?A       
FAEC	FISO	.{}	2017-09-08					M 	M?/3B     
FAEC	FISR	.{}	2017-09-08					M 	?A/3      
ICN	ICNA	-	2017-09-08					X 	/1        
ICN	ICNN	Aprince	2017-09-08					X 	?/1       
ICN	ICNP	-QS control sample	2017-09-08					G 	@1N?I     
ICN	ICNS	-	2017-09-08					X 	/1        
KLA 	KLA 	SENT TO KIESTRA	2017-09-06					X 	-JNH      
MLD1	MLDO	.{}	2017-09-08					X 	r/1       
MLD1	MLDS	.{}	2017-09-08					X 	/1        
FAEC	SAVD	This was a test sample for end-to-end testing.	2017-09-08					X 	N         
FAW2	SEL 	.{}	2017-09-08					X 	?r/2      
FAW2	XLD 	.{}	2017-09-08					X 	?r/1      
FAW1	CAM 	.l	2017-09-08					X 	?r/2      
CDIF	CDAP	.{}	2017-09-08					M 	Br?/1     
CDIF	CDCM	Entered in error.	2017-09-08	2017-09-08				M 	NA?r      
CDIF	CDIA	Cancelled - see comments	2017-09-08	2017-09-08				M 	NA?r      
CDIF	CDIF	CANCELLED	2017-09-08	2017-09-08				M 	HXp1p2AB?r
CDIF	CGDH	.{}	2017-09-08					M 	?r/1      
YER	CIN 	.	2017-09-08					X 	?r/2      
CDIF	CRQ7	No	2017-09-08					X 	N         
CDIF	CT14	No	2017-09-08					X 	N         
CDIF	CTOX	.{}	2017-09-08					M 	?r/1      
FAEC	FACA	Cancelled - see comments	2017-09-08	2017-09-08				M 	NA?       
FAEC	FACC	y	2017-09-08	2017-09-08				M 	?Ir/3     
FAEC	FAEA	.{}	2017-09-08					M 	?Br/1     
FAEC	FAEC	CANCELLED	2017-09-08	2017-09-08				M 	HXp1p2AB?r
FAEC	FAST	COMPLETE: 08/09/17	2017-09-08	2017-09-08				M 	?Ar/3     
FAEC	FCMT	Entered in error.	2017-09-08	2017-09-08				M 	N?A       
FAEC	FISO	.{}	2017-09-08					M 	M?/3B     
FAEC	FISR	.{}	2017-09-08					M 	?A/3      
ICN	ICNA	-	2017-09-08					X 	/1        
ICN	ICNN	APrince	2017-09-08					X 	?/1       
ICN	ICNP	QS Sample.	2017-09-08					G 	@1N?I     
ICN	ICNS	-	2017-09-08					X 	/1        
KLA 	KLA 	SENT TO KIESTRA	2017-09-06					X 	-JNH      
FAEC	SAVD	This was a test sample used for end-to-end
testing.	2017-09-08					X 	N         
FAW1	SEL 	.	2017-09-08					X 	?r/2      
SMA	SMA 	.	2017-09-08					X 	?r/1      
TCBS	TCBS	..	2017-09-08					X 	?r/2      
CSW2	BAN 	NG5	2017-09-22					X 	Nra?      
CSW2	BHI 	.{}	2017-09-22					X 	N?a       
CSFM	CDES	Clear Colourless Fluid	2017-09-20	2017-09-20				M 	?a        
CSFM	CGRM	No organisms seen.	2017-09-20	2017-09-20				M 	?Na       
CSW2	CHOC	NG2	2017-09-22					X 	N/2?ra    
CSFC	CISO	.{}	2017-09-22					M 	M/6?a     
CSFC	CPRE	No growth after 10 days.	2017-09-29	2017-09-29				M 	?ABNa/6   
CSFM	CRBC	3	2017-09-20	2017-09-20				M 	?/0a      
CSFC	CSFC	CSF CULTURE REPORT	2017-09-20	2017-09-20				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2017-09-20	2017-09-20				M 	Hp1p2AB?r 
CSFM	CSFV	<1ml in one bottle	2017-09-20	2017-09-20				M 	Na?       
CSFC	CSSC	y	2017-09-29	2017-09-29				M 	?Ir/6     
CSFC	CSST	COMPLETE: 29/09/17	2017-09-29	2017-09-29				M 	?Ar/6     
CSFM	CWBC	2	2017-09-20	2017-09-20				M 	r/0a      
KLA 	KLA 	SENT TO KIESTRA	2017-09-20					X 	-JNH      
CSFM	WBCS	Not numbered	2017-09-20	2017-09-20				M 	?NBra     
CSW1	BA  	NG2	2017-09-22					X 	Nra?      
BHI	BHI 	.	2017-09-22					X 	N?a       
CSFM	CDES	Bloodstained Fluid	2017-09-20	2017-09-20				M 	?a        
CSFM	CGRM	No organisms seen.	2017-09-20	2017-09-20				M 	?Na       
CSW1	CHOC	NG2	2017-09-22					X 	N/2?ra    
CSFC	CISO	.{}	2017-09-22					M 	M/6?a     
CSFC	CPRE	No growth after 2 days.	2017-09-22	2017-09-22				M 	?ABNa/6   
CSFM	CRBC	2684	2017-09-22	2017-09-22				M 	?/0a      
CSFC	CSFC	CSF CULTURE REPORT	2017-09-20	2017-09-20				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2017-09-20	2017-09-20				M 	Hp1p2AB?r 
CSFM	CSFV	<1ml in one bottle	2017-09-20	2017-09-20				M 	Na?       
CSFC	CSSC	y	2017-09-22	2017-09-22				M 	?Ir/6     
CSFC	CSST	COMPLETE: 22/09/17	2017-09-22	2017-09-22				M 	?Ar/6     
CSFM	CWBC	6	2017-09-20	2017-09-20				M 	r/0a      
CSFM	DIFA	2684	2017-09-20	2017-09-20				M 	?Na       
KLA 	KLA 	SENT TO KIESTRA	2017-09-20					X 	-JNH      
CSFM	WBCS	3	2017-09-20	2017-09-20				M 	?NBra     
67TF	67CP	Plates only	2017-09-20	2017-09-22				M 	HI-r?     
67PA	67D1	NG	2017-09-22					X 	H?NI-     
67PA	67D2	+/- mixed sf	2017-09-22					X 	H?NI-     
67TF	67PI	Choc, FAA and Cled	2017-09-22	2017-09-22				M 	HI-?      
FLUC	FCOM	y	2017-09-22	2017-09-22				M 	I?/3      
FLUC	FLUC	FLUID CULTURE REPORT	2017-09-20	2017-09-22				M 	HXp1p2A?r 
FLUC	FSTA	COMPLETE: 22/09/17	2017-09-22	2017-09-22				M 	?ABr/3    
KLA 	KLA 	SENT TO KIESTRA	2017-09-20					X 	-JNH      
FLUC	TISO	.{}	2017-09-22					M 	M?/4r     
FLUC	TPRE	No significant growth.	2017-09-22	2017-09-22				M 	?ANr/3    
68NR	67AC	Positive at 72 hours	2017-09-22					X 	?HNI-r    
67TF	67CP	Both BC bottles and Plates	2017-09-20	2017-09-20				M 	HI-r?     
68NR	67D1	NG	2017-09-22					X 	H?NI-     
68NR	67D2	NG	2017-09-22					X 	H?NI-     
68NR	67D3	+/- ?pseud on plates -> maldi and phx
Bottles also GNR - see primary	2017-09-22					X 	H?NI-     
68NR	67NC	NG5	2017-09-22	2017-09-22				E 	HNI-r?    
67TF	67PI	Choc, FAA and CLED	2017-09-22	2017-09-22				M 	HI-?      
AMSC	AMSC	Organisms sent 25/09/2017 08:57	2017-09-25					X 	J-        
AMSD	AMSD	PSEAER/	2017-09-25					X 	J-        
68NR	BCB1	41589654123	2017-09-22					X 	H-Jr?     
68NR	BCB2	59865447213	2017-09-22					X 	H-Jr?     
COSC	COSC	PSEAER/	2017-09-22					X 	J-        
COSD	COSD	Organisms sent 22/09/2017 17:45	2017-09-22					X 	J-        
FLUC	FCOM	y	2017-09-22	2017-09-22				M 	I?/3      
FLCR	FCRY	Intracellular sodium urate crystals seen.	2017-09-20	2017-09-20				M 	?/1       
FLUC	FLUC	FLUID CULTURE REPORT	2017-09-20	2017-09-20				M 	HXp1p2A?r 
FLCR	FLUM	FLUID MICROSCOPY REPORT	2017-09-20	2017-09-20				M 	HXp1p2ABr?
FLCR	FPUS	Scanty	2017-09-20	2017-09-20				M 	?/1       
FLUC	FSTA	COMPLETE: 22/09/17	2017-09-22	2017-09-22				M 	?ABr/3    
KLA 	KLA 	SENT TO KIESTRA	2017-09-20					X 	-JNH      
FLCR	ORGF	No organisms seen.	2017-09-20	2017-09-20				M 	?N/1      
FLUC	TISO	:	2017-09-22	2017-09-22				M 	M?/4r     
FLUC	TPRE	No growth after 2 days - cultures continuing.	2017-09-22	2017-09-22				M 	?ANr/3    
68NR	67AC	No Growth at 5 days	2017-09-22					X 	?HNI-r    
67TF	67CP	Both BC bottles and Plates	2017-09-20	2017-09-22				M 	HI-r?     
68NR	67D1	NG	2017-09-22					X 	H?NI-     
68NR	67D2	NG	2017-09-22					X 	H?NI-     
68NR	67D5	NG	2017-09-22					X 	H?NI-     
68NR	67NC	No Growth at 5 days	2017-09-22	2017-09-22				E 	HNI-r?    
67TF	67PI	FAA, Choc and CLED	2017-09-22	2017-09-22				M 	HI-?      
68NR	BCB1	15751327513	2017-09-22					X 	H-Jr?     
68NR	BCB2	45678643516	2017-09-22					X 	H-Jr?     
FLUC	FCOM	y	2017-09-22	2017-09-22				M 	I?/3      
FLCC	FDIF	50% Polymorphs : 50% Mononuclear	2017-09-20	2017-09-20				M 	N?/1      
FLUC	FLUC	FLUID CULTURE REPORT	2017-09-20	2017-09-22				M 	HXp1p2A?r 
FLCC	FLUM	FLUID MICROSCOPY REPORT	2017-09-20	2017-09-20				M 	HXp1p2ABr?
FLCC	FPUS	.{}	2017-09-22					M 	?/1       
FLCC	FRBC	20	2017-09-20	2017-09-20				M 	N/1       
FLUC	FSTA	COMPLETE: 22/09/17	2017-09-22	2017-09-22				M 	?ABr/3    
FLCC	FWBC	502	2017-09-20	2017-09-20				M 	?/1       
KLA 	KLA 	SENT TO KIESTRA	2017-09-20					X 	-JNH      
FLCC	ORGF	No organisms seen.	2017-09-20	2017-09-20				M 	?N/1      
FLUC	TISO	.{}	2017-09-22					M 	M?/4r     
FLUC	TPRE	No growth after 5 days.	2017-09-22	2017-09-22				M 	?ANr/3    
NNW2	67D1	+++ NLF - Pseud Gent : S	2017-09-25					X 	H?NI-     
NNWS	NISO	.{}	2017-09-25					M 	M?/3      
NNWS	NISP	Gentamicin-resistant coliforms NOT isolated.	2017-09-25	2017-09-25				M 	?N        
NNWS	NNCO	y	2017-09-25	2017-09-25				M 	?Ir/3     
NNWS	NNST	COMPLETE: 25/09/17	2017-09-25	2017-09-25				M 	?r/3      
NNWS	NNWS	SWAB CULTURE REPORT	2017-09-21	2017-09-25				M 	HXp1p2AB?r
NIES	67D1	choc/cled/ba = ng 22/09/17	2017-09-22					X 	H?NI-     
NIES	67D2	#1 maldi= p.aeruginosa 2.37 set up phx 27/09/17	2017-09-27					X 	H?NI-     
AMSC	AMSC	Organisms sent 29/09/2017 16:13	2017-09-29					X 	J-        
AMSD	AMSD	PSEAER/	2017-09-29					X 	J-        
COSC	COSC	PSEAER/	2017-09-29					X 	J-        
COSD	COSD	Organisms sent 29/09/2017 16:29	2017-09-29					X 	J-        
NNIS	NISO	:	2017-09-29	2017-09-29				M 	M?/3      
NNIS	NNCO	y	2017-09-29	2017-09-29				M 	?Ir/3     
NNIS	NNIS	NEONATAL SCREEN CULTURE REPORT	2017-09-21	2017-09-24				M 	HXp1p2A?r 
NNIS	NNST	COMPLETE: 29/09/17	2017-09-29	2017-09-29				M 	?r/3      
NNIS	NPRE	Culture under investigation.	2017-09-27					M 	?AN       
USPA	67SP	No growth	2017-09-22					X 	HI-?r     
KLA 	KLA 	SENT TO KIESTRA	2017-09-21					X 	-JNH      
URNM	UCAS	.{}	2017-09-21					M 	?Nr       
URNM	UEPC	Few	2017-09-21	2017-09-21				M 	?rN       
URNC	UISO	.{}	2017-09-22					M 	ABMr?/2aN 
URNC	UPRE	Screening culture negative.	2017-09-22	2017-09-22				M 	?ar       
URNM	URBC	Few	2017-09-21	2017-09-21				M 	?rN       
URNC	URCC	Y	2017-09-22	2017-09-22				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2017-09-21	2017-09-21				M 	Hp1p2AB?  
URNM	URNM	URINE MICROSCOPY REPORT	2017-09-21	2017-09-21				M 	HXp1p2AB? 
URNC	URST	COMPLETE: 22/09/17	2017-09-22	2017-09-22				M 	N?Ar/2    
URNM	UWBC	Moderate	2017-09-21	2017-09-21				M 	?r/0      
URNM	UYEA	Not seen	2017-09-21	2017-09-21				M 	?N        
UMPA	67UP	No significant growth	2017-09-22	2017-09-22				M 	HIJ-?r    
KLA 	KLA 	SENT TO KIESTRA	2017-09-21					X 	-JNH      
URNM	UCAS	.{}	2017-09-21					M 	?Nr       
URNM	UEPC	Not seen	2017-09-21	2017-09-21				M 	?rN       
URNC	UISO	.{}	2017-09-22					M 	ABMr?/2aN 
URNC	UPRE	No significant growth.	2017-09-22	2017-09-22				M 	?ar       
URNM	URBC	Not seen	2017-09-21	2017-09-21				M 	?rN       
URNC	URCC	Y	2017-09-22	2017-09-22				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2017-09-21	2017-09-21				M 	Hp1p2AB?  
URNM	URNM	URINE MICROSCOPY REPORT	2017-09-21	2017-09-21				M 	HXp1p2AB? 
URNC	URST	COMPLETE: 22/09/17	2017-09-22	2017-09-22				M 	N?Ar/2    
URNM	UWBC	Few	2017-09-21	2017-09-21				M 	?r/0      
URNM	UYEA	Not seen	2017-09-21	2017-09-21				M 	?N        
MPCP	PCP2	10^5	2018-03-26					X 	N?H-Jra   
MPCP	PCPC	Greater than 10^5 copies/mL of target detected
indicating Pneumocystis infection.	2018-03-26					M 	?N        
MPCP	PCPP	Positive	2018-03-26					M 	?r/4      
FLG	AO  	A1731	2018-01-25					X 	NJI       
FBCZ	BA  	 0.4%  0.03	2018-01-25	2018-01-25				A 	CDSN/0    
FBCZ	EO  	 2.2%  0.18	2018-01-25	2018-01-25				A 	CDSN/0    
FLG	FLG9	NRBC ?	2018-01-25	2018-01-25				A 	NJ-I?     
HBA	GHBE	.	2018-01-29					B 	NIJ-?     
HBA	GHBI	Cancelled - Duplicate request	2018-01-29	2018-01-30				B 	          
HBA	HBA 	Cancelled - Duplicate request	2018-01-29	2018-01-30				B 	          
FBCY	HBGL	139	2018-01-25	2018-01-25				A 	rCP/0     
FBCY	HCTU	0.472	2018-01-25	2018-01-25				A 	CPS/0     
FBCZ	IG  	.{}	2018-01-25					A 	SN/0      
FBCZ	IGP 	.{}	2018-01-25					A 	SN/0      
FBCZ	LY  	36.5%  3.00	2018-01-25	2018-01-25				A 	CDSP/0    
FBCY	MCGL	294	2018-01-25	2018-01-25				A 	CPS/0     
FBCY	MCHU	30.7	2018-01-25	2018-01-25				A 	CPS/0     
FBCY	MCVU	104.2	2018-01-25	2018-01-25				A 	CPS/0     
FBCZ	MO  	 7.3%  0.60	2018-01-25	2018-01-25				A 	CDS/0     
FBCY	MPVU	13.1	2018-01-25	2018-01-25				A 	CS?/0     
FBCZ	NE  	53.6%  4.41	2018-01-25	2018-01-25				A 	CDS/0     
FBCY	PLT 	250	2018-01-25	2018-01-25				A 	CS/0      
FBCY	RCC 	4.53	2018-01-25	2018-01-25				A 	P/0       
FBCY	RDWU	14.6	2018-01-25	2018-01-25				A 	CS/0      
FBCY	WCC 	8.22	2018-01-25	2018-01-25				A 	CWPS/0    
HBA	GHBI	31	2018-01-26	2018-01-26				B 	          
HBA	HBA 	5.0	2018-01-26	2018-01-26				B 	          
FBCY	HBGL	Request entered in error	2018-01-25	2018-01-25				A 	rCP/0     
FBCY	HCTU	Request entered in error	2018-01-25	2018-01-25				A 	CPS/0     
FBCZ	IG  	Request entered in error	2018-01-25	2018-01-25				A 	SN/0      
FBCZ	IGP 	Request entered in error	2018-01-25	2018-01-25				A 	SN/0      
FBCZ	LY  	Request entered in error	2018-01-25	2018-01-25				A 	CDSP/0    
FBCY	MCGL	Request entered in error	2018-01-25	2018-01-25				A 	CPS/0     
FBCY	MCHU	Request entered in error	2018-01-25	2018-01-25				A 	CPS/0     
FBCY	MCVU	Request entered in error	2018-01-25	2018-01-25				A 	CPS/0     
FBCZ	MO  	Request entered in error	2018-01-25	2018-01-25				A 	CDS/0     
FBCY	MPVU	Request entered in error	2018-01-25	2018-01-25				A 	CS?/0     
FBCZ	NE  	Request entered in error	2018-01-25	2018-01-25				A 	CDS/0     
FBCY	PLT 	Request entered in error	2018-01-25	2018-01-25				A 	CS/0      
FBCY	RCC 	Request entered in error	2018-01-25	2018-01-25				A 	P/0       
FBCY	RDWU	Request entered in error	2018-01-25	2018-01-25				A 	CS/0      
FBCY	WCC 	Cancelled - FBC Request entered in error	2018-01-25	2018-01-25				A 	CWPS/0    
FLG	AO  	A1658	2018-03-08					X 	NJI       
FBCZ	BA  	 0.4%  0.03	2018-03-08	2018-03-08				A 	CDSN/0    
FBCZ	EO  	 3.0%  0.22	2018-03-08	2018-03-08				A 	CDSN/0    
HBA	GHBI	Cancelled - see comments	2018-03-08	2018-03-08				B 	          
HBA	HBA 	Cancelled - see comments	2018-03-08	2018-03-08				B 	          
FBCY	HBGL	134	2018-03-08	2018-03-08				A 	rCP/0     
FBCY	HCTU	0.408	2018-03-08	2018-03-08				A 	CPS/0     
FBCZ	IG  	.{}	2018-03-08					A 	SN/0      
FBCZ	IGP 	.{}	2018-03-08					A 	SN/0      
FBCZ	LY  	30.3%  2.22	2018-03-08	2018-03-08				A 	CDSP/0    
FBCY	MCGL	328	2018-03-08	2018-03-08				A 	CPS/0     
FBCY	MCHU	29.8	2018-03-08	2018-03-08				A 	CPS/0     
FBCY	MCVU	90.7	2018-03-08	2018-03-08				A 	CPS/0     
FBCZ	MO  	 4.4%  0.32	2018-03-08	2018-03-08				A 	CDS/0     
FBCY	MPVU	10.4	2018-03-08	2018-03-08				A 	CS?/0     
FBCZ	NE  	61.9%  4.53	2018-03-08	2018-03-08				A 	CDS/0     
FBCY	PLT 	282	2018-03-08	2018-03-08				A 	CS/0      
FBCY	RCC 	4.50	2018-03-08	2018-03-08				A 	P/0       
FBCY	RDWU	14.7	2018-03-08	2018-03-08				A 	CS/0      
FBCY	WCC 	7.32	2018-03-08	2018-03-08				A 	CWPS/0    
LFT	ALB 	43	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	51	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	58	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	86	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	3	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.19	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.24	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	3.1	2018-05-02	2018-05-02				B 	          
LPF	CHOL	2.5	2018-05-02	2018-05-02				B 	PA        
CK	CK  	59	2018-05-02	2018-05-02				B 	          
ELU	CREA	50	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	<0.6	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	49	2018-05-02	2018-05-02				B 	          
ELU	FACR	2.09	2018-05-02					X 	N         
IRON	FE  	8.1	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	13.4	2018-05-02	2018-05-02				B 	Cr        
ELU	GFR 	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2018-05-02	2018-05-02				B 	          
GT	GGT 	36	2018-05-02	2018-05-02				B 	C         
LFT	H   	0	2018-05-02					  	JNr       
BIC	HCO3	27	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	<0.3	2018-05-02	2018-05-02				B 	          
LPF	HDL 	0.8	2018-05-02	2018-05-02				B 	          
LFT	I   	6	2018-05-02					  	JN        
IRON	IBS 	18	2018-05-02	2018-05-02				B 	B         
ELU	K   	3.6	2018-05-02	2018-05-02				B 	CP        
LFT	L   	26	2018-05-02					  	JN        
LD	LDH 	231	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	0.7	2018-05-02	2018-05-02				B 	          
MG	MG  	0.85	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	145	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	1.7	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.03	2018-05-02	2018-05-02				B 	CP        
ELU	SEX 	1.0	2018-05-02					X 	N         
IRON	TIBC	46	2018-05-02	2018-05-02				B 	          
LPF	TRIG	2.2	2018-05-02	2018-05-02				B 	P         
THY	TSH 	1.22	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	38.2	2018-05-02	2018-05-02				B 	          
ELU	UREA	3.1	2018-05-02	2018-05-02				B 	CP        
ELU	ZAGE	30	2018-05-02					X 	          
LFT	ALB 	38	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	102	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	22	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	65	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	3	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.25	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.39	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	3.2	2018-05-02	2018-05-02				B 	          
LPF	CHOL	8.6
Cholesterol > 8 mmol/L. If secondary causes
excluded, consider inherited dyslipidaemia
e.g. familial hypercholesterolaemia or combined
hyperlipidaemia. Please contact
catherine.lunken@uclh.nhs.uk for advice.	2018-05-02	2018-05-02				B 	PA        
CK	CK  	24	2018-05-02	2018-05-02				B 	          
ELU	CREA	34	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	0.8	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	35	2018-05-02	2018-05-02				B 	          
THY	DBRV	To be reviewed by Duty Biochemist	2018-05-02	2018-05-02				B 	NIJ       
IRON	FE  	10.6	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	15.9	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	10	2018-05-02	2018-05-02				B 	C         
LFT	H   	1	2018-05-02					  	JNr       
BIC	HCO3	24	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	0.8	2018-05-02	2018-05-02				B 	          
LPF	HDL 	2.7	2018-05-02	2018-05-02				B 	          
LFT	I   	21	2018-05-02					  	JN        
IRON	IBS 	12	2018-05-02	2018-05-02				B 	B         
ELU	K   	3.7	2018-05-02	2018-05-02				B 	CP        
LFT	L   	9	2018-05-02					  	JN        
LD	LDH 	203	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	4.9	2018-05-02	2018-05-02				B 	          
MG	MG  	0.77	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	136	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	5.9	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.04	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	87	2018-05-02	2018-05-02				B 	          
LPF	TRIG	2.3	2018-05-02	2018-05-02				B 	P         
THY	TSH 	1.24	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	76.0	2018-05-02	2018-05-02				B 	          
ELU	UREA	2.5	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	35	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	53	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	10	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	183	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	3	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.11	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.31	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	2.4	2018-05-02	2018-05-02				B 	          
LPF	CHOL	2.9	2018-05-02	2018-05-02				B 	PA        
CK	CK  	340	2018-05-02	2018-05-02				B 	          
ELU	CREA	86	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	9.8	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	85	2018-05-02	2018-05-02				B 	          
IRON	FE  	6.4	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	22.3	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	15	2018-05-02	2018-05-02				B 	C         
LFT	H   	7	2018-05-02					  	JNr       
BIC	HCO3	21	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	9.7	2018-05-02	2018-05-02				B 	          
LPF	HDL 	1.2	2018-05-02	2018-05-02				B 	          
LFT	I   	5	2018-05-02					  	JN        
IRON	IBS 	27	2018-05-02	2018-05-02				B 	B         
ELU	K   	3.9	2018-05-02	2018-05-02				B 	CP        
LFT	L   	12	2018-05-02					  	JN        
LD	LDH 	214	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	1.0	2018-05-02	2018-05-02				B 	          
MG	MG  	0.83	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	144	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	1.7	2018-05-02	2018-05-02				B 	r         
BON	PHOS	0.59	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	24	2018-05-02	2018-05-02				B 	          
LPF	TRIG	1.6	2018-05-02	2018-05-02				B 	P         
THY	TSH 	1.37	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	18.0	2018-05-02	2018-05-02				B 	          
ELU	UREA	3.2	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	50	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	63	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	33	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	40	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	8	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.47	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.39	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	4.7	2018-05-02	2018-05-02				B 	          
LPF	CHOL	5.6	2018-05-02	2018-05-02				B 	PA        
CK	CK  	344	2018-05-02	2018-05-02				B 	          
ELU	CREA	78	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	0.7	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	75	2018-05-02	2018-05-02				B 	          
IRON	FE  	14.0	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	19.1	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	30	2018-05-02	2018-05-02				B 	C         
LFT	H   	3	2018-05-02					  	JNr       
BIC	HCO3	30	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	0.6	2018-05-02	2018-05-02				B 	          
LPF	HDL 	1.2	2018-05-02	2018-05-02				B 	          
LFT	I   	14	2018-05-02					  	JN        
IRON	IBS 	20	2018-05-02	2018-05-02				B 	B         
ELU	K   	3.8	2018-05-02	2018-05-02				B 	CP        
LFT	L   	20	2018-05-02					  	JN        
LD	LDH 	204	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	3.2	2018-05-02	2018-05-02				B 	          
MG	MG  	0.78	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	143	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	4.4	2018-05-02	2018-05-02				B 	r         
BON	PHOS	0.93	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	69	2018-05-02	2018-05-02				B 	          
LPF	TRIG	2.6	2018-05-02	2018-05-02				B 	P         
THY	TSH 	4.00	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	54.7	2018-05-02	2018-05-02				B 	          
ELU	UREA	7.2	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	50	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	61	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	13	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	96	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	28	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.48	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.40	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	3.6	2018-05-02	2018-05-02				B 	          
LPF	CHOL	4.7	2018-05-02	2018-05-02				B 	PA        
CK	CK  	317	2018-05-02	2018-05-02				B 	          
ELU	CREA	85	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	<0.6	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	82	2018-05-02	2018-05-02				B 	          
IRON	FE  	8.9	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	22.5	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	11	2018-05-02	2018-05-02				B 	C         
LFT	H   	0	2018-05-02					  	JNr       
BIC	HCO3	25	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	0.3	2018-05-02	2018-05-02				B 	          
LPF	HDL 	1.3	2018-05-02	2018-05-02				B 	          
LFT	I   	41	2018-05-02					  	JN        
IRON	IBS 	12	2018-05-02	2018-05-02				B 	B         
ELU	K   	3.8	2018-05-02	2018-05-02				B 	CP        
LFT	L   	9	2018-05-02					  	JN        
LD	LDH 	184	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	3.1	2018-05-02	2018-05-02				B 	          
MG	MG  	0.86	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	139	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	3.4	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.26	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	72	2018-05-02	2018-05-02				B 	          
LPF	TRIG	0.7	2018-05-02	2018-05-02				B 	P         
THY	TSH 	1.05	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	63.3	2018-05-02	2018-05-02				B 	          
ELU	UREA	5.0	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	34	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	411	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	27	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	76	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	6	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.71	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.93	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	9.7	2018-05-02	2018-05-02				B 	          
LPF	CHOL	2.9	2018-05-02	2018-05-02				B 	PA        
CK	CK  	22	2018-05-02	2018-05-02				B 	          
ELU	CREA	152	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	35.1	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	151	2018-05-02	2018-05-02				B 	          
THY	DBRV	To be reviewed by Duty Biochemist	2018-05-02	2018-05-02				B 	NIJ       
IRON	FE  	4.3	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	16.5	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	233	2018-05-02	2018-05-02				B 	C         
LFT	H   	14	2018-05-02					  	JNr       
BIC	HCO3	25	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	44.3	2018-05-02	2018-05-02				B 	          
LPF	HDL 	0.3	2018-05-02	2018-05-02				B 	          
LFT	I   	11	2018-05-02					  	JN        
IRON	IBS 	8	2018-05-02	2018-05-02				B 	B         
ELU	K   	4.7	2018-05-02	2018-05-02				B 	CP        
LFT	L   	56	2018-05-02					  	JN        
LD	LDH 	259	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	0.6	2018-05-02	2018-05-02				B 	          
MG	MG  	0.95	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	137	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	2.6	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.60	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	52	2018-05-02	2018-05-02				B 	          
LPF	TRIG	4.4	2018-05-02	2018-05-02				B 	P         
THY	TSH 	3.12	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	47.2	2018-05-02	2018-05-02				B 	          
ELU	UREA	6.4	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	27	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	250	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	14	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	13	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	5	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.11	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.46	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	13.0	2018-05-02	2018-05-02				B 	          
LPF	CHOL	2.6	2018-05-02	2018-05-02				B 	PA        
CK	CK  	23	2018-05-02	2018-05-02				B 	          
ELU	CREA	66	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	416.0	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	59	2018-05-02	2018-05-02				B 	          
IRON	FE  	3.4	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	23.7	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	130	2018-05-02	2018-05-02				B 	C         
LFT	H   	25	2018-05-02					  	JNr       
BIC	HCO3	22	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	606.62	2018-05-03	2018-05-03				B 	          
LPF	HDL 	0.2	2018-05-02	2018-05-02				B 	          
LFT	I   	6	2018-05-02					  	JN        
IRON	IBS 	15	2018-05-02	2018-05-02				B 	B         
ELU	K   	4.6	2018-05-02	2018-05-02				B 	CP        
LFT	L   	7	2018-05-02					  	JN        
LD	LDH 	338	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	1.7	2018-05-02	2018-05-02				B 	          
MG	MG  	0.76	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	142	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	2.4	2018-05-02	2018-05-02				B 	r         
BON	PHOS	2.00	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	22	2018-05-02	2018-05-02				B 	          
LPF	TRIG	1.5	2018-05-02	2018-05-02				B 	P         
THY	TSH 	1.43	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	18.3	2018-05-02	2018-05-02				B 	          
ELU	UREA	6.1	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	40	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	70	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	15	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	99	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	3	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.51	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.62	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	4.3	2018-05-02	2018-05-02				B 	          
LPF	CHOL	5.2	2018-05-02	2018-05-02				B 	PA        
CK	CK  	33	2018-05-02	2018-05-02				B 	          
ELU	CREA	56	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	1.3	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	49	2018-05-02	2018-05-02				B 	          
IRON	FE  	7.7	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	14.8	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	18	2018-05-02	2018-05-02				B 	C         
LFT	H   	18	2018-05-02					  	JNr       
BIC	HCO3	28	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	1.1	2018-05-02	2018-05-02				B 	          
LPF	HDL 	1.2	2018-05-02	2018-05-02				B 	          
LFT	I   	10	2018-05-02					  	JN        
IRON	IBS 	12	2018-05-02	2018-05-02				B 	B         
ELU	K   	4.3	2018-05-02	2018-05-02				B 	CP        
LFT	L   	8	2018-05-02					  	JN        
LD	LDH 	150	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	3.4	2018-05-02	2018-05-02				B 	          
MG	MG  	0.82	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	141	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	4.0	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.20	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	62	2018-05-02	2018-05-02				B 	          
LPF	TRIG	1.4	2018-05-02	2018-05-02				B 	P         
THY	TSH 	0.96	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	54.3	2018-05-02	2018-05-02				B 	          
ELU	UREA	3.3	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	44	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	126	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	11	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	59	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	4	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.31	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.34	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	6.2	2018-05-02	2018-05-02				B 	          
LPF	CHOL	3.7	2018-05-02	2018-05-02				B 	PA        
CK	CK  	51	2018-05-02	2018-05-02				B 	          
ELU	CREA	68	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	11.6	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	68	2018-05-02	2018-05-02				B 	          
IRON	FE  	9.3	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	20.2	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	32	2018-05-02	2018-05-02				B 	C         
LFT	H   	5	2018-05-02					  	JNr       
BIC	HCO3	30	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	10.3	2018-05-02	2018-05-02				B 	          
LPF	HDL 	0.6	2018-05-02	2018-05-02				B 	          
LFT	I   	10	2018-05-02					  	JN        
IRON	IBS 	18	2018-05-02	2018-05-02				B 	B         
ELU	K   	4.1	2018-05-02	2018-05-02				B 	CP        
LFT	L   	12	2018-05-02					  	JN        
LD	LDH 	430	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	2.1	2018-05-02	2018-05-02				B 	          
MG	MG  	0.93	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	143	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	3.1	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.21	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	52	2018-05-02	2018-05-02				B 	          
LPF	TRIG	2.1	2018-05-02	2018-05-02				B 	P         
THY	TSH 	1.57	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	43.1	2018-05-02	2018-05-02				B 	          
ELU	UREA	5.9	2018-05-02	2018-05-02				B 	CP        
LFT	ALB 	35	2018-05-02	2018-05-02				B 	CP        
LFT	ALP 	69	2018-05-02	2018-05-02				B 	C         
LFT	ALT 	11	2018-05-02	2018-05-02				B 	C         
AMY	AMY 	47	2018-05-02	2018-05-02				B 	AB        
LFT	BILI	8	2018-05-02	2018-05-02				B 	CPr       
BON	CA  	2.29	2018-05-02	2018-05-02				B 	CP        
BON	CCA 	2.49	2018-05-02	2018-05-02				B 	C         
LPF	CHDR	2.8	2018-05-02	2018-05-02				B 	          
LPF	CHOL	4.2	2018-05-02	2018-05-02				B 	PA        
CK	CK  	170	2018-05-02	2018-05-02				B 	          
ELU	CREA	84	2018-05-02	2018-05-02				B 	CPr       
CRP 	CRP 	72.8	2018-05-02	2018-05-02				B 	AB        
CRQ	CRQ 	82	2018-05-02	2018-05-02				B 	          
IRON	FE  	5.9	2018-05-02	2018-05-02				B 	CPA       
THY	FT4 	15.4	2018-05-02	2018-05-02				B 	Cr        
GT	GGT 	36	2018-05-02	2018-05-02				B 	C         
LFT	H   	0	2018-05-02					  	JNr       
BIC	HCO3	26	2018-05-02	2018-05-02				B 	CP        
CRPS	HCRP	92.1	2018-05-02	2018-05-02				B 	          
LPF	HDL 	1.5	2018-05-02	2018-05-02				B 	          
LFT	I   	12	2018-05-02					  	JN        
IRON	IBS 	13	2018-05-02	2018-05-02				B 	B         
ELU	K   	4.5	2018-05-02	2018-05-02				B 	CP        
LFT	L   	8	2018-05-02					  	JN        
LD	LDH 	231	2018-05-02	2018-05-02				B 	C         
LPF	LDLU	2.2	2018-05-02	2018-05-02				B 	          
MG	MG  	0.63	2018-05-02	2018-05-02				B 	CP        
ELU	NA  	136	2018-05-02	2018-05-02				B 	CP        
LPF	NHDL	2.7	2018-05-02	2018-05-02				B 	r         
BON	PHOS	1.18	2018-05-02	2018-05-02				B 	CP        
IRON	TIBC	46	2018-05-02	2018-05-02				B 	          
LPF	TRIG	1.2	2018-05-02	2018-05-02				B 	P         
THY	TSH 	0.79	2018-05-02	2018-05-02				B 	Cr        
IRON	UIBC	40.2	2018-05-02	2018-05-02				B 	          
ELU	UREA	4.3	2018-05-02	2018-05-02				B 	CP        
BON	ALB 	27	2018-05-03	2018-05-03				B 	CP        
BON	ALP 	167	2018-05-03	2018-05-03				B 	C         
AMY	AMY 	194	2018-05-03	2018-05-03				B 	AB        
AST	AST 	105	2018-05-03	2018-05-03				B 	C         
BON	CA  	1.91	2018-05-03	2018-05-03				B 	CP        
CBIL	CBIL	<2	2018-05-03	2018-05-03				B 	          
BON	CCA 	2.26	2018-05-03	2018-05-03				B 	C         
CK	CK  	109	2018-05-03	2018-05-03				B 	          
CL	CL  	97	2018-05-03	2018-05-03				B 	CP        
CRQ	CRQ 	42	2018-05-08	2018-05-08	umol/L    			B 	          
BON	H   	2	2018-05-03					  	JNr       
BIC	HCO3	23	2018-05-03	2018-05-03				B 	CP        
CRPS	HCRP	126.7	2018-05-08	2018-05-08	mg/L      			B 	          
BON	I   	2	2018-05-03					  	JN        
BON	L   	13	2018-05-03					  	JN        
BON	PHOS	1.74	2018-05-03	2018-05-03				B 	CP        
LFT	ALB 	38	2018-05-03	2018-05-03				B 	CP        
LFT	ALP 	62	2018-05-03	2018-05-03				B 	C         
LFT	ALT 	20	2018-05-03	2018-05-03				B 	C         
LFT	BILI	5	2018-05-03	2018-05-03				B 	CPr       
LPF	CHDR	1.8	2018-05-03	2018-05-03				B 	          
LPF	CHOL	3.6	2018-05-03	2018-05-03				B 	PA        
ELU	CREA	71	2018-05-03	2018-05-03				B 	CPr       
IRON	FE  	4.3	2018-05-03	2018-05-03				B 	CPA       
GT	GGT 	12	2018-05-03	2018-05-03				B 	C         
LFT	H   	5	2018-05-03					  	JNr       
LPF	HDL 	2.0	2018-05-03	2018-05-03				B 	          
LFT	I   	9	2018-05-03					  	JN        
IRON	IBS 	6	2018-05-03	2018-05-03				B 	B         
ELU	K   	5.7	2018-05-03	2018-05-03				B 	CP        
LFT	L   	8	2018-05-03					  	JN        
LD	LDH 	210	2018-05-03	2018-05-03				B 	C         
LPF	LDLU	1.4	2018-05-03	2018-05-03				B 	          
MG	MG  	0.88	2018-05-03	2018-05-03				B 	CP        
ELU	NA  	138	2018-05-03	2018-05-03				B 	CP        
LPF	NHDL	1.6	2018-05-03	2018-05-03				B 	r         
TP	PROT	59	2018-05-03	2018-05-03				B 	CP        
IRON	TIBC	77	2018-05-03	2018-05-03				B 	          
LPF	TRIG	0.5	2018-05-03	2018-05-03				B 	P         
UA	UA  	196	2018-05-03	2018-05-03				B 	CP        
IRON	UIBC	72.2	2018-05-03	2018-05-03				B 	          
ELU	UREA	4.4	2018-05-03	2018-05-03				B 	CP        
PHT	ALB 	32	2018-05-03	2018-05-03				B 	CP        
AMIK	AMII	ADULTS:.....Pre-dose <10 mg/L
............Post-dose 20-30 mg/L
For further advice, please discuss with a micro-
biologist/ward pharmacist. The amikacin dosing
algorithms can be found in Inform (UCLH Online
Formulary).	2018-05-08	2018-05-08	          			B 	          
AMIK	AMIK	<0.8	2018-05-08	2018-05-08	mg/L      			B 	          
CBZ	CARM	<2	2018-05-03	2018-05-03				B 	          
GENT	GENI	ADULTS/CHILDREN:
7 mg/kg dose: Refer to Hartford nomogram
1-1.5 mg/kg dose:........Pre-dose: <2 mg/L
.........................Post-dose: 5-10 mg/L
Endocarditis (1 mg/kg):..Pre-dose: <1 mg/L
.........................Post-dose: 3-5 mg/L
NEONATES:................Pre-dose: <2 mg/L
For further advice, please discuss with a micro-
biologist/ward pharmacist. The gentamicin dosing
algorithms can be found in Inform (UCLH Online
Formulary).	2018-05-08	2018-05-08	          			B 	?         
GENT	GENT	<0.2	2018-05-08	2018-05-08	mg/L      			B 	r         
AMIK	H   	2	2018-05-03					  	JNr       
AMIK	I   	6	2018-05-03					  	JN        
AMIK	L   	7	2018-05-03					  	JN        
LI	LITH	<0.05	2018-05-03	2018-05-03				B 	          
MTX	MTX 	<0.04
(<0.1 after 48 hrs)	2018-05-08	2018-05-08	umol/L    			B 	A$        
PHT	PHEM	1	2018-05-08	2018-05-08	mg/L      			B 	          
PCET	PMOL	Not Detected	2018-05-08	2018-05-08	mg/L      			B 	          
SAL	SALY	Not Detected	2018-05-03	2018-05-03				B 	          
THEO	THEM	2.0	2018-05-08	2018-05-08	mg/L      			B 	          
VPA	VALM	<3
Therapeutic efficacy may be achievable at
concentrations lower than the therapeutic
reference range.	2018-05-08	2018-05-08	mg/L      			B 	          
VANC	VANC	<1.5	2018-05-03	2018-05-03				B 	          
VANC	VANI	Pre-dose: 10-15 mg/L
For further advice, please discuss with a micro-
biologist/ward pharmacist. The vancomycin dosing
algorithms can be found in Inform (UCLH Online
Formulary).	2018-05-03	2018-05-03				B 	          
ETH	ETHN	<100
For guidance the driving limit is <800 mg/L
Please note change of units effective 30/06/15	2018-05-03	2018-05-03				B 	?         
GLU	GLU 	4.4
Reference range applies to fasting samples only.	2018-05-03	2018-05-03				B 	AB        
LAC	LACT	1.56	2018-05-03	2018-05-03				B 	          
AMM	AMMO	574	2018-05-03	2018-05-03				B 	AB        
UCAL	CACR	0.97	2018-05-03	2018-05-03				B 	QN        
UCAL	CAX 	Not calculated. Random urine specimen received	2018-05-03	2018-05-03				B 	QN        
UURA	UACR	593	2018-05-03	2018-05-03				B 	rN        
UALB	UALB	12	2018-05-03	2018-05-03				B 	          
UAMY	UAMY	101	2018-05-03	2018-05-03				B 	A         
UCAL	UCA9	4.66	2018-05-03	2018-05-03				B 	P         
UCL	UCL 	77	2018-05-03	2018-05-03				B 	AS        
UPRT	UCR 	4803	2018-05-03	2018-05-03				B 	          
UUEL	UK  	25	2018-05-03	2018-05-03				B 	P         
UALB	UMA 	2.50	2018-05-03	2018-05-03				B 	S         
UMG	UMAG	2.2	2018-05-03	2018-05-03				B 	P         
UUEL	UNA 	65	2018-05-03	2018-05-03				B 	PS        
UPO4	UP  	<1.1	2018-05-03	2018-05-03				B 	P         
UURA	UUAM	2.85	2018-05-03	2018-05-03				B 	rP        
UURE	UUU 	81.8	2018-05-03	2018-05-03				B 	P         
CORT	CORT	434
Reference range 6-10 am: 133 - 537 nmol/L	2018-05-03	2018-05-03				B 	          
DIG	DIGM	0.2
Target range 0.5 - 1.0 ug/L in heart failure
Note change in reference range effective 01/02/16.	2018-05-03	2018-05-03				B 	          
THY	FT4 	15.7	2018-05-03	2018-05-03				B 	Cr        
TPT	H   	2	2018-05-03					  	JNr       
HCG	HCG 	1.1	2018-05-08	2018-05-08	IU/L      			B 	          
TPT	HTRT	49	2018-05-03	2018-05-03				B 	          
TPT	I   	6	2018-05-03					  	JN        
TPT	L   	8	2018-05-03					  	JN        
THY	TSH 	3.47	2018-05-03	2018-05-03				B 	Cr        
FALB	FALB	<2
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FAMY	FAMY	101
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FCHO	FCHO	0.0
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FELU	FCR 	4688
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-08	2018-05-08	umol/L    			B 	r         
FTP	FH  	0	2018-05-03					  	JNr       
FTP	FI  	3	2018-05-03					  	JN        
FELU	FK  	24.8
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FTP	FL  	4	2018-05-03					  	JN        
FLDH	FLDH	78
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FELU	FNA 	65
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FTB	FTB 	4
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FTG	FTG 	0.1
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FTP	FTP 	6
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-03	2018-05-03				B 	r         
FELU	FU  	76.1
NOTE: this assay has been validated for serum but
not fluid.Interpret with caution.	2018-05-08	2018-05-08	mmol/L    			B 	r         
UHCG	UHCG	Cancelled - see comments	2018-01-25	2018-01-26				B 	?         
UPHM	UPHM	Cancelled - see comments	2018-01-25	2018-01-26				B 	          
SPCO	SPCO	Cancelled - Unlabelled specimen received.
Not processed.	2018-03-20	2018-03-20				B 	          
UTMA	FTMC	99	2018-04-25	2018-04-25				B 	r         
UTMA	PNOX	90
Results from Sheffield Children''s Hospital	2018-04-25	2018-04-25				B 	r         
UTMA	SEND	.	2018-04-25					B 	I?J       
URCP	UCP 	5.00	2018-04-25	2018-04-25				B 	r         
URCP	URCR	10.00
For advice and interpretation please visit
diabetesgenes.org/content/
urine-c-peptide-creatinine-ratio
Result from Royal Devon & Exeter	2018-04-25	2018-04-25				B 	r         
UTMA	UTMO	120.0	2018-04-25	2018-04-25				B 	r         
UTMA	UTMT		1899-12-30					B 	TAr       
FLG	AO  		1899-12-30					X 	NJI       
FBCZ	BA  		1899-12-30					A 	CDSN/0    
FBCZ	BLAA		1899-12-30					A 	DSN       
FBCZ	EO  		1899-12-30					A 	CDSN/0    
FBCY	FBCU		1899-12-30					A 	TH        
FBCX	FBCX	Request entered in error	2018-04-06					X 	I         
FBCZ	FCOM		1899-12-30					A 	K?Nr      
FLG	FLG1		1899-12-30					A 	NJ-I?     
FLG	FLG2		1899-12-30					A 	NJ-I?     
FLG	FLG4		1899-12-30					A 	NJ-I?     
FLG	FLG7		1899-12-30					A 	NJ-I?     
FLG	FLG9		1899-12-30					A 	NJ-I?     
FBCY	HBGL	Request entered in error	2018-04-06	2018-04-06				A 	rCP/0     
FBCY	HCTU	Request entered in error	2018-04-06	2018-04-06				A 	CPS/0     
FBCZ	IG  	Request entered in error	2018-04-06	2018-04-06				A 	SN/0      
FBCZ	IGP 	Request entered in error	2018-04-06	2018-04-06				A 	SN/0      
FBCZ	LY  	Request entered in error	2018-04-06	2018-04-06				A 	CDSP/0    
FBCY	MCGL	Request entered in error	2018-04-06	2018-04-06				A 	CPS/0     
FBCY	MCHU	Request entered in error	2018-04-06	2018-04-06				A 	CPS/0     
FBCY	MCVU	Request entered in error	2018-04-06	2018-04-06				A 	CPS/0     
FBCZ	MET 		1899-12-30					A 	DSN       
FBCZ	MO  	Request entered in error	2018-04-06	2018-04-06				A 	CDS/0     
FBCY	MPVU	Request entered in error	2018-04-06	2018-04-06				A 	CS?/0     
FBCZ	MYEA		1899-12-30					A 	DSN       
FBCZ	NE  	Request entered in error	2018-04-06	2018-04-06				A 	CDS/0     
FBCY	NRB 		1899-12-30					A 	SND       
FBCY	PLT 	Request entered in error	2018-04-06	2018-04-06				A 	CS/0      
FBCZ	PROA		1899-12-30					A 	DSN       
FBCY	RAKH		1899-12-30					X 	NJ        
FBCY	RCC 	Request entered in error	2018-04-06	2018-04-06				A 	P/0       
FBCY	RDWU	Request entered in error	2018-04-06	2018-04-06				A 	CS/0      
FBCY	WCC 	Cancelled - FBC Request entered in error	2018-04-06	2018-04-06				A 	CWPS/0    
MGW1	GC  	.	2018-01-26					X 	I/2?      
MGC	MGCO	y	2018-01-26	2018-01-26				M 	I?/3      
MGC	MGIS	.{}	2018-01-26					M 	M/3       
MGC	MGPR	No Growth	2018-01-26	2018-01-26				M 	?N        
MGC	MGST	COMPLETE: 26/01/18	2018-01-26	2018-01-26				M 	Ar?/3     
MGM	ORGK	No organisms seen.	2018-01-25	2018-01-25				M 	?N/1      
MGM	WBCK	Not seen	2018-01-25	2018-01-25				M 	?/0       
XYZA	XYZ1	4.0	2016-10-25	2016-10-25				B 	          
XYZA	XYZ2	140	2016-10-25	2016-10-25				B 	          
XYZA	XYZ3	4	2016-10-25	2016-10-25				B 	          
XYZA	XYZ1	.{.}	2017-10-26					B 	          
XYZA	XYZ2	.{.}	2017-10-26					B 	          
XYZA	XYZ3	.{..}	2017-10-26					B 	          
XYZA	XYZ1	4.5	2016-11-02	2016-11-02				B 	          
XYZA	XYZ2	140	2016-11-02	2016-11-02				B 	          
XYZA	XYZ3	5	2016-11-02	2016-11-02				B 	          
XYZB	XYZ4	10.0	2016-11-03	2016-11-03				B 	          
HSVS	HV10	Not Detected	2017-12-13	2017-12-13				H 	?/2       
HSVS	HV20	Not Detected	2017-12-13	2017-12-13				H 	?/2       
HIVL	2VL	Please note that this test is validated for
EDTA/EDTA plama samples only. Results from samples
other than EDTA/EDTA plasma should be interpreted
with caution. Please send repeat if clinically
indicated.	2015-02-17	2015-02-17				H 	NA?       
HIVL	HVL1	.	2015-02-17		opies/ml			H 	HAr?/5    
HIVL	HVL2	.	2015-02-17					H 	?r/5      
HIVL	HVLS	.	2015-02-17					H 	?rB/5     
ACAP	ACAP	TESTING	2015-02-17	2015-02-17				P 	?NAhm     
KLA	KLA	SENT TO KIESTRA	2015-02-17					X 	-JNH      
AMSC	AMSC	Organisms sent 05/07/2017 12:06	2017-07-05					X 	J-        
AMSD	AMSD	ESCCOL/	2017-07-05					X 	J-        
COSC	COSC	ESCCOL/	2017-07-05					X 	J-        
COSD	COSD	Organisms sent 05/07/2017 12:05	2017-07-05					X 	J-        
KLA 	KLA 	SENT TO KIESTRA	2017-07-04					X 	-JNH      
URNC	UISO	:	2017-07-05	2017-07-05				M 	ABMr?/2aN 
URNC	UPRE	.{}	2017-07-04					M 	?ar       
URNC	URCC	y	2017-07-04	2017-07-05				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2017-07-04	2017-07-05				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 04/07/17	2017-07-04	2017-07-05				M 	N?Ar/2    
URNW	UWN1	Test patient for Bruce	2017-07-04	2017-07-05				M 	NIa?      
VTK	VTK 	Sent to Vitek 04/07/2017 17:13	2017-07-04					X 	JaN       
BON	ALB 	40	2016-11-03	2016-11-04				B 	CP        
BON	ALP 	100	2016-11-03	2016-11-04				B 	C         
BON	CA  	2.40	2016-11-03	2016-11-04				B 	CP        
BON	CCA 	2.51	2016-11-03	2016-11-04				B 	C         
ELU	CREA	50	2016-11-03	2016-11-04				B 	CPr       
ELU	FACR	2.09	2016-11-04					X 	N         
ELU	GFR 	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-11-04	2016-11-04				B 	          
ELU	K   	3.6	2016-11-03	2016-11-04				B 	CP        
ELU	NA  	140	2016-11-03	2016-11-04				B 	CP        
BON	PHOS	0.90	2016-11-03	2016-11-04				B 	CP        
ELU	SEX 	0.742	2016-11-04					X 	N         
ELU	UREA	2.0	2016-11-03	2016-11-04				B 	CP        
ELU	ZAGE	26	2016-11-03					X 	          
XYZA	XYZ1	4	2018-01-31	2018-01-31				B 	          
XYZA	XYZ2	140	2018-01-31	2018-01-31				B 	          
XYZA	XYZ3	4.1	2018-01-31	2018-01-31				B 	          
XYZA	XYZ1	4	2018-02-07	2018-02-07				B 	          
XYZA	XYZ2	140	2018-02-07	2018-02-07				B 	          
XYZA	XYZ3	5	2018-02-07	2018-02-07				B 	          
XYZA	XYZ1	4.0	2018-02-16	2018-02-16				B 	          
XYZA	XYZ2	140	2018-02-16	2018-02-16				B 	          
XYZA	XYZ3	6.5	2018-02-16	2018-02-16				B 	          
XYZA	XYZ1	.	2017-10-10					B 	          
XYZA	XYZ2	140	2017-10-10	2017-10-10				B 	          
XYZA	XYZ3	4.3	2017-10-10	2017-10-10				B 	          
XYZB	XYZ4	.	2017-10-10					B 	          
XYZB	XYZ5	.	2017-10-10					B 	          
XYZB	XYZ6	test 2	2017-10-10	2017-10-10				B 	          
XYZB	XYZ4	.{}	2017-10-10					B 	          
XYZB	XYZ5	.{}	2017-10-10					B 	          
XYZB	XYZ6	.{}	2017-10-10					B 	          
XYZA	XYZ1	.{ T	2017-10-12					B 	          
XYZA	XYZ2	.{}	2017-10-12					B 	          
XYZA	XYZ3	new test	2017-10-12	2017-10-12				B 	          
XYZA	XYZ1	4	2017-12-20	2017-12-20				B 	          
XYZA	XYZ2	140	2017-12-20	2017-12-20				B 	          
XYZA	XYZ3	4.5	2017-12-20	2017-12-20				B 	          
XYZA	XYZ1	4.2	2017-12-20	2017-12-20				B 	          
XYZA	XYZ2	138	2017-12-20	2017-12-20				B 	          
XYZA	XYZ3	4	2017-12-20	2017-12-20				B 	          
XYZA	XYZ1	3.5	2017-12-20	2017-12-20				B 	          
XYZA	XYZ2	141	2017-12-20	2017-12-20				B 	          
XYZA	XYZ3	4.2	2017-12-20	2017-12-20				B 	          
CM1 	BLA	.{}	2014-02-26		%			A 	N         
CM1 	CDS	Bone Marrow	2014-02-26	2014-02-28				A 	N?        
CM4 	CMCO	.{}	2014-02-26					A 	N?        
CM4 	CONS	.{}	2014-02-26					A 	N         
CM1 	GATE	.{}	2014-02-26					A 	N         
CM4 	SETU	.{}	2014-02-26					X 	NI        
CM1 	BLA	.{}	2014-02-26		%			A 	N         
CM1 	CDS	Peripheral Blood	2014-02-26	2014-02-28				A 	N?        
CM4 	CMCO	.{}	2014-02-26					A 	N?        
CM4 	CONS	.{}	2014-02-26					A 	N         
CM1 	GATE	.{}	2014-02-26					A 	N         
CM4 	SETU	.{}	2014-02-26					X 	NI        
CM1 	BLA	.{}	2014-02-26		%			A 	N         
CM1 	CDS	Bone Marrow	2014-02-26	2014-02-28				A 	N?        
CM4 	CMCO	.{}	2014-02-26					A 	N?        
CM4 	CONS	.{}	2014-02-26					A 	N         
CM1 	GATE	.{}	2014-02-26					A 	N         
CM4 	SETU	.{}	2014-02-26					X 	NI        
FBCZ	BA	 0.1%  0.01	2014-01-29	2014-01-29	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCY	CHCU	32.0	2014-01-29	2014-01-29	g/dl	32.0	34.9	A 	NCPS/0    
FBCZ	EO	 0.8%  0.06	2014-01-29	2014-01-29	x10^9/L	0.0	0.4	A 	CDSN/0    
EPOU	EPOH	13.0	2014-01-29		g/dl			X 	NP        
EPOU	EPOU	12.5	2014-02-05	2014-02-05	IU/L			A 	/7        
FBCY	HCTU	0.400	2014-01-29	2014-01-29	L/L	0.33	0.45	A 	CPS/0     
FBCY	HGB	13.0	2014-01-29	2014-01-29	g/dl	11.5	15.5	A 	NrCP/0    
FBCZ	LY	35.0%  2.80	2014-01-29	2014-01-29	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCHU	30.0	2014-01-29	2014-01-29	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	88.0	2014-01-29	2014-01-29	fL	80	99	A 	CPS/0     
FBCZ	MO	 4.0%  0.32	2014-01-29	2014-01-29	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	10.0	2014-01-29	2014-01-29	fL	7	13	A 	CS?/0     
FBCZ	NE	60.0%  4.80	2014-01-29	2014-01-29	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	269	2014-01-29	2014-01-29	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	4.50	2014-01-29	2014-01-29	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	15.0	2014-01-29	2014-01-29	%	11.5	15.0	A 	CS/0      
FBCY	WCC	8.00	2014-01-29	2014-01-29	x10^9/L	3.0	10.0	A 	CWPS/0    
EPO	EPO	.{}	2014-02-11		IU/L			A 	          
EPO	REFL	Sample for EPO sent to Kings College Hospital,
Clinical Chemistry Dept for analysis.	2014-02-10	2014-02-13				A 	          
EPOU	EPOH	.{}	2014-02-11		g/dl			X 	NP        
EPOU	EPOU	.{}	2014-02-11		IU/L			A 	/7        
FAMY	FAMY	.	2017-11-14					B 	r         
FLDH	FLDH	.	2017-11-14					B 	r         
FTP	FTP 	.	2017-11-14					B 	r         
FBCZ	BA  	 1.0%  0.10	2017-07-26	2017-07-26				A 	CDSN/0    
FBCZ	EO  	 1.0%  0.10	2017-07-26	2017-07-26				A 	CDSN/0    
FBCY	HBGL	120	2017-07-26	2017-07-26				A 	rCP/0     
FBCY	HCTU	0.354	2017-07-26	2017-07-26				A 	CPS/0     
FBCZ	LY  	30.0%  3.00	2017-07-26	2017-07-26				A 	CDSP/0    
FBCY	MCGL	340	2017-07-26	2017-07-26				A 	CPS/0     
FBCY	MCHU	30.0	2017-07-26	2017-07-26				A 	CPS/0     
FBCY	MCVU	87.0	2017-07-26	2017-07-26				A 	CPS/0     
FBCZ	MO  	 8.0%  0.80	2017-07-26	2017-07-26				A 	CDS/0     
FBCY	MPVU	10.0	2017-07-26	2017-07-26				A 	CS?/0     
FBCZ	NE  	60.0%  6.00	2017-07-26	2017-07-26				A 	CDS/0     
NR1 	NR1 	5.0	2017-07-26					X 	SJ/0      
NR2 	NR2 	0.50	2017-07-26					X 	SJ/0      
NRC 	NRC 	0.50	2017-07-26	2017-07-26				A 	SN?/0     
NRP 	NRP 	5.0	2017-07-26	2017-07-26				A 	SN/0      
FBCY	PLT 	350	2017-07-26	2017-07-26				A 	CS/0      
FBCY	RCC 	3.50	2017-07-26	2017-07-26				A 	P/0       
FBCY	RDWU	10.0	2017-07-26	2017-07-26				A 	CS/0      
FBCY	WCC 	10.00
WBC adjusted for NRBC.	2017-07-26	2017-07-26				A 	CWPS/0    
FBCZ	BA  	 0.2%  0.03	2017-07-26	2017-07-26				A 	CDSN/0    
FBCZ	EO  	 0.8%  0.12	2017-07-26	2017-07-26				A 	CDSN/0    
FBCY	HBGL	130	2017-07-26	2017-07-26				A 	rCP/0     
FBCY	HCTU	0.400	2017-07-26	2017-07-26				A 	CPS/0     
FBCZ	LY  	15.0%  2.25	2017-07-26	2017-07-26				A 	CDSP/0    
FBCY	MCGL	350	2017-07-26	2017-07-26				A 	CPS/0     
FBCY	MCHU	33.0	2017-07-26	2017-07-26				A 	CPS/0     
FBCY	MCVU	88.0	2017-07-26	2017-07-26				A 	CPS/0     
FBCZ	MO  	 4.0%  0.60	2017-07-26	2017-07-26				A 	CDS/0     
FBCY	MPVU	10.0	2017-07-26	2017-07-26				A 	CS?/0     
FBCZ	NE  	80.0% 12.00	2017-07-26	2017-07-26				A 	CDS/0     
NR	NR1 	3.5	2017-07-26					X 	SJ/0      
NR	NR2 	0.35	2017-07-26					X 	SJ/0      
NR	NRC 	0.35	2017-07-26	2017-07-26				A 	SN?/0     
NR	NRP 	3.5	2017-07-26	2017-07-26				A 	SN/0      
FBCY	PLT 	250	2017-07-26	2017-07-26				A 	CS/0      
FBCY	RCC 	5.00	2017-07-26	2017-07-26				A 	P/0       
FBCY	RDWU	10.0	2017-07-26	2017-07-26				A 	CS/0      
FBCY	WCC 	15.00
WBC adjusted for NRBC.	2017-07-26	2017-07-26				A 	CWPS/0    
FBCZ	BA  	 1.0%  0.09	2017-07-27	2017-07-27				A 	CDSN/0    
FBCZ	EO  	 1.0%  0.09	2017-07-27	2017-07-27				A 	CDSN/0    
FBCX	FBCX	COMPLETE	2017-07-28					X 	I         
FBCY	HBGL	120	2017-07-27	2017-07-27				A 	rCP/0     
FBCY	HCTU	0.400	2017-07-27	2017-07-27				A 	CPS/0     
FBCZ	LY  	40.0%  3.60	2017-07-27	2017-07-27				A 	CDSP/0    
FBCY	MCGL	350	2017-07-27	2017-07-27				A 	CPS/0     
FBCY	MCHU	30.0	2017-07-27	2017-07-27				A 	CPS/0     
FBCY	MCVU	89.0	2017-07-27	2017-07-27				A 	CPS/0     
FBCZ	MO  	 8.0%  0.72	2017-07-27	2017-07-27				A 	CDS/0     
FBCY	MPVU	10.0	2017-07-27	2017-07-27				A 	CS?/0     
FBCZ	NE  	50.0%  4.50	2017-07-27	2017-07-27				A 	CDS/0     
NR1 	NR1 	1.5	2017-07-27					X 	SJ/0      
NR2 	NR2 	0.15	2017-07-27					X 	SJ/0      
NRC 	NRC 	0.15	2017-07-27	2017-07-27				A 	SN?/0     
NRP 	NRP 	1.5	2017-07-27	2017-07-27				A 	SN/0      
FBCY	PLT 	287	2017-07-28	2017-07-28				A 	CS/0      
FBCY	RCC 	4.50	2017-07-27	2017-07-27				A 	P/0       
FBCY	RDWU	15.0	2017-07-27	2017-07-27				A 	CS/0      
FBCY	WCC 	9.00	2017-07-27	2017-07-27				A 	CWPS/0    
FBCZ	BA  	Manual differential to follow.	2017-07-28	2017-07-28				A 	CDSN/0    
DIFF	DIFF	See differential results.	2017-07-28					X 	          
FBCZ	EO  	Manual differential to follow.	2017-07-28	2017-07-28				A 	CDSN/0    
FBCX	FBCX	COMPLETE	2017-07-28					X 	I         
FBCZ	FCOM	.	2017-07-28					A 	K?Nr      
FBCY	HBGL	102	2017-07-28	2017-07-28				A 	rCP/0     
FBCY	HCTU	0.345	2017-07-28	2017-07-28				A 	CPS/0     
FBCZ	LY  	Manual differential to follow.	2017-07-28	2017-07-28				A 	CDSP/0    
FBCY	MCGL	350	2017-07-28	2017-07-28				A 	CPS/0     
FBCY	MCHU	30.0	2017-07-28	2017-07-28				A 	CPS/0     
FBCY	MCVU	88.0	2017-07-28	2017-07-28				A 	CPS/0     
FBCZ	MO  	Manual differential to follow.	2017-07-28	2017-07-28				A 	CDS/0     
FBCY	MPVU	10.0	2017-07-28	2017-07-28				A 	CS?/0     
FBCZ	NE  	Manual differential to follow.	2017-07-28	2017-07-28				A 	CDS/0     
FBCY	PLT 	149	2017-07-28	2017-07-28				A 	CS/0      
FBCY	RCC 	2.96	2017-07-28	2017-07-28				A 	P/0       
FBCY	RDWU	12.0	2017-07-28	2017-07-28				A 	CS/0      
FBCY	WCC 	5.00	2017-07-28	2017-07-28				A 	CWPS/0    
BM	BM  	This test has been performed as part of the
investigation of a SIHMDS specimen. An up to date
integrated report for this sample will be
available on HILIS4 at
https://nww.hmds.leedsth.nhs.uk/uclh.html
A scanned report will also be available on CDR.
From CDR MAIN MENU click on VIEW DOCS for your
patient. Select image from date test required.	2017-12-08	2017-12-08				A 	?         
XYZA	XYZ1	3.5	2015-09-01	2015-09-01		3.0	7.0	B 	          
XYZA	XYZ2	135	2015-09-01	2015-09-01		133	143	B 	          
XYZA	XYZ3	5.0	2015-09-01	2015-09-01		3.7	5.2	B 	          
BON	ALB	38	2014-10-06	2014-10-06	g/L	34	50	B 	CP        
BON	ALP	120	2014-10-06	2014-10-06	IU/L	35	104	B 	C         
BON	CA	2.50	2014-10-06	2014-10-06	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.64	2014-10-06	2014-10-06	mmol/L	2.15	2.55	B 	C         
ELU	CREA	200	2014-10-06	2014-10-06	umol/L	49	92	B 	CPr       
CRP	CRP	5.0	2014-10-06	2014-10-06	mg/L	0	5.0	B 	AB        
ESR	ESR	10	2014-10-06	2014-10-06	mm/hr	1	7	A 	C?/0      
ELU	FACR	0.40	2014-10-06					X 	N         
ELU	GFR	25
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2014-10-06	2014-10-06	.			B 	          
ELU	K	4.2	2014-10-06	2014-10-06	mmol/L	3.5	5.1	B 	CP        
ELU	NA	142	2014-10-06	2014-10-06	mmol/L	135	145	B 	CP        
BON	PHOS	1.50	2014-10-06	2014-10-06	mmol/L	0.87	1.45	B 	CP        
ELU	SEX	0.742	2014-10-06					X 	N         
ELU	UREA	14.2	2014-10-06	2014-10-06	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	34	2014-10-06		y			X 	          
ELU	CREA	80	2015-10-29	2015-10-29	umol/L	49	92	B 	CPr       
FBCZ	EO	 4.0%  0.32	2015-10-29	2015-10-29	x10^9/L	0.0	0.4	A 	CDSN/0    
ELU	GFR	>90
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2015-10-29	2015-10-29	.			B 	          
FBCY	HBGL	120	2015-10-29	2015-10-29	g/L			A 	rCP/0     
FBCY	HCTU	0.400	2015-10-29	2015-10-29	L/L	0.33	0.45	A 	CPS/0     
ELU	K	4.0	2015-10-29	2015-10-29	mmol/L	3.5	5.1	B 	CP        
FBCZ	LY	20.0%  1.60	2015-10-29	2015-10-29	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	330	2015-10-29	2015-10-29	g/L			A 	CPS/0     
FBCY	MCHU	30.0	2015-10-29	2015-10-29	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	90.0	2015-10-29	2015-10-29	fL	80	99	A 	CPS/0     
FBCZ	MO	 5.0%  0.40	2015-10-29	2015-10-29	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	12.0	2015-10-29	2015-10-29	fL	7	13	A 	CS?/0     
ELU	NA	140	2015-10-29	2015-10-29	mmol/L	135	145	B 	CP        
FBCZ	NE	75.0%  6.00	2015-10-29	2015-10-29	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	300	2015-10-29	2015-10-29	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	4.00	2015-10-29	2015-10-29	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	13.0	2015-10-29	2015-10-29	%	11.5	15.0	A 	CS/0      
ELU	UREA	7.0	2015-10-29	2015-10-29	mmol/L	1.7	8.3	B 	CP        
FBCY	WCC	8.00	2015-10-29	2015-10-29	x10^9/L	3.0	10.0	A 	CWPS/0    
ELU	ZAGE	31	2015-10-29		y			X 	          
LFT	ALB	40	2015-10-29	2015-10-29	g/L	34	50	B 	CP        
LFT	ALP	55	2015-10-29	2015-10-29	IU/L	35	104	B 	C         
LFT	ALT	30	2015-10-29	2015-10-29	IU/L	10	35	B 	C         
LFT	BILI	12	2015-10-29	2015-10-29	umol/L	0	137	B 	CPr       
XYZA	XYZ1	5.0	2015-11-03	2015-11-03		3.0	7.0	B 	          
XYZA	XYZ2	140	2015-11-03	2015-11-03		133	143	B 	          
XYZA	XYZ3	5.0	2015-11-03	2015-11-03		3.7	5.2	B 	          
XYZA	XYZ1	5	2015-11-05	2015-11-05		3.0	7.0	B 	          
XYZA	XYZ2	140	2015-11-05	2015-11-05		133	143	B 	          
XYZA	XYZ3	5	2015-11-05	2015-11-05		3.7	5.2	B 	          
LFT	ALB	50	2015-11-05	2015-11-05	g/L	38	54	B 	CP        
LFT	ALP	200	2015-11-05	2015-11-05	IU/L	0	300	B 	C         
LFT	ALT	20	2015-11-05	2015-11-05	IU/L	10	35	B 	C         
AMY	AMY	80	2015-11-05	2015-11-05	IU/L	28	100	B 	AB        
LFT	BILI	15	2015-11-05	2015-11-05	umol/L	0	137	B 	CPr       
UBJP	BJP	5	2015-11-05	2015-11-05				B 	          
BJPQ	BJPQ	5.00
Approximate result from scan of electrophoresis.	2015-11-05	2015-11-05	g/L	0	0	B 	P         
BJPQ	BJPR	50000	2015-11-05	2015-11-05	mg/mmol			B 	QN        
BON	CA	2.50	2015-11-05	2015-11-05	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.42	2015-11-05	2015-11-05	mmol/L	2.15	2.55	B 	C         
ELU	CREA	50	2015-11-05	2015-11-05	umol/L	28	52	B 	CPr       
CRP	CRP	4.0	2015-11-05	2015-11-05	mg/L	0	5.0	B 	AB        
FBCZ	EO	 5.0%  0.50	2015-11-05	2015-11-05	x10^9/L	0.0	0.8	A 	CDSN/0    
ESR	ESR	5	2015-11-05	2015-11-05	mm/hr	1	7	A 	C?/0      
ELU	GFR	Not calculated. Age less than 18yrs.	2015-11-05	2015-11-05	.			B 	          
FBCY	HBGL	120	2015-11-05	2015-11-05	g/L			A 	rCP/0     
FBCY	HCTU	0.400	2015-11-05	2015-11-05	L/L	0.33	0.44	A 	CPS/0     
ELU	K	4.0	2015-11-05	2015-11-05	mmol/L	3.5	5.1	B 	CP        
FBCZ	LY	25.0%  2.50	2015-11-05	2015-11-05	x10^9/L	1.5	7.0	A 	CDSP/0    
FBCY	MCGL	350	2015-11-05	2015-11-05	g/L			A 	CPS/0     
FBCY	MCHU	25.0	2015-11-05	2015-11-05	pg	21.0	31.0	A 	CPS/0     
FBCY	MCVU	80.0	2015-11-05	2015-11-05	fL	76	94	A 	CPS/0     
FBCZ	MO	10.0%  1.00	2015-11-05	2015-11-05	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	10.0	2015-11-05	2015-11-05	fL	7	13	A 	CS?/0     
ELU	NA	140	2015-11-05	2015-11-05	mmol/L	135	145	B 	CP        
FBCZ	NE	70.0%  7.00	2015-11-05	2015-11-05	x10^9/L	1.5	8.0	A 	CDS/0     
BON	PHOS	1.60	2015-11-05	2015-11-05	mmol/L	1.45	1.78	B 	CP        
FBCY	PLT	300	2015-11-05	2015-11-05	x10^9/L	150	400	A 	CS/0      
FBCY	RCC	5.00	2015-11-05	2015-11-05	x10^12/L	4.1	5.4	A 	P/0       
FBCY	RDWU	12.0	2015-11-05	2015-11-05	%	11.5	15.0	A 	CS/0      
UBJP	UCPR	50000	2015-11-05	2015-11-05	mg/mmol	0	13	B 	QN        
RN	UCR	100	2015-11-05	2015-11-05	umol/L			B 	          
ELU	UREA	8.0	2015-11-05	2015-11-05	mmol/L	1.7	8.3	B 	CP        
UBJP	UTP	5.00	2015-11-05	2015-11-05	g/L	0	0.10	B 	P         
FBCY	WCC	10.00	2015-11-05	2015-11-05	x10^9/L	4.5	13.5	A 	CWPS/0    
ELU	ZAGE	6	2015-11-05		y			X 	          
XYZA	XYZ1	6.0	2015-11-05	2015-11-05		3.0	7.0	B 	          
XYZA	XYZ2	140	2015-11-05	2015-11-05		133	143	B 	          
XYZA	XYZ3	5	2015-11-05	2015-11-05		3.7	5.2	B 	          
NA	NA  	140	2016-09-16	2016-09-16				B 	CP        
L	ALB	38	2016-06-28	2016-06-28	g/L	34	50	B 	CP        
L	ALP	42	2016-06-28	2016-06-28	IU/L	35	104	B 	C         
L	ALT	9	2016-06-28	2016-06-28	IU/L	10	35	B 	C         
CT	APRA	1.1	2016-06-28	2016-06-28		2.0	3.0	A 	?/1       
CT	APTT	35	2016-06-28	2016-06-28	secs	22	41	A 	P/1       
FBCZ	BA	 0.2%  0.02	2016-06-28	2016-06-28	x10^9/L	0.0	0.1	A 	CDSN/0    
L	BILI	15	2016-06-28	2016-06-28	umol/L	0	137	B 	CPr       
B	CA	2.55	2016-06-28	2016-06-28	mmol/L	2.15	2.55	B 	CP        
B	CCA	2.69	2016-06-28	2016-06-28	mmol/L	2.15	2.55	B 	C         
E	CREA	88	2016-06-28	2016-06-28	umol/L	49	92	B 	CPr       
FBCZ	EO	 2.0%  0.18	2016-06-28	2016-06-28	x10^9/L	0.0	0.4	A 	CDSN/0    
E	FACR	1.05	2016-06-28					X 	N         
E	GFR	61
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-06-28	2016-06-28	.			B 	          
FBCY	HBGL	133	2016-06-28	2016-06-28	g/L			A 	rCP/0     
FBCY	HCTU	0.387	2016-06-28	2016-06-28	L/L	0.33	0.45	A 	CPS/0     
CT	INR	1.10	2016-06-28	2016-06-28				A 	/1        
E	K	5.8	2016-06-28	2016-06-28	mmol/L	3.5	5.1	B 	CP        
FBCZ	LY	32.7%  2.96	2016-06-28	2016-06-28	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	344	2016-06-28	2016-06-28	g/L			A 	CPS/0     
FBCY	MCHU	30.5	2016-06-28	2016-06-28	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	88.8	2016-06-28	2016-06-28	fL	80	99	A 	CPS/0     
FBCZ	MO	 7.5%  0.68	2016-06-28	2016-06-28	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	10.1	2016-06-28	2016-06-28	fL	7	13	A 	CS?/0     
E	NA	155	2016-06-28	2016-06-28	mmol/L	135	145	B 	CP        
FBCZ	NE	57.6%  5.21	2016-06-28	2016-06-28	x10^9/L	2.0	7.5	A 	CDS/0     
B	PHOS	1.10	2016-06-28	2016-06-28	mmol/L	0.87	1.45	B 	CP        
FBCY	PLT	304	2016-06-28	2016-06-28	x10^9/L	150	400	A 	CS/0      
L	PROT	82	2016-06-28	2016-06-28	g/L	63	83	B 	CP        
CT	PT	12.5	2016-06-28	2016-06-28	secs	10.0	12.0	A 	/1        
FBCY	RCC	4.36	2016-06-28	2016-06-28	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	12.5	2016-06-28	2016-06-28	%	11.5	15.0	A 	CS/0      
E	SEX	0.742	2016-06-28					X 	N         
E	UREA	9.2	2016-06-28	2016-06-28	mmol/L	1.7	8.3	B 	CP        
FBCY	WCC	9.04	2016-06-28	2016-06-28	x10^9/L	3.0	10.0	A 	CWPS/0    
E	ZAGE	52	2016-06-28		y			X 	          
AT	A1AT	1.44	2016-06-29	2016-06-29	g/L			B 	AB        
LFT	ALB	41	2016-06-29	2016-06-29	g/L	34	50	B 	CP        
LFT	ALP	95	2016-06-29	2016-06-29	IU/L	35	104	B 	C         
LFT	ALT	109	2016-06-29	2016-06-29	IU/L	10	35	B 	C         
COAT	APRA	0.8	2016-06-29	2016-06-29		2.0	3.0	A 	?/1       
COAT	APTT	25	2016-06-29	2016-06-29	secs	22	41	A 	P/1       
LFT	BILI	4	2016-06-29	2016-06-29	umol/L	0	137	B 	CPr       
CERU	CERU	0.27	2016-06-29	2016-06-29	g/L	0.20	0.60	B 	AB        
FERR	FERR	534	2016-06-29	2016-06-29	ug/L	13	150	B 	          
COAT	FIB	2.90	2016-06-29	2016-06-29	g/L			A 	p1/1      
LFT	H	14	2016-06-29					  	JNr       
LFT	I	10	2016-06-29					  	JN        
COAT	INR	0.96	2016-06-29	2016-06-29				A 	/1        
COAT	PT	10.6	2016-06-29	2016-06-29	secs	10.0	12.0	A 	/1        
CPTE	BH2	10.1	2016-06-29		nmol/L	0.4	13.9	D 	          
CPTE	BH4	47	2016-06-29		nmol/L	9	39	D 	          
MAM	C5HI	85	2016-06-29		nmol/L	58	220	D 	          
C5MT	C5MT	92	2016-06-29		nmol/L	46	160	D 	A         
MAM	CHHR	4.90
Elevated HVA:5HIAA ratio noted.  The signifance of
this is not clear as the monoamine metabolites are
within their ranges.	2016-06-29					D 	N         
MAM	CHVA	420	2016-06-29		nmol/L	71	565	D 	          
CPLP	CPLP	28	2016-06-29		nmol/L	16	44	D 	          
CPTE	TNPT	21
The significance of the elevated
tetrahydrobiopterin conentration is not clear.	2016-06-29		nmol/L	7	65	D 	          
FBCZ	BA	 0.4%  0.03	2016-06-29	2016-06-29	x10^9/L	0.0	0.1	A 	CDSN/0    
FBCZ	EO	 7.8%  0.65	2016-06-29	2016-06-29	x10^9/L	0.0	0.4	A 	CDSN/0    
FBCY	HBGL	149	2016-06-29	2016-06-29	g/L			A 	rCP/0     
FBCY	HCTU	0.443	2016-06-29	2016-06-29	L/L	0.33	0.45	A 	CPS/0     
IGSC	IG1	7.35	2016-06-29		g/L	4.56	9.00	B 	r/23      
IGSC	IG2	2.71	2016-06-29		g/L	1.2	2.6	B 	r/23      
IGSC	IG3	0.51	2016-06-29		g/L	0.2	1.9	B 	r/23      
IGSC	IG4	0.02
Result from Northern General Hosp, Sheffield	2016-06-29		g/L	0	1.3	B 	r/23      
IGS	IGA	1.67	2016-06-29		g/L	0.7	4.0	B 	S         
IGE	IGE	70	2016-06-29		kIU/L	0	100	B 	A         
IGS	IGG	11.87	2016-06-29		g/L	7.0	16.0	B 	AS        
IGS	IGM	1.02	2016-06-29		g/L	0.4	2.3	B 	BS        
FBCZ	LY	42.9%  3.58	2016-06-29	2016-06-29	x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	336	2016-06-29	2016-06-29	g/L			A 	CPS/0     
FBCY	MCHU	30.0	2016-06-29	2016-06-29	pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	89.3	2016-06-29	2016-06-29	fL	80	99	A 	CPS/0     
FBCZ	MO	 5.0%  0.42	2016-06-29	2016-06-29	x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	11.7	2016-06-29	2016-06-29	fL	7	13	A 	CS?/0     
FBCZ	NE	43.9%  3.66	2016-06-29	2016-06-29	x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	273	2016-06-29	2016-06-29	x10^9/L	150	400	A 	CS/0      
RAS	RASI	  Dermatophagoides pteronyssinus, Blatella germanica
 Grass mix....................................0.01.........0
  Cocksfoot, Meadow fescue, Rye-grass, Timothy grass,
  Kentucky blue [Meadow grass]
 Weed mix.....................................0.01.........0
  Common ragweed, Western ragweed, Giant ragweed
 Mould mix including:.........................0.01.........0
  Penicillium notatum, Cladosporium herbarum, Candida albicans,
  Aspergillus fumigatus, Alternaria tenius, Helminthosporum

 SINGLE ALLERGENS:
 Cockroach (asian).....0.01..0    Oat..............0.01..0
 Beef..................0.01..0    Olive............0.01..0
 Bermuda grass.........0.01..0    Orange...........0.01..0
 Cat dander............0.01..0    Peanut...........0.01..0
 Cheese (cheddar)......0.01..0    Rice.............0.01..0
 Chicken...............0.01..0    Shrimp/prawn.....0.01..0
 Corn (maize)..........0.01..0    Soya bean........0.01..0
 Cows milk.............0.01..0    Wheat............0.01..0
 Crab..................0.01..0    Yeast............0.01..0
 Dog dander ...........0.01..0    Walnut...........0.01..0
 Egg white.............0.01..0    Penicillin.......0.01..0
 Egg yolk..............0.01..0    Latex............0.01..0
 White fish (cod)......0.01..0    Coffee...........0.01..0	2016-06-29					I 	r         
FBCY	RCC	4.96	2016-06-29	2016-06-29	x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	13.9	2016-06-29	2016-06-29	%	11.5	15.0	A 	CS/0      
FBCY	WCC	8.34	2016-06-29	2016-06-29	x10^9/L	3.0	10.0	A 	CWPS/0    
COAT	APRA	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29			2.0	3.0	A 	?/1       
COAT	APTM	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		secs	22	41	A 	N         
COAT	APTT	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		secs	22	41	A 	P/1       
FBCZ	BA	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	0.0	0.1	A 	CDSN/0    
CORT	CORT	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		nmol/l			B 	          
FBCZ	EO	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	0.0	0.4	A 	CDSN/0    
FBCZ	FCOM	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29					A 	K?Nr      
COAT	FIB	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		g/L			A 	p1/1      
FBCY	HBGL	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		g/L			A 	rCP/0     
FBCY	HCTU	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		L/L	0.33	0.45	A 	CPS/0     
HMCO	HMCO	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29					A 	          
COAT	INR	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29					A 	/1        
FBCZ	LY	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	1.2	3.65	A 	CDSP/0    
FBCY	MCGL	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		g/L			A 	CPS/0     
FBCY	MCHU	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		pg	27.0	33.5	A 	CPS/0     
FBCY	MCVU	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		fL	80	99	A 	CPS/0     
FBCZ	MO	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	0.2	1.0	A 	CDS/0     
FBCY	MPVU	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		fL	7	13	A 	CS?/0     
FBCZ	NE	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	2.0	7.5	A 	CDS/0     
FBCY	PLT	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	150	400	A 	CS/0      
COAT	PT	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		secs	10.0	12.0	A 	/1        
COAT	PTM	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		secs	10.0	12.0	A 	N         
FBCY	RCC	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^12/L	3.95	5.15	A 	P/0       
FBCY	RDWU	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		%	11.5	15.0	A 	CS/0      
FBCY	WCC	Cancelled - Unlabelled specimen received.
Not processed.	2016-06-29		x10^9/L	3.0	10.0	A 	CWPS/0    
HBVL	BVL1	.{26}	2016-06-29		IU/ml			H 	HAr?/5    
HBVL	BVL2	POSITIVE - Below the Limit of Quantification.	2016-06-29					H 	?r/5      
HBVL	BVLL	Please note that this test is validated for
EDTA/EDTA plasma samples only. Results from
samples other than EDTA/EDTA plasma should be
interpreted with caution. Please send repeat if
clinically indicated.	2016-06-29					H 	NA?       
HBVL	BVLP	.{ None in past 300 days }	2016-06-29					H 	NI?       
HBVL	BVLR	.	2016-06-29					H 	Ir?       
COSC	COSC	HBVR/	2016-06-29					X 	N         
COSD	COSD	Organisms sent 29/06/2016 13:32	2016-06-29					X 	N         
HBMS	EABA	0.035	2016-06-29					H 	HIr/2     
HBMS	EABR	POSITIVE	2016-06-29					H 	?r/2      
HBMS	EAGA	0.137	2016-06-29					H 	HIr/2     
HBMS	EAGR	NOT detected	2016-06-29					H 	?/2       
HBMS	HBCC	.{}	2016-06-29					H 	Nr?/2     
HBMS	HBCO	Y	2016-06-29					H 	NIr?      
HBMS	HBVA	7651000	2016-06-29					H 	HIr/1     
HBVL	HBVL	REPORT	2016-06-29					H 	HABp1Nr?  
HBMS	HBVR	POSITIVE	2016-06-29					H 	?r/2m     
HBVL	HBVS	EDTA	2016-06-29					H 	?rB/5     
SAVP	SAVP	.	2016-06-29					X 	r?/5      
HBSS	BCMA	0.16	2016-06-29					H 	HIr/2     
HBSS	BCMR	NOT detected	2016-06-29					H 	?/2m      
HIV	CHIV	.	2016-06-29					H 	N?/2      
HBSS	EABA	0.003	2016-06-29					H 	HIr/2     
HBSS	EABR	POSITIVE	2016-06-29					H 	?r/2      
HBSS	EAGA	0.131	2016-06-29					H 	HIr/2     
HBSS	EAGR	NOT detected	2016-06-29					H 	?/2       
HAVM	HAMA	0.348	2016-06-29					H 	Ir/1      
HAVM	HAMR	NOT detected	2016-06-29					H 	?/1m      
HAVM	HAVM	REPORT	2016-06-29					H 	NAHp1r?   
HBC	HBCA	0.009	2016-06-29					H 	HIr/1     
HBSS	HBCC	.	2016-06-29					H 	Nr?/2     
HBAG	HBCO	Y	2016-06-29					H 	NIr?      
HBC	HBCR	POSITIVE	2016-06-29					H 	?r/2      
HBS	HBSA	.{ . }	2016-06-29					H 	HIr/1     
HBS	HBSI	.	2016-06-29					H 	r?/2      
HBS	HBSR	.	2016-06-29		IU/l			H 	?r/2      
HBAG	HBVA	2776.000	2016-06-29					H 	HIr/1     
HBAG	HBVR	POSITIVE	2016-06-29					H 	?r/2m     
HBVV	HBVV	Please 99Q999999	2016-06-29					H 	HI        
HCAG	HCAC	.	2016-06-29					H 	N?        
HCAG	HCAG	NOT detected	2016-06-29					H 	?r/1      
HCAG	HCAR	<3.0	2016-06-29					H 	Ir?       
HCAG	HCAT	REPORT	2016-06-29					H 	NAHrp1?   
HIV	HIVA	0.285	2016-06-29					H 	Ir/1      
HIV	HIVR	Not Detected	2016-06-29					H 	?/2       
SAVI	SAVI	.	2016-06-29					H 	I?/0      
HBAG	1AG	Cancelled - see comments	2016-06-29	2016-06-29				H 	NA?       
HCV	1HC	Cancelled - see comments	2016-06-29	2016-06-29				H 	NA?       
BMTP	2BM	Please note that this test is validated for
EDTA/EDTA plasma samples only. Results from
samples other than EDTA/EDTA plasma should be
interpreted with caution. Please send repeat if
clinically indicated.	2016-06-29					H 	NAr?      
BMTP	ADV1	.{0}	2016-06-29		Copies/ml			H 	r/7       
BMTP	ADV2	Not Detected	2016-06-29					H 	?r/7m     
BMTP	BMTP	REPORT	2016-06-29					H 	NAHp1?r   
BMTP	BMTS	EDTA	2016-06-29					H 	N?        
BMTP	CMV1	.{0}	2016-06-29		Copies/ml			H 	r/7       
BMTP	CMV2	NOT detected	2016-06-29					H 	?r/7m     
HERP	CMVP	NOT detected	2016-06-29					H 	?r/3m     
COSC	COSC	EBVP/	2016-06-29					X 	N         
COSD	COSD	Organisms sent 29/06/2016 13:32	2016-06-29					X 	N         
BMTP	EBV1	.{0}	2016-06-29		Copies/ml			H 	r/7       
BMTP	EBV2	Not Detected	2016-06-29					H 	?r/7m     
HERP	EBVP	POSITIVE	2016-06-29					H 	?r/3m     
HBAG	HBCO	y	2016-06-29	2016-06-29				H 	NIr?      
HBAG	HBVA	.	2016-06-29					H 	HIr/1     
HBAG	HBVR	Insufficient sample	2016-06-29	2016-06-29				H 	?r/2m     
HCAG	HCAA	Cancelled - see comments	2016-06-29	2016-06-29				H 	NA?       
HCAG	HCAC	Insufficient sample	2016-06-29	2016-06-29				H 	N?        
HCAG	HCAG	.	2016-06-29					H 	?r/1      
HCAG	HCAR	.	2016-06-29					H 	Ir?       
HCAG	HCAT	REPORT	2016-06-29	2016-06-29				H 	NAHrp1?   
HCV	HCV	CANCELLED	2016-06-29	2016-06-29				H 	NAHp1?r   
HCV	HCVA	.	2016-06-29					H 	Ir/1      
HCV	HCVR	.	2016-06-29					H 	?/2m      
HCV	HCVV	.{}	2016-06-29					H 	I/3       
HEV	HEGE	NOT detected	2016-06-29	2016-06-29				H 	H?/4      
HEV	HEME	NOT detected	2016-06-29	2016-06-29				H 	H?/4      
HERP	HERC	.	2016-06-29					H 	N?        
HERP	HERP	REPORT	2016-06-29					H 	NHAp1?r   
HERP	HERS	EDTA	2016-06-29					H 	Nr?       
HEV	HEV	REPORT	2016-06-29	2016-06-29				H 	HABNp1r?  
HIRI	HIIR		1899-12-30					H 	@1H/10    
HIRG	HIRR		1899-12-30					H 	@1H/10    
HIVL	HIVL	REPORT	2016-06-29					H 	HABp1Nr?  
HERP	HRPN	Please note that this test is validated for
EDTA/EDTA plasma samples only. Results from
samples other than EDTA/EDTA plasma should be
interpreted with caution. Please send repeat if
clinically indicated.	2016-06-29					H 	IN        
HERP	HS1P	NOT detected	2016-06-29					H 	?r/3m     
HERP	HS2P	NOT detected	2016-06-29					H 	?r/3m     
HIRI	HVIS	EDTA	2016-06-29					H 	N?        
HIVL	HVL1	1400000	2016-06-29		Copies/ml			H 	HAr?/5    
HIVL	HVL2	.{ POSITIVE }	2016-06-29					H 	?r/5      
HIVL	HVLC	The change in viral load is noted. If unexpected,
suggest early repeat blood.	2016-06-29					H 	N?        
HIVL	HVLK	.	2016-06-29					H 	NA?       
HIVL	HVLL	.	2016-06-29					H 	NA?       
HIVL	HVLP	None in past 300 days	2016-06-29					H 	NI?       
HIVL	HVLS	EDTA	2016-06-29					H 	?rB/5     
HIRG	HVRS	EDTA	2016-06-29					H 	r?/10     
SAVI	SAVI	Sample insufficient for save.	2016-06-29	2016-06-29				H 	I?/0      
HERP	VZVP	NOT detected	2016-06-29					H 	?r/3m     
COAT	APRA	.	2016-04-26			2.0	3.0	A 	?/1       
COAT	APTT	.	2016-04-26		secs	22	41	A 	P/1       
COAT	FIB	.	2016-04-26		g/L			A 	p1/1      
COAT	INR	.	2016-04-26					A 	/1        
COAT	PT	.	2016-04-26		secs	10.0	12.0	A 	/1        
E	CREA	92	2016-06-10	2016-06-20	umol/L	49	92	B 	CPr       
E	FACR	1.00	2016-06-10					X 	N         
E	GFR	63
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-06-10	2016-06-20	.			B 	          
E	K	5.1	2016-06-10	2016-06-20	mmol/L	3.5	5.1	B 	CP        
E	NA	145	2016-06-10	2016-06-20	mmol/L	135	145	B 	CP        
E	SEX	0.742	2016-06-10					X 	N         
E	UREA	8.3	2016-06-10	2016-06-20	mmol/L	1.7	8.3	B 	CP        
E	ZAGE	35	2016-06-10		y			X 	          
OSM	OSMO	15	2016-05-26	2016-05-26	mosmol/kg	285	295	B 	          
SCDX	BVL1	.{ 0 }	2014-04-23		IU/ml			H 	HAr?/5    
SCDX	BVL2	NOT detected	2014-04-23	2014-04-23				H 	?r/5      
SCDI	CMGA	0	2014-04-23	2014-04-23				H 	Ir/1      
SCDX	CMGR	NOT detected	2014-04-23	2014-04-23				H 	?/2       
SCDI	CMMA	0.2	2014-04-23	2014-04-23				H 	Ir/1      
SCDX	CMMR	NOT detected	2014-04-23	2014-04-23				H 	?/2m      
SCDX	CVL1	.{ 0 }	2014-04-23		IU/ml			H 	Hr?/5     
SCDX	CVL2	NOT detected	2014-04-23	2014-04-23				H 	?r/5m     
SCDI	EBN1	.{}	2014-04-23					H 	HIr/2     
SCDI	HBCA	.{ 0.700 }	2014-04-23					H 	HIr/1     
SCDX	HBCR	Weak Reactive	2014-04-23	2014-04-23				H 	?r/2      
SCDI	HBVA	.{ 0.500 }	2014-04-23					H 	HIr/1     
SCDX	HBVR	NOT detected	2014-04-23	2014-04-23				H 	?r/2m     
SCDI	HCVA	0.100	2014-04-23	2014-04-23				H 	Ir/1      
SCDX	HCVR	NOT detected
This does not exclude acute HCV infection as
seroconversion may be delayed. If you consider
this patient to have risk factors for HCV
infection, please contact us to discuss further
testing of this sample.	2014-04-23	2014-04-23				H 	?/2m      
SCDI	HCVV	.{}	2014-04-23					H 	I/3       
SCDI	HIVA	0.500	2014-04-23	2014-04-23				H 	Ir/1      
SCDX	HIVR	NOT detected
HIV-1 p24 Antigen Not Detected	2014-04-23	2014-04-23				H 	?/2       
SCDX	HVL1	.{ 0 }	2014-04-23		Copies/ml			H 	HAr?/5    
SCDX	HVL2	NOT detected (<50 Copies/ml)	2014-04-23	2014-04-23				H 	?r/5      
SCDX	SCDS	RESULTS	2014-04-23	2014-04-23				H 	Hr?       
SCDI	SYPA	0.010	2014-04-23	2014-04-23				H 	?Ir/1     
SCDX	SYPR	Negative	2014-04-23	2014-04-23				H 	?r/2m     
SCDI	TLVA	0.700	2014-04-23	2014-04-23				H 	Ir/1      
SCDX	TLVR	NOT detected
No evidence of infection.	2014-04-23	2014-04-23				H 	?/2m      
SCDY	TOXG	NOT detected	2014-04-23	2014-04-23				H 	?/2       
SCDY	TOXM	NOT detected	2014-04-23	2014-04-23				H 	?/2m      
SCDI	TXGA	0.2	2014-04-23	2014-04-23				H 	Ir/1      
SCDI	VCA1	0.01	2014-04-23	2014-04-23				H 	HIr/2     
SCDI	VCA2	0.1	2014-04-23	2014-04-23				H 	HIr/2     
SCDX	VCAG	NOT detected	2014-04-23	2014-04-23				H 	?/2       
SCDX	VCAM	NOT detected	2014-04-23	2014-04-23				H 	?/2m      
SCDI	VZGE	POSITIVE	2014-04-23	2014-04-23				H 	?IN/3r    
SCDY	VZGR	POSITIVE	2014-04-23	2014-04-23				H 	?/3r      
SCDI	VZGV	7.5	2014-04-23	2014-04-23				H 	INr?/2    
COSC	COSC	SYPR/	2014-04-30					X 	N         
COSD	COSD	Organisms sent 30/04/2014 22:45	2014-04-30					X 	N         
STS	RPR	Negative	2014-04-30	2014-04-30				H 	?Hr/2m    
STS	SYPA	1.100	2014-04-30	2014-04-30				H 	?Ir/1     
STS	SYPR	POSITIVE	2014-04-30	2014-04-30				H 	?r/2m     
STS	TPC	The significance of these treponemal results is
uncertain. If this is the first sample, please
send another to confirm the pattern of test
results. If this is the second sample, then no
further testing is warranted unless clinically
indicated.	2014-04-30	2014-04-30				H 	?/2       
STS	TPPA	Negative	2014-04-30	2014-04-30				H 	?Hr/2m    
SCDI	CMGA	1	2014-05-04	2014-05-05				H 	Ir/1      
SCDX	CMGR	Not Detected	2014-05-04	2014-05-05				H 	?/2       
SCDI	HCVV	.{}	2014-05-04					H 	I/3       
SCDX	SCDS	RESULTS	2014-05-04	2014-05-05				H 	Hr?       
VZVS	VZGE	.{}	2014-09-02					H 	?IN/3r    
VZVS	VZGL	100	2014-09-02	2014-09-03				H 	Ir/2      
VZVS	VZGR	NOT detected	2014-09-02	2014-09-03				H 	?/3r      
VZVS	VZGV	.{}	2014-09-02					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-08-31	2014-09-01				H 	NAHp1?    
ANDX	ANDS	COMPLETE REPORT	2014-09-08	2014-09-08				H 	Hr?       
ANDX	BVL1	.{ 0 }	2014-09-08		IU/ml			H 	HAr?/5    
ANDX	BVL2	Not Detected	2014-09-08	2014-09-08				H 	?r/5      
ANDW	CMGA	0	2014-09-08	2014-09-08				H 	Ir/1      
ANDX	CMGR	Not Detected	2014-09-08	2014-09-08				H 	?/2       
ANDW	CMMA	0.1	2014-09-08	2014-09-08				H 	Ir/1      
ANDX	CMMR	Not Detected	2014-09-08	2014-09-08				H 	?/2m      
ANDW	CMMV	.{}	2014-11-17					H 	Ir        
ANDX	CVL1	.{ 0 }	2014-09-08		IU/ml			H 	Hr?/5     
ANDX	CVL2	Not Detected	2014-09-08	2014-09-08				H 	?r/5m     
ANDW	EBN1	0.1	2014-09-08	2014-09-08				H 	HIr/2     
ANDX	EBNA	Weak Reactive	2014-09-08	2014-09-08				H 	?/2       
ANDW	HBCA	.{ 0.400 }	2014-09-08					H 	HIr/1     
ANDX	HBCR	Positive	2014-09-08	2014-09-08				H 	?r/2      
ANDW	HBVA	.{ 0.100 }	2014-09-08					H 	HIr/1     
ANDX	HBVR	Not Detected	2014-09-08	2014-09-08				H 	?r/2m     
ANDW	HCVA	0.200	2014-09-08	2014-09-08				H 	Ir/1      
ANDX	HCVR	Not Detected	2014-09-08	2014-09-08				H 	?/2m      
ANDW	HCVV	.{}	2014-09-08					H 	I/3       
ANDW	HIVA	0.300	2014-09-08	2014-09-08				H 	Ir/1      
ANDX	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2014-09-08	2014-09-08				H 	?/2       
ANDX	HVL1	.{ 0 }	2014-09-08		Copies/ml			H 	HAr?/5    
ANDX	HVL2	Not Detected (<50 Copies/ml)	2014-09-08	2014-09-08				H 	?r/5      
ANDI	SAVI	Sample saved in Virology.	2014-09-08	2014-09-08				H 	I?/0      
ANDY	SCSS	END OF ANDX SCREEN REPORT	2014-09-08	2014-09-08				H 	NA?       
ANDW	SYPA	0.100	2014-09-08	2014-09-08				H 	?Ir/1     
ANDY	SYPR	Negative	2014-09-08	2014-09-08				H 	?r/2m     
ANDW	TLVA	0.100	2014-09-08	2014-09-08				H 	Ir/1      
ANDY	TLVR	Not Detected
No evidence of infection.	2014-09-08	2014-09-08				H 	?/2m      
ANDY	TOXG	Not Detected	2014-09-08	2014-09-08				H 	?/2       
ANDY	TOXM	Not Detected	2014-09-08	2014-09-08				H 	?/2m      
ANDW	TXGA	0.1	2014-09-08	2014-09-08				H 	Ir/1      
ANDW	TXMA	0.1	2014-09-08	2014-09-08				H 	Ir/1      
ANDW	TXMV	.{}	2014-11-17					H 	IN        
ANDW	VCA1	0.2	2014-09-08	2014-09-08				H 	HIr/2     
ANDW	VCA2	0.1	2014-09-08	2014-09-08				H 	HIr/2     
ANDX	VCAG	NOT detected	2014-11-17	2014-11-17				H 	?/2       
ANDX	VCAM	Not Detected	2014-09-08	2014-09-08				H 	?/2m      
ANDI	VCGL	10	2014-11-17	2014-11-17				H 	Ir/2      
ANDW	VZGE	.{}	2014-09-08					H 	?IN/3r    
ANDW	VZGL	0.1	2014-09-08	2014-09-08				H 	Ir/2      
ANDY	VZGR	NOT detected	2014-09-08	2014-09-08				H 	?/3r      
ANDW	VZGV	.{}	2014-09-08					H 	INr?/2    
HCVL	CVL1	.{ 0 }	2014-09-28		IU/ml			H 	Hr?/5     
HCVL	CVL2	Not Detected	2014-09-28	2014-09-28				H 	?r/5m     
HCVL	HCVS	EDTA	2014-09-28	2014-09-28				H 	?r/5      
HIVL	HVLS	CLB	2014-09-27	2014-09-27				H 	?rB/5     
COSC	COSC	VCAM/	2014-12-02					X 	N         
COSD	COSD	Organisms sent 02/12/2014 13:00	2014-12-02					X 	N         
EBVS	EBN1	.{}	2014-11-19					H 	HIr/2     
EBVS	EBNA	POSITIVE	2014-11-19	2014-11-20				H 	?/2       
EBVS	EBNL	150	2014-11-19	2014-11-20				H 	Ir/2      
EBVS	EBVC	Consistent with a past infection.	2014-11-19	2014-11-20				H 	Nr?       
EBVS	EBVS	REPORT	2014-11-19	2014-11-20				H 	HNAp1r?   
IVS	IVS	IDENTIFIED VALIDATED SAMPLE	2014-11-28	2014-11-29				H 	?         
PARV	PRGL	1.2	2014-12-01	2014-12-02				H 	I?/2      
PARV	PRM2	1.2	2014-12-02	2014-12-02				H 	I?N       
PARV	PRML	1.1	2014-12-02	2014-12-02				H 	I?/2      
PARV	PRVG	POSITIVE	2014-12-01	2014-12-02				H 	?r/2      
PARV	PRVM	POSITIVE	2014-12-02	2014-12-02				H 	?r/2m     
EBVS	VCA1	.{}	2014-11-19					H 	HIr/2     
EBVM	VCA2	.{}	2014-12-17					H 	HIr/2     
EBVS	VCAG	POSITIVE	2014-11-19	2014-11-20				H 	?/2       
EBVM	VCAM	POSITIVE	2014-12-01	2014-12-02				H 	?/2m      
EBVS	VCGL	200	2014-11-19	2014-11-20				H 	Ir/2      
EBVM	VCML	40	2014-12-01	2014-12-02				H 	Ir/2      
VZVS	VZGE	.{}	2014-12-17					H 	?IN/3r    
VZVS	VZGL	.{}	2014-12-17					H 	Ir/2      
VZVS	VZGR	.{}	2014-12-17					H 	?/3r      
VZVS	VZGV	.{}	2014-12-17					H 	INr?/2    
VZVS	VZVS	RESULTS	2014-12-17	2014-12-17				H 	NAHp1?    
RESP	ADVP	Not Detected	2014-11-28	2014-11-28	2m			H 	?H/2m     
COSC	COSC	PFLP/	2014-11-28					X 	N         
COSD	COSD	Organisms sent 28/11/2014 11:04	2014-11-28					X 	N         
RESP	FLAP	Not Detected	2014-11-28	2014-11-28	2m			H 	?H/2m     
RESP	FLBP	Not Detected	2014-11-28	2014-11-28	2m			H 	?H/2m     
RESP	MPVP	Not Detected	2014-11-28	2014-11-28	2m			H 	?H/2m     
RESP	PFLP	POSITIVE	2014-11-28	2014-11-28	/2m			H 	?Hr/2m    
RESP	RSVP	Not Detected	2014-11-28	2014-11-28	2m			H 	?H/2m     
HBVL	2HB	Please note that this test is validated for
EDTA/EDTA plama samples only. Results from samples
other than EDTA/EDTA plasma should be interpreted
with caution. Please send repeat if clinically
indicated.	2014-12-16	2014-12-16				H 	NA?       
HBVL	BVL1	.	2014-12-16		IU/ml			H 	HAr?/5    
HBVL	BVL2	.	2014-12-16					H 	?r/5      
HBVL	BVLC	.{ AMEND }
This is an AMENDED report and replaces the
previous report issued under the same laboratory
number.	2014-12-31					H 	N?        
HBVL	HBVL	REPORT	2015-06-16	2015-06-16				H 	HABp1Nr?  
HBVL	HBVS	EDTA	2014-12-16	2014-12-16				H 	?rB/5     
HDVT	HDVT	.	2014-12-16					H 	?Hr/4     
HEAB	HEAB	Not tested	2015-01-27	2015-01-27				H 	A?        
HEAG	HEAG	POSITIVE	2015-01-27	2015-01-27				H 	A?/3      
HEAG	HEAT	REPORT	2015-01-27	2015-01-27				H 	NHp1p2Ar? 
HEAB	HEC2	This test is no longer performed. Please send a
faeces specimen for Helicobacter pylori antigen
testing if clinically indicated.	2015-01-27	2015-01-27				H 	N?A       
HEAB	HELA	Cancelled - see comments	2015-01-27	2015-01-27				H 	NA?       
HEAB	HELB	.{}	2015-01-27					H 	r         
HEAB	HELC	.{}	2015-01-27					H 	HI        
HEAB	HELD	.{}	2015-01-27					H 	HI        
HEAB	HELI	CANCELLED	2015-01-27	2015-01-27				H 	NHr?      
BRUS	BRAB	.{}	2015-06-15					H 	?r/14     
BRUS	BRME	.{}	2015-06-15					H 	?r/14     
BRUS	BRUG	Negative	2015-06-15	2015-06-15				H 	NI?       
BRUS	BRUM	POSITIVE	2015-06-15	2015-06-15				H 	NI?       
BRUS	BRUS	REPORT	2015-06-15	2015-06-15				H 	NAHrp1?   
HCAG	HCAG	.{}	2015-02-04					H 	?r/1      
HCAG	HCAR	.{}	2015-02-04					H 	Ir?       
HCAS	HCAS	4	2015-01-29	2015-01-30				H 	IrN       
HCAG	HCAT	REPORT	2015-05-29	2015-05-29				H 	NAHrp1?   
MPL	MPL	REPORT	2015-03-09	2015-03-09				H 	HNr?p1p2AB
MPL	MYCT	.{}	2015-03-09					H 	?/2       
MPL	MYGR	POSITIVE	2015-03-09	2015-03-09				H 	?Nr/2     
MPL	MYGV	10	2015-03-09	2015-03-09				H 	?NI/2     
MPL	MYMR	Negative	2015-03-09	2015-03-09				H 	?Nr/2     
MPL	MYMV	9	2015-03-09	2015-03-09				H 	?NI/2     
SAVI	SAVI	.{}	2015-06-15					H 	I?/0      
HBVL	BVL1	.{ 0 }	2015-06-16		IU/ml			H 	HAr?/5    
HBVL	BVL2	Not Detected	2015-06-16	2015-06-17				H 	?r/5      
HBAG	HBCO	Y	2015-11-06	2015-11-06				H 	NIr?      
HBAG	HBVA	.{}	2015-11-06					H 	HIr/1     
HBVL	HBVL	REPORT	2015-06-16	2015-06-17				H 	HABp1Nr?  
HBAG	HBVR	.{}	2015-11-06					H 	?r/2m     
HBVL	HBVS	EDTA	2015-06-16	2015-06-17				H 	?rB/5     
HBVV	HBVV	22	2015-10-20	2015-10-21				H 	HI        
HIVL	HIVL	REPORT	2015-06-16	2015-06-17				H 	HABp1Nr?  
HIVL	HVL1	.	2015-06-16		Copies/ml			H 	HAr?/5    
HIVL	HVL2	.	2015-06-16					H 	?r/5      
HIVL	HVLS	EDTA	2015-06-16	2015-06-17				H 	?rB/5     
YERS	SAVI	.{}	2015-06-29					H 	I?/0      
YERS	VREF	SENT	2015-06-26	2015-07-01				H 	I?/4      
YERS	YECM	The Gastrointestinal Bacteria Reference Unit at
PHE Colindale is experiencing reagent problems and
currently has suspended the Yersinia
serodiagnostic service. This sample will be saved.
Please contact Microbiology on 02034479515 if you
wish to discuss further.	2015-06-26	2015-07-01				H 	N?        
YERS	YECO	Not tested	2015-06-26	2015-07-01				H 	r?        
YERS	YEER	.{}	2015-06-26					H 	?m/7      
YERS	YEET	.{}	2015-06-26					H 	r?        
YERS	YEPR	.{}	2015-06-26					H 	?Bm/7     
YERS	YEPT	.{}	2015-06-26					H 	r?        
YERS	YERA	Cancelled - see comments	2015-06-26	2015-07-01				H 	NA?       
YERS	YERR	.{}	2015-06-26					H 	rB?       
YERS	YERS	CANCELLED	2015-06-26	2015-07-01				H 	HABp1Nr?  
YERS	YERT	.{}	2015-06-26					H 	I         
YERS	YEST	Not sent	2015-06-26	2015-07-01				H 	?I/4      
SCRW	CMGA	.{}	2015-08-05					H 	Ir/1      
SCRX	CMGR	.{}	2015-08-05					H 	?/2       
SCRW	CMMA	.{}	2015-08-05					H 	Ir/1      
SCRX	CMMR	.{}	2015-08-05					H 	?/2m      
SCRX	EBNA	.{}	2015-08-05					H 	?/2       
SCRW	EBNL	.{}	2015-08-04					H 	Ir/2      
SCRW	HBCA	.{}	2015-08-05					H 	HIr/1     
HBAG	HBCO	Y	2015-10-20	2015-10-21				H 	NIr?      
SCRX	HBCR	.{}	2015-08-05					H 	?r/2      
SCRW	HBVA	.{}	2015-08-05					H 	HIr/1     
SCRX	HBVR	.{}	2015-08-05					H 	?r/2m     
HBVV	HBVV	45	2015-10-20	2015-10-21				H 	HI        
SCRW	HCVA	.{}	2015-08-05					H 	Ir/1      
SCRX	HCVR	.{}	2015-08-05					H 	?/2m      
SCRW	HIVA	.{}	2015-08-05					H 	Ir/1      
SCRX	HIVR	.{}	2015-08-05					H 	?/2       
SCRX	SYPA	.{}	2015-08-05					H 	?Ir/1     
SCRW	TLVA	.{}	2015-08-05					H 	Ir/1      
SCRX	TLVR	.{}	2015-08-05					H 	?/2m      
SCRX	TOXG	.{}	2015-08-05					H 	?/2       
SCRX	TOXM	.{}	2015-08-05					H 	?/2m      
SCRW	TXGA	.{}	2015-08-05					H 	Ir/1      
SCRW	TXMA	.{}	2015-08-05					H 	Ir/1      
SCRX	VCAG	.{}	2015-08-05					H 	?/2       
SCRX	VCAM	.{}	2015-08-05					H 	?/2m      
SCRW	VCGL	.{}	2015-08-04					H 	Ir/2      
SCRW	VCML	.{}	2015-08-04					H 	Ir/2      
SCRW	VZG2	.{}	2015-08-05					H 	IrN       
SCRW	VZGL	.{}	2015-08-04					H 	Ir/2      
SCRX	VZGR	.{}	2015-08-05					H 	?/3r      
HBAG	HBCO	Y	2015-10-22	2015-10-22				H 	NIr?      
HBAG	HBVA	.{}	2015-10-22					H 	HIr/1     
HBAG	HBVR	.{}	2015-10-22					H 	?r/2m     
HBVV	HBVV	.{}	2015-10-22					H 	HI        
STS	RPR	.{}	2015-07-28					H 	?Hr/2m    
STS	SYPA	0.010	2015-07-28	2015-07-28				H 	?Ir/1     
STS	SYPR	Negative	2015-07-28	2015-07-28				H 	?r/2m     
STS	TPC	.{}	2015-07-28					H 	?/2       
STS	TPPA	.{}	2015-07-28					H 	?Hr/2m    
FBCY	HBGL	Request entered in error	2017-01-17	2017-01-18				A 	rCP/0     
ASR	HCON	.{}	2017-01-19					A 	?p1       
FBCY	HCTU	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
ASR	HGBA	.{}	2017-01-19					A 	?         
FBCZ	IG  	Request entered in error	2017-01-17	2017-01-18				A 	SN/0      
FBCZ	IGP 	Request entered in error	2017-01-17	2017-01-18				A 	SN/0      
FBCZ	LY  	Request entered in error	2017-01-17	2017-01-18				A 	CDSP/0    
FBCY	MCGL	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
FBCY	MCHU	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
FBCY	MCVU	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
FBCZ	MO  	Request entered in error	2017-01-17	2017-01-18				A 	CDS/0     
FBCY	MPVU	Request entered in error	2017-01-17	2017-01-18				A 	CS?/0     
FBCZ	NE  	Request entered in error	2017-01-17	2017-01-18				A 	CDS/0     
NR	NR1 	Request entered in error	2017-01-17					X 	SJ/0      
NR	NR2 	Request entered in error	2017-01-17					X 	SJ/0      
NR	NRC 	Request entered in error	2017-01-17	2017-01-18				A 	SN?/0     
NR	NRP 	Request entered in error	2017-01-17	2017-01-18				A 	SN/0      
FBCY	PLT 	Request entered in error	2017-01-17	2017-01-18				A 	CS/0      
FBCY	RCC 	Request entered in error	2017-01-17	2017-01-18				A 	P/0       
FBCY	RDWU	Request entered in error	2017-01-17	2017-01-18				A 	CS/0      
RET	REP 	Cancelled - Request entered in error	2017-01-17	2017-01-18				A 	/0        
RET	RET 	Request entered in error	2017-01-17	2017-01-18				A 	P/0       
FBCY	WCC 	Cancelled - FBC Request entered in error	2017-01-17	2017-01-18				A 	CWPS/0    
FBCY	HBGL	Request entered in error	2017-01-17	2017-01-18				A 	rCP/0     
ASR	HCON	.{}	2017-01-19					A 	?p1       
FBCY	HCTU	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
ASR	HGBA	.{}	2017-01-19					A 	?         
FBCZ	IG  	Request entered in error	2017-01-17	2017-01-18				A 	SN/0      
FBCZ	IGP 	Request entered in error	2017-01-17	2017-01-18				A 	SN/0      
FBCZ	LY  	Request entered in error	2017-01-17	2017-01-18				A 	CDSP/0    
FBCY	MCGL	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
FBCY	MCHU	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
FBCY	MCVU	Request entered in error	2017-01-17	2017-01-18				A 	CPS/0     
FBCZ	MO  	Request entered in error	2017-01-17	2017-01-18				A 	CDS/0     
FBCY	MPVU	Request entered in error	2017-01-17	2017-01-18				A 	CS?/0     
FBCZ	NE  	Request entered in error	2017-01-17	2017-01-18				A 	CDS/0     
FBCY	PLT 	Request entered in error	2017-01-17	2017-01-18				A 	CS/0      
FBCY	RCC 	Request entered in error	2017-01-17	2017-01-18				A 	P/0       
FBCY	RDWU	Request entered in error	2017-01-17	2017-01-18				A 	CS/0      
RET	REP 	Cancelled - Request entered in error	2017-01-17	2017-01-18				A 	/0        
RET	RET 	Request entered in error	2017-01-17	2017-01-18				A 	P/0       
FBCY	WCC 	Cancelled - FBC Request entered in error	2017-01-17	2017-01-18				A 	CWPS/0    
CRP	CRP 	.	2016-11-23					B 	AB        
HIV	CHIV	.{}	2013-06-11					H 	N?/2      
HIV	HIVA	0.300	2013-06-11	2013-06-11				H 	Ir/1      
HIVS	HIVI	Not Tested	2013-06-11	2013-06-11				H 	IN?/2     
HIV	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2013-06-11	2013-06-11				H 	?/2       
HIVS	HIVV	0.1	2013-06-11	2013-06-11				H 	Ir/2      
HIV 	CHIV	.{}	2013-06-11					H 	N?/2      
HIV 	HIVA	0.300	2013-06-11	2013-06-11				H 	Ir/1      
HIVS	HIVI	Not Tested	2013-06-11	2013-06-11				H 	IN?/2     
HIV 	HIVR	Not Detected
HIV-1 p24 Antigen Not Detected	2013-06-11	2013-06-11				H 	?/2       
HIVS	HIVV	0.1	2013-06-11	2013-06-11				H 	Ir/2      
EBVS	EBN1	0.21	2013-06-14	2013-06-14				H 	HIr/2     
EBVS	EBNA	Positive	2013-06-14	2013-06-14				H 	?/2       
EBVS	EBVC	Consistent with a past infection.	2013-06-14	2013-06-14				H 	Nr?       
MEAS	MEGR	POSITIVE	2013-06-13	2013-06-13				H 	r?/2      
MEAS	MEGV	0.59	2013-06-12	2013-06-12				H 	NIr/2     
MEAS	MELG	16.5	2013-06-13	2013-06-13				H 	Ir/2      
EBVS	VCA1	0.32	2013-06-14	2013-06-14				H 	HIr/2     
EBVM	VCA2	0.1	2013-06-13	2013-06-13				H 	HIr/2     
EBVS	VCAG	Positive	2013-06-14	2013-06-14				H 	?/2       
EBVM	VCAM	Not Detected	2013-06-13	2013-06-13				H 	?/2m      
ACV1	ACV1	.{}	2013-06-20					H 	?H/2m     
ANDX	ANDS	RESULTS	2013-06-20	2013-06-20				H 	Hr?       
ANDX	BVL1	200	2013-07-04	2013-07-04	IU/ml			H 	HAr?/5    
ANDX	BVL2	.{ Positive }	2013-07-04					H 	?r/5      
ANDI	CMGA	.{}	2013-06-20					H 	Ir/1      
ANDX	CMGR	.{}	2013-06-20					H 	?/2       
ANDI	CMMA	.{}	2013-06-20					H 	Ir/1      
ANDX	CMMR	.{}	2013-06-20					H 	?/2m      
ANDX	CVL1	.	2013-07-04		IU/ml			H 	Hr?/5     
ANDX	CVL2	.	2013-07-04					H 	?r/5m     
ANDI	HBCA	.{}	2013-06-20					H 	HIr/1     
ANDI	HBCO	Y	2013-06-20	2013-06-20				H 	NIr?      
ANDX	HBCR	.{}	2013-06-20					H 	?r/2      
ANDI	HBVA	.{}	2013-06-20					H 	HIr/1     
ANDX	HBVR	.{}	2013-06-20					H 	?r/2m     
ANDI	HCVA	.{}	2013-06-20					H 	Ir/1      
ANDX	HCVR	.{}	2013-06-20					H 	?/2m      
ANDI	HCVV	.{}	2013-06-14					H 	I/3       
ANDI	HIVA	.{}	2013-06-20					H 	Ir/1      
ANDX	HIVR	.{}	2013-06-20					H 	?/2       
ANDX	HVL1	.{}	2013-06-20		Copies/ml			H 	HAr?/5    
ANDX	HVL2	.{}	2013-06-20					H 	?r/5      
ANDI	SAVI	Sample saved in Virology.	2013-07-04	2013-07-04				H 	I?/0      
ANDI	SYPA	.{}	2013-06-20					H 	?Ir/1     
ANDX	SYPR	.{}	2013-06-20					H 	?r/2m     
ANDI	TLVA	.{}	2013-06-20					H 	Ir/1      
ANDX	TLVR	.{}	2013-06-20					H 	?/2m      
ANDX	TOXG	.{}	2013-06-20					H 	?/2       
ANDI	TPCO	Y	2013-06-20	2013-06-20				H 	IN?       
ANDI	TXGA	.{}	2013-06-20					H 	Ir/1      
ANDI	VCA1	.{}	2013-06-20					H 	HIr/2     
ANDX	VCAG	.{}	2013-06-20					H 	?/2       
ANDX	VZGR	POSITIVE	2013-07-04	2013-07-04				H 	?/3r      
ANDI	VZGV	10	2013-07-04	2013-07-04				H 	INr?/2    
RESP	2RE	AMENDED REPORT: This report replaces any previous
reports under this laboratory number. Printed
copies of any previous reports must be destroyed.	2013-07-03	2013-07-03				H 	NA?       
RESP	ADVP	Not Detected	2013-07-03	2013-07-03				H 	?H/2m     
HBVL	BVL1	1000	2013-07-10	2013-07-10	IU/ml			H 	HAr?/5    
HBVL	BVL2	.{ Positive }	2013-07-10					H 	?r/5      
HBVL	BVLP	.{ X }	2016-08-19					H 	NI?       
BVLR	BVLR	.{}	2016-08-31					H 	Ir?       
COSC	COSC	FLAP/	2013-07-03					X 	N         
COSD	COSD	Organisms sent 03/07/2013 16:13	2013-07-03					X 	N         
RESP	FLAP	POSITIVE	2013-07-03	2013-07-03				H 	?H/2m     
RESP	FLBP	Not Detected	2013-07-03	2013-07-03				H 	?H/2m     
HBVL	HBVL	REPORT	2016-08-19	2016-09-01				H 	HABp1Nr?  
HBVL	HBVS	SWAB	2013-07-10	2013-07-10				H 	?rB/5     
HDVP	HDRN	Not Detected	2013-07-10	2013-07-10				H 	?Hrm/20   
HDV	HDV 	REPORT	2016-08-19	2016-08-31				H 	NAp1?     
HDVP	HDVS	SWAB	2016-08-19	2016-09-01				H 	N?        
HDV	HDVT	Weak Reactive	2013-07-10	2013-07-10				H 	?Hr/4     
HIVL	HIVL	REPORT	2016-08-19	2016-09-01				H 	HABp1Nr?  
HIVL	HVL1	.{ 0 }	2016-08-19					H 	HAr?/5    
HIVL	HVL2	NOT detected (<50 Copies/ml)	2016-08-19	2016-09-01				H 	?r/5      
HIVL	HVLC	Please note that this test was performed on the
Hologic Aptima DX assay.	2016-08-19	2016-09-01				H 	N?        
HIVL	HVLH	NOT detected	2016-08-19	2016-09-01				H 	Ir?/5     
HIVL	HVLL	Please note that this test is validated for
EDTA/EDTA plasma samples only. Results from
samples other than EDTA/EDTA plasma should be
interpreted with caution. Please send repeat if
clinically indicated.	2016-08-19	2016-09-01				H 	NA?       
HIVL	HVLP	X	2016-08-19	2016-09-01				H 	NI?       
HIVL	HVLS	SWAB	2013-07-10	2013-07-10				H 	?rB/5     
RESP	MPVP	Not Detected	2013-07-03	2013-07-03				H 	?H/2m     
RESP	PFLP	Not Detected
AMENDED RESULT: The above result has been
amended since it was first issued.	2013-07-03	2013-07-03				H 	?Hr/2m    
RESP	RESP	REPORT	2016-08-19	2016-09-01				H 	NAHp1?r   
RESP	RESS	SWAB	2013-07-10	2013-07-10				H 	N?        
RESP	RSVP	Not Detected	2013-07-03	2013-07-03				H 	?H/2m     
SAVP	SAVP	Sample saved in Virology.	2016-08-22					X 	r?/5      
ASO	ASL5	<5	2013-07-05	2013-07-10				H 	Ir?       
ASO	ASOR	BORDERLINE POSITIVE: 100 IU/ml	2013-07-10	2013-07-10				H 	?/3       
HBVL	BVL1	400	2013-07-10	2013-07-10	IU/ml			H 	HAr?/5    
HBVL	BVL2	.{ Positive }	2013-07-10					H 	?r/5      
COSC	COSC	VCAM/	2013-07-04					X 	N         
COSD	COSD	Organisms sent 04/07/2013 18:01	2013-07-04					X 	N         
EBVS	EBN1	0.0O	2013-07-04	2013-07-04				H 	HIr/2     
EBVS	EBNA	Not Detected	2013-07-04	2013-07-04				H 	?/2       
HBVL	HBVS	EDTA	2013-07-10	2013-07-10				H 	?rB/5     
EBVS	VCA1	3.38	2013-07-04	2013-07-04				H 	HIr/2     
EBVM	VCA2	3.37	2013-07-04	2013-07-04				H 	HIr/2     
EBVS	VCAG	Positive	2013-07-04	2013-07-04				H 	?/2       
EBVM	VCAM	Positive	2013-07-04	2013-07-04				H 	?/2m      
HIV	CHIV	Comment	2015-12-03	2015-12-03				H 	N?/2      
HIVS	GEEN	.	2015-12-03					H 	I?/2      
HIV	HIVA	10.000	2015-12-03	2015-12-03				H 	Ir/1      
HIVS	HIVI	HIV-1 POSITIVE	2015-12-03	2015-12-03				H 	IN?/2     
HIV	HIVR	anti-HIV 1 Detected	2015-12-03	2015-12-03				H 	?/2       
HIVS	HIVV	3	2015-12-03	2015-12-03				H 	Ir/2      
HIV2	GEEN	.{}	2015-12-04					H 	I?/2      
HIV2	H2NA	.{}	2015-12-04					H 	?Hr/20    
HIV2	HI2I	.{}	2015-12-04					H 	I?r/20    
HIV2	HIV2	RESULTS	2015-12-04	2015-12-09				H 	NANr?p1   
HIV2	HV21	.{}	2015-12-04		Copies/ml			H 	?Hr/20    
HIV2	HV22	.{}	2015-12-04					H 	r/20      
TOXO	TOXG	NOT detected	2015-02-11	2015-02-11				H 	?/2       
TOXO	TOXM	NOT detected	2015-02-11	2015-02-11				H 	?/2m      
TOXO	TOXO	REPORT	2015-02-11	2015-02-11				H 	NHAp1?    
TOXO	TXGA	0.1	2015-02-11	2015-02-11				H 	Ir/1      
TOXO	TXMA	0.2	2015-02-11	2015-02-11				H 	Ir/1      
TOXO	TXPC	No serological evidence of toxoplasma infection.
The patient is susceptible to toxoplasma.
Pregnant and immunosuppressed patients should be
advised of the appropriate precautions to avoid
infections.	2015-02-11	2015-02-11				H 	Nr?       
VTES	VTES	.{}	2014-12-18					H 	          
HCVG	HCVG	RESULTS	2014-10-29	2014-10-30				H 	HABNp1r?  
HCVG	HCVT	Genotype 1b	2014-10-29	2014-10-30				H 	?Hr/10    
HCVG	HVGS	EDTA	2014-10-29	2014-10-30				H 	N?        
FOB	FOB 	Negative
FOB testing is NOT indicated for investigation of:
a) suspected symptomatic bowel cancer (requires
specialist referral - guidance.nice.org.uk/CG27)
b) iron deficiency anaemia	2017-11-16	2017-11-16				B 	?r        
FOB	FOBM	6	2017-11-16	2017-11-16				B 	NIJ-H     
FOB	FOB 	POSITIVE
FOB testing is NOT indicated for investigation of:
a) suspected symptomatic bowel cancer (requires
specialist referral - guidance.nice.org.uk/CG27)
b) iron deficiency anaemia	2017-11-16	2017-11-16				B 	?r        
FOB	FOBM	100	2017-11-16	2017-11-16				B 	NIJ-H     
HPV	HP16	DETECTED	2017-09-26	2017-09-26				H 	?/2       
HPV	HP18	NOT detected	2017-09-26	2017-09-26				H 	?/2       
HPV	HPC1	Please note: this methodology has changed from
Digene HC2 assay to the Abbott RealTime High Risk
HPV assay.
The Abbott RealTime High Risk (HR) assay is a
qualitative test for the detection of DNA from
fourteen high risk HPV subtypes: 16, 18
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68	2017-09-26	2017-09-26				H 	?         
HPV	HPHR	NOT detected	2017-09-26	2017-09-26				H 	B?/2      
HPV	HPST	Cervical swab	2017-09-26	2017-09-26				H 	?rN       
HPV	HPVA	REPORT	2017-09-26	2017-09-26				H 	NBHp1?r   
HPV	HPVO	High Risk (HR) HPV DNA has been DETECTED.
Manage as clinically indicated in view of the
patient''s cervical history.	2017-09-26	2017-09-26				H 	A?        
TBQ4	TB41	.	2017-07-18					I 	A         
TBQ4	TB42	.	2017-07-18					I 	          
TBQ4	TB4C	.{}	2017-09-22					I 	?B        
TBQ4	TB4F	.{}	2017-09-22					I 	?         
TBQ4	TB4H	REPORT	2017-07-18	2017-07-18				I 	NAHp1?    
TBQ4	TB4N	.	2017-07-18					I 	IN?       
TBQ4	TB4R	.	2017-07-18					I 	?r        
HIV	CHIV	.{}	2017-10-13					H 	N?/2      
HAVS	HAGA	60.00	2017-10-13	2017-10-13				H 	Ir/1      
HAVS	HAGR	POSITIVE	2017-10-13	2017-10-13				H 	?/2       
HAVS	HAVC	Immune to Hepatitis A.
~
Note that ACUTE Hepatitis A infection has not been
excluded.  Therefore, if this is suspected, please
contact us immediately to arrange anti-HAV IgM
testing.	2017-10-13	2017-10-13				H 	N?        
HAVS	HAVS	REPORT	2017-10-13	2017-10-13				H 	NAHp1?    
HBC	HBCA	2.390	2017-10-13	2017-10-13				H 	HIr/1     
HBS	HBCC	.{}	2017-10-13					H 	Nr?/2     
HBS	HBCO	Y	2017-10-13	2017-10-13				H 	NIr?      
HBC	HBCR	NOT detected	2017-10-13	2017-10-13				H 	?r/2      
HBS	HBSA	2.00	2017-10-13	2017-10-13				H 	HIr/1     
HBS	HBSI	NOT detected	2017-10-13	2017-10-13				H 	r?/2      
HBS	HBSR	<10	2017-10-13	2017-10-13				H 	?r/2      
HIV	HIVA	0.269	2017-10-13	2017-10-13				H 	Ir/1      
HIV	HIVR	NOT detected
HIV-1 p24 Antigen NOT detected	2017-10-13	2017-10-13				H 	?/2       
STS	RPR 	.{}	2017-10-13					H 	?Hr/2m    
STS	STS 	REPORT	2017-10-13	2017-10-13				H 	NAHrp1?   
STS	SYPA	0.070	2017-10-13	2017-10-13				H 	?Ir/1     
STS	SYPR	Negative	2017-10-13	2017-10-13				H 	?r/2m     
STS	TPC 	.{}	2017-10-13					H 	?/2       
STS	TPPA	.{}	2017-10-13					H 	?Hr/2m    
HBS	HBCC	.{}	2017-10-18					H 	Nr?/2     
HBS	HBCO	Y	2017-10-17	2017-10-17				H 	NIr?      
HBS	HBSA	0.02	2017-10-17	2017-10-17				H 	HIr/1     
HBS	HBSI	NOT detected	2017-10-17	2017-10-17				H 	r?/2      
HBS	HBSR	<10	2017-10-17	2017-10-17				H 	?r/2      
STS	RPR 	.{}	2017-10-17					H 	?Hr/2m    
STS	STS 	REPORT	2017-10-17	2017-10-17				H 	NAHrp1?   
STS	SYPA	0.010	2017-10-17	2017-10-17				H 	?Ir/1     
STS	SYPR	Negative	2017-10-17	2017-10-17				H 	?r/2m     
STS	TPC 	.{}	2017-10-17					H 	?/2       
STS	TPPA	.{}	2017-10-17					H 	?Hr/2m    
BKVL	BK10	REPORT	2017-10-26	2017-10-26				H 	NAHp1?r   
BKVL	BK20	EDTA	2017-10-26	2017-10-26				H 	Nr?       
BKVL	BK30	POSITIVE	2017-10-26	2017-10-26				H 	?         
BKVL	BK40	>10000000	2017-10-26	2017-10-26				H 	?         
COSC	COSC	SYPR/TPPA/	2017-11-27					X 	N         
COSD	COSD	Organisms sent 27/11/2017 11:24	2017-11-27					X 	N         
STS	RPR 	POSITIVE with undiluted serum	2017-11-26	2017-11-26				H 	?Hr/2m    
STS	SERJ	.{}	2017-11-26					H 	NIJ-      
STS	STS 	REPORT	2017-11-26	2017-11-26				H 	NAHrp1?   
STS	SYPA	100.000	2017-11-26	2017-11-26				H 	?Ir/1     
STS	SYPR	POSITIVE	2017-11-26	2017-11-26				H 	?r/2m     
STS	TPC 	Consistent with treponemal infection at some time.
Please send a further sample for confirmation if
this is the first positive result.	2017-11-26	2017-11-26				H 	?/2       
STS	TPPA	POSITIVE	2017-11-26	2017-11-26				H 	?Hr/2m    
AA	GP  	Cancelled - insufficient	2017-11-26	2017-11-26				I 	?Ar       
AA	LK2T	.{}	2017-11-26					I 	NIJ-H     
AA	MIT 	Negative	2017-11-26	2017-11-26				I 	?Ar       
AA	SMM 	Negative	2017-11-26	2017-11-26				I 	?A        
HSVS	HV10	Not Detected	2017-11-28	2017-11-29				H 	?/2       
HSVS	HV20	Not Detected	2017-11-28	2017-11-29				H 	?/2       
XYZA	XYZ1	3	2017-03-30	2017-03-30				B 	          
XYZA	XYZ2	140	2017-03-30	2017-03-30				B 	          
XYZA	XYZ3	5	2017-03-30	2017-03-30				B 	          
XYZ6	XYZ6	20	2017-03-30					B 	          
XYZA	XYZ1	4	2017-03-30	2017-03-30				B 	          
XYZA	XYZ2	140	2017-03-30	2017-03-30				B 	          
XYZA	XYZ3	5	2017-03-30	2017-03-30				B 	          
XYZB	XYZ4	10	2017-03-30	2017-03-30				B 	          
XYZB	XYZ5	50	2017-03-30	2017-03-30				B 	          
XYZB	XYZ6	40	2017-03-30					B 	          
XYZA	XYZ1	4	2017-03-30	2017-03-30				B 	          
XYZA	XYZ2	140	2017-03-30	2017-03-30				B 	          
XYZA	XYZ3	4	2017-03-30	2017-03-30				B 	          
XYZA	XYZ1	4	2017-03-30	2017-03-30				B 	          
XYZA	XYZ2	140	2017-03-30	2017-03-30				B 	          
XYZA	XYZ3	5	2017-03-30	2017-03-30				B 	          
XYZB	XYZ4	10	2017-03-30	2017-03-30				B 	          
XYZB	XYZ5	100	2017-03-30	2017-03-30				B 	          
XYZB	XYZ6	20	2017-03-30	2017-03-30				B 	          
XYZA	XYZ1	4	2017-04-06	2017-04-06				B 	          
XYZA	XYZ2	140	2017-04-06	2017-04-06				B 	          
XYZA	XYZ3	4.1	2017-04-06	2017-04-06				B 	          
XYZB	XYZ4	10	2017-04-06	2017-04-06				B 	          
XYZB	XYZ5	100	2017-04-06	2017-04-06				B 	          
XYZB	XYZ6	40	2017-04-06	2017-04-06				B 	          
XYZA	XYZ1	5	2017-04-06	2017-04-06				B 	          
XYZA	XYZ2	141	2017-04-06	2017-04-06				B 	          
XYZA	XYZ3	4	2017-04-06	2017-04-06				B 	          
XYZB	XYZ4	12	2017-04-06	2017-04-06				B 	          
XYZB	XYZ5	70	2017-04-06	2017-04-06				B 	          
XYZB	XYZ6	35	2017-04-06	2017-04-06				B 	          
XYZA	XYZ1	4	2017-04-06	2017-04-06				B 	          
XYZA	XYZ2	139	2017-04-06	2017-04-06				B 	          
XYZA	XYZ3	.{.}	2017-10-26					B 	          
XYZ5	XYZ5	101	2017-04-06	2017-04-06				B 	          
XYZA	XYZ1	.{.}	2017-10-26					B 	          
XYZA	XYZ2	140	2017-04-20	2017-04-20				B 	          
XYZA	XYZ3	5	2017-04-20	2017-04-20				B 	          
XYZB	XYZ4	11	2017-04-20	2017-04-20				B 	          
XYZB	XYZ5	.{.}	2017-10-26					B 	          
XYZB	XYZ6	.{.}	2017-10-26					B 	          
XYZA	XYZ1	5	2017-04-20	2017-04-20				B 	          
XYZA	XYZ2	139	2017-04-20	2017-04-20				B 	          
XYZA	XYZ3	4	2017-04-20	2017-04-20				B 	          
XYZB	XYZ4	10	2017-04-20	2017-04-20				B 	          
XYZB	XYZ5	101	2017-04-20	2017-04-20				B 	          
XYZB	XYZ6	41	2017-04-20	2017-04-20				B 	          
XYZA	XYZ1	5	2017-04-20	2017-04-20				B 	          
XYZA	XYZ2	141	2017-04-20	2017-04-20				B 	          
XYZA	XYZ3	.{.}	2017-10-26					B 	          
XYZ5	XYZ5	.{.}	2017-10-26					B 	          
XYZA	XYZ1	5	2017-04-20	2017-04-20				B 	          
XYZA	XYZ2	141	2017-04-20	2017-04-20				B 	          
XYZA	XYZ3	5	2017-04-20	2017-04-20				B 	          
XYZB	XYZ4	11	2017-04-20	2017-04-20				B 	          
XYZB	XYZ5	112	2017-04-20	2017-04-20				B 	          
XYZB	XYZ6	.{.}	2017-10-26					B 	          
XYZA	XYZ1	4	2017-05-30	2017-05-30				B 	          
XYZA	XYZ2	140	2017-05-30	2017-05-30				B 	          
XYZA	XYZ3	4.5	2017-05-30	2017-05-30				B 	          
XYZB	XYZ4	10	2017-06-06	2017-06-06				B 	          
XYZB	XYZ5	60	2017-06-06	2017-06-06				B 	          
XYZB	XYZ6	30	2017-06-06	2017-06-06				B 	          
XYZA	XYZ1	4	2017-07-27	2017-07-27				B 	          
XYZA	XYZ2	140	2017-07-27	2017-07-27				B 	          
XYZA	XYZ3	5	2017-07-27	2017-07-27				B 	          
XYZB	XYZ4	10	2017-08-23	2017-08-23				B 	          
XYZB	XYZ5	50	2017-08-23	2017-08-23				B 	          
XYZB	XYZ6	20	2017-08-23	2017-08-23				B 	          
XYZA	XYZ1	4	2017-08-23	2017-08-23				B 	          
XYZA	XYZ2	135	2017-08-23	2017-08-23				B 	          
XYZA	XYZ3	5	2017-08-23	2017-08-23				B 	          
ESR	ESR 	5	2016-11-16	2016-11-16				A 	C?/0      
TELC	DATC	.	2016-11-16					A 	/0        
INR	INR 	10.00	2016-11-16	2016-11-16				A 	/1        
TELC	PERC	.	2016-11-16					A 	/0        
INR	PT  	11.0	2016-11-16	2016-11-16				A 	/1        
GLU	GLU 	5.0
Reference range applies to fasting samples only.	2016-11-16	2016-11-16				B 	AB        
CRP	CRP 	Cancelled - Request entered in error.	2016-11-22	2016-11-22				B 	AB        
ELU	CREA	.{.}	2017-10-26					B 	CPr       
ELU	GFR 	.{.}	2017-10-26					B 	          
ELU	K   	.{.}	2017-10-26					B 	CP        
ELU	NA  	.{.}	2017-10-26					B 	CP        
ELU	UREA	.{.}	2017-10-26					B 	CP        
XYZA	XYZ1	5.0	2016-11-22	2016-11-22				B 	          
XYZA	XYZ2	140	2016-11-22	2016-11-22				B 	          
XYZA	XYZ3	5.0	2016-11-22	2016-11-22				B 	          
ELU	ZAGE	91	2016-12-20					X 	          
XYZA	XYZ1	.	2016-12-04					B 	          
XYZA	XYZ2	.	2016-12-04					B 	          
XYZA	XYZ3	.	2016-12-04					B 	          
XYZA	XYZ1	5	2017-01-19	2017-01-19				B 	          
XYZA	XYZ2	140	2017-01-19	2017-01-19				B 	          
XYZA	XYZ3	5	2017-01-19	2017-01-19				B 	          
XYZA	XYZ1	4.5	2017-01-27	2017-01-27				B 	          
XYZA	XYZ2	140	2017-01-27	2017-01-27				B 	          
XYZA	XYZ3	4.5	2017-01-27	2017-01-27				B 	          
GLU	GLU 	4.5
Reference range applies to fasting samples only.	2016-11-09	2016-11-09				B 	AB        
ESR	ESR 	5	2016-11-09	2016-11-09				A 	C?/0      
ESR	ESR 	5	2016-11-09	2016-11-09				A 	C?/0      
CRP	CRP 	3.5	2016-11-09	2016-11-09				B 	AB        
GLU	GLU 	4.5
Reference range applies to fasting samples only.	2016-11-11	2016-11-11				B 	AB        
GLU	GLU 	.	2016-11-22					B 	AB        
XYZ5	XYZ5	Positive	2014-02-26	2014-02-26				B 	          
XYZ6	XYZ6	43C3.	2014-02-26	2014-02-26				B 	          
LFT	ALB	40	2014-03-05	2014-03-05	g/L	34	50	B 	CP        
LFT	ALP	40	2014-03-05	2014-03-05	IU/L	35	104	B 	C         
LFT	ALT	20	2014-03-05	2014-03-05	IU/L	10	35	B 	C         
LFT	BILI	Cancelled - see comments	2014-03-05	2014-03-05	umol/L	0	137	B 	CPr       
BON	CA	2.40	2014-03-05	2014-03-05	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.51	2014-03-05	2014-03-05	mmol/L	2.15	2.55	B 	C         
BON	PHOS	sample haemolysed	2014-03-05	2014-03-05	mmol/L	0.87	1.45	B 	CP        
BON	ALB	50	2014-03-11	2014-03-11	g/L	38	54	B 	CP        
BON	ALP	150	2014-03-11	2014-03-11	IU/L	0	187	B 	C         
BON	CA	2.50	2014-03-11	2014-03-11	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.42	2014-03-11	2014-03-11	mmol/L	2.15	2.55	B 	C         
ELU	CREA	65	2014-03-11	2014-03-11	umol/L	50	77	B 	CPr       
ELU	FACR	.	2014-03-11					X 	N         
ELU	GFR	.
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to
UK CKD guidelines: www.renal.org/CKDguide/ckd.html
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2014-03-11		.			B 	          
ELU	H	.	2014-03-11					  	JNr       
ELU	I	.	2014-03-11					  	JN        
ELU	K	4.0	2014-03-11	2014-03-11	mmol/L	3.5	5.1	B 	CP        
ELU	L	.	2014-03-11					  	JN        
ELU	NA	140	2014-03-11	2014-03-11	mmol/L	135	145	B 	CP        
BON	PHOS	1.20	2014-03-11	2014-03-11	mmol/L	0.87	1.45	B 	CP        
ELU	SEX	.	2014-03-11					X 	N         
ELU	UREA	4.0	2014-03-11	2014-03-11	mmol/L	1.7	8.3	B 	CP        
ELU	ZAGE	13	2014-03-11		y			X 	          
LFT	ALB	40	2014-03-11	2014-03-11	g/L	38	54	B 	CP        
LFT	ALP	150	2014-03-11	2014-03-11	IU/L	0	187	B 	C         
LFT	ALT	20	2014-03-11	2014-03-11	IU/L	10	35	B 	C         
LFT	BILI	15	2014-03-11	2014-03-11	umol/L	0	137	B 	CPr       
BON	ALB	45	2014-03-11	2014-03-11	g/L	38	54	B 	CP        
BON	ALP	150	2014-03-11	2014-03-11	IU/L	0	187	B 	C         
BON	CA	2.40	2014-03-11	2014-03-11	mmol/L	2.15	2.55	B 	CP        
BON	CCA	2.41	2014-03-11	2014-03-11	mmol/L	2.15	2.55	B 	C         
BON	PHOS	1.20	2014-03-11	2014-03-11	mmol/L	0.87	1.45	B 	CP        
AFP	AFP 	4.0
Method used for AFP: Roche Modular	2017-07-05	2017-07-05				B 	          
LFT	ALB	25	2016-01-07	2016-01-07	g/L	34	50	B 	CP        
LFT	ALP	Positive	2016-01-07	2016-01-07	IU/L	35	104	B 	C         
LFT	ALT	Low Level Positive	2016-01-07	2016-01-07	IU/L	10	35	B 	C         
LFT	BILI	18	2016-01-07	2016-01-07	umol/L	0	137	B 	CPr       
C125	C125	25
Method used for CA125 :Roche Modular	2015-12-16	2015-12-16	kIU/L	0	35	B 	          
C153	C153	15
Method used for CA153 :Roche Modular	2015-12-16	2015-12-16	kIU/L	0	25	B 	          
C199	C199	19
Method used for CA199 :Roche Modular	2015-12-16	2015-12-16	kIU/L	0	27	B 	          
CRP	CRP	Not detected	2016-01-07	2016-01-07	mg/L	0	5.0	B 	AB        
HERP	CMVP	.{}	2017-03-27					H 	?r/3m     
HERP	EBVP	.{}	2017-03-27					H 	?r/3m     
HERP	HERP	REPORT	2017-03-27	2017-03-27				H 	NHAp1?r   
HERP	HS1P	.{}	2017-03-27					H 	?r/3m     
HERP	HS2P	.{}	2017-03-27					H 	?r/3m     
HERP	VZVP	.{}	2017-03-27					H 	?r/3m     
XYZA	XYZ1	5	2016-03-03	2016-03-03		3.0	7.0	B 	          
XYZA	XYZ2	140	2016-03-03	2016-03-03		133	143	B 	          
XYZA	XYZ3	5	2016-03-03	2016-03-03		3.7	5.2	B 	          
XYZA	XYZ1	5	2016-03-03	2016-03-03		3.0	7.0	B 	          
XYZA	XYZ2	140	2016-03-03	2016-03-03		133	143	B 	          
XYZA	XYZ3	4.0	2016-03-03	2016-03-03		3.7	5.2	B 	          
XYZA	XYZ1	4	2017-11-10	2017-11-10				B 	          
XYZA	XYZ2	140	2017-11-10	2017-11-10				B 	          
XYZA	XYZ3	5	2017-11-10	2017-11-10				B 	          
XYZA	XYZ1	5	2017-11-10	2017-11-10				B 	          
XYZA	XYZ2	138	2017-11-10	2017-11-10				B 	          
XYZA	XYZ3	4.8	2017-11-10	2017-11-10				B 	          
XYZA	XYZ1	4	2017-11-23	2017-11-23				B 	          
XYZA	XYZ2	140	2017-11-23	2017-11-23				B 	          
XYZA	XYZ1	4	2017-11-30	2017-11-30				B 	          
XYZA	XYZ2	140	2017-11-30	2017-11-30				B 	          
XYZA	XYZ3	5	2017-11-30	2017-11-30				B 	          
CSFW	CTP 	.{test patient}	2017-06-13					B 	          
CSFW	CWCC	.	2017-06-13					A 	N         
HESP	HCON	.{}	2017-02-01					A 	?p1       
HESP	HGBA	.{}	2017-02-01					A 	?         
HESP	HGMF	.{}	2017-02-01					A 	          
HESP	HGMH	.{}	2017-02-01					A 	          
HESP	HGMS	.{}	2017-02-01					A 	          
HESP	HCON	.{}	2017-03-22					A 	?p1       
HESP	HGBA	.{}	2017-03-22					A 	?         
HESP	HGMF	.{}	2017-03-22					A 	          
HESP	HGMH	.{}	2017-03-22					A 	          
HESP	HGMS	.{}	2017-03-22					A 	          
COAT	APRA	Coagulation request entered in error.	2016-12-14	2016-12-14				A 	?/1       
COAT	APTT	Coagulation request entered in error.	2016-12-14	2016-12-14				A 	P/1       
COAT	FIB 	Coagulation request entered in error.	2016-12-14	2016-12-14				A 	p1/1      
FBCY	HBGL	Request entered in error	2016-12-14	2016-12-14				A 	rCP/0     
FBCY	HCTU	Request entered in error	2016-12-14	2016-12-14				A 	CPS/0     
FBCZ	IG  	Request entered in error	2016-12-14	2016-12-14				A 	SN/0      
FBCZ	IGP 	Request entered in error	2016-12-14	2016-12-14				A 	SN/0      
COAT	INR 	Coagulation request entered in error.	2016-12-14	2016-12-14				A 	/1        
FBCZ	LY  	Request entered in error	2016-12-14	2016-12-14				A 	CDSP/0    
FBCY	MCGL	Request entered in error	2016-12-14	2016-12-14				A 	CPS/0     
FBCY	MCHU	Request entered in error	2016-12-14	2016-12-14				A 	CPS/0     
FBCY	MCVU	Request entered in error	2016-12-14	2016-12-14				A 	CPS/0     
FBCZ	MO  	Request entered in error	2016-12-14	2016-12-14				A 	CDS/0     
FBCY	MPVU	Request entered in error	2016-12-14	2016-12-14				A 	CS?/0     
FBCZ	NE  	Request entered in error	2016-12-14	2016-12-14				A 	CDS/0     
FBCY	PLT 	Request entered in error	2016-12-14	2016-12-14				A 	CS/0      
COAT	PT  	Cancelled - Coagulation request entered in error.	2016-12-14	2016-12-14				A 	/1        
FBCY	RCC 	Request entered in error	2016-12-14	2016-12-14				A 	P/0       
FBCY	RDWU	Request entered in error	2016-12-14	2016-12-14				A 	CS/0      
FBCY	WCC 	Cancelled - FBC Request entered in error	2016-12-14	2016-12-14				A 	CWPS/0    
CRP	CRP 	4.0	2017-02-23	2017-02-23				B 	AB        
LFT	ALB 	35	2016-11-15	2016-11-15				B 	CP        
LFT	ALP 	50	2016-11-15	2016-11-15				B 	C         
LFT	ALT 	25	2016-11-15	2016-11-15				B 	C         
LFT	BILI	15	2016-11-15	2016-11-15				B 	CPr       
GLU	GLU 	.	2016-11-22					B 	AB        
LFT	ALB 	.	2016-11-22					B 	CP        
LFT	ALP 	.	2016-11-22					B 	C         
LFT	ALT 	.	2016-11-22					B 	C         
LFT	BILI	.	2016-11-22					B 	CPr       
GLU	GLU 	.
Reference range applies to fasting samples only.	2016-11-22					B 	AB        
LFT	H   	.	2016-11-22					  	JNr       
LFT	I   	.	2016-11-22					  	JN        
LFT	L   	.	2016-11-22					  	JN        
LFT	ALB 	.	2016-11-22					B 	CP        
LFT	ALP 	.	2016-11-22					B 	C         
LFT	ALT 	.	2016-11-22					B 	C         
LFT	BILI	.	2016-11-22					B 	CPr       
GLU	GLU 	.
Reference range applies to fasting samples only.	2016-11-22					B 	AB        
LFT	H   	.	2016-11-22					  	JNr       
LFT	I   	.	2016-11-22					  	JN        
LFT	L   	.	2016-11-22					  	JN        
ELU	CREA	.	2016-11-22					B 	CPr       
ELU	FACR	.	2016-11-22					X 	N         
ELU	GFR 	.
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-11-22					B 	          
GLU	GLU 	.
Reference range applies to fasting samples only.	2016-11-22					B 	AB        
ELU	H   	.	2016-11-22					  	JNr       
ELU	I   	.	2016-11-22					  	JN        
ELU	K   	.	2016-11-22					B 	CP        
ELU	L   	.	2016-11-22					  	JN        
ELU	NA  	.	2016-11-22					B 	CP        
ELU	SEX 	.	2016-11-22					X 	N         
ELU	UREA	.	2016-11-22					B 	CP        
ELU	ZAGE	59	2016-11-15					X 	          
GLU	GLU 	.	2016-11-24					B 	AB        
GLU	GLU 	4.0
Reference range applies to fasting samples only.	2016-11-22	2016-11-22				B 	AB        
CRP	CRP 	.	2016-11-23					B 	AB        
LFT	ALB 	35	2016-11-11	2016-11-11				B 	CP        
LFT	ALP 	50	2016-11-11	2016-11-11				B 	C         
LFT	ALT 	20	2016-11-11	2016-11-11				B 	C         
LFT	BILI	10	2016-11-11	2016-11-11				B 	CPr       
BON	CA  	2.40	2016-11-11	2016-11-11				B 	CP        
BON	CCA 	2.60	2016-11-11	2016-11-11				B 	C         
ELU	CREA	70	2016-11-11	2016-11-11				B 	CPr       
ELU	GFR 	5
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-11-11	2016-11-11				B 	          
ELU	K   	4.0	2016-11-11	2016-11-11				B 	CP        
MG	MG  	0.80	2016-11-11	2016-11-11				B 	CP        
ELU	NA  	140	2016-11-11	2016-11-11				B 	CP        
BON	PHOS	1.00	2016-11-11	2016-11-11				B 	CP        
ELU	SEX 	M	2016-11-11					X 	N         
ELU	UREA	2.0	2016-11-11	2016-11-11				B 	CP        
ELU	ZAGE	70	2016-11-11					X 	          
FBCZ	BA  	 0.0%  0.00	2016-11-11	2016-11-11				A 	CDSN/0    
FBCZ	BLAA	 0.0%  0.00	2016-11-11	2016-11-11				A 	DSN       
FBCZ	EO  	 0.0%  0.00	2016-11-11	2016-11-11				A 	CDSN/0    
FBCZ	FCOM	Occasional	2016-11-11	2016-11-11				A 	K?Nr      
FLG	FLG1	Blasts ?	2016-11-11	2016-11-11				A 	NJ-I?     
FLG	FLG2	Fragment	2016-11-11	2016-11-11				A 	NJ-I?     
FLG	FLG4	WBC Abn	2016-11-11	2016-11-11				A 	NJ-I?     
FLG	FLG7	L-Blasts?	2016-11-11	2016-11-11				A 	NJ-I?     
FLG	FLG9	NRBC ?	2016-11-11	2016-11-11				A 	NJ-I?     
FBCY	HBGL	140	2016-11-11	2016-11-11				A 	rCP/0     
FBCY	HCTU	0.400	2016-11-11	2016-11-11				A 	CPS/0     
FBCZ	IG  	.{}	2016-11-11					A 	SN/0      
FBCZ	IGP 	.{}	2016-11-11					A 	SN/0      
FBCZ	LY  	 100%  3.00	2016-11-11	2016-11-11				A 	CDSP/0    
FBCY	MCGL	330	2016-11-11	2016-11-11				A 	CPS/0     
FBCY	MCHU	28.0	2016-11-11	2016-11-11				A 	CPS/0     
FBCY	MCVU	88.0	2016-11-11	2016-11-11				A 	CPS/0     
FBCZ	MET 	 0.0%  0.00	2016-11-11	2016-11-11				A 	DSN       
FBCZ	MO  	10.0%  0.30	2016-11-11	2016-11-11				A 	CDS/0     
FBCY	MPVU	8.0	2016-11-11	2016-11-11				A 	CS?/0     
FBCZ	MYEA	 0.0%  0.00	2016-11-11	2016-11-11				A 	DSN       
FBCZ	NE  	 100%  3.00	2016-11-11	2016-11-11				A 	CDS/0     
FBCY	NRB 	 0.0%  0.00	2016-11-11	2016-11-11				A 	SND       
FBCY	PLT 	160	2016-11-11	2016-11-11				A 	CS/0      
FBCZ	PROA	 0.0%  0.00	2016-11-11	2016-11-11				A 	DSN       
FBCY	RCC 	5.00	2016-11-11	2016-11-11				A 	P/0       
FBCY	RDWU	11.6	2016-11-11	2016-11-11				A 	CS/0      
FBCY	WCC 	3.00	2016-11-11	2016-11-11				A 	CWPS/0    
LFT	ALB 	Cancelled - see comments	2016-12-04	2016-12-04				B 	CP        
LFT	ALP 	Cancelled - see comments	2016-12-04	2016-12-04				B 	C         
LFT	ALT 	Cancelled - see comments	2016-12-04	2016-12-04				B 	C         
LFT	BILI	Cancelled	2016-12-04	2016-12-04				B 	CPr       
GLU	GLU 	Cancelled - see comments	2016-12-04	2016-12-04				B 	AB        
LFT	H   	Cancelled - see comments	2016-12-04					  	JNr       
LFT	I   	Cancelled - see comments	2016-12-04					  	JN        
LFT	L   	Cancelled - see comments	2016-12-04					  	JN        
GLU	GLU 	Cancelled - see comments	2016-12-04	2016-12-04				B 	AB        
GLU	GLU 	4.8
Reference range applies to fasting samples only.	2016-11-09	2016-11-09				B 	AB        
LFT	ALB 	40	2016-11-09	2016-11-09				B 	CP        
LFT	ALP 	50	2016-11-09	2016-11-09				B 	C         
LFT	ALT 	13	2016-11-09	2016-11-09				B 	C         
LFT	BILI	10	2016-11-09	2016-11-09				B 	CPr       
GLU	GLU 	4.9
Reference range applies to fasting samples only.	2016-11-09	2016-11-09				B 	AB        
GLU	GLU 	5.0
Reference range applies to fasting samples only.	2016-11-09	2016-11-09				B 	AB        
GLU	GLU 	5.0
Reference range applies to fasting samples only.	2016-11-09	2016-11-09				B 	AB        
GLU	GLU 	4.0
Reference range applies to fasting samples only.	2016-11-09	2016-11-09				B 	AB        
HIV	CHIV	.{}	2016-11-22					H 	N?/2      
HBVZ	HBCC	.{}	2016-11-22					H 	Nr?/2     
HBAG	HBCO	Y	2016-11-22	2016-11-22				H 	NIr?      
HBAG	HBVA	.{}	2016-11-22					H 	HIr/1     
HBAG	HBVR	.{}	2016-11-22					H 	?r/2m     
HIV	HIVA	.{}	2016-11-22					H 	Ir/1      
HIV	HIVR	.{}	2016-11-22					H 	?/2       
STS	RPR 	.{}	2016-11-09					H 	?Hr/2m    
SAVC	SAVC	.{}	2016-11-22					H 	?r/2      
SAVE	SAVE	.{}	2016-11-22					H 	?/2       
STS	STS 	REPORT	2016-11-22	2016-11-22				H 	NAHrp1?   
STS	SYPA	.{}	2016-11-22					H 	?Ir/1     
STS	SYPR	.{}	2016-11-22					H 	?r/2m     
STS	TPC 	.{}	2016-11-09					H 	?/2       
STS	TPPA	.{}	2016-11-09					H 	?Hr/2m    
C1QR	C1QR	16	2016-11-09	2016-11-10				I 	rA        
C1QR	CQDR	.	2016-11-23					I 	I         
C1QR	CQDS	.	2016-11-23					I 	I         
C1QR	CQRC	Test. Please ignore	2016-11-09	2016-11-10				I 	NA        
C1QR	CQRL	.	2016-11-23					I 	?         
CRP	CRP 	4.0	2016-11-09	2016-11-09				B 	AB        
FBCZ	BA  	 1.4%  0.05	2016-11-18	2016-11-18				A 	CDSN/0    
FBCZ	BLAA	 0.0%  0.00	2016-11-18	2016-11-18				A 	DSN       
FBCZ	EO  	 3.8%  0.14	2016-11-18	2016-11-18				A 	CDSN/0    
FBCZ	FCOM	Test. Please ignore	2016-11-18	2016-11-18				A 	K?Nr      
FBCY	HBGL	134	2016-11-18	2016-11-18				A 	rCP/0     
FBCY	HCTU	0.400	2016-11-18	2016-11-18				A 	CPS/0     
FBCZ	IG  	.{}	2016-11-18					A 	SN/0      
FBCZ	IGP 	.{}	2016-11-18					A 	SN/0      
FBCZ	LY  	80.0%  2.96	2016-11-18	2016-11-18				A 	CDSP/0    
FBCY	MCGL	330	2016-11-18	2016-11-18				A 	CPS/0     
FBCY	MCHU	30.0	2016-11-18	2016-11-18				A 	CPS/0     
FBCY	MCVU	88.0	2016-11-18	2016-11-18				A 	CPS/0     
FBCZ	MET 	 0.0%  0.00	2016-11-18	2016-11-18				A 	DSN       
FBCZ	MO  	13.2%  0.49	2016-11-18	2016-11-18				A 	CDS/0     
FBCY	MPVU	10.8	2016-11-18	2016-11-18				A 	CS?/0     
FBCZ	MYEA	 0.0%  0.00	2016-11-18	2016-11-18				A 	DSN       
FBCZ	NE  	66.5%  2.46	2016-11-18	2016-11-18				A 	CDS/0     
FBCY	NRB 	 0.0%  0.00	2016-11-18	2016-11-18				A 	SND       
FBCY	PLT 	156	2016-11-18	2016-11-18				A 	CS/0      
FBCZ	PROA	 0.0%  0.00	2016-11-18	2016-11-18				A 	DSN       
FBCY	RCC 	4.60	2016-11-18	2016-11-18				A 	P/0       
FBCY	RDWU	12.0	2016-11-18	2016-11-18				A 	CS/0      
FBCY	WCC 	3.70	2016-11-18	2016-11-18				A 	CWPS/0    
FBCZ	BA  	 0.0%  0.00	2016-11-22	2016-11-22				A 	CDSN/0    
FBCZ	BLAA	-	2016-11-22	2016-11-22				A 	DSN       
FBCZ	EO  	10.0%  0.30	2016-11-22	2016-11-22				A 	CDSN/0    
FBCY	HBGL	140	2016-11-22	2016-11-22				A 	rCP/0     
FBCY	HCTU	0.400	2016-11-22	2016-11-22				A 	CPS/0     
FBCZ	IG  	.{}	2016-11-22					A 	SN/0      
FBCZ	IGP 	.{}	2016-11-22					A 	SN/0      
FBCZ	LY  	80.0%  2.40	2016-11-22	2016-11-22				A 	CDSP/0    
FBCY	MCGL	330	2016-11-22	2016-11-22				A 	CPS/0     
FBCY	MCHU	28.0	2016-11-22	2016-11-22				A 	CPS/0     
FBCY	MCVU	88.0	2016-11-22	2016-11-22				A 	CPS/0     
FBCZ	MET 	 0.0%  0.00	2016-11-22	2016-11-22				A 	DSN       
FBCZ	MO  	20.0%  0.60	2016-11-22	2016-11-22				A 	CDS/0     
FBCY	MPVU	8.0	2016-11-22	2016-11-22				A 	CS?/0     
FBCZ	MYEA	 0.0%  0.00	2016-11-22	2016-11-22				A 	DSN       
FBCZ	NE  	80.0%  2.40	2016-11-22	2016-11-22				A 	CDS/0     
FBCY	NRB 	50.0%  1.50	2016-11-22	2016-11-22				A 	SND       
FBCY	PLT 	160	2016-11-22	2016-11-22				A 	CS/0      
FBCZ	PROA	 0.0%  0.00	2016-11-22	2016-11-22				A 	DSN       
FBCY	RCC 	4.50	2016-11-22	2016-11-22				A 	P/0       
FBCY	RDWU	12.0	2016-11-22	2016-11-22				A 	CS/0      
FBCY	WCC 	3.00	2016-11-22	2016-11-22				A 	CWPS/0    
LFT	ALB 	Cancelled - see comments	2016-12-04	2016-12-04				B 	CP        
LFT	ALP 	Cancelled - see comments	2016-12-04	2016-12-04				B 	C         
LFT	ALT 	Cancelled - see comments	2016-12-04	2016-12-04				B 	C         
LFT	BILI	Cancelled - see comments	2016-12-04	2016-12-04				B 	CPr       
LFT	H   	Cancelled - see comments	2016-12-04					  	JNr       
LFT	I   	Cancelled - see comments	2016-12-04					  	JN        
LFT	L   	Cancelled - see comments	2016-12-04					  	JN        
GLU	GLU 	5.9
Reference range applies to fasting samples only.	2016-11-11	2016-11-11				B 	AB        
HBVL	2HB 	.{}	2016-10-23					H 	NA?       
HBVL	BVL1	.{}	2016-10-23					H 	HAr?/5    
HBVL	BVL2	.{}	2016-10-23					H 	?r/5      
HBVL	BVLC	TEST	2016-10-23	2016-10-23				H 	N?        
HBVL	BVLH	.{}	2016-10-23					H 	Ir?       
HBVL	BVLK	.{}	2016-10-23					H 	NA?       
HBVL	BVLL	.{}	2016-10-23					H 	NA?       
HBVL	BVLP	.{ None in past 300 days }	2016-10-21					H 	NI?       
HBVL	HBVS	.{}	2016-10-23					H 	?rB/5     
GLU	GLU 	Cancelled - see comments	2016-12-04	2016-12-04				B 	AB        
VITE	VITE	Cancelled - see comments
Ordercomms testing	2017-06-30	2017-06-30				D 	          
NIAT	BTP 	.	2016-12-20					F 	A         
NIAT	NIF 	.	2016-12-20					F 	?N        
NIAT	QDES	.	2016-12-20					F 	?AB       
CP13	CP13	.	2016-10-26					A 	/3        
ADVP	ADVM	.{}	2016-10-25					H 	?H/3m     
ACHR	ACHR	Negative	2016-12-12	2016-12-15				I 	?Aar      
ACHR	ACRE	Royal Free Hospital	2016-10-21	2016-10-22				I 	rA?       
DHC	DHCN	Cancelled	2016-10-27	2016-10-28				B 	r/30      
GLU	GLU 	No Fl/ox sample received.
Reference range applies to fasting samples only.	2016-10-25	2016-10-25				B 	AB        
ACAN	ACAN	.{}	2016-10-25					A 	/1        
RCAM	1CAM	Cancelled	2016-10-24	2016-10-24				H 	NA?       
RCAM	CAM1	.{}	2016-10-24					H 	Ir/4      
RCAM	CAM2	.{}	2016-10-24					H 	I/10      
RCAM	RCA1	.{}	2016-10-24					H 	r?/21     
RCAM	RCAC	.{}	2016-10-24					H 	N?        
RCAM	RCAM	CANCELLED	2016-10-24	2016-10-24				H 	HNAp1r?   
RCAM	RCAN	.{}	2016-10-24					H 	IN        
RCAM	RCAS	.{}	2016-10-24					H 	Nr?       
RCAM	SAVI	.{}	2016-10-24					H 	I?/0      
RCAM	VREF	SENT	2016-10-24	2016-10-24				H 	I?/4      
ELU	CREA	66	2016-10-18	2016-10-18				B 	CPr       
ELU	GFR 	50
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-10-18	2016-10-18				B 	          
ELU	K   	3.5	2016-10-18	2016-10-18				B 	CP        
ELU	NA  	135	2016-10-18	2016-10-18				B 	CP        
ELU	UREA	1.7	2016-10-18	2016-10-18				B 	CP        
ELU	ZAGE	59	2016-10-18					X 	          
VITA	VITA	1.05
Please note, change to age related reference
ranges from 28/9/14. Ranges for ages less than
one year not yet defined - interpret with caution.	2016-10-18	2016-10-18				D 	          
RAS	RASI	NEGATIVE	2016-10-18	2016-10-18				I 	r         
ELU	CREA	66	2016-10-18	2016-10-18				B 	CPr       
ELU	GFR 	50
Units: mL/min/1.73sqm
Multiply eGFR by 1.21 for people of African
Caribbean origin. Interpret with regard to UK CKD
guidelines: www.renal.org/information-resources
Use with caution for adjusting drug dosages -
contact clinical pharmacist for advice.	2016-10-18	2016-10-18				B 	          
ELU	K   	3.5	2016-10-18	2016-10-18				B 	CP        
ELU	NA  	135	2016-10-18	2016-10-18				B 	CP        
ELU	UREA	1.7	2016-10-18	2016-10-18				B 	CP        
ELU	ZAGE	59	2016-10-18					X 	          
LFT	ALB 	34	2016-11-10	2016-11-10				B 	CP        
LFT	ALP 	35	2016-11-10	2016-11-10				B 	C         
LFT	ALT 	35	2016-11-10	2016-11-10				B 	C         
LFT	BILI	15	2016-11-10	2016-11-10				B 	CPr       
LFT	ALB 	34	2016-11-10	2016-11-10				B 	CP        
LFT	ALP 	35	2016-11-10	2016-11-10				B 	C         
LFT	ALT 	10	2016-11-10	2016-11-10				B 	C         
LFT	BILI	21	2016-11-10	2016-11-10				B 	CPr       
LFT	ALB 	24	2016-11-10	2016-11-10				B 	CP        
LFT	ALP 	45	2016-11-10	2016-11-10				B 	C         
LFT	ALT 	25	2016-11-10	2016-11-10				B 	C         
LFT	BILI	10	2016-11-10	2016-11-10				B 	CPr       
LFT	ALB 	40	2016-11-10	2016-11-10				B 	CP        
LFT	ALP 	50	2016-11-10	2016-11-10				B 	C         
LFT	ALT 	15	2016-11-10	2016-11-10				B 	C         
LFT	BILI	1	2016-11-10	2016-11-10				B 	CPr       
FBCZ	BA  	 1.0%  0.05	2016-11-10	2016-11-10				A 	CDSN/0    
FBCZ	EO  	 1.0%  0.05	2016-11-10	2016-11-10				A 	CDSN/0    
FBCY	HBGL	120	2016-11-10	2016-11-10				A 	rCP/0     
FBCY	HCTU	0.400	2016-11-10	2016-11-10				A 	CPS/0     
FBCZ	IG  	.{}	2016-11-10					A 	SN/0      
FBCZ	IGP 	.{}	2016-11-10					A 	SN/0      
FBCZ	LY  	25.0%  1.25	2016-11-10	2016-11-10				A 	CDSP/0    
FBCY	MCGL	340	2016-11-10	2016-11-10				A 	CPS/0     
FBCY	MCHU	30.0	2016-11-10	2016-11-10				A 	CPS/0     
FBCY	MCVU	85.0	2016-11-10	2016-11-10				A 	CPS/0     
FBCZ	MO  	 8.0%  0.40	2016-11-10	2016-11-10				A 	CDS/0     
FBCY	MPVU	10.0	2016-11-10	2016-11-10				A 	CS?/0     
FBCZ	NE  	65.0%  3.25	2016-11-10	2016-11-10				A 	CDS/0     
FBCY	PLT 	250	2016-11-10	2016-11-10				A 	CS/0      
FBCY	RCC 	5.00	2016-11-10	2016-11-10				A 	P/0       
FBCY	RDWU	13.0	2016-11-10	2016-11-10				A 	CS/0      
FBCY	WCC 	5.00	2016-11-10	2016-11-10				A 	CWPS/0    
GLU	GLU 	5.4
Reference range applies to fasting samples only.	2016-11-10	2016-11-10				B 	AB        
HBVL	BVL1	44	2016-02-11	2016-02-11	IU/ml			H 	HAr?/5    
HBVL	BVL2	.{ POSITIVE }	2016-02-11					H 	?r/5      
HBVL	BVLC	Please note that this test was performed on the
Hologic Aptima DX assay.	2016-08-23	2016-08-23				H 	N?        
HBVL	BVLH	.	2016-08-23					H 	Ir?       
HBVL	BVLP	.{ None in past 300 days }	2016-02-11					H 	NI?       
HBVL	BVLR	44	2016-02-11	2016-02-11				H 	Ir?       
HCVL	CVL1	.{ 0 }	2016-02-10		IU/ml			H 	Hr?/5     
HCVL	CVL2	NOT detected	2016-02-10	2016-02-10				H 	?r/5m     
HCVL	CVLC	Please note that this test was performed on the
Hologic Aptima DX assay.	2016-08-23	2016-08-23				H 	N?        
HCVL	CVLH	.	2016-08-23					H 	Ir?       
HCVL	CVLP	None in past 300 days	2016-02-10	2016-02-10				H 	NI?       
HCVL	CVLR	0	2016-02-10	2016-02-10				H 	Ir?       
HIVK	H1NA	.{ Not Tested }	2015-12-09					H 	?Hr/6     
HBVL	HBVL	REPORT	2016-02-11	2016-02-11				H 	HABp1Nr?  
HBVL	HBVS	EDTA	2016-02-11	2016-02-11				H 	?rB/5     
HCVL	HCVL	REPORT	2016-02-10	2016-02-10				H 	HABp1Nr?  
HCVL	HCVS	EDTA	2016-02-10	2016-02-10				H 	?r/5      
HIVK	HIPA	.{ Not Tested }	2015-12-09					H 	HIr       
HIVK	HIPD	Not Tested	2015-12-09	2015-12-10				H 	HI?       
HIVK	HIPR	.{ Not Tested }	2015-12-09					H 	Ir        
HIRG	HIRR	#000000001000000280#	2016-08-23	2016-08-23				H 	@1H/10    
HIVK	HVKS	EDTA	2016-02-10	2016-02-10				H 	N?r       
HVPS	HVPS	EDTA	2016-02-10	2016-02-10				H 	N?        
HIRG	HVRS	.	2016-08-23					H 	r?/10     
SAVP	SAVP	.	2016-08-23					X 	r?/5      
VTES	VTES	.{}	2014-12-18					H 	          
VZVS	VZG2	134	2015-07-28	2015-07-31				H 	IrN       
VZVS	VZGE	.{}	2015-07-28					H 	?IN/3r    
VZVS	VZGL	151	2015-07-28	2015-07-31				H 	Ir/2      
VZVS	VZGR	.{}	2015-07-31					H 	?/3r      
VZVS	VZGV	.{}	2015-07-28					H 	INr?/2    
VZVS	VZVS	x	2016-08-23	2016-08-23				H 	NAHp1?    
CDIF	CDAP	Liquid	2013-06-11	2013-06-11				M 	Br?/1     
CDIF	CDCM	This patient has C. difficile toxin positive
diarrhoea. The patient must be isolated and
infection control precautions implemented. Stop
antibiotics if possible. First line treatment is
oral Metronidazole. A root cause analysis is
necessary.	2013-06-11	2013-06-11				M 	NA?r      
CDIF	CDIF	CLOSTRIDIUM DIFFICILE TESTING REPORT	2013-06-11	2013-06-11				M 	HXp1p2AB?r
CDRT	CDRL	PHE, Barts and the London NHS Trust,
Department of Medical Microbiology.
Department of Medical Microbiology.	2014-05-23	2014-08-21				M 	I?/1      
CDRT	CDST	.{}	2014-08-21					M 	I/1       
CDIF	CGDH	DETECTED	2013-06-11	2013-06-11				M 	?r/1      
CDIF	CRQ7	No	2013-06-28					X 	N         
CDIF	CT14	No	2013-06-28					X 	N         
CDIF	CTOX	DETECTED	2013-06-11	2013-06-11				M 	?r/1      
ICN	ICNA	test run - no action.	2013-06-11					X 	/1        
ICN	ICNN	MH	2013-06-11					X 	?/1       
ICN	ICNS	see below	2013-06-11					X 	/1        
CDRT	RREF	SENT	2014-08-21	2014-08-21				M 	I/1       
ROS	BFIN	Y	2014-06-03	2014-06-04				M 	Ir?/3     
ROS	BSTA	COMPLETE: 03/06/14	2014-06-03	2014-06-04				M 	?ABr/6    
COSC	COSC	KLEPNE/ESCCOL/	2014-06-04					X 	J-        
COSD	COSD	Organisms sent 04/06/2014 10:20	2014-06-04					X 	J-        
KLA	KLA	SENT TO KIESTRA	2014-05-30					X 	-JNH      
ROS	MACM	Two colonial types close to disc -  large (1) and
small (2)	2014-06-03					X 	          
MLD2	MLC2	small	2014-06-03					X 	N         
MLD2	MLDC	large	2014-06-11					X 	N         
MLD2	MLDO	Klebsiella pneumoniae	2014-06-03					X 	r/1       
MLD2	MLDS	1.01	2014-06-03					X 	/1        
MLD2	MLO2	E. coli	2014-06-03					X 	r/1       
MLD2	MLS2	1.22	2014-06-03					X 	/1        
ROS	ROCC	This is a screening specimen and does not need
treatment. It should be considered when making
future antibiotic decisions.	2014-05-30	2014-06-11				M 	N?        
ROS	ROCS	- - - - - - - - - - - - - - - - - - - - - - - -	2014-06-11	2014-06-11					
ROS	ROIS	:
     Klebsiella pneumoniae
     Escherichia coli	1899-12-30	2014-06-04				M 	M/2Nr     
ROS	ROS	RESULTS	2014-06-11	2014-06-11				M 	HXp1p2AB?r
ROS	ROSI	ALERT! The patient must be isolated in a single
room if an inpatient.	2014-06-11	2014-06-11				M 	N?        
GYNM	GETV	.	2014-09-26					M 	?/1       
GYNC	GISO	.	2014-09-26					M 	M?AB/3    
GYNM	GNCK	Few	2014-09-22	2014-09-26				M 	N?        
GYNC	GYCO	Y	2014-09-26	2014-09-26				M 	?Ir/3     
GYNC	GYNC	GYNAECOLOGY CULTURE REPORT	2014-09-22	2014-09-26				M 	HXp1p2A?r 
GYNM	GYNM	GYNAECOLOGY MICROSCOPY REPORT	2014-09-22	2014-09-26				M 	HXp1p2A?r 
GYNC	GYST	COMPLETE: 26/09/14	2014-09-26	2014-09-26				M 	?Ar/3     
KLA	KLA	SENT TO KIESTRA	2014-05-30					X 	-JNH      
ROS	MACM	.	2014-09-22					X 	          
ROS	ROS	RESULTS	2014-09-22	2014-09-22				M 	HXp1p2AB?r
ROS	ROS3	COMPLETE: 26/09/14	2014-09-26	2014-09-26				M 	?r        
ROS	ROS4	Y	2014-09-22	2014-09-22				M 	?Ir       
ROS	ROSM	.	2014-09-22			80	1200	M 	r?        
KLA	KLA	SENT TO KIESTRA	2014-05-30					X 	-JNH      
ROS	MACM	.	2014-09-22					X 	          
ROS	ROS	RESULTS	2014-09-22	2014-09-22				M 	HXp1p2AB?r
ROS	ROS3	COMPLETE: 22/09/14	2014-09-22	2014-09-22				M 	?r        
ROS	ROS4	Y	2014-09-22	2014-09-22				M 	?Ir       
ROS	ROSM	.	2014-09-22			80	1200	M 	r?        
BC	BC	CANCELLED	2015-02-03	2015-02-03				M 	HXp1p2AB?r
BC	BCCA	Cancelled - see comments	2015-02-03	2015-02-03				M 	NA?       
BC	BCCC	.	2017-10-10					M 	?N        
BC	BCOM	Entered in error.	2015-02-03	2015-02-03				M 	?N        
BC	BCST	COMPLETE: 10/10/17	2017-10-10	2017-10-10				M 	?NA       
BC	BISO	.{}	2015-02-03			0	70	M 	Mr?/6     
BC	CFIN	y	2015-02-03	2015-02-03				M 	?I/6      
BCP	PCUL	.	2015-02-03					X 	?         
KLA	KLA	SENT TO KIESTRA	2014-05-02					X 	-JNH      
URNC	UAMA	AMA not detected	2014-05-02					X 	HNJ-      
URNC	UISO	.{}	2014-05-02					M 	ABMr?/2aN 
URNC	UPRE	Screening culture negative.	2014-05-02	2014-05-02				M 	?ar       
URNC	URCC	Y	2014-05-02	2014-05-02				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2014-05-02	2014-05-02				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 02/05/14	2014-05-02	2014-05-02				M 	N?Ar/2    
KLA	KLA	SENT TO KIESTRA	2014-05-02					X 	-JNH      
URNC	UAMA	AMA not detected	2014-05-02					X 	HNJ-      
URNC	UISO	.{}	2014-05-02					M 	ABMr?/2aN 
URNC	UPRE	No significant growth.	2014-05-02	2014-05-02				M 	?ar       
URNC	URCC	Y	2014-05-02	2014-05-02				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2014-05-02	2014-05-02				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 02/05/14	2014-05-02	2014-05-02				M 	N?Ar/2    
GYW1	GC	.	2014-08-30					X 	I/2?      
GYNM	GETV	.{}	2014-09-18					M 	?/1       
GYNC	GISO	.{}	2014-09-18					M 	M?AB/3    
GYNC	GYCO	y	2014-09-18	2014-09-18				M 	?Ir/3     
GYNC	GYNC	GYNAECOLOGY CULTURE REPORT	2014-08-27	2014-08-27				M 	HXp1p2A?r 
GYNM	GYNM	GYNAECOLOGY MICROSCOPY REPORT	2014-08-27	2014-08-27				M 	HXp1p2A?r 
GYNC	GYST	COMPLETE: 18/09/14	2014-09-18	2014-09-18				M 	?Ar/3     
KLA	KLA	SENT TO KIESTRA	2014-08-27					X 	-JNH      
MISL	MIDR	.	2014-11-11					X 	/10       
MISL	MILA	Cancelled - see comments	2014-11-11	2014-11-11				M 	NA?       
MISL	MILC	System test	2014-11-11	2014-11-11				M 	?N        
MISL	MILT	.{}	2014-11-11					M 	?/10      
MISL	MISB	.{}	2014-11-11					M 	?/10      
MISL	MISQ	.{}	2014-11-11					M 	?         
MISL	MISR	.{}	2014-11-11		mg/L			M 	/10       
MISL	MIST	.	2014-11-11					X 	r/1       
BC	BC	BLOOD CULTURE REPORT	2014-10-29	2014-10-29				M 	HXp1p2AB?r
BCW	BCAN	No growth after 5 days	2014-10-29					X 	Nr/5      
BC	BCCC	New comment	2014-12-09	2014-12-09				M 	?N        
BC	BCOM	No aerobic bottle received.	2014-10-29	2014-10-29				M 	?N        
BC	BCST	COMPLETE: 09/12/14	2014-12-09	2014-12-09				M 	?NA       
BC	BISO	.{}	2014-10-29			0	70	M 	Mr?/6     
BC	BPRE	No growth after 5 days.	2014-10-29	2014-10-29				M 	N?ra      
BC	CFIN	Y	2014-10-29	2014-10-29				M 	?I/6      
SFC	BCOM	Please note:
Microbiology is currently introducing plastic
blood culture bottles (not paediatric /
mycobacterial). Please use up all stocks of glass
bottles prior to using the new plastic bottles.
Microbiology is currently introducing plastic
blood culture bottles (not paediatric /
mycobacterial). Please use up all stocks of glass
bottles prior to using the new plastic bottles.	2014-12-16	2014-12-16				M 	?N        
SFC	BCST	COMPLETE: 19/12/14	2014-12-19	2014-12-19				M 	?NA       
SFC	BISO	.{}	2014-12-16			0	70	M 	Mr?/6     
SFC	CFIN	Y	2014-12-16	2014-12-16				M 	?I/6      
SFC	SFC	STERILE FLUID CULTURE REPORT	2014-12-16	2014-12-16				M 	HXp1p2AB? 
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	.{}	2015-03-01					M 	M/6?a     
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	CSF CULTURE REPORT	2015-01-05	2015-03-01				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-05	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-05					X 	-JNH      
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	.{}	2015-03-01					M 	M/6?a     
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	CSF CULTURE REPORT	2015-01-05	2015-03-01				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-05	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-05					X 	-JNH      
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	.{}	2015-03-01					M 	M/6?a     
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	CSF CULTURE REPORT	2015-01-05	2015-03-01				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-05	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-05					X 	-JNH      
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	.{}	2015-03-01					M 	M/6?a     
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	CSF CULTURE REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-07					X 	-JNH      
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	.{}	2016-09-20					M 	M/6?a     
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	NOTE: We are now using EUCAST methodology and
criteria for determining the antibiotic
susceptibilities of bacterial isolates.	2016-09-15	2016-09-20				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-07					X 	-JNH      
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	:
     Neisseria gonorrhoeae	1899-12-30	2015-03-01				M 	M/6?a     
COSC	COSC	NEIGON/	2015-03-01					X 	J-        
COSD	COSD	Organisms sent 01/03/2015 13:17	2015-03-01					X 	J-        
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	CSF CULTURE REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-07					X 	-JNH      
CSFB	CBAR	.{}	2015-03-01					M 	?I/0      
CSFM	CDES	.{}	2015-03-01					M 	?a        
CSFC	CISO	:
     Neisseria gonorrhoeae	1899-12-30	2015-03-01				M 	M/6?a     
COSC	COSC	NEIGON/	2015-03-01					X 	J-        
COSD	COSD	Organisms sent 01/03/2015 13:17	2015-03-01					X 	J-        
CSFM	CRBC	.{}	2015-03-01		/cu.mm			M 	?/0a      
CSFB	CSFB	.{}	2015-03-01					M 	INJ-      
CSFC	CSFC	CSF CULTURE REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFM	CSFM	CSF MICROSCOPY REPORT	2015-01-07	2015-03-01				M 	Hp1p2AB?r 
CSFC	CSSC	Y	2015-03-01	2015-03-01				M 	?Ir/6     
CSFC	CSST	COMPLETE: 01/03/15	2015-03-01	2015-03-01				M 	?Ar/6     
CSFM	CWBC	.{}	2015-03-01		/cu.mm			M 	r/0a      
KLA	KLA	SENT TO KIESTRA	2015-01-07					X 	-JNH      
CRS	CRS	REPORT	2013-06-29	2013-06-29				M 	HXp1p2AB?r
CRS	CRSR	.	2013-06-25					M 	?         
TISC	FCOM	Y	2013-06-26	2013-06-29				M 	I?/3      
TISC	FSTA	COMPLETE: 29/06/13	2013-06-29	2013-06-29				M 	?ABr/3    
KLA	KLA	SENT TO KIESTRA	2013-06-21					X 	-JNH      
NNWS	NISO	.{}	2013-06-29					M 	M?/3      
NNWS	NISP	Pseudomonas sp. NOT isolated.
Amikacin-resistant coliforms NOT isolated.	2013-06-26	2013-06-29				M 	?N        
NNWS	NNCO	Y	2013-06-26	2013-06-29				M 	?Ir/3     
NNWS	NNST	COMPLETE: 25/06/13	2013-06-26	2013-06-29				M 	?r/3      
NNWS	NNWS	SWAB CULTURE REPORT	2013-06-29	2013-06-29				M 	HXp1p2AB?r
TISC	TISO	.{}	2013-06-26			35	130	M 	M?/4r     
TISC	TPRE	No growth after 4 days.	2013-06-26	2013-06-29				M 	?ANr/3    
SREF	SREA	.	2013-07-26					M 	I?/10     
SREF	SREB	.	2013-07-26					M 	I?/10     
SREF	SREC	.	2013-07-26					M 	I?/10     
SREF	SRED	.	2013-07-26					M 	I?/10     
SREF	SREE	.	2013-07-26					M 	I?/10     
SREF	SREF	.	2013-07-26					M 	I?/10     
SREF	SREG	.	2013-07-26					M 	I?/10     
SREF	SREH	.	2013-07-26					M 	I?/10     
SREF	SREI	.	2013-07-26					M 	I?/10     
SREF	SREJ	.	2013-07-26					M 	I?/10     
SREF	SRPT	.	2013-07-26					M 	I?/10     
SREF	SRPV	.	2013-07-26					M 	I?/10     
SREF	SRTA	.	2013-07-26					M 	I?/10     
SREF	SRTB	.	2013-07-26					M 	I?/10     
SREF	SRTD	.	2013-07-26					M 	I?/10     
SREF	SRTS	.	2013-07-26					M 	I?/10     
AMSC	AMSC	ESCCOL/	2016-06-10					X 	J-        
AMSD	AMSD	Organisms sent 10/06/2016 14:05	2016-06-10					X 	J-        
COSC	COSC	ESCCOL/	2016-06-10					X 	J-        
COSD	COSD	Organisms sent 10/06/2016 13:43	2016-06-10					X 	J-        
KLA	KLA	SENT TO KIESTRA	2016-06-10					X 	-JNH      
URNC	UISO	:
>100,000 CFU/ml Escherichia coli	1899-12-30	2016-06-10				M 	ABMr?/2aN 
URNC	UPRE	.{}	2016-06-10					M 	?ar       
URNC	URCC	Y	2016-06-10	2016-06-10				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-06-10	2016-06-10				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 10/06/16	2016-06-10	2016-06-10				M 	N?Ar/2    
VTK	VTK	Sent to Vitek 10/06/2016 13:11	2016-06-10					X 	JaN       
KLA	KLA	SENT TO KIESTRA	2016-06-10					X 	-JNH      
URNC	UISO	:
>100,000 CFU/ml Escherichia coli	1899-12-30	2016-06-10				M 	ABMr?/2aN 
URNC	UPRE	.{}	2016-06-10					M 	?ar       
URNC	URCC	Y	2016-06-10	2016-06-10				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-06-10	2016-06-10				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 10/06/16	2016-06-10	2016-06-10				M 	N?Ar/2    
VTK	VTK	Sent to Vitek 10/06/2016 13:13	2016-06-10					X 	JaN       
AMSC	AMSC	ESCCOL/STAAUR/	2016-08-10					X 	J-        
AMSD	AMSD	Organisms sent 10/08/2016 14:44	2016-08-10					X 	J-        
WDC	BFIN	Y	2016-08-10	2016-08-10				M 	Ir?/3     
WDC	BSTA	COMPLETE: 10/08/16	2016-08-10	2016-08-10				M 	?ABr/6    
COSC	COSC	ESCCOL/STAAUR/	2016-08-10					X 	J-        
COSD	COSD	Organisms sent 10/08/2016 14:44	2016-08-10					X 	J-        
KLA	KLA	SENT TO KIESTRA	2016-08-10					X 	-JNH      
VTK	VTK	Sent to Vitek 10/08/2016 14:25	2016-08-10					X 	JaN       
WDC	WISO	:
Heavy growth of Escherichia coli
Moderate growth of Staphylococcus aureus	1899-12-30	2016-08-10				M 	Mr?/3     
WDC	WRES	SWAB CULTURE REPORT	2016-08-10	2016-08-10				M 	Hp1p2A?   
AMSC	AMSC	STRPYO/CITFRE/PSEAER/	2016-08-10					X 	J-        
AMSD	AMSD	Organisms sent 10/08/2016 14:44	2016-08-10					X 	J-        
COSC	COSC	STRPYO/CITFRE/PSEAER/	2016-08-10					X 	J-        
COSD	COSD	Organisms sent 10/08/2016 14:44	2016-08-10					X 	J-        
ICN	ICNA	.	2016-08-10					X 	/1        
ICN	ICNN	.	2016-08-10					X 	?/1       
ICN	ICNS	.	2016-08-10					X 	/1        
KLA	KLA	SENT TO KIESTRA	2016-08-10					X 	-JNH      
URNC	UISO	:
Heavy growth of Streptococcus pyogenes (Group A)
Light growth of Citrobacter freundii
Very light growth of Pseudomonas aeruginosa	1899-12-30	2016-08-10				M 	ABMr?/2aN 
URNC	UPRE	.{}	2016-08-10					M 	?ar       
URNC	URCC	Y	2016-08-10	2016-08-10				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-08-10	2016-08-10				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 10/08/16	2016-08-10	2016-08-10				M 	N?Ar/2    
WDC	BFIN	y	2017-02-18	2017-02-18				M 	Ir?/3     
WDC	BSTA	COMPLETE: 18/02/17	2017-02-18	2017-02-18				M 	?ABr/6    
KLA 	KLA 	SENT TO KIESTRA	2016-10-21					X 	-JNH      
WDC	WDCA	Cancelled - see comments	2017-02-18	2017-02-18				M 	NAp1?     
WDC	WISO	.{}	2017-02-18					M 	Mr?/3     
WDC	WNOT	To check with Ian Riddoch	2016-11-01					X 	N         
WDC	WPRE	Culture under investigation.	2016-10-21	2016-10-21				M 	?ANa      
WDC	WRES	CANCELLED	2017-02-18	2017-02-18				M 	Hp1p2A?   
BC	BC  	CANCELLED	2017-09-07	2017-09-07				M 	HXp1p2AB?r
BC	BCCA	Cancelled - see comments	2017-09-07	2017-09-07				M 	NA?       
BC	BCST	COMPLETE: 07/09/17	2017-09-07	2017-09-07				M 	?NA       
BC	BISO	.{}	2017-09-07					M 	Mr?/6     
BC	CFIN	y	2017-09-07	2017-09-07				M 	?I/6      
URNM	UCAS	.{}	2017-11-26					M 	?Nr       
URNC	UISO	.{}	2017-11-26					M 	ABMr?/2aN 
URNC	UPRE	Screening culture negative.	2017-11-26	2017-11-26				M 	?ar       
URNC	URCC	Y	2017-11-26	2017-11-26				M 	NI?r/2    
URNM	URMA	Cancelled - entered in error	2017-11-26	2017-11-26				M 	NA?       
URNC	URNC	URINE CULTURE REPORT	2017-11-26	2017-11-26				M 	Hp1p2AB?  
URNM	URNM	CANCELLED	2017-11-26	2017-11-26				M 	HXp1p2AB? 
URNC	URST	COMPLETE: 26/11/17	2017-11-26	2017-11-26				M 	N?Ar/2    
URNM	UWBC	.{}	2017-11-26					M 	?r/0      
AMSC	AMSC	Organisms sent 27/11/2017 13:08	2017-11-27					X 	J-        
AMSD	AMSD	ESCCOL/	2017-11-27					X 	J-        
WDC	BFIN	Y	2017-11-26	2017-11-26				M 	Ir?/3     
WDC	BSTA	COMPLETE: 26/11/17	2017-11-26	2017-11-26				M 	?ABr/6    
COSC	COSC	ESCCOL/	2017-11-27					X 	J-        
COSD	COSD	Organisms sent 27/11/2017 12:46	2017-11-27					X 	J-        
WDC	WISO	:	2017-11-26	2017-11-26				M 	Mr?/3     
WDC	WRES	SWAB CULTURE REPORT	2017-11-26	2017-11-26				M 	Hp1p2A?   
MRSC	FSTH	COMPLETE: 16/11/16	2016-11-16	2016-11-16				M 	?r/3      
MRSC	HCOM	Y	2016-11-16	2016-11-16				M 	I?/3      
KLA 	KLA 	SENT TO KIESTRA	2016-11-16					X 	-JNH      
MRSC	MISO	Negative	2016-11-16	2016-11-16				M 	Mr/3      
MRSC	MRSC	MRSA CULTURE REPORT	2016-11-16	2016-11-16				M 	Hp1p2A?r  
KLA 	KLA 	SENT TO KIESTRA	2016-11-16					X 	-JNH      
URNC	UISO	.{}	2016-11-16					M 	ABMr?/2aN 
URNC	UPRE	A mixed growth of uncertain significance.	2016-11-16	2016-11-16				M 	?ar       
URNC	URCC	Y	2016-11-16	2016-11-16				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-11-16	2016-11-16				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 16/11/16	2016-11-16	2016-11-16				M 	N?Ar/2    
MPCP	PCP2	Negative	2018-04-17					X 	N?H-Jra   
MPCP	PCP3		1899-12-30					X 	HNaJ-     
MPCP	PCP4		1899-12-30					X 	HNaJ-     
MPCP	PCP5		1899-12-30					X 	HNaJ-     
MPCP	PCPC		1899-12-30					M 	?N        
MPCP	PCPP	Negative	2018-04-17	2018-04-17				M 	?r/4      
MPCP	PCP2	10^8	2018-04-17					X 	N?H-Jra   
MPCP	PCP3		1899-12-30					X 	HNaJ-     
MPCP	PCP4		1899-12-30					X 	HNaJ-     
MPCP	PCP5		1899-12-30					X 	HNaJ-     
MPCP	PCPC	Greater than 10^5 copies/mL of target detected
indicating Pneumocystis infection.	2018-04-17	2018-04-17				M 	?N        
MPCP	PCPP	Positive	2018-04-17	2018-04-17				M 	?r/4      
MPCP	PCP2	10^3	2018-04-17					X 	N?H-Jra   
MPCP	PCP3		1899-12-30					X 	HNaJ-     
MPCP	PCP4		1899-12-30					X 	HNaJ-     
MPCP	PCP5		1899-12-30					X 	HNaJ-     
MPCP	PCPC	.{This is a low positive result and may represent
colonisation or low grade infection. Please
interpret alongside clinical presentation.	2018-04-17					M 	?N        
MPCP	PCPP	Pneumocystis PCR has been performed on this sample
Please contact Microbiology to discuss this result	2018-04-17	2018-04-17				M 	?r/4      
WDC	BFIN	Y	2016-11-22	2016-11-22				M 	Ir?/3     
WDC	BSTA	COMPLETE: 22/11/16	2016-11-22	2016-11-22				M 	?ABr/6    
KLA 	KLA 	SENT TO KIESTRA	2016-11-22					X 	-JNH      
WDC	NEO 	Negative	2016-11-22					X 	?r/2      
WDCM	WBCB	None seen	2016-11-22	2016-11-22				M 	?/0       
WDCM	WDCM	SWAB MICROSCOPY REPORT	2016-11-22	2016-11-22				M 	Hp1p2AB?  
WDC	WISO	Negative	2016-11-22	2016-11-22				M 	Mr?/3     
WDC	WRES	SWAB CULTURE REPORT	2016-11-22	2016-11-22				M 	Hp1p2A?   
COSC	COSC	ESCCOL/	2017-09-11					X 	J-        
COSD	COSD	Organisms sent 11/09/2017 11:02	2017-09-11					X 	J-        
KLA 	KLA 	SENT TO KIESTRA	2016-11-22					X 	-JNH      
URNC	UISO	:	2017-09-09	2017-09-11				M 	ABMr?/2aN 
URNC	UPRE	.{}	2017-09-09					M 	?ar       
URNC	URCC	y	2017-09-09	2017-09-11				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-11-22	2016-11-22				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 09/09/17	2017-09-09	2017-09-11				M 	N?Ar/2    
VTK	VTK 	Sent to Vitek 31/08/2017 13:22	2017-08-31					X 	JaN       
KLA 	KLA 	SENT TO KIESTRA	2016-11-22					X 	-JNH      
URNC	UISO	.{}	2016-11-22					M 	ABMr?/2aN 
URNC	UPRE	Screening culture negative.	2016-11-22	2016-11-22				M 	?ar       
URNC	URCC	Y	2016-11-22	2016-11-22				M 	NI?r/2    
URNC	URNC	URINE CULTURE REPORT	2016-11-22	2016-11-22				M 	Hp1p2AB?  
URNC	URST	COMPLETE: 22/11/16	2016-11-22	2016-11-22				M 	N?Ar/2    
FLUC	FLUC	FLUID CULTURE REPORT	2016-11-09					M 	HXp1p2A?r 
FLUM	FLUM	FLUID MICROSCOPY REPORT	2016-11-09					M 	HXp1p2ABr?
FLUC	FSTA	INCOMPLETE - LAST UPDATED: 25/03/17	2017-03-25					M 	?ABr/3    
KLA 	KLA 	SENT TO KIESTRA	2016-11-09					X 	-JNH      
WDW4	BA  	NG2	2016-10-20					X 	Nra?      
WDW4	BAN 	NG2	2016-10-20					X 	Nra?      
WDC	BFIN	Y	2016-10-20	2016-10-24				M 	Ir?/3     
WDCM	BMCM	This is a test. Please IGNORE	2016-10-20	2016-10-24				M 	N?        
WDC	BSTA	COMPLETE: 20/10/16	2016-10-20	2016-10-24				M 	?ABr/6    
KLA 	KLA 	SENT TO KIESTRA	2016-10-20					X 	-JNH      
WDC	NEO 	N	2016-10-20					X 	?r/2      
WDCM	ORGB	No organisms seen.	2016-10-20	2016-10-24				M 	B?N/1     
WDCM	WBCB	None seen	2016-10-20	2016-10-24				M 	?/0       
WDC	WDCA	Cancelled - see comments	2016-10-20	2016-10-24				M 	NAp1?     
WDCM	WDCM	CANCELLED	2016-10-20	2016-10-24				M 	Hp1p2AB?  
WDCM	WDMA	Cancelled - see comments	2016-10-20	2016-10-24				M 	NAp1?     
WDC	WISO	.{}	2016-10-24					M 	Mr?/3     
WDC	WPRE	Entered in error.	2016-10-24	2016-10-24				M 	?ANa      
WDC	WRES	CANCELLED	2016-10-20	2016-10-24				M 	Hp1p2A?   
BC	BC  	BLOOD CULTURE REPORT	2016-11-22	2016-11-22				M 	HXp1p2AB?r
BCW	BCA 	5	2016-11-22					X 	N         
BCW	BCAN	5	2016-11-22					X 	Nr/5      
BC	BCCA	AMENDED RESULT:
This is an amended result and replaces the
previous report issued under the same laboratory
number. Printed copies of any previous reports
should be destroyed.
Date:                       Time:	2016-11-22	2016-11-22				M 	NA?       
BC	BCCC	Test - Ignore	2016-11-22	2016-11-22				M 	?N        
BC	BCDR	Test	2016-11-22	2016-11-22				M 	NI?       
BCW	BCO 	5	2016-11-22					X 	N         
BC	BCOM	This is a test. Please ignore	2016-11-22	2016-11-22				M 	?N        
BC	BCST	COMPLETE: 22/11/16	2016-11-22	2016-11-22				M 	?NA       
BC	BISO	None	2016-11-22	2016-11-22				M 	Mr?/6     
BCW	BNOT	Test	2016-11-22					X 	N         
BC	BPRE	No growth after 5 days.	2016-11-22	2016-11-22				M 	N?ra      
BC	BTEL	N/A	2016-11-22	2016-11-22				M 	N?        
BC	CFIN	Y	2016-11-22	2016-11-22				M 	?I/6      
BCW	NCON	5	2016-11-22					X 	Nr/5      
BC	BC  	BLOOD CULTURE REPORT	2016-11-30	2016-11-30				M 	HXp1p2AB?r
BC	BCST	COMPLETE: 30/11/16	2016-11-30	2016-11-30				M 	?NA       
BC	BISO	None	2016-11-30	2016-11-30				M 	Mr?/6     
BC	CFIN	Y	2016-11-30	2016-11-30				M 	?I/6      
BC	BC  	CANCELLED	2017-09-07	2017-09-07				M 	HXp1p2AB?r
BC	BCCA	Cancelled - see comments	2017-09-07	2017-09-07				M 	NA?       
BC	BCST	COMPLETE: 07/09/17	2017-09-07	2017-09-07				M 	?NA       
BC	BISO	.{}	2017-09-07					M 	Mr?/6     
BC	CFIN	y	2017-09-07	2017-09-07				M 	?I/6      
MRSC	FSTH	COMPLETE: 20/10/16	2016-10-20	2016-10-20				M 	?r/3      
MRSC	HCOM	Y	2016-10-20	2016-10-20				M 	I?/3      
KLA 	KLA 	SENT TO KIESTRA	2016-10-20					X 	-JNH      
MRSC	MISO	None	2016-10-20	2016-10-20				M 	Mr/3      
MRSC	MPRE	No MRSA isolated.	2016-10-20	2016-10-20				M 	?NA       
MRSC	MRCM	This is a test - Please ignore	2016-10-20	2016-10-20				M 	N?        
MRSC	MRSA	AMENDED RESULT:
This is an amended result and replaces the
previous report issued under the same laboratory
number. Printed copies of any previous reports
should be destroyed.
Date:                       Time:	2016-10-20	2016-10-20				M 	NAp1?     
MRSC	MRSC	MRSA CULTURE REPORT	2016-10-20	2016-10-20				M 	Hp1p2A?r  
